QUARTERLY REPORT

Q3 2023 — Quarterly report

Q3 2023PDF · 188 pages1.7 MB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the Quarterly Period Ended September 30, 2023
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
Commission file number: 001-16751
ELEVANCE HEALTH, INC.
(Exact name of registrant as specified in its charter)
Indiana 35-2145715
(State or other jurisdiction of
incorporation or organization) (I.R.S. Employer
Identification Number)
220 Virginia Avenue
Indianapolis, Indiana 46204
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (833) 401-1577
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading symbol(s) Name of each exchange on which registered
Common Stock, $0.01 par value ELV New York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period
that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller
reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”,
“smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filer ☒ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act). Yes ☐ No ☒
As of October 11, 2023, 234,959,135 shares of the Registrant’s Common Stock were outstanding.

-- 1 of 188 --

Elevance Health, Inc.
Quarterly Report on Form 10-Q
For the Period Ended September 30, 2023
Table of Contents
Page
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Consolidated Balance Sheets as of September 30, 2023 (Unaudited) and December 31, 2022 . . . . . . . . . . 2
Consolidated Statements of Income (Unaudited) for the Three and Nine Months Ended September 30,
2023 and 2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Consolidated Statements of Comprehensive Income (Unaudited) for the Three and Nine Months Ended
September 30, 2023 and 2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Consolidated Statements of Cash Flows (Unaudited) for the Nine Months Ended September 30, 2023
and 2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Consolidated Statements of Changes in Equity (Unaudited) for the Nine Months Ended September 30,
2023 and 2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Notes to Consolidated Financial Statements (Unaudited) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK . . . . . . . . . . . . . . . 57
ITEM 4. CONTROLS AND PROCEDURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
ITEM 1A. RISK FACTORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER
PURCHASES OF EQUITY SECURITIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
ITEM 3. DEFAULTS UPON SENIOR SECURITIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
ITEM 4. MINE SAFETY DISCLOSURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
ITEM 5. OTHER INFORMATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
ITEM 6. EXHIBITS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
SIGNATURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
-1-

-- 2 of 188 --

PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Elevance Health, Inc.
Consolidated Balance Sheets
September 30,
2023 December 31,
2022
(In millions, except share and per share data) (Unaudited) (Restated)
Assets
Current assets:
Cash and cash equivalents $ 10,919 $ 7,387
Fixed maturity securities (amortized cost of $30,139 and $28,226; allowance for credit losses of $3 and $9) 27,811 25,952
Equity securities 165 953
Premium receivables 7,883 7,083
Self-funded receivables 3,756 4,663
Other receivables 5,293 4,298
Other current assets 5,358 5,281
Total current assets 61,185 55,617
Long-term investments:
Fixed maturity securities (amortized cost of $874 and $789; allowance for credit losses of $0 and $0) 816 752
Other invested assets 6,118 5,685
Property and equipment, net 4,248 4,316
Goodwill 25,291 24,383
Other intangible assets 10,491 10,315
Other noncurrent assets 2,329 1,687
Total assets $ 110,478 $ 102,755
Liabilities and equity
Liabilities
Current liabilities:
Medical claims payable $ 16,176 $ 15,596
Other policyholder liabilities 5,681 5,933
Unearned income 4,332 1,112
Accounts payable and accrued expenses 5,983 5,607
Short-term borrowings — 265
Current portion of long-term debt 799 1,500
Other current liabilities 10,366 9,683
Total current liabilities 43,337 39,696
Long-term debt, less current portion 24,045 22,349
Reserves for future policy benefits 807 803
Deferred tax liabilities, net 1,779 2,015
Other noncurrent liabilities 1,971 1,562
Total liabilities 71,939 66,425
Commitments and contingencies – Note 11
Shareholders’ equity
Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none — —
Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding –
234,906,987 and 237,958,067 2 2
Additional paid-in capital 8,830 9,084
Retained earnings 32,103 29,647
Accumulated other comprehensive loss (2,512) (2,490)
Total shareholders’ equity 38,423 36,243
Noncontrolling interests 116 87
Total equity 38,539 36,330
Total liabilities and equity $ 110,478 $ 102,755
See accompanying notes.
-2-

-- 3 of 188 --

Elevance Health, Inc.
Consolidated Statements of Income
(Unaudited)
Three Months Ended
September 30 Nine Months Ended
September 30
2023 2022 2023 2022
(In millions, except per share data) (Restated) (Restated)
Revenues
Premiums $ 35,259 $ 33,722 $ 107,716 $ 99,583
Product revenue 5,177 3,972 14,058 10,841
Service fees 2,044 1,931 5,981 5,569
Total operating revenue 42,480 39,625 127,755 115,993
Net investment income 493 371 1,296 1,112
Net losses on financial instruments (124) (57) (358) (439)
Total revenues 42,849 39,939 128,693 116,666
Expenses
Benefit expense 30,606 29,421 92,996 86,447
Cost of products sold 4,648 3,437 12,456 9,389
Operating expense 5,470 4,516 15,088 13,133
Interest expense 259 213 771 622
Amortization of other intangible assets 212 225 668 520
Total expenses 41,195 37,812 121,979 110,111
Income before income tax expense 1,654 2,127 6,714 6,555
Income tax expense 354 529 1,554 1,544
Net income 1,300 1,598 5,160 5,011
Net (income) loss attributable to noncontrolling interests (11) 5 (29) 18
Shareholders’ net income $ 1,289 $ 1,603 $ 5,131 $ 5,029
Shareholders’ net income per share
Basic $ 5.48 $ 6.69 $ 21.70 $ 20.91
Diluted $ 5.45 $ 6.62 $ 21.56 $ 20.67
Dividends per share $ 1.48 $ 1.28 $ 4.44 $ 3.84
See accompanying notes.
-3-

-- 4 of 188 --

Elevance Health, Inc.
Consolidated Statements of Comprehensive Income
(Unaudited)
Three Months Ended
September 30 Nine Months Ended
September 30
(In millions) 2023 2022 2023 2022
(Restated) (Restated)
Net income $ 1,300 $ 1,598 $ 5,160 $ 5,011
Other comprehensive (loss) income, net of tax:
Change in net unrealized losses/gains on investments (352) (639) (44) (2,630)
Change in non-credit component of impairment losses on
investments 2 (1) (1) (3)
Change in net unrealized gains/losses on cash flow hedges 1 2 16 8
Change in net periodic pension and postretirement costs 2 7 7 23
Change in future policy benefits 3 7 2 24
Foreign currency translation adjustments (4) (7) (2) (15)
Other comprehensive loss (348) (631) (22) (2,593)
Net (income) loss attributable to noncontrolling interests (11) 5 (29) 18
Other comprehensive loss attributable to noncontrolling interests 2 3 — 11
Total shareholders’ comprehensive income $ 943 $ 975 $ 5,109 $ 2,447
See accompanying notes.
-4-

-- 5 of 188 --

Elevance Health, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
Nine Months Ended
September 30
2023 2022
(In millions) (Restated)
Operating activities
Net income $ 5,160 $ 5,011
Adjustments to reconcile net income to net cash provided by operating activities:
Net losses on financial instruments 358 439
Equity in net earnings of other invested assets 70 (304)
Depreciation and amortization 1,321 1,202
Impairment of property and equipment 446 —
Deferred income taxes (361) (183)
Share-based compensation 217 191
Changes in operating assets and liabilities:
Receivables, net (727) (678)
Other invested assets (46) 46
Other assets (936) (465)
Policy liabilities 333 1,588
Unearned income 3,220 2,548
Accounts payable and other liabilities 1,717 598
Income taxes 257 (41)
Other, net 3 (35)
Net cash provided by operating activities 11,032 9,917
Investing activities
Purchases of investments (24,337) (19,612)
Proceeds from sale of investments 7,830 9,402
Maturities, calls and redemptions from investments 14,531 7,606
Changes in securities lending collateral 55 (677)
Purchases of subsidiaries, net of cash acquired (1,570) (623)
Purchases of property and equipment (970) (854)
Other, net (82) (91)
Net cash used in investing activities (4,543) (4,849)
Financing activities
Net proceeds from commercial paper borrowings — 375
Proceeds from long-term borrowings 2,574 1,286
Repayments of long-term borrowings (1,908) (982)
Proceeds from short-term borrowings — 1,365
Repayments of short-term borrowings (265) (1,375)
Changes in securities lending payable (54) 685
Changes in bank overdrafts (523) 181
Repurchase and retirement of common stock (1,748) (1,748)
Cash dividends (1,049) (924)
Proceeds from issuance of common stock under employee stock plans 112 152
Taxes paid through withholding of common stock under employee stock plans (99) (91)
Other, net 5 16
Net cash used in financing activities (2,955) (1,060)
Effect of foreign exchange rates on cash and cash equivalents (2) (16)
Change in cash and cash equivalents 3,532 3,992
Cash and cash equivalents at beginning of period 7,387 4,880
Cash and cash equivalents at end of period $ 10,919 $ 8,872
See accompanying notes.
-5-

-- 6 of 188 --

Elevance Health, Inc.
Consolidated Statements of Changes in Equity
(Unaudited)
Total Shareholders’ Equity
Common Stock Additional
Paid-in
Capital Retained
Earnings
Accumulated
Other
Comprehensive
Loss Noncontrolling
Interests Total
Equity	(In millions) Number of
Shares Par
Value
December 31, 2022 (restated) 238.0 $ 2 $ 9,084 $ 29,647 $ (2,490) $ 87 $ 36,330
Net income — — — 1,989 — 15 2,004
Other comprehensive income — — — — 440 2 442
Repurchase and retirement of
common stock, including excise tax (1.3) — (51) (575) — — (626)
Dividends and dividend equivalents — — — (354) — — (354)
Issuance of common stock under
employee stock plans, net of related
tax benefits 0.4 — 6 — — — 6
Convertible debenture repurchases,
conversions and tax adjustments — — (342) — — — (342)
March 31, 2023 237.1 2 8,697 30,707 (2,050) 104 37,460
Net income — — — 1,853 — 3 1,856
Other comprehensive loss — — — — (116) — (116)
Repurchase and retirement of
common stock, including excise tax (1.4) — (52) (600) — — (652)
Dividends and dividend equivalents — — — (352) — — (352)
Issuance of common stock under
employee stock plans, net of related
tax benefits 0.2 — 116 — — — 116
June 30, 2023 235.9 2 8,761 31,608 (2,166) 107 38,312
Net income — — — 1,289 — 11 1,300
Other comprehensive loss — — — — (346) (2) (348)
Repurchase and retirement of
common stock, including excise tax (1.1) — (40) (445) — — (485)
Dividends and dividend equivalents — — — (349) — — (349)
Issuance of common stock under
employee stock plans, net of related
tax benefits 0.1 — 109 — — — 109
September 30, 2023 234.9 $ 2 $ 8,830 $ 32,103 $ (2,512) $ 116 $ 38,539
See accompanying notes.
-6-

-- 7 of 188 --

Elevance Health, Inc.
Consolidated Statements of Changes in Equity (continued)
(Unaudited)
Total Shareholders’ Equity
Common Stock Additional
Paid-in
Capital Retained
Earnings
Accumulated
Other
Comprehensive
Loss Noncontrolling
Interests Total
Equity	(In millions) Number of
Shares Par
Value
December 31, 2021 (restated) 241.8 $ 2 $ 9,148 $ 27,142 $ (197) $ 68 $ 36,163
Adoption of Accounting Standards
Update 2020-06 — — — (23) — — (23)
January 1, 2022 (restated) 241.8 2 9,148 27,119 (197) 68 36,140
Net income (loss) (restated) — — — 1,789 — (10) 1,779
Other comprehensive loss (restated) — — — — (1,049) (5) (1,054)
Noncontrolling interests adjustment — — — — — 3 3
Repurchase and retirement of
common stock (1.2) — (45) (500) — — (545)
Dividends and dividend equivalents — — — (312) — — (312)
Issuance of common stock under
employee stock plans, net of related
tax benefits 0.5 — 39 — — — 39
Convertible debenture repurchases
and conversions — — 9 — — — 9
March 31, 2022 (restated) 241.1 2 9,151 28,096 (1,246) 56 36,059
Net income (loss) restated — — — 1,637 — (3) 1,634
Other comprehensive loss (restated) — — — — (905) (3) (908)
Noncontrolling interests adjustment — — — — — 5 5
Repurchase and retirement of
common stock (1.3) — (48) (576) — — (624)
Dividends and dividend equivalents — — — (310) — — (310)
Issuance of common stock under
employee stock plans, net of related
tax benefits 0.2 — 111 — — — 111
Convertible debenture repurchases
and conversions — — (80) — — — (80)
June 30, 2022 (restated) 240.0 2 9,134 28,847 (2,151) 55 35,887
Net income (loss) restated — — — 1,603 — (5) 1,598
Other comprehensive loss — — — — (628) (3) (631)
Noncontrolling interests adjustment — — — — — 5 5
Repurchase and retirement of
common stock (1.2) — (47) (532) — — (579)
Dividends and dividend equivalents — — — (307) — — (307)
Issuance of common stock under
employee stock plans, net of related
tax benefits 0.2 — 103 — — — 103
Convertible debenture repurchases
and conversions — — (21) — — — (21)
September 30, 2022 (restated) 239.0 $ 2 $ 9,169 $ 29,611 $ (2,779) $ 52 $ 36,055
See accompanying notes.
-7-

-- 8 of 188 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements
(Unaudited)
September 30, 2023
(In Millions, Except Per Share Data or As Otherwise Stated Herein)
1. Organization
References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial
Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and
indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico unless the context otherwise
requires.
Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest
health insurers in the United States in terms of medical membership, serving over 47 million medical members through our
affiliated health plans as of September 30, 2023. We offer a broad spectrum of network-based managed care risk-based plans
to Individual, Employer Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care
services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical
management, care management, wellness programs, actuarial services and other administrative services. We provide services
to the federal government in connection with our Federal Health Products & Services business, which administers the Federal
Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to customers of our subsidiary
health plans and also unaffiliated health plans, including pharmacy services and dental, vision, life, disability and
supplemental health insurance benefits, as well as integrated health services.
We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of
independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and
Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30
counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate
New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of
these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue
Shield or Empire Blue Cross. We also serve members in numerous states as Amerigroup, Freedom Health, HealthLink,
HealthSun, MMM, Optimum HealthCare, Simply Healthcare, UniCare and/or Wellpoint. We also conduct business through
arrangements with other BCBS licensees as well as other strategic partners. We are licensed to conduct insurance operations
in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries. Through various subsidiaries, we also offer
pharmacy services as CarelonRx and other healthcare-related services as Carelon Services, Aspire Health, Carelon
Behavioral Health and CareMore.
As we announced in 2022, over the next several years we are organizing our brand portfolio into the following core go-
to-market brands:
• Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated
Blue Cross and/or Blue Shield licensed plans; and
• Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the
Wellpoint name; and
• Carelon — this brand brings together our healthcare-related brands and capabilities, including our CarelonRx and
Carelon Services businesses, under a single brand name.
Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime,
trusted health partner. Given this evolution, we reviewed and modified how we manage our business, monitor our
performance and allocate our resources, and made changes to our reportable segments beginning in the first quarter of 2023.
We now report our results of operations in the following four reportable segments: Health Benefits (aggregates our
previously reported Commercial & Specialty Business and Government Business segments), CarelonRx, Carelon Services
(previously included in our Other segment) and Corporate & Other (our businesses that do not individually meet the
quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable
-8-

-- 9 of 188 --

segments). In 2022, we managed and presented our operations through the following four reportable segments: Commercial
& Specialty Business, Government Business, CarelonRx and Other. Previously reported information in this Quarterly Report
on Form 10-Q has been reclassified to conform to the new presentation. For additional discussion regarding our segments,
including the changes made, see Note 15 “Segment Information.”
2. Basis of Presentation and Significant Accounting Policies
Basis of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance
with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not
include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain
footnote disclosures that would substantially duplicate the disclosures in our Annual Report on Form 10-K for the year ended
December 31, 2022 (the “2022 Annual Report on Form 10-K”), unless the information contained in those disclosures
materially changed or is required by GAAP. We have filed Exhibit 99.1 to this Quarterly Report on 10-Q to recast certain
prior years’ financial information and related disclosures to reflect the changes to our reportable segments beginning in the
first quarter of 2023 discussed above, as well as the impact of the adoption of a new accounting standard related to the
accounting for long-duration insurance contracts, which we adopted on January 1, 2023, using a modified retrospective
transition method as of January 1, 2021. The recast financial information and related disclosures set forth in Exhibit 99.1 to
this Quarterly Report on Form 10-Q present such financial information and related disclosures in these items as they would
have appeared had we changed our reportable segments and adopted the new accounting standard prior to January 1, 2023
and do not reflect events or developments that may have occurred subsequent to the filing of our 2022 Annual Report on
Form 10-K.
In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of
the consolidated financial statements as of and for the three and nine months ended September 30, 2023 and 2022 have been
recorded. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of
the results that may be expected for the full year ending December 31, 2023, or any other period. The seasonal nature of
portions of our health care and related benefits business, as well as competitive and other market conditions, may cause full-
year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial
statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended
December 31, 2022 included in Exhibit 99.1 to this Quarterly Report on Form 10-Q.
Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar
(“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the
period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during
the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our
consolidated statements of comprehensive income.
Cash and Cash Equivalents: We control a number of bank accounts that are used exclusively to hold customer funds for
the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory
requirements. These amounts totaled $300 and $258 at September 30, 2023 and December 31, 2022, respectively, and are
included in the cash and cash equivalents line on our consolidated balance sheets.
Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those
securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we
classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy
contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.
If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it
is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we
write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements
of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not
have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit
component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment
loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated
other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed
-9-

-- 10 of 188 --

maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated
other comprehensive loss.
The credit component of an impairment is determined primarily by comparing the net present value of projected future
cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our
best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of
purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the
underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default
rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding
probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated
with a default.
For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on
anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the
effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the
securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date
of the securities. Such adjustments are reported within net investment income.
The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains
and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations and are
reported under the caption “Other invested assets” in our consolidated balance sheets.
We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other
members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the
caption “Other invested assets” in our consolidated balance sheets.
We use the equity method of accounting for investments in companies in which our ownership interest may enable us to
influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of
these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under
the caption “Other invested assets” in our consolidated balance sheets.
Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on
the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities
sold.
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred
to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which
is reported under the caption “Other current assets” on our consolidated balance sheets, and we record a corresponding
liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current
liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets.
Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate
component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in
non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value
of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities
and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily,
the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises.
The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality
and shorter duration instruments.
Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is
based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.
Premium receivables include the uncollected amounts from employer risk-based groups, individuals and government
programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $188 and
$152 at September 30, 2023 and December 31, 2022, respectively.
-10-

-- 11 of 188 --

Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for
administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $93 and $68 at
September 30, 2023 and December 31, 2022, respectively.
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due
from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables
are reported net of an allowance for doubtful accounts of $875 and $744 at September 30, 2023 and December 31, 2022,
respectively.
Revenue Recognition: For our non-risk-based contracts, we had no material contract assets, contract liabilities or
deferred contract costs recorded on our consolidated balance sheet at September 30, 2023. For the three and nine months
ended September 30, 2023 and 2022, revenue recognized from performance obligations related to prior periods, such as
changes in transaction price, were not material. For contracts that have an original, expected duration of greater than one
year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and
contracts with variable consideration related to undelivered performance obligations is not material.
Recently Adopted Accounting Guidance: In November 2020, the Financial Accounting Standards Board (“FASB”)
issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early
Application (“ASU 2020-11”). The amendments in ASU 2020-11 change the effective date and early application of
Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the
Accounting for Long-Duration Contracts, which was issued in November 2018. The amendments in ASU 2020-11 extended
the original effective date by one year, and now the amendments are required for our interim and annual reporting periods
beginning after December 15, 2022. This standard requires us to review cash flow assumptions for our long-duration
insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This
standard also requires us to update discount rate assumptions quarterly and recognize the effect of changes in these
assumptions in other comprehensive income. The rate used to discount our reserves for future policy benefits will be based on
an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of our
liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. We adopted these
amendments on January 1, 2023, using the modified retrospective transition method for changes to the liability for future
policy benefits and deferred acquisition costs as of the transition date, January 1, 2021. While the adoption did not have an
overall material impact, our prior period financial statements presented in this Form 10-Q have been restated to reflect the
impacts of our adoption as required by the new standard.
Recent Accounting Guidance Not Yet Adopted: In August 2023, the FASB issued Accounting Standards Update No.
2023-05, Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement
(“ASU 2023-05”). ASU 2023-05 clarifies existing guidance to reduce diversity in practice and is requiring a joint venture to
recognize and initially measure its assets and liabilities using a new basis of accounting, at fair value, upon formation. These
amendments are effective prospectively for all joint venture formations with a formation date on or after January 1, 2025. We
do not believe the adoption of ASU 2023-05 will have a material impact on our consolidated financial statements and
disclosures.
There were no other new accounting pronouncements that were issued or became effective since December 31, 2022 that
had, or are expected to have, a material impact on our consolidated financial position, results of operations or cash flows.
3. Business Acquisitions and Divestitures
Pending Divestiture
On March 28, 2023, we announced our entrance into an agreement to sell our life and disability businesses to StanCorp
Financial Group, Inc. (“The Standard”), a provider of financial protection products and services for employers and
individuals. Upon closing, we and The Standard will enter into a product distribution partnership. The divestiture is expected
to close in the first half of 2024 and is subject to standard closing conditions and customary approvals. The related net assets
held for sale and results of operations for the life and disability businesses to be divested as of and for the three and nine
months ending September 30, 2023 were not material.
-11-

-- 12 of 188 --

Pending Acquisition
On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service & Indemnity
Company, d/b/a Blue Cross and Blue Shield of Louisiana (“BCBSLA”), an independent licensee of the BCBSA that provides
healthcare plans to the Individual, Employer Group, Medicaid and Medicare markets, primarily in the State of Louisiana.
This acquisition aligns with our mission to become a lifetime, trusted health partner as we bring our innovative whole-health
solutions to BCBSLA’s members. The acquisition is expected to close in the first half of 2024 and is subject to standard
closing conditions and customary approvals.
Completed Acquisitions
On February 15, 2023, we completed our acquisition of BioPlus Parent, LLC and subsidiaries (“BioPlus”) from
CarepathRx Aggregator, LLC. Prior to the acquisition, BioPlus was one of the largest independent specialty pharmacy
organizations in the United States. BioPlus, which operates as part of CarelonRx, seeks to connect payors and providers of
specialty pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition
aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs
that improve the lives of the people we serve. As of September 30, 2023, the purchase price was allocated to the tangible and
intangible net assets acquired based on management’s initial estimates of their fair values, of which $820 has been allocated
to finite-lived intangible assets and $877 to goodwill. There were no changes to goodwill for measurement period
adjustments during the three months ended September 30, 2023. The majority of goodwill is not deductible for income tax
purposes. As of September 30, 2023, the initial accounting for the acquisition had not been finalized. The proforma effects of
this acquisition for prior periods were not material to our consolidated results of operations.
On May 5, 2022, we completed our acquisition of Integra Managed Care (“Integra”). Integra is a managed long-term
care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities to live
safely and independently in their own homes. The initial accounting for this acquisition was finalized as of June 30, 2023.
The purchase price was allocated to tangible and intangible net assets acquired based on management’s estimates of their fair
values, of which $89 was allocated to finite-lived intangible assets, $250 to indefinite-lived intangible assets, and $139 to
goodwill. The majority of goodwill is deductible for income tax purposes. The proforma effects of this acquisition for prior
periods were not material to our consolidated results of operations.
4. Business Optimization Initiatives
During the third quarter of 2023, based on a strategic review of our operations, assets and investments, management
implemented the “2023-2024 Business Efficiency Program” to enhance operating efficiency, refine the focus of our
investments, and optimize our physical footprint. The 2023-2024 Business Efficiency Program includes the write-off of
certain information technology assets and contract exit costs, a reduction in staff including the relocation of certain job
functions, and the impairment of assets associated with the closure or partial closure of data centers and offices. The
2023-2024 Business Efficiency Program is expected to be substantially complete by the end of the third quarter of 2024. Cash
outlays associated with this program, which primarily relate to the personnel-related costs, are expected to be paid through
2024.
In the third quarter of 2023, we incurred $730 of costs towards the 2023-2024 Business Efficiency Program. This
included $446 of pre-tax charges for information technology assets and contract write-offs related to projects that have been
de-prioritized and stopped, $230 of pre-tax personnel-related charges for the reduction and/or relocation of staff, which
includes severance and related costs primarily determined under the Company's existing severance plans, and $54 of pre-tax
charges from asset impairments related to the closure or partial closure of data centers and offices, including operating lease-
related right-of-use assets and other property and equipment. These charges were recognized in operating expense in the
Corporate & Other segment; see Note 15, “Segment Information.”
-12-

-- 13 of 188 --

In the third quarter of 2023, we also released $33 of severance related accruals from our business optimization initiatives
introduced in 2020 (“2020 Business Optimization Initiatives”). A summary of the activity for the nine months ended
September 30, 2023 and ending balance at September 30, 2023 related to the liability for employee termination costs, is as
follows:
Health
Benefits CarelonRx
Carelon
Services
Corporate
& Other Total
2023-2024 Business Efficiency Program
Liabilities for employee termination costs at January 1,
2023 $ — $ — $ — $ — $ —
Charges — — — 230 230
Payments and releases — — — — —
Total liabilities for employee termination costs ending
balance at September 30, 2023 $ — $ — $ — $ 230 $ 230
Health
Benefits CarelonRx
Carelon
Services
Corporate
& Other Total
2020 Business Optimization Initiatives
Liabilities for employee termination costs at January 1,
2023 $ 80 $ 1 $ — $ — $ 81
Payments (31) (1) — — (32)
Releases (33) — — — (33)
Total liabilities for employee termination costs ending
balance at September 30, 2023 $ 16 $ — $ — $ — $ 16
5. Investments
Fixed Maturity Securities
We evaluate our available-for-sale fixed maturity securities for declines based on qualitative and quantitative factors. We
have established an allowance for credit loss and recorded credit loss expense as a reflection of our expected impairment
losses. We continue to review our investment portfolios under our impairment review policy. Given the inherent uncertainty
of changes in market conditions and the significant judgments involved, there is a continuing risk that declines in fair value
may occur and additional material impairment losses for credit losses on investments may be recorded in future periods.
-13-

-- 14 of 188 --

A summary of current and long-term fixed maturity securities, available-for-sale, at September 30, 2023 and
December 31, 2022 is as follows:
Cost or
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Allowance
For Credit
Losses Estimated
Fair Value
September 30, 2023
Fixed maturity securities:
United States Government securities $ 1,906 $ — $ (129) $ — $ 1,777
Government sponsored securities 110 — (8) — 102
Foreign government securities 14 — (2) — 12
States, municipalities and political subdivisions, tax-exempt 3,898 6 (325) — 3,579
Corporate securities 14,548 22 (1,156) (1) 13,413
Residential mortgage-backed securities 3,876 6 (438) — 3,444
Commercial mortgage-backed securities 2,153 1 (188) (2) 1,964
Other asset-backed securities 4,508 17 (189) — 4,336
Total fixed maturity securities $ 31,013 $ 52 $ (2,435) $ (3) $ 28,627
December 31, 2022
Fixed maturity securities:
United States Government securities $ 1,502 $ 2 $ (103) $ — $ 1,401
Government sponsored securities 82 1 (5) — 78
Foreign government securities 321 1 (46) (2) 274
States, municipalities and political subdivisions, tax-exempt 4,389 19 (265) — 4,143
Corporate securities 13,721 31 (1,218) (5) 12,529
Residential mortgage-backed securities 2,978 9 (324) — 2,663
Commercial mortgage-backed securities 2,055 1 (176) (2) 1,878
Other asset-backed securities 3,967 12 (241) — 3,738
Total fixed maturity securities $ 29,015 $ 76 $ (2,378) $ (9) $ 26,704
Other asset-backed securities primarily consists of collateralized loan obligations and other debt securities.
-14-

-- 15 of 188 --

For fixed maturity securities in an unrealized loss position at September 30, 2023 and December 31, 2022, the following
table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously
been in an unrealized loss position:
Less than 12 Months 12 Months or Greater
(Securities are whole amounts) Number of
Securities Estimated
Fair Value
Gross
Unrealized
Loss Number of
Securities Estimated
Fair Value
Gross
Unrealized
Loss
September 30, 2023
Fixed maturity securities:
United States Government securities 55 $ 1,170 $ (58) 55 $ 423 $ (71)
Government sponsored securities 6 50 (2) 40 52 (6)
Foreign government securities 5 5 — 5 7 (2)
States, municipalities and political
subdivisions, tax-exempt 833 1,503 (55) 1,132 1,876 (270)
Corporate securities 2,160 4,995 (180) 2,908 7,542 (976)
Residential mortgage-backed securities 583 1,339 (59) 1,583 1,895 (379)
Commercial mortgage-backed securities 176 517 (22) 579 1,395 (166)
Other asset-backed securities 323 1,154 (50) 879 2,577 (139)
Total fixed maturity securities 4,141 $ 10,733 $ (426) 7,181 $ 15,767 $ (2,009)
December 31, 2022
Fixed maturity securities:
United States Government securities 61 $ 701 $ (40) 38 $ 442 $ (63)
Government sponsored securities 39 73 (4) 6 5 (1)
Foreign government securities 150 100 (10) 198 142 (36)
States, municipalities and political
subdivisions, tax-exempt 1,398 2,615 (147) 396 652 (118)
Corporate securities 3,551 7,826 (549) 2,204 3,521 (669)
Residential mortgage-backed securities 1,341 1,435 (121) 496 982 (203)
Commercial mortgage-backed securities 457 1,082 (76) 324 719 (100)
Other asset-backed securities 784 2,203 (124) 398 1,074 (117)
Total fixed maturity securities 7,781 $ 16,035 $ (1,071) 4,060 $ 7,537 $ (1,307)
Unrealized losses on our securities shown in the table above have not been recognized into income because, as of
September 30, 2023, we do not intend to sell these investments and it is likely that we will not be required to sell these
investments prior to their maturity or anticipated recovery. The declines in fair values are largely due to increasing interest
rates driven by the higher rate of inflation and other market conditions.
Allowances for credit losses have been recorded in the amounts of $3 and $9 at September 30, 2023 and December 31,
2022, respectively, for declines in fair value due to unfavorable changes in the credit quality characteristics that impact our
assessment of collectability of principal and interest.
-15-

-- 16 of 188 --

The amortized cost and fair value of fixed maturity securities at September 30, 2023, by contractual maturity, are shown
below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to
prepay obligations.
Amortized
Cost Estimated
Fair Value
Due in one year or less $ 757 $ 749
Due after one year through five years 8,146 7,729
Due after five years through ten years 10,062 9,300
Due after ten years 6,019 5,441
Mortgage-backed securities 6,029 5,408
Total fixed maturity securities $ 31,013 $ 28,627
During the three and nine months ended September 30, 2023, we received total proceeds from sales, maturities, calls or
redemptions of fixed maturity securities of $6,236 and $21,321, respectively. During the three and nine months ended
September 30, 2022, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of
$5,281 and $15,953, respectively.
In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to:
(i) changes in the investment environment; (ii) expectation that the fair value could deteriorate further; (iii) desire to reduce
exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.
All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are
determined on the basis of the cost or amortized cost of the specific securities sold.
Equity Securities
A summary of marketable equity securities at September 30, 2023 and December 31, 2022 is as follows:
September 30, 2023 December 31, 2022
Equity securities:
Exchange traded funds $ 56 $ 822
Common equity securities 40 43
Private equity securities 69 88
Total $ 165 $ 953
Other Invested Assets
Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled
corporations, mortgage loans and the cash surrender value of corporate-owned life insurance policies. Investments in limited
partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed
earnings, which approximates fair value. Financial information for certain of these investments is reported on a one or three
month lag due to the timing of when we receive financial information from the companies.
-16-

-- 17 of 188 --

Investment Gains and Losses
Net investment (losses) gains for the three and nine months ended September 30, 2023 and 2022 are as follows:
Three Months Ended
September 30 Nine Months Ended
September 30
2023 2022 2023 2022
Net (losses) gains:
Fixed maturity securities:
Gross realized gains from sales $ 13 $ 8 $ 34 $ 44
Gross realized losses from sales (164) (99) (377) (353)
Impairment recoveries (losses) recognized in income 2 (5) (8) (25)
Net realized losses from sales of fixed maturity securities (149) (96) (351) (334)
Equity securities:
Unrealized losses recognized on equity securities still
held at the end of the period — (43) (1) (192)
Net realized gains (losses) recognized on equity
securities sold during the period 2 4 5 (20)
Net gains (losses) on equity securities 2 (39) 4 (212)
Other investments:
Gross gains 86 95 91 126
Gross losses (68) (2) (62) (45)
Impairment losses recognized in income (8) (12) (37) (17)
Net gains (losses) on other investments 10 81 (8) 64
Net losses on investments $ (137) $ (54) $ (355) $ (482)
Accrued Investment Income
At September 30, 2023 and December 31, 2022, accrued investment income totaled $281 and $245, respectively. We
recognize accrued investment income under the caption “Other receivables” on our consolidated balance sheets.
Securities Lending Programs
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred
to independent brokers or dealers in exchange for cash and securities collateral. The fair value of the collateral received at the
time of the transactions amounted to $2,403 and $2,457 at September 30, 2023 and December 31, 2022, respectively. The
value of the collateral represented 102% of the market value of the securities on loan at each of September 30, 2023 and
December 31, 2022. We recognize the collateral as an asset under the caption “Other current assets” in our consolidated
balance sheets, and we recognize a corresponding liability for the obligation to return the collateral to the borrower under the
caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our
consolidated balance sheets.
At September 30, 2023 and December 31, 2022, the remaining contractual maturity of our securities lending agreements
included overnight and continuous transactions of cash for $2,266 and $2,221, respectively, of United States Government
securities for $92 and $224, respectively, of States, Municipalities, and Political Subdivisions securities for $7 and $0,
respectively, and of Residential Mortgage-Backed securities for $38 and $12, respectively.
6. Derivative Financial Instruments
We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward
contracts, put and call options, swaptions, embedded derivatives and warrants. We also enter into master netting agreements,
which reduce credit risk by permitting net settlement of transactions.
-17-

-- 18 of 188 --

We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-
term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to the
Secured Overnight Financing Rate (“SOFR”). Any amounts recognized for changes in fair value of these derivatives are
included in the captions “Other current assets,” “Other noncurrent assets,” “Other current liabilities” or “Other noncurrent
liabilities” in our consolidated balance sheets.
The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive
loss, net of tax, was $213 and $229 at September 30, 2023 and December 31, 2022, respectively.
During the three and nine months ended months ended September 30, 2023, we recognized net gains of $13 and net
losses of $3, respectively, on non-hedging derivatives. During the three and nine months ended months ended September 30,
2022, we recognized net losses of $3 and net gains of $43 on non-hedging derivatives, respectively.
For additional information relating to the fair value of our derivative assets and liabilities, see Note 7, “Fair Value,” of
this Form 10-Q.
7. Fair Value
Assets and liabilities recorded at fair value in our consolidated balance sheets are categorized based upon the level of
judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair
value measurements and disclosures, are as follows:
Level Input Input Definition
Level I Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II Inputs other than quoted prices included in Level I that are observable for the asset or liability through
corroboration with market data at the measurement date.
Level III Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing
the asset or liability at the measurement date.
The following methods, assumptions and inputs were used to determine the fair value of each class of the following
assets and liabilities recorded at fair value in our consolidated balance sheets:
Cash equivalents: Cash equivalents primarily consist of highly rated money market funds with maturities of three
months or less and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of
the funds, we designate all cash equivalents as Level I.
Fixed maturity securities, available-for-sale: Fair values of available-for-sale fixed maturity securities are based on
quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which
generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements and
disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political
subdivisions, mortgage-backed securities, United States government securities, foreign government securities, and certain
other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of
comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets
for similar securities. We have controls in place to review the pricing services’ qualifications and procedures used to
determine fair values. In addition, we periodically review the pricing services’ pricing methodologies, data sources and
pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies
include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also
have certain fixed maturity securities, primarily collateralized loan obligation securities and corporate debt securities, that are
designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or discounted
cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates
and prepayment speeds that are not observable in the markets.
-18-

-- 19 of 188 --

Equity securities: Fair values of equity securities are generally designated as Level I and are based on quoted market
prices. For certain equity securities, quoted market prices for the identical security are not always available, and the fair value
is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II.
We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each
security’s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these
private equity securities are generally based on either broker quotes or discounted cash flow projections using assumptions
for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes,
depreciation and amortization, and/or revenue multiples that are not observable in the markets.
Securities lending collateral: Fair values of securities lending collateral are based on quoted market prices, where
available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II
inputs for the determination of fair value, to facilitate fair value measurements and disclosures.
Derivatives: Fair values are based on the quoted market prices by the financial institution that is the counterparty to the
derivative transaction. We independently verify prices provided by the counterparties using valuation models that incorporate
observable market inputs for similar derivative transactions. Derivatives are designated as Level II securities. Derivatives
presented within the fair value hierarchy table below are presented on a gross basis and not on a master netting basis by
counterparty.
-19-

-- 20 of 188 --

A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at
September 30, 2023 and December 31, 2022 is as follows:
Level I Level II Level III Total
September 30, 2023
Assets:
Cash equivalents $ 7,036 $ — $ — $ 7,036
Fixed maturity securities, available-for-sale:
United States Government securities — 1,777 — 1,777
Government sponsored securities — 102 — 102
Foreign government securities — 12 — 12
States, municipalities and political subdivisions, tax-exempt — 3,579 — 3,579
Corporate securities — 13,303 110 13,413
Residential mortgage-backed securities — 3,442 2 3,444
Commercial mortgage-backed securities — 1,964 — 1,964
Other asset-backed securities — 3,917 419 4,336
Total fixed maturity securities, available-for-sale — 28,096 531 28,627
Equity securities:
Exchange traded funds 56 — — 56
Common equity securities 11 29 — 40
Private equity securities — — 69 69
Total equity securities 67 29 69 165
Other invested assets - common equity securities 102 — — 102
Securities lending collateral — 2,405 — 2,405
Derivatives - other assets — 11 — 11
Total assets $ 7,205 $ 30,541 $ 600 $ 38,346
Liabilities:
Derivatives - other liabilities $ — $ (92) $ — $ (92)
Total liabilities $ — $ (92) $ — $ (92)
December 31, 2022
Assets:
Cash equivalents $ 3,567 $ — $ — $ 3,567
Fixed maturity securities, available-for-sale:
United States Government securities — 1,401 — 1,401
Government sponsored securities — 78 — 78
Foreign government securities — 274 — 274
States, municipalities and political subdivisions, tax-exempt — 4,143 — 4,143
Corporate securities — 12,392 137 12,529
Residential mortgage-backed securities — 2,663 — 2,663
Commercial mortgage-backed securities — 1,878 — 1,878
Other asset-backed securities — 3,382 356 3,738
Total fixed maturity securities, available-for-sale — 26,211 493 26,704
Equity securities:
Exchange traded funds 822 — — 822
Common equity securities 2 41 — 43
Private equity securities — — 88 88
Total equity securities 824 41 88 953
Other invested assets - common equity securities 103 — — 103
Securities lending collateral — 2,457 — 2,457
Derivatives - other assets — 3 — 3
Total assets $ 4,494 $ 28,712 $ 581 $ 33,787
Liabilities:
Derivatives - other liabilities $ — $ (60) $ — $ (60)
Total liabilities $ — $ (60) $ — $ (60)
-20-

-- 21 of 188 --

A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level
III inputs for the three months ended September 30, 2023 and 2022 is as follows:
Corporate
Securities
Residential
Mortgage-
backed
Securities
Other Asset-
backed
Securities Equity
Securities Total
Three Months Ended September 30, 2023
Beginning balance at July 1, 2023 $ 103 $ — $ 366 $ 75 $ 544
Total gains (losses):
Recognized in net income (2) — — 2 —
Recognized in accumulated other comprehensive loss 1 — — — 1
Purchases 17 — 60 3 80
Sales (2) — (6) (11) (19)
Settlements (12) — — — (12)
Transfers into Level III 6 2 — — 8
Transfers out of Level III (1) — (1) — (2)
Ending balance at September 30, 2023 $ 110 $ 2 $ 419 $ 69 $ 600
Change in unrealized gains (losses) included in net income
related to assets still held at September 30, 2023 $ — $ — $ — $ — $ —
Three Months Ended September 30, 2022
Beginning balance at July 1, 2022 $ 155 $ — $ 218 $ 94 $ 467
Total gains (losses):
Recognized in net income — — — — —
Recognized in accumulated other comprehensive loss 1 — 17 — 18
Purchases 15 — 77 3 95
Sales (26) — (1) (2) (29)
Settlements (10) — — — (10)
Transfers into Level III — — — — —
Transfers out of Level III (6) — — — (6)
Ending balance at September 30, 2022 $ 129 $ — $ 311 $ 95 $ 535
Change in unrealized gains (losses) included in net income
related to assets still held at September 30, 2022 $ — $ — $ — $ — $ —
-21-

-- 22 of 188 --

A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level
III inputs for the nine months ended September 30, 2023 and 2022 is as follows:
Corporate
Securities
Residential
Mortgage-
backed
Securities
Other Asset-
backed
Securities Equity
Securities Total
Nine Months Ended September 30, 2023
Beginning balance at January 1, 2023 $ 137 $ — $ 356 $ 88 $ 581
Total gains (losses):
Recognized in net income (8) — — (3) (11)
Recognized in accumulated other comprehensive loss 5 — 2 — 7
Purchases 22 — 72 4 98
Sales (43) — (17) (20) (80)
Settlements (18) — — — (18)
Transfers into Level III 35 2 6 — 43
Transfers out of Level III (20) — — — (20)
Ending balance at September 30, 2023 $ 110 $ 2 $ 419 $ 69 $ 600
Change in unrealized losses included in net income related
to assets still held at September 30, 2023 $ — $ — $ — $ (4) $ (4)
Nine Months Ended September 30, 2022
Beginning balance at January 1, 2022 $ 336 $ 5 $ 19 $ 89 $ 449
Total gains (losses):
Recognized in net income — — — 1 1
Recognized in accumulated other comprehensive loss (1) — 17 — 16
Purchases 40 — 281 24 345
Sales (201) — (1) (19) (221)
Settlements (42) — — — (42)
Transfers into Level III 9 — — — 9
Transfers out of Level III (12) (5) (5) — (22)
Ending balance at September 30, 2022 $ 129 $ — $ 311 $ 95 $ 535
Change in unrealized gains included in net income related to
assets still held at September 30, 2022 $ — $ — $ — $ 1 $ 1
There were no individually material transfers into or out of Level III during the three and nine months ended
September 30, 2023 or 2022.
Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured
at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in
Note 3, “Business Acquisitions and Divestitures,” we completed our acquisition of BioPlus in the first quarter of 2023 and
Integra during the second quarter of 2022. The net assets acquired in our acquisitions of BioPlus and Integra and resulting
goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of tangible
assets acquired and liabilities assumed were recorded at their carrying values as of the acquisition date, as their carrying
values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets
acquired in our acquisitions of BioPlus and Integra were internally estimated based on the income approach. The income
approach estimates fair value based on the present value of the cash flows that the assets could be expected to generate in the
future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Other
than the assets acquired and liabilities assumed in our acquisitions of BioPlus and Integra described above, there were no
material assets or liabilities measured at fair value on a nonrecurring basis during the three and nine months ended
September 30, 2023 or 2022.
-22-

-- 23 of 188 --

Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our
policy is to obtain quoted market prices in active markets to estimate fair values for recognition and disclosure purposes.
Where quoted market prices in active markets are not available, fair values are estimated using discounted cash flow
analyses, broker quotes, unobservable inputs or other valuation techniques. These techniques are significantly affected by our
assumptions, including discount rates and estimates of future cash flows. The use of assumptions for unobservable inputs for
the determination of fair value involves a level of judgment and uncertainty. Changes in assumptions that reasonably could
have been different at the reporting date may result in a higher or lower determination of fair value. Changes in fair value
measurements, if significant, may affect performance of cash flows.
Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally
to obtain quoted prices for each security from third-party pricing services, which are derived through recently reported trades
for identical or similar securities making adjustments through the reporting date based upon available market observable
information. As we are responsible for the determination of fair value, we perform analysis on the prices received from the
pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our
internal treasury personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation
techniques and inputs used. Our analysis includes procedures such as a review of month-to-month price fluctuations and price
comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing
services during the three and nine months ended September 30, 2023 or 2022.
In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB
guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to
estimate fair value, whether or not such values are recognized in our consolidated balance sheets.
Non-financial instruments such as property and equipment, other current assets, deferred income taxes, intangible assets
and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair
value amounts cannot be aggregated to determine our underlying economic value.
The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables,
other receivables, unearned income, accounts payable and accrued expenses, and certain other current liabilities approximate
fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below.
The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is
recorded at its carrying value in our consolidated balance sheets:
Other invested assets: Other invested assets include primarily our investments in limited partnerships, joint ventures and
other non-controlled corporations and mortgage loans, as well as the cash surrender value of corporate-owned life insurance
policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in
the entities’ undistributed earnings, which approximates fair value. Mortgage loans are carried at amortized cost, which
approximates fair value. The carrying value of corporate-owned life insurance policies represents the cash surrender value as
reported by the respective insurer, which approximates fair value.
Short-term borrowings: The fair value of our short-term borrowings is based on quoted market prices for the same or
similar debt, or, if no quoted market prices were available, on the current market interest rates estimated to be available to us
for debt of similar terms and remaining maturities. The carrying amount for commercial paper approximates fair value, as the
underlying instruments have variable interest rates at market value.
Long-term debt—senior unsecured notes and surplus notes: The fair values of our notes are based on quoted market
prices in active markets for the same or similar debt, or, if no quoted market prices are available, on the current market
observable rates estimated to be available to us for debt of similar terms and remaining maturities.
Long-term debt—convertible debentures: The fair value of our convertible debentures is based on the quoted market
price in the active private market in which the convertible debentures trade.
-23-

-- 24 of 188 --

A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value
on our consolidated balance sheets at September 30, 2023 and December 31, 2022 is as follows:
Carrying
Value
Estimated Fair Value
Level I Level II Level III Total
September 30, 2023
Assets:
Other invested assets $ 6,016 $ — $ — $ 6,016 $ 6,016
Liabilities:
Debt:
Notes 24,844 — 21,815 — 21,815
December 31, 2022
Assets:
Other invested assets $ 5,582 $ — $ — $ 5,582 $ 5,582
Liabilities:
Debt:
Short-term borrowings 265 — 265 — 265
Notes 23,786 — 21,861 — 21,861
Convertible debentures 63 — 463 — 463
8. Income Taxes
During the three months ended September 30, 2023 and 2022, we recognized income tax expense of $354 and $529
(restated), respectively, which represent effective income tax rates of 21.4% and 24.9% (restated), respectively. The decrease
in our effective income tax rate from the three months ended September 30, 2022 is primarily due to the tax impact of
expected geographic changes in our mix of 2023 earnings.
During the nine months ended September 30, 2023 and 2022, we recognized income tax expense of $1,554 and $1,544
(restated), respectively, which represent effective income tax rates of 23.1% and 23.6% (restated), respectively. The decrease
in our effective income tax rate from the nine months ended September 30, 2022 is primarily related to the tax impact of
expected geographic changes in our mix of 2023 earnings.
Income taxes receivable totaled $258 and $440 at September 30, 2023 and December 31, 2022, respectively. At
September 30, 2023, we recognized the income tax receivable as $183 under the caption “Other current assets” and as $75
under the caption “Other noncurrent assets”.
-24-

-- 25 of 188 --

9. Medical Claims Payable
A reconciliation of the beginning and ending balances for medical claims payable for the nine months ended September
30, 2023 and 2022 is as follows:
2023 2022
Gross medical claims payable, beginning of period $ 15,348 $ 13,282
Ceded medical claims payable, beginning of period (6) (21)
Net medical claims payable, beginning of period 15,342 13,261
Business combinations and purchase adjustments — 133
Net incurred medical claims:
Current period 91,058 84,177
Prior periods redundancies (1,342) (901)
Total net incurred medical claims 89,716 83,276
Net payments attributable to:
Current period medical claims 77,048 70,453
Prior periods medical claims 12,097 11,219
Total net payments 89,145 81,672
Net medical claims payable, end of period 15,913 14,998
Ceded medical claims payable, end of period 4 3
Gross medical claims payable, end of period $ 15,917 $ 15,001
At September 30, 2023, the total of net incurred but not reported liabilities plus expected development on reported claims
was $481, $1,421 and $14,011 for the claim years 2021 and prior, 2022 and 2023, respectively.
The favorable development recognized in the nine months ended September 30, 2023 resulted from trend factors in late
2022 developing more favorably than originally expected and completion factors in the latter parts of 2022 developing faster
than expected. The favorable development recognized in the nine months ended September 30, 2022 resulted primarily from
trend factors in late 2021 developing more favorably than originally expected.
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income
for the periods in 2023 is as follows:
Three Months Ended Nine Months Ended
September 30, 2023	March 31, 2023 June 30, 2023 September 30, 2023
Total net incurred medical claims $ 29,683 $ 30,495 $ 29,538 $ 89,716
Quality improvement and other claims expense 1,103 1,109 1,068 3,280
Benefit expense $ 30,786 $ 31,604 $ 30,606 $ 92,996
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income
for the periods in 2022 is as follows:
Three Months Ended Nine Months Ended
September 30, 2022	March 31, 2022 June 30, 2022 September 30, 2022
(Restated) (Restated) (Restated) (Restated)
Total net incurred medical claims $ 27,131 $ 27,634 $ 28,511 $ 83,276
Quality improvement and other claims expense 1,100 1,161 910 3,171
Benefit expense $ 28,231 $ 28,795 $ 29,421 $ 86,447
-25-

-- 26 of 188 --

The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for
medical claims payable included in the consolidated balance sheet, as of September 30, 2023 and December 31, 2022, is as
follows:
September 30, 2023 December 31, 2022
Net medical claims payable, end of period $ 15,913 $ 15,342
Ceded medical claims payable, end of period 4 6
Insurance lines other than short duration 259 248
Gross medical claims payable, end of period $ 16,176 $ 15,596
10. Debt
We generally issue senior unsecured notes for long-term borrowing purposes. At September 30, 2023 and December 31,
2022, we had $24,819 and $23,761, respectively, outstanding under these notes.
On February 8, 2023, we issued $500 aggregate principal amount of 4.900% Notes due 2026 (the “2026 Notes”), $1,000
aggregate principal amount of 4.750% Notes due 2033 (the “2033 Notes”), and $1,100 aggregate principal amount of 5.125%
Notes due 2053 (the “2053 Notes”) under our shelf registration statement. Interest on the 2026 Notes is payable semi-
annually in arrears on February 8 and August 8 of each year, commencing August 8, 2023. Interest on the 2033 Notes and
2053 Notes is payable semi-annually in arrears on February 15 and August 15 of each year, commencing August 15, 2023.
We intend to use the proceeds for working capital and general corporate purposes, including, but not limited to, the funding
of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share
repurchase program.
On January 17, 2023, we repaid, at maturity, the $1,000 outstanding balance of our 3.300% senior unsecured notes. On
March 15, 2023, we repaid, at maturity, the $500 outstanding balance of our 0.450% senior unsecured notes.
We have an unsecured surplus note with an outstanding principal balance of $25 at both September 30, 2023 and
December 31, 2022.
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes.
The 5-Year Facility provides credit of up to $4,000 and matures in April 2027. Our ability to borrow under the 5-Year
Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-
capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year
Facility. As of September 30, 2023, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.2%.
We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating
flexibility. As of September 30, 2023, we were in compliance with all of our debt covenants under the 5-Year Facility. There
were no amounts outstanding under the 5-Year Facility at any time during the nine months ended September 30, 2023 or the
year ended December 31, 2022.
We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general
corporate purposes. At both September 30, 2023 and December 31, 2022, we had no amounts outstanding under this
program. Beginning June 30, 2023, we have reclassified our commercial paper balances from long-term debt to short-term
debt as our intent is to not replace short-term commercial paper outstanding at expiration with additional short-term
commercial paper for an uninterrupted period extending for more than one year.
On March 15, 2023, we redeemed all of our outstanding senior unsecured convertible debentures due 2042 (the
“Debentures”), pursuant to the indenture dated as of October 9, 2012 between us and The Bank of New York Mellon Trust
Company, N.A., as trustee. The Debentures were redeemed at a redemption price equal to 100% of the principal amount of
the Debentures plus accrued and unpaid interest to, but excluding, the date of redemption, for cash totaling $5. During the
three months ended March 31, 2023, $59 of aggregate principal amount of the Debentures was surrendered for conversion by
certain holders in accordance with the terms and conditions of the indenture. We elected to settle the excess of the principal
amount of the conversions with cash for total payments during the three months ended March 31, 2023 of $404.
-26-

-- 27 of 188 --

We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan
Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively,
the “FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral
requirements. We had $0 and $265 of outstanding short-term borrowings from the FHLBs at September 30, 2023 and
December 31, 2022, respectively.
All debt is a direct obligation of Elevance Health, Inc., except for the surplus note and the FHLBs borrowings.
11. Commitments and Contingencies
Litigation and Regulatory Proceedings
In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or
proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint, or in other court
filings, the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to
the cases described below, we contest liability and/or the amount of damages in each matter and believe we have meritorious
defenses.
Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated
financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to
income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In
addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a
previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or
range of loss.
With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses,
or the range of possible losses in excess of the amount, if any, accrued, for various reasons, including but not limited to
some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages,
(iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the
class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be
resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. For
those legal proceedings where a loss is probable, or reasonably possible, and for which it is possible to reasonably estimate
the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of
established reserves is, in the aggregate, from $0 to approximately $250 at September 30, 2023. This estimated aggregate
range of reasonably possible losses is based upon currently available information taking into account our best estimate of
such losses for which such an estimate can be made.
Blue Cross Blue Shield Antitrust Litigation
We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue
Shield licensees (the “Blue plans”) across the country. Cases filed in 28 states were consolidated into a single, multi-district
proceeding captioned In re Blue Cross Blue Shield Antitrust Litigation that is pending in the U.S. District Court for the
Northern District of Alabama (the “Court”). Generally, the suits allege that the BCBSA and the Blue plans have conspired to
horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue
revenue of each plan, restrictions on acquisitions, rules governing the BlueCard® and National Accounts programs and other
arrangements in violation of the Sherman Antitrust Act (“Sherman Act”) and related state laws. The cases were brought by
two putative nationwide classes of plaintiffs, health plan subscribers and providers.
In April 2018, the Court issued an order on the parties’ cross motions for partial summary judgment, determining that the
defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of
review, and the BlueCard® program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of
reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of
the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of
genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed.
-27-

-- 28 of 188 --

The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the “Subscriber
Settlement Agreement”), which agreement required the Court’s approval to become effective. The Subscriber Settlement
Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non-
monetary obligations including (i) eliminating the “national best efforts” rule in the BCBSA license agreements (which rule
limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers
with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue
plan.
In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following
which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to
opt out of the class. A small number of subscribers submitted valid opt-outs by the opt-out deadline.
In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the “Final Approval
Order”). The Court amended its Final Approval Order in September 2022, further clarifying the injunctive relief that may be
available to subscribers who submitted valid opt-outs. In compliance with the Subscriber Settlement Agreement, the
Company paid $506 into an escrow account in September 2022, for an aggregate and full settlement payment by the
Company of $596, which amount was accrued in 2020.
Four notices of appeal of the Final Approval Order were filed prior to the September 2022 appeal deadline. Those
appeals were heard by a panel of the United States Court of Appeals for the Eleventh Circuit in September 2023. In the event
that all appellate rights are exhausted in a manner that affirms the Court’s Final Approval Order, the defendants’ payment and
non-monetary obligations under the Subscriber Settlement Agreement will become effective and the funds held in escrow
will be distributed in accordance with the Subscriber Settlement Agreement.
In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for
class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for
class certification until the Court determined the standard of review applicable to the providers’ claims. In response to that
order, the parties filed renewed standard of review motions in May 2021. In June 2021, the parties filed summary judgment
motions not critically dependent on class certification. In February 2022, the Court issued orders (i) granting certain
defendants’ motion for partial summary judgment against the provider plaintiffs who had previously released claims against
such defendants, and (ii) granting the provider plaintiffs’ motion for partial summary judgment, determining that Ohio v.
American Express Co. does not affect the standard of review in this case. In August 2022, the Court issued orders (i) granting
in part the defendants’ motion regarding the antitrust standard of review, holding that for the period of time after the
elimination of the “national best efforts” rule, the rule of reason applies to the provider plaintiffs’ market allocation
conspiracy claims, and (ii) denying the provider plaintiffs’ motion for partial summary judgment on the standard of review,
reaffirming its prior holding that the provider groups’ boycott claims are subject to the rule of reason. In November 2022, the
Court issued an order requiring the parties to submit supplemental briefs on certain questions related to the providers’
renewed motion for class certification. We intend to continue to vigorously defend the provider litigation, which we believe is
without merit; however, its ultimate outcome cannot be presently determined.
A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed.
Those actions are: Alaska Air Group, Inc., et al. v. Anthem, Inc., et al., No. 2:21-cv-01209-AMM (N.D. Ala.) ("Alaska Air");
JetBlue Airways Corp., et al. v. Anthem, Inc., et al., No. 2:22-cv-00558-GMB (N.D. Ala.) ("Jet Blue"); Metropolitan
Transportation Authority v. Blue Cross and Blue Shield of Alabama et al., No. 2:22-cv-00265-RDP (N.D. Ala.); Bed Bath &
Beyond Inc. v. Anthem, Inc., No. 2:22-cv-01256-SGC (N.D. Ala.) ("Bed Bath & Beyond"); Hoover, et al. v. Blue Cross Blue
Shield Association, et al., No. 2:22-cv-00261-RDP (N.D. Ala.); and VHS Liquidating Trust v. Blue Cross of California, et al.,
No. RG21106600 (Cal. Super.). In February 2023, the Court denied the defendants’ motion to dismiss based on a statute of
limitations defense in Alaska Air and Jet Blue. In March 2023, pursuant to a stipulation by the parties, the Court denied the
defendants’ motion to dismiss also based on a statute of limitations defense in Bed Bath & Beyond. We intend to continue to
vigorously defend these follow-on cases, which we believe are without merit; however, their ultimate outcome cannot be
presently determined.
Blue Cross of California Taxation Litigation
In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue Cross) (“BCC”) was
named as a defendant in a California taxpayer action filed in Los Angeles County Superior Court (the “Superior Court”)
-28-

-- 29 of 188 --

captioned Michael D. Myers v. State Board of Equalization, et al. This action was brought under a California statute that
permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to enforce
governing law. Plaintiff contends that BCC, a licensed Health Care Service Plan, is an “insurer” for purposes of taxation
despite acknowledging it is not an “insurer” under regulatory law. At the time, under California law, “insurers” were required
to pay a gross premiums tax (“GPT”) calculated as 2.35% on gross premiums. As a licensed Health Care Service Plan, BCC
has paid the California Corporate Franchise Tax (“CFT”), the tax paid by California businesses generally. Plaintiff contends
that BCC must pay the GPT rather than the CFT and seeks a writ of mandate directing the taxing agencies to collect the GPT
and an order requiring BCC to pay GPT back taxes, interest, and penalties for the eight-year period prior to the filing of the
complaint.
Because the GPT is constitutionally imposed in lieu of certain other taxes, BCC has filed protective tax refund claims
with the City of Los Angeles, the California Department of Health Care Services and the Franchise Tax Board to protect its
rights to recover certain taxes previously paid should BCC eventually be determined to be subject to the GPT for the tax
periods at issue in the litigation.
In December 2020, the Superior Court granted BCC’s motion for summary judgment, dismissing the plaintiff’s lawsuit.
In November 2021, the plaintiff appealed the summary judgment order. In March 2023, the appeal was argued before the
California Second District Court of Appeal (the “Second District”). The Second District affirmed the Superior Court's
summary judgment order in April 2023. The plaintiff filed a petition for review with the California Supreme Court in June
2023, and BCC filed its answer to the petition in the same month. In July 2023, the California Supreme Court denied the
plaintiff’s petition for review. This matter is now resolved, and the protective tax refund claims mentioned above have been
withdrawn.
Express Scripts, Inc. Pharmacy Benefit Management Litigation
In March 2016, we filed a lawsuit against Express Scripts, Inc. (“Express Scripts”), our vendor at the time for pharmacy
benefit management services, captioned Anthem, Inc. v. Express Scripts, Inc., in the U.S. District Court for the Southern
District of New York (the “District Court”). The lawsuit seeks to recover over $14,800 in damages for pharmacy pricing that
is higher than competitive benchmark pricing under the agreement between the parties (the “ESI Agreement”), over $158 in
damages related to operational breaches, as well as various declarations under the ESI Agreement, including that Express
Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to
provide competitive benchmark pricing to us through the term of the ESI Agreement; (iii) has breached the ESI Agreement;
and (iv) is required under the ESI Agreement to provide post-termination services, at competitive benchmark pricing, for one
year following any termination.
Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the
periodic pricing review under the ESI Agreement, and (ii) that it has no obligation to ensure that we receive any specific level
of pricing, that we have no contractual right to any change in pricing under the ESI Agreement and that its sole obligation is
to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that we have been unjustly
enriched by its payment of $4,675 at the time we entered into the ESI Agreement. In March 2017, the District Court granted
our motion to dismiss Express Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing,
and (ii) unjust enrichment with prejudice. After such ruling, Express Scripts’ only remaining claims were for breach of
contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which we opposed. In
March 2022, the District Court granted in part and denied in part Express Scripts’ motion for summary judgment. The
District Court dismissed our declaratory judgment claim, our breach of contract claim for failure to prove damages and most
of our operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of
this Quarterly Report on Form 10-Q are (i) our operational breach claim based on Express Scripts’ prior authorization
processes and (ii) Express Scripts’ counterclaim for breach of the market check provision of the ESI Agreement. Express
Scripts filed a second motion for summary judgment in June 2022, challenging our remaining operational breach claims,
which we opposed, and the District Court denied in March 2023, allowing our operational breach claim to proceed. A trial
date has been set for December 2023. We intend to appeal the earlier summary judgment decision at the appropriate time,
vigorously pursue our claims and defend against counterclaims, which we believe are without merit; however, the ultimate
outcome of this litigation cannot be presently determined.
-29-

-- 30 of 188 --

Medicare Risk Adjustment Litigation
In March 2020, the U.S. Department of Justice (“DOJ”) filed a civil lawsuit against Elevance Health, Inc. in the U.S.
District Court for the Southern District of New York (the “New York District Court”) in a case captioned United States v.
Anthem, Inc. The DOJ’s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we
submitted to the Centers for Medicare and Medicaid Services (“CMS”) for risk-adjustment purposes under Medicare Part C
and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts,
we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled us to
obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended
complaint in July 2020, alleging the same causes of action but revising some of its factual allegations. In September 2020, we
filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to
strike certain allegations in the amended complaint, all of which the New York District Court denied in October 2022. In
November 2022, we filed an answer. In March 2023, discovery commenced, and an initial case management conference was
held in April 2023. The Court entered a scheduling order requiring fact discovery to be completed by June 2024 and expert
discovery to be complete by February 2025. We intend to continue to vigorously defend this suit, which we believe is without
merit; however, the ultimate outcome cannot be presently determined.
Investigations of CareMore and HealthSun
With the assistance of outside counsel, we are conducting investigations of risk-adjustment practices involving data
submitted to CMS (unrelated to our retrospective chart review program) at CareMore Health Plans, Inc. (“CareMore”), one of
our California subsidiaries, and HealthSun Health Plans, Inc. (“HealthSun”), one of our Florida subsidiaries. Our CareMore
investigation has resulted in the termination of CareMore’s relationship with one contracted provider in California. Our
HealthSun investigation has focused on risk adjustment practices initiated prior to our acquisition of HealthSun in December
2017 that continued after the acquisition. We have voluntarily self-disclosed the existence of both of our investigations to
CMS and the Criminal and Civil Divisions of the DOJ. We are cooperating with the ongoing investigations of the Criminal
and Civil Divisions of the DOJ related to these risk adjustment practices, and have entered into a tolling agreement with the
Civil Division of the DOJ related to its investigation. We have submitted corrected data to CMS related to these
investigations. We have also asserted indemnity claims for escrowed funds under the HealthSun purchase agreement for,
among other things, breach of healthcare and financial representation provisions, based on the conduct discovered during our
investigation. While certain elements of the indemnity claims were resolved in the fourth quarters of 2021 and 2022,
litigation in the Delaware Court of Chancery related to the remaining indemnity claims for escrowed funds remains ongoing.
Other Contingencies
From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve
claims for coverage encountered in the ordinary course of business. We, like Health Maintenance Organizations (“HMOs”)
and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, Preferred
Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees
arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results
in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability
under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage
claims.
In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the
character incidental to our business and are from time to time involved as a party in various governmental investigations,
audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include
routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and
subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the
imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our
business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material
adverse effect on our consolidated financial position or results of operations.
-30-

-- 31 of 188 --

Contractual Obligations and Commitments
In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related
management and support services through June 2025. The agreement superseded certain prior agreements for such services
and includes provisions for additional services not provided under those agreements. Our remaining commitment under this
agreement at September 30, 2023 is approximately $554. We will have the ability to terminate the agreement upon the
occurrence of certain events, subject to early termination fees.
We formed CarelonRx, to market and offer pharmacy services to our affiliated health plan customers, as well as to
external customers outside of the health plans we own, starting in the second quarter of 2019. The comprehensive pharmacy
services portfolio includes, but is not limited to, formulary management, pharmacy networks, specialty and home delivery
pharmacy services and member services. CarelonRx delegates certain pharmacy services, such as claims processing and
prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a
five-year agreement, which is set to terminate on December 31, 2024. With CarelonRx, we retain the responsibilities for
clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account
management and retail network strategy.
12. Capital Stock
Use of Capital – Dividends and Stock Repurchase Program
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases
and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is
at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity
needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
A summary of our cash dividend activity for the nine months ended September 30, 2023 and 2022 is as follows:
Declaration Date Record Date Payment Date
Cash
Dividend
per Share Total
Nine Months Ended September 30, 2023
January 24, 2023 March 10, 2023 March 24, 2023 $1.48 $ 351
April 18, 2023 June 9, 2023 June 23, 2023 $1.48 $ 350
July 18, 2023 September 8, 2023 September 22, 2023 $1.48 $ 348
Nine Months Ended September 30, 2022
January 25, 2022 March 10, 2022 March 25, 2022 $1.28 $ 309
April 19, 2022 June 10, 2022 June 24, 2022 $1.28 $ 309
July 19, 2022 September 9, 2022 September 23, 2022 $1.28 $ 306
On October 17, 2023, our Audit Committee declared a fourth quarter 2023 dividend to shareholders of $1.48 per share,
payable on December 21, 2023 to shareholders of record at the close of business on December 6, 2023.
Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On January 24, 2023,
our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to the
common stock repurchase program. No duration has been placed on the common stock repurchase program, and we reserve
the right to discontinue the program at any time. Repurchases may be made from time to time at prevailing market prices,
subject to certain restrictions on volume, pricing and timing. The repurchases are affected from time to time in the open
market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to
comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is
discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe
it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to
additional paid-in capital and retained earnings.
-31-

-- 32 of 188 --

A summary of common stock repurchases for the nine months ended September 30, 2023 and 2022 is as follows:
Nine Months Ended September 30
2023 2022
Shares repurchased 3.8 3.7
Average price per share $ 462.42 $ 473.36
Aggregate cost $ 1,748 $ 1,748
Authorization remaining at the end of the period $ 5,128 $ 2,444
For additional information regarding the use of capital for debt security repurchases, see Note 10, “Debt,” included in
this Quarterly Report on Form 10-Q and Note 13, “Debt,” to our audited consolidated financial statements as of and for the
year ended December 31, 2022 included in Exhibit 99.1 to this Quarterly Report on Form 10-Q.
Stock Incentive Plans
A summary of stock option activity for the nine months ended September 30, 2023 is as follows:
Number of
Shares
Weighted-
Average
Option Price
per Share
Weighted-
Average
Remaining
Contractual
Life (Years)
Aggregate
Intrinsic
Value
Outstanding at January 1, 2023 2.8 $ 293.28
Granted 0.6 468.92
Exercised (0.2) 265.25
Forfeited or expired (0.1) 399.28
Outstanding at September 30, 2023 3.1 324.74 6.25 $ 370
Exercisable at September 30, 2023 2.0 266.01 5.07 $ 346
A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for
the nine months ended September 30, 2023 is as follows:
Restricted
Stock Shares
and Units
Weighted-
Average
Grant Date
Fair Value
per Share
Nonvested at January 1, 2023 1.2 $ 357.21
Granted 0.6 469.30
Vested (0.6) 301.90
Forfeited (0.1) 413.59
Nonvested at September 30, 2023 1.1 423.34
During the nine months ended September 30, 2023, we granted approximately 0.2 restricted stock units that are
contingent upon us achieving earnings targets over the three-year period from 2023 to 2025. These grants have been included
in the activity shown above but will be subject to adjustment at the end of 2025 based on results in the three-year period.
Fair Value
We use a binomial lattice valuation model to estimate the fair value of all stock options granted. For a more detailed
discussion of our stock incentive plan fair value methodology, see Note 15, “Capital Stock,” to our audited consolidated
financial statements as of and for the year ended December 31, 2022 included in Exhibit 99.1 to this Quarterly Report on
Form 10-Q.
-32-

-- 33 of 188 --

The following weighted-average assumptions were used to estimate the fair values of options granted during the nine
months ended September 30, 2023 and 2022:
Nine Months Ended September 30
2023 2022
Risk-free interest rate 3.95 % 1.97 %
Volatility factor 29.00 % 29.00 %
Quarterly dividend yield 0.316 % 0.282 %
Weighted-average expected life (years) 4.40 5.10
The following weighted-average fair values per option or share were determined for the nine months ended September
30, 2023 and 2022:
Nine Months Ended September 30
2023 2022
Options granted during the period $ 127.08 $ 116.85
Restricted stock awards granted during the period 469.30 453.16
-33-

-- 34 of 188 --

13. Accumulated Other Comprehensive Loss
A reconciliation of the components of accumulated other comprehensive loss at September 30, 2023 and 2022 is as
follows:
Three Months Ended
September 30 Nine Months Ended
September 30
2023 2022 2023 2022
(Restated) (Restated)
Net unrealized investment (losses) gains:
Beginning of period balance $ (1,449) $ (1,489) $ (1,755) $ 494
Other comprehensive loss before reclassifications, net of tax benefit (expense) of
$145, $220, $119 and $896, respectively (464) (719) (317) (2,914)
Amounts reclassified from accumulated other comprehensive loss, net of tax
expense of $(35), $(21), $(86) and $(75), respectively 112 80 273 284
Other comprehensive loss (352) (639) (44) (2,630)
Other comprehensive loss (income) attributable to noncontrolling interests, net of
tax benefit (expense) of $(1), $(1), $(1) and $(4), respectively 2 3 — 11
End of period balance (1,799) (2,125) (1,799) (2,125)
Non-credit components of impairments on investments:
Beginning of period balance (6) (2) (3) —
Other comprehensive income (loss), net of tax benefit of $(1), $0, $0 and $1,
respectively 2 (1) (1) (3)
End of period balance (4) (3) (4) (3)
Net cash flow hedges:
Beginning of period balance (214) (233) (229) (239)
Other comprehensive income, net of tax (expense) of $(1), $0, $6 and $(2),
respectively 1 2 16 8
End of period balance (213) (231) (213) (231)
Pension and other postretirement benefits:
Beginning of period balance (494) (413) (499) (429)
Other comprehensive income, net of tax expense of $0, $(3), $(2) and $(9),
respectively 2 7 7 23
End of period balance (492) (406) (492) (406)
Future policy benefits:
Beginning of period balance 12 (2) 13 (19)
Other comprehensive income, net of tax expense of $0, $(2), $0 and $(7),
respectively 3 7 2 24
End of period balance 15 5 15 5
Foreign currency translation adjustments:
Beginning of period balance (15) (12) (17) (4)
Other comprehensive loss, net of tax benefit of $1, $2, $0 and $4, respectively (4) (7) (2) (15)
End of period balance (19) (19) (19) (19)
Total:
Total beginning of period accumulated other comprehensive loss (2,166) (2,151) (2,490) (197)
Total other comprehensive loss, net of tax benefit (expense) of $109, $196, $37,
and $808, respectively (348) (631) (22) (2,593)
Total other comprehensive loss attributable to noncontrolling interests, net of tax
benefit (expense) of $(1), $(1), $(1) and $(4) respectively 2 3 — 11
Total end of period accumulated other comprehensive loss $ (2,512) $ (2,779) $ (2,512) $ (2,779)
-34-

-- 35 of 188 --

14. Earnings per Share
The denominator for basic and diluted earnings per share for the three and nine months ended September 30, 2023 and
2022 is as follows:
Three Months Ended
September 30 Nine Months Ended
September 30
2023 2022 2023 2022
Denominator for basic earnings per share – weighted-average shares 235.3 239.6 236.4 240.5
Effect of dilutive securities – employee stock options, nonvested
restricted stock awards and convertible debentures 1.2 2.6 1.6 2.8
Denominator for diluted earnings per share 236.5 242.2 238.0 243.3
During the three months ended September 30, 2023 and 2022, weighted-average shares related to certain stock options of
0.9 and 0.5 respectively, were excluded from the denominator for diluted earnings per share because the stock options were
anti-dilutive. During the nine months ended September 30, 2023 and 2022, weighted-average shares related to certain stock
options of 0.8 and 0.4, respectively, were excluded from each of the denominators for diluted earnings per share because the
stock options were anti-dilutive.
During the three and nine months ended September 30, 2023, we issued approximately 0.0 and 0.6 restricted stock units
under our stock incentive plans, 0.0 and 0.2 of which vesting is contingent upon us meeting specified annual earnings targets
for the three-year period of 2023 through 2025. During the three and nine months ended months ended September 30, 2022,
we issued approximately 0.0 and 0.6 restricted stock units under our stock incentive plans, 0.0 and 0.2 of which vesting is
contingent upon us meeting specified annual earnings targets for the three-year period of 2022 through 2024. The contingent
restricted stock units have been excluded from the denominators for diluted earnings per share and will be included only if
and when the contingency is met.
15. Segment Information
As discussed in Note 1 “Organization”, we have changed our reportable segment presentation and its composition to
reflect how we began managing our operations and monitoring performance, aligning strategies and allocating resources
beginning on January 1, 2023. We now report our results of operations in the following four reportable segments: Health
Benefits (aggregates our previously reported Commercial & Specialty Business and Government Business segments),
CarelonRx, Carelon Services (previously included in our Other segment) and Corporate & Other. In 2022, we managed and
presented our operations through the following four reportable segments: Commercial & Specialty Business, Government
Business, CarelonRx and Other. Previously reported information throughout this Quarterly Report on Form 10-Q has been
reclassified to conform to the new presentation.
Our Health Benefits segment offers a comprehensive suite of health plans and services to our Individual, Employer
Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid and FEHB program members. Our Health
Benefits segment also includes our National Government Services business. The Health Benefits segment offers health
products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and
provides a variety of specialty and other insurance products and services such as stop loss, dental, vision, life, disability and
supplemental health insurance benefits.
Our CarelonRx segment includes our pharmacy business. CarelonRx markets and offers pharmacy services to our
affiliated health plan customers, as well as to external customers outside of the health plans we own. CarelonRx offers a
comprehensive pharmacy services portfolio, which includes services such as formulary management, pharmacy networks,
specialty and home delivery pharmacy services and member services.
Our Carelon Services segment is focused on lowering the cost and improving the quality of healthcare by enabling and
creating new care delivery and payment models, with a special emphasis on serving those with complex and chronic
conditions. Carelon Services offers a broad array of healthcare-related services and capabilities to internal and external
customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity
services and subrogation services, as well as health and wellness programs.
-35-

-- 36 of 188 --

Our Corporate & Other segment includes our businesses that do not individually meet the quantitative threshold for an
operating segment, as well as corporate expenses not allocated to our other reportable segments.
We define operating revenues to include premium income, product revenue and service fees. Operating revenues are
derived from premiums and fees received, primarily from the sale and administration of health benefits and pharmacy
products and services. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and
operating expense.
Affiliated revenues represent revenues or costs for services provided to our subsidiaries by CarelonRx and Carelon
Services, in addition to certain back-office services provided by our international businesses, which are recorded at cost or
management’s estimate of fair market value. These affiliated revenues are eliminated in consolidation.
Financial data by reportable segment for the three months ended September 30, 2023 and 2022 is as follows:
Carelon
Health
Benefits CarelonRx Carelon
Services Total Corporate
& Other Eliminations Total
Three Months Ended September 30, 2023
Premiums $ 34,934 $ — $ 422 $ 422 $ — $ (97) $ 35,259
Product revenue — 5,177 — 5,177 — — 5,177
Service fees 1,810 4 196 200 34 — 2,044
Operating revenue -
unaffiliated 36,744 5,181 618 5,799 34 (97) 42,480
Operating revenue - affiliated — 3,337 2,756 6,093 208 (6,301) —
Operating revenue - total $ 36,744 $ 8,518 $ 3,374 $ 11,892 $ 242 $ (6,398) $ 42,480
Operating gain (loss) $ 1,847 $ 477 $ 173 $ 650 $ (741) $ — $ 1,756
Three Months Ended September 30, 2022
Premiums $ 33,376 $ — $ 412 $ 412 $ — $ (66) $ 33,722
Product revenue — 3,972 — 3,972 — — 3,972
Service fees 1,689 — 224 224 18 — 1,931
Operating revenue -
unaffiliated 35,065 3,972 636 4,608 18 (66) 39,625
Operating revenue - affiliated — 3,277 2,518 5,795 193 (5,988) —
Operating revenue - total $ 35,065 $ 7,249 $ 3,154 $ 10,403 $ 211 $ (6,054) $ 39,625
Operating gain (loss) (restated) $ 1,634 $ 516 $ 125 $ 641 $ (24) $ — $ 2,251
-36-

-- 37 of 188 --

Financial data by reportable segment for the nine months ended September 30, 2023 and 2022 is as follows:
Carelon
Health
Benefits CarelonRx Carelon
Services Total Corporate
& Other Eliminations Total
Nine Months Ended September 30, 2023
Premiums $ 106,701 $ — $ 1,261 $ 1,261 $ — $ (246) $ 107,716
Product revenue — 14,058 — 14,058 — — 14,058
Service fees 5,323 4 604 608 50 — 5,981
Operating revenue -
unaffiliated 112,024 14,062 1,865 15,927 50 (246) 127,755
Operating revenue - affiliated — 10,946 8,262 19,208 730 (19,938) —
Operating revenue - total $ 112,024 $ 25,008 $ 10,127 $ 35,135 $ 780 $ (20,184) $ 127,755
Operating gain (loss) $ 6,154 $ 1,485 $ 518 $ 2,003 (942) — 7,215
Nine Months Ended September 30, 2022
Premiums $ 98,626 $ — $ 1,105 $ 1,105 $ — $ (148) $ 99,583
Product revenue — 10,841 — 10,841 — — 10,841
Service fees 4,862 — 670 670 37 — 5,569
Operating revenue -
unaffiliated 103,488 10,841 1,775 12,616 37 (148) 115,993
Operating revenue - affiliated — 10,162 7,310 17,472 762 (18,234) —
Operating revenue - total $ 103,488 $ 21,003 $ 9,085 $ 30,088 $ 799 $ (18,382) $ 115,993
Operating gain (loss) (restated) $ 5,266 $ 1,393 $ 438 $ 1,831 $ (73) $ — $ 7,024
For segment reporting, we present all capitated risk arrangements on a gross basis; therefore, eliminations also include
adjustments for unaffiliated capitated risk arrangements that are recognized on a net basis under GAAP, as well as affiliated
eliminations.
A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated
statements of income for the three and nine months ended September 30, 2023 and 2022 is as follows:
Three Months Ended
September 30 Nine Months Ended
September 30
2023 2022 2023 2022
Reportable segments’ operating revenue $ 42,480 $ 39,625 $ 127,755 $ 115,993
Net investment income 493 371 1,296 1,112
Net losses on financial instruments (124) (57) (358) (439)
Total revenues $ 42,849 $ 39,939 $ 128,693 $ 116,666
-37-

-- 38 of 188 --

A reconciliation of income before income tax expense to reportable segments’ operating gain included in our
consolidated statements of income for the three and nine months ended September 30, 2023 and 2022 is as follows:
Three Months Ended
September 30 Nine Months Ended
September 30
2023 2022 2023 2022
(Restated) (Restated)
Income before income tax expense $ 1,654 $ 2,127 $ 6,714 $ 6,555
Net investment income (493) (371) (1,296) (1,112)
Net losses on financial instruments 124 57 358 439
Interest expense 259 213 771 622
Amortization of other intangible assets 212 225 668 520
Reportable segments’ operating gain $ 1,756 $ 2,251 $ 7,215 $ 7,024
16. Leases
We lease office space and certain computer and related equipment using noncancellable operating leases. Our leases
have remaining lease terms of 1 year to 12 years.
The information related to our leases is as follows:
Balance Sheet Location September 30, 2023 December 31, 2022
Operating Leases
Right-of-use assets Other noncurrent assets $ 573 $ 604
Lease liabilities, current Other current liabilities 172 181
Lease liabilities, noncurrent Other noncurrent liabilities 695 751
Three Months Ended
September 30 Nine Months Ended
September 30
2023 2022 2023 2022
Lease Expense
Operating lease expense $ 69 $ 35 $ 126 $ 100
Short-term and variable lease expense — 11 28 35
Sublease income (1) (1) (4) (3)
Total lease expense $ 68 $ 45 $ 150 $ 132
Other information
Operating cash paid for amounts included in the measurement of
lease liabilities, operating leases $ 53 $ 53 $ 156 $ 158
Right-of-use assets obtained in exchange for new lease liabilities,
operating leases $ — $ 23 $ 47 $ 62
As of September 30, 2023 and December 31, 2022, the weighted average remaining lease term of our operating leases
was 7 years for each period. The lease liabilities reflect a weighted average discount rate of 3.53% at September 30, 2023 and
2.98% at December 31, 2022. Our activities as disclosed in Note 4, “Business Optimization Initiatives”, include reducing our
office space footprint. As a result, during the quarter ended September 30, 2023 we recorded impairment charges of $23 for
abandonment of right-of-use assets which are included in the operating lease expense shown above.
-38-

-- 39 of 188 --

Future lease payments for noncancellable operating leases with initial or remaining terms of one year or more are as
follows:
2023 (excluding the nine months ended September 30, 2023) $ 54
2024 195
2025 163
2026 130
2027 97
Thereafter 335
Total future minimum payments 974
Less imputed interest 107
Total lease liabilities $ 867
-39-

-- 40 of 188 --

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
(In Millions, Except Per Share Data or as Otherwise Stated Herein)
This Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be
read in conjunction with the accompanying consolidated financial statements and notes, as well as our consolidated financial
statements and notes as of and for the year ended December 31, 2022 and the MD&A included in Exhibit 99.1 to this
Quarterly Report on Form 10-Q. References to the terms “we,” “our,” “us,” or “Elevance Health” used throughout this
MD&A refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and
indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico, unless the context
otherwise requires.
We are filing Exhibit 99.1 to this Quarterly Report on Form 10-Q to recast certain prior years’ financial information and
related disclosures included in Part I, Item 1, “Business,” Part II, Item 7, “Management's Discussion and Analysis of
Financial Condition and Results of Operations” and Part II, Item 8, “Financial Statements and Supplementary Data” of our
2022 Annual Report on Form 10-K to reflect changes to our reportable segments beginning in the first quarter of 2023, as
well as the impact of the adoption of a new accounting standard related to the accounting for long-duration insurance
contracts, which we adopted on January 1, 2023, using a modified retrospective transition method as of January 1, 2021. The
recast financial information and related disclosures set forth in Exhibit 99.1 to this Quarterly Report on Form 10-Q present
such financial information and related disclosures in these items as they would have appeared had we changed our reportable
segments and adopted the new accounting standard prior to January 1, 2023 and do not reflect events or developments that
may have occurred subsequent to the filing of our 2022 Annual Report on Form 10-K.
Results of operations, cost of care trends, investment yields and other measures for the three and nine months ended
September 30, 2023 are not necessarily indicative of the results and trends that may be expected for the full year ending
December 31, 2023, or any other period.
Overview
Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest
health insurers in the United States in terms of medical membership, serving over 47 million medical members through our
affiliated health plans as of September 30, 2023. We are an independent licensee of the Blue Cross and Blue Shield
Association (“BCBSA”), an association of independent health benefit plans, and serve members as the Blue Cross or Blue
Cross and Blue Shield licensee in 14 states. We are licensed to conduct insurance operations in all 50 states, the District of
Columbia and Puerto Rico through our subsidiaries. Through various subsidiaries, we also offer pharmacy services and other
healthcare-related services.
As we announced in 2022, over the next several years we are organizing our brand portfolio into the following core go-
to-market brands:
• Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated
Blue Cross and/or Blue Shield licensed plans; and
• Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the
Wellpoint name; and
• Carelon — this brand brings together our healthcare-related brands and capabilities, including our CarelonRx and
Carelon Services businesses, under a single brand name.
Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime,
trusted health partner. Given this evolution, we reviewed and modified how we manage our business, monitor our
performance and allocate our resources, and made changes to our reportable segments beginning in the first quarter of 2023.
-40-

-- 41 of 188 --

We now report our results of operations in the following four reportable segments: Health Benefits (aggregates our
previously reported Commercial & Specialty Business and Government Business segments), CarelonRx, Carelon Services
(previously included in our Other segment) and Corporate & Other (our businesses that do not individually meet the
quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable
segments). In 2022, we managed and presented our operations through the following four reportable segments: Commercial
& Specialty Business, Government Business, CarelonRx and Other. Previously reported information in this Quarterly Report
on Form 10-Q has been reclassified to conform to the new presentation. For additional information, see Note 15, “Segment
Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form
10-Q.
For additional information about our organization, see Part I, Item 1, “Business” and Part II, Item 7, “Management’s
Discussion and Analysis of Financial Condition and Results of Operations,” included in Exhibit 99.1 to this Quarterly Report
on Form 10-Q.
Business Trends
We made the decision to expand our participation in the Individual state- or federally-facilitated marketplaces (the
“Public Exchange”) for 2023. As a result, for 2023, we are offering Individual Public Exchange products in 138 of the 143
rating regions in which we operate, in comparison to 122 of 143 rating regions in 2022. As described in “Regulatory Trends
and Uncertainties” below, we expect growth in our Public Exchange membership as Medicaid members who are no longer
eligible for Medicaid coverage continue to exit the Medicaid program and seek coverage elsewhere. Changes to our business
environment are likely to continue as elected officials at the national and state levels continue to enact, and both elected
officials and candidates for election continue to propose, significant modifications to existing laws and regulations, including
changes to taxes and fees. In addition, growth in our government-sponsored business exposes us to increased regulatory
oversight.
Our CarelonRx subsidiary markets and offers pharmacy services to our affiliated health plan customers throughout the
country, as well as to customers outside of the health plans we own. Our comprehensive pharmacy services portfolio includes
features such as formulary management, pharmacy networks, specialty and home delivery pharmacy services and member
services. CarelonRx delegates certain pharmacy services, such as claims processing and prescription fulfillment, to
CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement, which is
set to terminate on December 31, 2024. With CarelonRx, we retain the responsibilities for clinical and formulary strategy and
development, member and employer experiences, operations, sales, marketing, account management and retail network
strategy.
Pricing Trends: We strive to price our health benefit products consistent with anticipated underlying medical cost trends.
We frequently make adjustments to respond to legislative and regulatory changes as well as pricing and other actions taken
by existing competitors and new market entrants. Revenues from the Medicare and Medicaid programs are dependent, in
whole or in part, upon annual funding from the federal government and/or applicable state governments. Product pricing
remains competitive.
Medical Cost Trends: Our medical cost trends are primarily driven by increases in the utilization of services across all
provider types and the unit cost increases of these services. We work to mitigate these trends through various medical
management programs such as care and condition management, program integrity and specialty pharmacy management and
utilization management, as well as benefit design changes. There are many drivers of medical cost trends that can cause
variance from our estimates, such as changes in the level and mix of services utilized, regulatory changes, aging of the
population, health status and other demographic characteristics of our members, epidemics, pandemics, advances in medical
technology, new high-cost prescription drugs, provider contracting inflation, labor costs and healthcare provider or member
fraud.
For additional discussion regarding business trends, see Part I, Item 1, “Business” included in Exhibit 99.1 to this
Quarterly Report on Form 10-Q.
-41-

-- 42 of 188 --

Regulatory Trends and Uncertainties
Under the Consolidated Appropriations Act of 2023 (the “2023 Appropriations Act”), Congress decoupled Medicaid
eligibility redeterminations from the Public Health Emergency initially declared in January 2020 relating to COVID-19 (the
“PHE”). As a result, states were permitted to begin removing ineligible beneficiaries from their Medicaid programs starting
April 1, 2023, and the majority of our Medicaid markets began doing so as of June 30, 2023. As redeterminations have
resumed, we have experienced a decline in our Medicaid membership. Over time, we expect growth in our commercial plans,
including through the Public Exchanges, as members who are no longer eligible for Medicaid coverage in our 14 commercial
states seek coverage elsewhere. On May 11, 2023, the PHE ended in accordance with the Biden Administration’s January 30,
2023 announcement. Some states such as California have extended their COVID-19 related policies beyond the PHE.
The Inflation Reduction Act of 2022, which was signed into law in August 2022, contains a variety of provisions that
impact our business including an extension of the American Rescue Plan Act of 2021’s enhanced Premium Tax Credits
(“PTC”) through 2025; imposing a new corporate alternative minimum tax; providing a one percent excise tax on
repurchases of stock made after December 31, 2022; allowing Centers for Medicare and Medicaid Services (“CMS”) to
negotiate prices on a limited set of prescription drugs in Medicare Parts B and D beginning in 2026; instituting caps on
insulin cost sharing in Medicare Parts B and D; redesigning of the Medicare Part D benefit; adding a requirement that drug
manufacturers pay rebates if prices increase beyond inflation; and delaying the implementation of the Trump Administration
Medicare drug rebate rule until 2032. The extension of the enhanced PTC has allowed for growth in Individual Public
Exchange enrollment as Medicaid eligibility redeterminations have resumed, supporting continuity of coverage for more
people.
The Consolidated Appropriations Act of 2021 (the “Appropriations Act”) has impacted and in the future may have a
material effect upon our business, including procedures and coverage requirements related to surprise medical bills and new
mandates for continuity of care for certain patients, price comparison tools, disclosure of broker compensation, mental health
parity reporting, and reporting on pharmacy benefits and drug costs. The requirements of the Appropriations Act applicable
to us have varying effective dates, some of which were effective in December 2021 and others that were extended into 2023
since the enactment of the Appropriations Act.
The health plan price transparency regulations issued by the U.S. Departments of Health and Human Services, Labor and
Treasury required us in 2022 to begin disclosing detailed pricing information regarding negotiated rates for all covered items
and services between the plan or issuer and in-network providers and historical payments to, and billed charges from, out-of-
network providers. Additionally, beginning in 2023, we are now required to make available to members personalized out-of-
pocket cost information and the underlying negotiated rates for 500 covered healthcare items and services, including
prescription drugs. In 2024, this requirement will expand to all items and services.
The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as
amended (collectively, the “ACA”), continues to impact our business and results of operations, including pricing, minimum
medical loss ratios and the geographies in which our products are available. We also expect further and ongoing regulatory
guidance on a number of issues related to Medicare, including evolving methodology for ratings and quality bonus payments.
CMS also frequently proposes changes to its program that audits data submitted under the risk adjustment programs in ways
that could increase financial recoveries from plans.
For additional discussion regarding regulatory trends and uncertainties and risk factors, see Part I, Item 1, “Business –
Regulation” and the “Regulatory Trends and Uncertainties” section of Part II, Item 7, “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” included in Exhibit 99.1 to this Quarterly Report on Form 10-Q,
and Part I, Item 1A, “Risk Factors” of our 2022 Annual Report on Form 10-K.
-42-

-- 43 of 188 --

Other Significant Items
Business and Operational Matters
During the third quarter of 2023, based on a strategic review of our operations, assets and investments, management
implemented the “2023-2024 Business Efficiency Program” to refine the focus of our investments, and optimize our physical
footprint. The 2023-2024 Business Efficiency Program includes the write-off of certain information technology assets and
contract exit costs, a reduction in staff including the relocation of certain job functions, and the impairment of assets
associated with the closure or partial closure of data centers and offices. The 2023-2024 Business Efficiency Program is
expected to be substantially complete by the end of the third quarter of 2024. For additional information, see Note 4,
“Business Optimization Initiatives” and Note 16, “Leases,” of the Notes to Consolidated Financial Statements included in
Part 1, Item 1 of this Quarterly Report on Form 10-Q.
Pursuant to CMS’s Medicare Advantage Star ratings system, CMS annually awards between 1.0 and 5.0 Stars to
Medicare Advantage plans based on performance in several categories. Plans must have a Star rating of 4.0 or higher to
qualify for bonus payments. CMS released the Company’s 2024 Star ratings in October 2023. The Company’s 2024 Star
ratings will be used to determine the Company’s Medicare Advantage plans' Star quality bonus payments in 2025. Based on
membership at September 1, 2023, 34% of our Medicare Advantage members were in plans with 2024 Star ratings of at least
4.0 Stars, compared to 64% of our Medicare Advantage members being in plans with 2023 Star ratings of at least 4.0 Stars
based on the Company’s membership at September 1, 2022. The change in our 2024 Star ratings is not projected to impact
our Star quality bonus payments and plan level rebates until 2025. We expect a reduction to our 2025 operating revenue of
approximately $500, net of offsets from contracting provisions. Further, we expect to mitigate the financial impact to our
2025 operating gain and net income per share through various strategies such as contract diversification, operating expense
efficiencies, capital deployment alternatives and network enhancements.
On March 28, 2023, we announced our entrance into an agreement to sell our life and disability businesses to StanCorp
Financial Group, Inc. (“The Standard”), a provider of financial protection products and services for employers and
individuals. Upon closing, we and The Standard will enter into a product distribution partnership. The divestiture is expected
to close in the first half of 2024 and is subject to standard closing conditions and customary approvals.
On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service & Indemnity
Company, d/b/a Blue Cross and Blue Shield of Louisiana (“BCBSLA”), an independent licensee of the BCBSA that provides
healthcare plans to the Individual, Employer Group, Medicaid and Medicare markets, primarily in the State of Louisiana.
This acquisition aligns with our mission to become a lifetime, trusted health partner as we bring our innovative whole-health
solutions to BCBSLA’s members. The acquisition is expected to close in the first half of 2024 and is subject to standard
closing conditions and customary approvals.
On February 15, 2023, we completed our acquisition of BioPlus Parent, LLC and subsidiaries (“BioPlus”) from
CarepathRx Aggregator, LLC. Prior to the acquisition, BioPlus was one of the largest independent specialty pharmacy
organizations in the United States. BioPlus, which operates as part of CarelonRx, seeks to connect payors and providers of
specialty pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition
aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs
that improve the lives of the people we serve.
On May 5, 2022, we completed our acquisition of Integra Managed Care (“Integra”). Integra is a managed long-term
care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities to live
safely and independently in their own homes.
For additional information, see Note 3, “Business Acquisitions and Divestitures,” of the Notes to Consolidated Financial
Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Litigation Matters
In the consolidated multi-district proceeding in the United States District Court for the Northern District of Alabama (the
“Court”) captioned In re Blue Cross Blue Shield Antitrust Litigation (“BCBSA Litigation”), the BCBSA and Blue Cross and/
or Blue Shield licensees, including us (the “Blue plans”) previously approved a settlement agreement and release with the
-43-

-- 44 of 188 --

plaintiffs representing a putative nationwide class of health plan subscribers (the “Subscriber Settlement Agreement”), which
agreement required the Court’s approval to become effective. Generally, the lawsuits in the BCBSA Litigation challenge
elements of the licensing agreements between the BCBSA and the independently owned and operated Blue plans. The cases
were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers. The Subscriber
Settlement Agreement applies only to the subscriber class. The defendants continue to contest the consolidated cases brought
by the provider plaintiffs.
In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the “Final Approval
Order”). In compliance with the Subscriber Settlement Agreement, the Company paid $506 into an escrow account in
September 2022, for an aggregate and full settlement payment by the Company of $596, which amount was accrued in 2020.
Four notices of appeal of the Final Approval Order were filed prior to the September 2022 appeal deadline. Those appeals
were heard by a panel of the United States Court of Appeals for the Eleventh Circuit in September 2023. In the event all
appellate rights are exhausted in a manner that affirms the Court’s Final Approval Order, the defendants’ payment and non-
monetary obligations under the Subscriber Settlement Agreement will become effective and the funds held in escrow will be
distributed in accordance with the Subscriber Settlement Agreement. For additional information regarding the BCBSA
Litigation, see Note 11, “Commitments and Contingencies – Litigation and Regulatory Proceedings – Blue Cross Blue Shield
Antitrust Litigation,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on
Form 10-Q.
Selected Operating Performance
For the twelve months ended September 30, 2023, total medical membership increased slightly. This was primarily
driven by increases in our BlueCard business, as well as growth in our Individual Public Exchange and Medicare Advantage
products. These increases were partially offset by attrition in our Medicaid business due to the resumption of eligibility
redeterminations and reduced membership due to a new entrant into one of our state Medicaid programs, as well as lapses
exceeding sales in our Employer Group risk-based business.
Operating revenue for the three months ended September 30, 2023 was $42,480, an increase of $2,855, or 7.2%, from the
three months ended September 30, 2022. The increase was primarily a result of higher premium revenues due to premium
rate increases in our Health Benefits business to more accurately reflect the cost of care. The increase was further attributable
to growth in our CarelonRx pharmacy product revenue driven by growth in external pharmacy members and the acquisition
of BioPlus in the first quarter of 2023.
Operating revenue for the nine months ended September 30, 2023 was $127,755, an increase of $11,762, or 10.1%, from
the nine months ended September 30, 2022. This increase in operating revenue was primarily a result of higher premium
revenues due to premium rate increases in our Health Benefits business to more accurately reflect the cost of care and
membership growth in our Medicaid business in the first half of 2023, as well as in our Medicare Advantage business. The
increase was further attributable to growth in our CarelonRx pharmacy product revenue driven by growth in external
pharmacy members and the acquisition of BioPlus in the first quarter of 2023.
Net income for the three months ended September 30, 2023 was $1,300, a decrease of $298, or 18.6%, from the three
months ended September 30, 2022. This decline was primarily due to business optimization charges recorded during the third
quarter of 2023 and increased net losses on financial instruments, partially offset by operating gain increases in our Health
Benefits and Carelon Services segments, higher net investment income and lower income taxes.
Net income for the nine months ended September 30, 2023 was $5,160, an increase of $149, or 3.0%, from the nine
months ended September 30, 2022. This increase in net income was primarily due to operating gain increases in our Health
Benefits, CarelonRx and Carelon Services segments and increased net investment income. These increases were offset by
business optimization charges recorded in the third quarter of 2023 and higher interest expense and amortization of other
intangible assets.
Our fully-diluted shareholders’ earnings per share (“EPS”) was $5.45 for the three months ended September 30, 2023,
which represented a 17.7% decrease from EPS of $6.62 for the three months ended September 30, 2022. This decrease in
EPS for the three months ending September 30, 2023 resulted primarily from lower shareholders' net income, partially offset
by the impact of fewer diluted shares outstanding.
-44-

-- 45 of 188 --

Our fully-diluted EPS was $21.56 for the nine months ended September 30, 2023, which represented a 4.3% increase
from fully-diluted EPS of $20.67 for the nine months ended September 30, 2022. This increase in EPS for the nine months
ending September 30, 2023 resulted primarily from fewer diluted shares outstanding, as well as increased shareholders' net
income.
Operating cash flow for the nine months ended September 30, 2023 and 2022 was $11,032 and $9,917, respectively. The
increase was primarily due to higher net income in 2023, when excluding the non-cash impact of business optimization
charges recognized in the third quarter of 2023, as well as the non-recurrence of the Subscriber Settlement Agreement
payment made in September 2022.
Membership and Other Metrics
The following table presents our medical membership by customer type as of September 30, 2023 and 2022. Also
included below are other membership by product and other metrics. The membership data and other metrics presented are
unaudited and in certain instances include estimates of the number of members represented by each contract at the end of the
period. The CarelonRx Quarterly Adjusted Scripts metric represents adjusted script volume based on the number of days a
prescription covers. On an adjusted basis, one 90-day script counts the same as three 30-day scripts. The Carelon Services
Consumers Served metric represents the number of consumers receiving one or more healthcare-related services from
Carelon Services who are members of our affiliated health plans as well as those who are members of non-affiliated health
plans. For a more detailed description of our medical membership, see the “Membership” section of Part II, Item 7,
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Exhibit 99.1 to this
Quarterly Report on Form 10-Q.
September 30
2023 2022 Change % Change
Medical Membership (in thousands)
Individual 999 800 199 24.9 %
Employer Group Risk-Based 3,754 3,988 (234) (5.9) %
Commercial Risk-Based 4,753 4,788 (35) (0.7) %
BlueCard® 6,756 6,453 303 4.7 %
Employer Group Fee-Based 20,166 20,184 (18) (0.1) %
Commercial Fee-Based 26,922 26,637 285 1.1 %
Medicare Advantage 2,064 1,969 95 4.8 %
Medicare Supplement 928 945 (17) (1.8) %
Total Medicare 2,992 2,914 78 2.7 %
Medicaid 11,018 11,319 (301) (2.7) %
Federal Employees Health Benefits (“FEHB”) 1,640 1,625 15 0.9 %
Total Medical Membership 47,325 47,283 42 0.1 %
Other Membership (in thousands)
Life and Disability Members 4,611 4,796 (185) (3.9) %
Dental Members 6,775 6,655 120 1.8 %
Dental Administration Members 1,708 1,577 131 8.3 %
Vision Members 9,861 9,628 233 2.4 %
Medicare Part D Standalone Members 261 274 (13) (4.7) %
Other Metrics (in millions)
CarelonRx Quarterly Adjusted Scripts 77.3 76.9 0.4 0.5 %
Carelon Services Consumers Served 104.8 105.3 (0.5) (0.5) %
-45-

-- 46 of 188 --

Medical Membership
Medical membership increased slightly during the twelve months ended September 30, 2023. This was primarily driven
by increases in our BlueCard business, as well as growth in our Individual Public Exchange and Medicare Advantage
products. These increases were partially offset by attrition in our Medicaid business due to the resumption of eligibility
redeterminations and reduced membership due to a new entrant into one of our state Medicaid programs, as well as lapses
exceeding sales in our Employer Group risk-based business.
Other Membership
Our other membership can be impacted by changes in our medical membership, as our medical members often purchase
our other products that are ancillary to our health business. Life and disability membership decreased primarily due to lapses
associated with our Employer Group risk-based accounts. Dental membership increased primarily due to increases in our
FEHB program. Dental administration membership increased primarily due to favorable in-group change with other BCBSA
plans associated with the FEHB program. Vision membership increased due to sales exceeding lapses in our Employer Group
risk based accounts and increases associated with our Medicare Advantage plans.
Consolidated Results of Operations
Our consolidated summarized results of operations and other financial information for the three and nine months ended
September 30, 2023 and 2022 are as follows:
Three Months Ended
September 30 Nine Months Ended
September 30
Change
Three Months Ended
September 30 Nine Months Ended
September 30
2023 vs. 2022 2023 vs. 2022
2023 2022 2023 2022 $ % $ %
(Restated) (Restated)
Total operating revenue $ 42,480 $ 39,625 $ 127,755 $ 115,993 $ 2,855 7.2 % $ 11,762 10.1 %
Net investment income 493 371 1,296 1,112 122 32.9 % 184 16.5 %
Net losses on financial instruments (124) (57) (358) (439) (67) 117.5 % 81 (18.5) %
Total revenues 42,849 39,939 128,693 116,666 2,910 7.3 % 12,027 10.3 %
Benefit expense 30,606 29,421 92,996 86,447 1,185 4.0 % 6,549 7.6 %
Cost of products sold 4,648 3,437 12,456 9,389 1,211 35.2 % 3,067 32.7 %
Operating expense 5,470 4,516 15,088 13,133 954 21.1 % 1,955 14.9 %
Other expense1 471 438 1,439 1,142 33 7.5 % 297 26.0 %
Total expenses 41,195 37,812 121,979 110,111 3,383 8.9 % 11,868 10.8 %
Income before income tax expense 1,654 2,127 6,714 6,555 (473) (22.2) % 159 2.4 %
Income tax expense 354 529 1,554 1,544 (175) (33.1) % 10 0.6 %
Net income $ 1,300 $ 1,598 $ 5,160 $ 5,011 $ (298) (18.6) % $ 149 3.0 %
Net (income) loss attributable to
noncontrolling interests (11) 5 (29) 18 (16) NM (47) NM
Shareholders’ net income $ 1,289 $ 1,603 $ 5,131 $ 5,029 $ (314) (19.6) % $ 102 2.0 %
Average diluted shares outstanding 236.5 242.2 238.0 243.3 (5.7) (2.4) % (5.3) (2.2) %
Diluted shareholders’ net income per share $ 5.45 $ 6.62 $ 21.56 $ 20.67 $ (1.17) (17.7) % $ 0.89 4.3 %
Effective tax rate 21.4 % 24.9 % 23.1 % 23.6 % (350) bp3 (50) bp3
Benefit expense ratio2 86.8 % 87.2 % 86.3 % 86.8 % (40) bp3 (50) bp3
Operating expense ratio4 12.9 % 11.4 % 11.8 % 11.3 % 150 bp3 50 bp3
Income before income tax expense as a
percentage of total revenues 3.9 % 5.3 % 5.2 % 5.6 % (140) bp3 (40) bp3
Shareholders’ net income as a percentage of
total revenues 3.0 % 4.0 % 4.0 % 4.3 % (100) bp3 (30) bp3
-46-

-- 47 of 188 --

Certain of the following definitions are also applicable to all other results of operations tables in this discussion:
NM Not meaningful.
1 Includes interest expense and amortization of other intangible assets.
2 Benefit expense ratio represents benefit expense as a percentage of premium revenue. Premiums for the three months ended September 30, 2023 and
2022 were $35,259 and $33,722, respectively. Premiums for the nine months ended September 30, 2023 and 2022 were $107,716 and $99,583,
respectively.
3 bp = basis point; one hundred basis points = 1%.
4 Operating expense ratio represents operating expense as a percentage of total operating revenue.
Three Months Ended September 30, 2023 Compared to the Three Months Ended September 30, 2022
Total operating revenue increased primarily as a result of higher premium revenues due to premium rate increases in our
Health Benefits business to more accurately reflect the cost of care. The increase was further attributable to growth in our
CarelonRx pharmacy product revenue driven by growth in external pharmacy members and the acquisition of BioPlus in the
first quarter of 2023.
Net investment income increased primarily due to higher income from fixed maturity securities, partially offset by
reduced income from alternative investments and equity securities.
Net losses on financial instruments increased primarily due to increased losses on the sale of fixed maturity securities
and other invested assets.
Benefit expense increased primarily due to medical cost trends.
Our benefit expense ratio decreased, driven by premium rate increases to more accurately reflect cost of care, partially
offset by the impact of the realignment of certain year-to-date quality improvement costs from benefit expense to operating
expense that occurred in the third quarter of 2022 and did not recur in the third quarter of 2023.
Cost of products sold reflects the cost of pharmaceuticals dispensed by CarelonRx for our unaffiliated customers. Cost of
products sold increased as the corresponding pharmacy product revenues increased.
Operating expense increased primarily due to the business optimization charges recorded in the third quarter of 2023,
including internally developed software impairment and severance costs. There were no business optimization charges
recorded in the third quarter of 2022. These increases were partially offset by the realignment of certain year-to-date quality
improvement costs from benefit expense to operating expense that occurred in the third quarter of 2022 and did not recur in
the third quarter of 2023.
Our operating expense ratio increased primarily due to the business optimization charges recognized in the third quarter
of 2023, partially offset by the favorable impact of operating revenue growth and the impact of the realignment of certain
year-to-date quality improvement costs from benefit expense that occurred in the third quarter of 2022 and did not recur in
the third quarter of 2023.
Other expense increased primarily due to an increase in interest expense, partially offset by a decline in amortization of
other intangible assets.
Our effective income tax rate decreased in 2023 primarily due to the tax impact of expected geographic changes in our
mix of 2023 earnings.
Our shareholders’ net income as a percentage of total revenues declined in 2023 as compared to 2022 as a result of all
factors discussed above.
Nine Months Ended September 30, 2023 Compared to the Nine Months Ended September 30, 2022
Total operating revenue increased primarily as a result of higher premium revenues due to premium rate increases in our
Health Benefits business to more accurately reflect the cost of care and membership growth in our Medicaid business in the
first half of 2023, as well as in our Medicare Advantage business. The increase was further attributable to growth in our
-47-

-- 48 of 188 --

CarelonRx pharmacy product revenue driven by growth in external pharmacy members and the acquisition of BioPlus in the
first quarter of 2023.
Net investment income increased primarily due to higher income from fixed maturity securities, partially offset by
reduced income from alternative investments and equity securities.
Net losses on financial instruments decreased primarily due to increased mark-to-market gains on equity securities still
held at the period end date, partially offset by reduced net gains on other invested assets and increased net losses on fixed
maturity securities.
Benefit expense increased primarily due to medical cost trends as well as healthcare costs associated with membership
growth.
Our benefit expense ratio decreased, primarily driven by premium rate increases in our Health Benefits segment to more
accurately reflect the cost of care.
Cost of products sold reflects the cost of pharmaceuticals dispensed by CarelonRx for our unaffiliated customers. Cost of
products sold increased as the corresponding pharmacy product revenues increased.
Operating expense increased primarily due to the business optimization charges recorded in the third quarter of 2023 and
increased costs to support growth. There were no business optimization charges recorded in 2022.
Our operating expense ratio increased primarily due to the business optimization charges recorded in the third quarter of
2023 and increased costs to support growth, partially offset by the favorable impact of operating revenue growth.
Other expense increased primarily due to an increase in interest expense and additional amortization of other intangible
assets.
Our effective income tax rate decreased in 2023 primarily due to the tax impact of expected geographic changes in our
mix of 2023 earnings.
Our shareholders’ net income as a percentage of total revenues decreased in 2023 as compared to 2022 as a result of all
factors discussed above.
Reportable Segments Results of Operations
Our results of operations discussed throughout this MD&A are determined in accordance with U.S. generally accepted
accounting principles (“GAAP”). We also calculate operating gain and operating margin to further aid investors in
understanding and analyzing our core operating results and comparing them among periods. We define operating revenue as
premium income, product revenue and service fees. Operating gain is calculated as total operating revenue less benefit
expense, cost of products sold and operating expense. It does not include net investment income, net losses on financial
instruments, interest expense, amortization of other intangible assets or income taxes, as these items are managed in our
corporate shared service environment and are not the responsibility of operating segment management. Operating margin is
calculated as operating gain divided by operating revenue. We use these measures as a basis for evaluating segment
performance, allocating resources, forecasting future operating periods and setting incentive compensation targets. This
information is not intended to be considered in isolation or as a substitute for income before income tax expense,
shareholders’ net income or EPS prepared in accordance with GAAP, and may not be comparable to similarly titled measures
reported by other companies. For a reconciliation of reportable segments’ operating revenue to the amounts of total revenue
included in the consolidated statements of income and a reconciliation of income before income tax expense to reportable
segments’ operating gain, see Note 15, “Segment Information,” of the Notes to Consolidated Financial Statements included
in Part I, Item 1 of this Quarterly Report on Form 10-Q.
As discussed in Note 1 “Organization,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of
this Quarterly Report on Form 10-Q, we changed our reportable segment presentation and its composition to reflect how we
began managing our operations and monitoring performance, aligning strategies and allocating resources beginning on
January 1, 2023. We now report our results of operations in the following four reportable segments: Health Benefits
(aggregates our previously reported Commercial & Specialty Business and Government Business segments), CarelonRx,
-48-

-- 49 of 188 --

Carelon Services (previously included in our Other segment) and Corporate & Other (our businesses that do not individually
meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable
segments). In 2022, we managed and presented our operations through the following four reportable segments: Commercial
& Specialty Business, Government Business, CarelonRx and Other. Previously reported information in this Quarterly Report
on Form 10-Q has been reclassified to conform to the new presentation. For additional information, see Note 15, “Segment
Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form
10-Q.
The following table presents a summary of the reportable segment financial information for the three and nine months
ended September 30, 2023 and 2022:
Nine Months Ended
September 30
Change
Three Months Ended
September 30
Three Months Ended
September 30 Nine Months Ended
September 30
2023 vs. 2022 2023 vs. 2022
2023 2022 2023 2022 $ % $ %
Operating Revenue
Health Benefits $ 36,744 $ 35,065 $ 112,024 $ 103,488 $ 1,679 4.8 % $ 8,536 8.2 %
CarelonRx 8,518 7,249 25,008 21,003 1,269 17.5 % 4,005 19.1 %
Carelon Services 3,374 3,154 10,127 9,085 220 7.0 % 1,042 11.5 %
Corporate & Other 242 211 780 799 31 14.7 % (19) (2.4) %
Eliminations (6,398) (6,054) (20,184) (18,382) (344) 5.7 % (1,802) 9.8 %
Total operating revenue $ 42,480 $ 39,625 $ 127,755 $ 115,993 $ 2,855 7.2 % $ 11,762 10.1 %
Operating Gain (Loss) (Restated) (Restated)
Health Benefits $ 1,847 $ 1,634 $ 6,154 $ 5,266 $ 213 13.0 % $ 888 16.9 %
CarelonRx 477 516 1,485 1,393 (39) (7.6) % 92 6.6 %
Carelon Services 173 125 518 438 48 38.4 % 80 18.3 %
Corporate & Other (741) (24) (942) (73) (717) NM (869) NM
Operating Margin
Health Benefits 5.0 % 4.7 % 5.5 % 5.1 % 30 bp 40 bp
CarelonRx 5.6 % 7.1 % 5.9 % 6.6 % (150) bp (70) bp
Carelon Services 5.1 % 4.0 % 5.1 % 4.8 % 110 bp 30 bp
bp = basis point; one hundred basis points = 1%.
Three Months Ended September 30, 2023 Compared to the Three Months Ended September 30, 2022
Health Benefits
Operating revenue and operating gain increased primarily as a result of higher premium revenues due to premium rate
increases to more accurately reflect the cost of care.
CarelonRx
Operating revenue increased primarily as a result of growth in external pharmacy members and the acquisition of
BioPlus in the first quarter of 2023, partially offset by the impact of a favorable out-of-period adjustment in the third quarter
of 2022 that did not recur in the third quarter of 2023.
Operating gain decreased primarily due to the impact of a favorable out-of-period adjustment in the third quarter of 2022
that did not recur in the third quarter of 2023, partially offset by the acquisition of BioPlus in the first quarter of 2023 and
growth in external pharmacy members.
-49-

-- 50 of 188 --

Carelon Services
Operating revenue increased primarily due to the continued expansion of our post-acute care services business performed
for our Medicare business and behavioral health services performed for our Medicaid business.
The increase in operating gain was primarily driven by the continued expansion of our post-acute care services business
and improved performance in our behavioral health business.
Corporate & Other
Operating revenue increased primarily due to higher affiliated revenue in our international operations.
Operating loss increased primarily due to the business optimization charges recorded in the third quarter of 2023.
Nine Months Ended September 30, 2023 Compared to the Nine Months Ended September 30, 2022
Health Benefits
Operating revenue increased primarily due to higher premium revenues due to premium rate increases to more accurately
reflect the cost of care and membership growth in our Medicaid business in the first half of 2023, as well as in our Medicare
Advantage business.
Operating gain increased primarily due to premium rate increases to more accurately reflect the cost of care and
membership growth in our Medicaid business, partially offset by a charge associated with a court ruling impacting health
plans in a certain state related to prior years’ COVID-19 costs.
CarelonRx
Operating revenue increased primarily as a result of growth in external pharmacy members and the acquisition of
BioPlus in the first quarter of 2023.
Operating gain increased primarily due to growth in external pharmacy members and the acquisition of BioPlus in the
first quarter of 2023, partially offset by the impact of a favorable out-of-period adjustment in the third quarter of 2022 that did
not recur in the third quarter of 2023.
Carelon Services
Operating revenue increased primarily due to the continued expansion of our post-acute care services business performed
for our Medicare business and behavioral health services performed for our Medicaid business.
The increase in operating gain was primarily driven by the continued expansion of our post-acute care services and
improved performance in our medical management businesses, partially offset by medical cost trends.
Corporate & Other
Operating revenue decreased primarily due to lower affiliated revenues in our international operations.
Operating loss increased primarily due to an increase in corporate expenses, including primarily for the business
optimization charges recorded in the third quarter of 2023.
Critical Accounting Policies and Estimates
We prepare our consolidated financial statements in conformity with GAAP. Application of GAAP requires management
to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and
accompanying notes and within this MD&A. We consider our most important accounting policies that require significant
estimates and management judgment to be those policies with respect to liabilities for medical claims payable, income taxes,
goodwill and other intangible assets, investments and retirement benefits. Our accounting policies related to these items are
discussed in Exhibit 99.1 to this Quarterly Report on Form 10-Q in Note 2, “Basis of Presentation and Significant Accounting
-50-

-- 51 of 188 --

Policies,” to our audited consolidated financial statements as of and for the year ended December 31, 2022, as well as in the
“Critical Accounting Policies and Estimates” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial
Condition and Results of Operations.” As of September 30, 2023, our critical accounting policies and estimates have not
changed from those described in Exhibit 99.1 to this Quarterly Report on Form 10-Q.
Medical Claims Payable
The most subjective accounting estimate in our consolidated financial statements is our liability for medical claims
payable. Our accounting policies related to medical claims payable are discussed in the references cited above. As of
September 30, 2023, our critical accounting policies and estimates related to medical claims payable have not changed from
those described in Exhibit 99.1 to this Quarterly Report on Form 10-Q. For a reconciliation of the beginning and ending
balance for medical claims payable for the nine months ended September 30, 2023 and 2022, see Note 9, “Medical Claims
Payable,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-
Q.
The following table provides a summary of the two key assumptions having the most significant impact on our incurred
but not paid liability estimates for the nine months ended September 30, 2023 and 2022, which are the trend and completion
factors. These two key assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs,
provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing
patterns, claim submission patterns and operational changes resulting from business combinations.
Favorable Developments by
Changes in Key Assumptions
Nine Months Ended
September 30
2023 2022
Assumed trend factors $ 789 $ 850
Assumed completion factors 553 51
Total $ 1,342 $ 901
The favorable development recognized in the nine months ended September 30, 2023 resulted from trend factors in late
2022 developing more favorably than originally expected and completion factors in the latter parts of 2022 developing faster
than expected. The favorable development recognized in the nine months ended September 30, 2022 resulted primarily from
trend factors in late 2021 developing more favorably than originally expected.
The ratio of current year medical claims paid as a percent of current year net medical claims incurred was 84.6% and
83.7% for the nine months ended September 30, 2023 and 2022, respectively. This ratio serves as an indicator of claims
processing speed whereby speed for claims payments was slightly higher during the nine months ended September 30, 2023
as compared to the nine months ended September 30, 2022.
We calculate the percentage of prior year redundancies in the current period as a percent of prior year net medical claims
payable less prior year redundancies in the current period in order to demonstrate the development of prior year reserves. For
the nine months ended September 30, 2023, this metric was 9.6%, largely driven by favorable trend factor development at the
end of 2022 as well as favorable completion factor development from 2022. For the nine months ended September 30, 2022,
this metric was 7.3%, largely driven by favorable trend factor development at the end of 2021.
We calculate the percentage of prior year redundancies in the current period as a percent of prior year net incurred
medical claims to indicate the percentage of redundancy included in the preceding year calculation of current year net
incurred medical claims. We believe this calculation supports the reasonableness of our prior year estimate of incurred
medical claims and the consistency in our methodology. For the nine months ended September 30, 2023, this metric was
1.2%, which was calculated using the redundancy of $1,342. For the nine months ended September 30, 2022, the comparable
metric was 0.9%, which was calculated using the redundancy of $901. We believe these metrics demonstrate an appropriate
level of reserve conservatism.
-51-

-- 52 of 188 --

New Accounting Pronouncements
We adopted accounting standard amendments on long-duration insurance accounting which became effective for us on
January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and
deferred acquisition costs as of the transition date, January 1, 2021. While the adoption did not have an overall material
impact, our prior period financial statements presented in this Quarterly Report on Form 10-Q have been restated to reflect
the impacts of our adoption as required by the new standard. For more information regarding this new accounting
pronouncement that was adopted and new accounting pronouncements that were issued during the nine months ended
September 30, 2023, see the “Recently Adopted Accounting Guidance” and “Recent Accounting Guidance Not Yet Adopted”
sections of Note 2, “Basis of Presentation and Significant Accounting Policies,” of the Notes to Consolidated Financial
Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Liquidity and Capital Resources
Sources and Uses of Capital
Our cash receipts result primarily from premiums, product revenue, service fees, investment income, proceeds from the
sale or maturity of our investment securities, proceeds from borrowings and proceeds from the issuance of common stock
under our employee stock plans. Cash disbursements result mainly from claims payments, operating expenses, taxes,
purchases of investment securities, interest expense, payments on borrowings, acquisitions, capital expenditures, repurchases
of our debt securities and common stock and the payment of cash dividends. Cash outflows fluctuate with the amount and
timing of settlement of these transactions. Any future decline in our profitability would likely have an unfavorable impact on
our liquidity.
For a more detailed overview of our liquidity and capital resources management, see the “Introduction” section included
in the “Liquidity and Capital Resources” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” included in Exhibit 99.1 to this Quarterly Report on Form 10-Q.
For additional information regarding our sources and uses of capital during the three and nine months ended
September 30, 2023, see Note 6, “Derivative Financial Instruments,” Note 10, “Debt,” and Note 12, “Capital Stock – Use of
Capital – Dividends and Stock Repurchase Program,” of the Notes to Consolidated Financial Statements included in Part I,
Item 1 of this Form 10-Q.
-52-

-- 53 of 188 --

Liquidity
A summary of our major sources and uses of cash and cash equivalents for the nine months ended September 30, 2023
and 2022 is as follows:
Nine Months Ended
September 30
2023 2022 Change
Sources of Cash:
Net cash provided by operating activities $ 11,032 $ 9,917 $ 1,115
Issuances of short- and long-term debt, net of repayments 401 669 (268)
Proceeds from issuance of common stock under employee stock plans 112 152 (40)
Other sources of cash, net — 23 (23)
Total sources of cash 11,545 10,761 784
Uses of Cash:
Purchases of investments, net of proceeds from sales, maturities, calls and
redemptions (1,976) (2,604) 628
Purchases of subsidiaries, net of cash acquired (1,570) (623) (947)
Repurchase and retirement of common stock (1,748) (1,748) —
Purchases of property and equipment (970) (854) (116)
Cash dividends (1,049) (924) (125)
Changes in bank overdrafts (523) — (523)
Other uses of cash, net (175) — (175)
Total uses of cash (8,011) (6,753) (1,258)
Effect of foreign exchange rates on cash and cash equivalents (2) (16) 14
Net increase in cash and cash equivalents $ 3,532 $ 3,992 $ (460)
The increase in net cash provided by operating activities was primarily due to higher net income in 2023, when
excluding the non-cash impact of business optimization charges recognized in the third quarter of 2023, as well as the non-
recurrence of the Subscriber Settlement Agreement payment made in September 2022.
Other significant changes in sources or uses of cash year-over-year included higher amounts for purchases of
subsidiaries, net of cash acquired, a decrease in the issuance of short- and long term debt, net of repayments, a decline in bank
overdrafts outstanding, an increase in the purchase of property and equipment and an increase in cash dividends. These
additional uses of cash were partially offset by reduced purchases of investments, net of proceeds from sales, maturities, calls
and redemptions.
We maintained a strong financial condition and liquidity position, with consolidated cash, cash equivalents and investments
in fixed maturity and equity securities of $39,711 at September 30, 2023. Since December 31, 2022, total cash, cash
equivalents and investments in fixed maturity and equity securities increased by $4,667, primarily due to cash generated from
operations, partially offset by cash used for the purchase of subsidiaries, cash used for the repurchase and retirement of
common stock, the purchase of property and equipment and dividends paid to shareholders.
Many of our subsidiaries are subject to various government regulations that restrict the timing and amount of dividends
and other distributions that may be paid to their respective parent companies. Certain accounting practices prescribed by
insurance regulatory authorities, or statutory accounting practices, differ from GAAP. Changes that occur in statutory
accounting practices, if any, could impact our subsidiaries’ future dividend capacity. In addition, we have agreed to certain
undertakings to regulatory authorities, including the requirement to maintain certain capital levels in certain of our
subsidiaries.
At September 30, 2023, we held $1,659 of cash, cash equivalents and investments at the parent company, which are
available for general corporate use, including investment in our businesses, acquisitions, potential future common stock
repurchases and dividends to shareholders, repurchases of debt securities and debt and interest payments.
-53-

-- 54 of 188 --

Periodically, we access capital markets and issue debt (“Notes”) for long-term borrowing purposes, for example, to
refinance debt, to finance acquisitions or for share repurchases. Certain of these Notes may have a call feature that allows us
to redeem the Notes at any time at our option and/or a put feature that allows a Note holder to redeem the Notes upon the
occurrence of both a change in control event and a downgrade of the Notes below an investment grade rating. For more
information on our debt, including redemptions and issuances, see Note 10, “Debt,” of the Notes to Consolidated Financial
Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
We calculate our consolidated debt-to-capital ratio, a non-GAAP measure, from the amounts presented on our
consolidated balance sheets included in Part I, Item 1 of this Quarterly Report on Form 10-Q. Our debt-to-capital ratio is
calculated as total debt divided by total debt plus total equity. Total debt is the sum of short-term borrowings, current portion
of long-term debt and long-term debt, less current portion. We believe our debt-to-capital ratio assists investors and rating
agencies in measuring our overall leverage and additional borrowing capacity. In addition, our bank covenants include a
maximum debt-to-capital ratio that we cannot and did not exceed. Our debt-to-capital ratio may not be comparable to
similarly titled measures reported by other companies. Our consolidated debt-to-capital ratio was 39.2% and 39.9% as of
September 30, 2023 and December 31, 2022, respectively.
Our senior debt is rated “A” by S&P Global Ratings, “BBB” by Fitch Ratings, Inc., “Baa2” by Moody’s Investor
Service, Inc. and “bbb+” by AM Best Company, Inc. We intend to maintain our senior debt investment grade ratings. If our
credit ratings are downgraded, our business, liquidity, financial condition and results of operations could be adversely
impacted by limitations on future borrowings and a potential increase in our borrowing costs.
Capital Resources
We have a shelf registration statement on file with the U.S. Securities and Exchange Commission to register an unlimited
amount of any combination of debt or equity securities in one or more offerings. Specific information regarding terms and
securities being offered will be provided at the time of an offering. Proceeds from future offerings are expected to be used for
general corporate purposes, including, but not limited to, the repayment of debt, investments in or extensions of credit to our
subsidiaries, the financing of possible acquisitions or business expansions.
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes.
The 5-Year Facility provides for a credit of up to $4,000 and matures in April 2027. Our ability to borrow under the 5-Year
Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-
capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year
Facility. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or
operating flexibility. We had no amounts outstanding under the 5-Year Facility as of September 30, 2023 or December 31,
2022. As of September 30, 2023, we were in compliance with all of the debt covenants under the 5-Year Facility.
We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general
corporate purposes. Should commercial paper issuance become unavailable, we have the ability to use a combination of cash
on hand and/or our 5-Year Facility to redeem any outstanding commercial paper upon maturity. At September 30, 2023 and
December 31, 2022, we had no commercial paper outstanding under our commercial paper program. Beginning June 30,
2023, we have reclassified our commercial paper balances, if any, from long-term debt to short-term debt as our intent is to
not replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an
uninterrupted period extending for more than one year.
While there is no assurance in the current economic environment, we believe the lenders participating in our 5-Year
Facility, if market conditions allow, would be willing to provide financing in accordance with their legal obligations.
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan
Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively the
“FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral
requirements. We had $0 and $265 of outstanding short-term borrowings from the FHLBs at September 30, 2023 and
December 31, 2022, respectively.
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases
and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is
-54-

-- 55 of 188 --

at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity
needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
For additional information regarding our sources and uses of capital at September 30, 2023, see Note 5, “Investments,”
Note 6, “Derivative Financial Instruments,” Note 10, “Debt,” and Note 12, “Capital Stock – Use of Capital – Dividends and
Stock Repurchase Program,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly
Report on Form 10-Q.
In addition to regulations regarding the timing and amount of dividends, our regulated subsidiaries’ states of domicile
have statutory risk-based capital (“RBC”) requirements for health and other insurance companies and health maintenance
organizations largely based on the National Association of Insurance Commissioners (“NAIC”) Risk-Based Capital (RBC)
for Health Organizations Model Act (the “RBC Model Act”). These RBC requirements are intended to measure capital
adequacy, taking into account the risk characteristics of an insurer’s investments and products. The NAIC sets forth the
formula for calculating the RBC requirements, which are designed to take into account asset risks, insurance risks, interest
rate risks and other relevant risks with respect to an individual insurance company’s business. In general, under the RBC
Model Act, an insurance company must submit a report of its RBC level to the state insurance department or insurance
commissioner, as appropriate, at the end of each calendar year. Our regulated subsidiaries’ respective RBC levels as of
December 31, 2022, which was the most recent date for which reporting was required, were in excess of all applicable
mandatory RBC requirements. In addition to exceeding these RBC requirements, we are in compliance with the liquidity and
capital requirements for a licensee of the BCBSA and with the tangible net worth requirements applicable to certain of our
California subsidiaries. For additional information, see Note 22, “Statutory Information,” in our audited consolidated
financial statements as of and for the year ended December 31, 2022 included in Part II, Item 8 of Exhibit 99.1 to this
Quarterly Report on Form 10-Q.
Future Sources and Uses of Liquidity
We believe that cash on hand, future operating cash receipts, investments and funds available under our commercial
paper program, our 5-Year Facility and borrowings available from the FHLBs will be adequate to fund our expected cash
disbursements over the next twelve months.
There have been no material changes to our long-term liquidity requirements as disclosed in Part II, Item 7 of Exhibit
99.1 to this Quarterly Report on Form 10-Q. For additional updates regarding our estimated long-term liquidity requirements,
see Note 6, “Derivative Financial Instruments,” Note 10, “Debt,” and the “Other Contingencies” and “Contractual
Obligations and Commitments” sections of Note 11 “Commitments and Contingencies,” of the Notes to Consolidated
Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. We believe that funds from future
operating cash flows, cash and investments and funds available under our 5-Year Facility and/or from public or private
financing sources will be sufficient for future operations and commitments, and for capital acquisitions and other strategic
transactions.
-55-

-- 56 of 188 --

FORWARD-LOOKING STATEMENTS
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are
generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,”
“estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements.
These statements include, but are not limited to: financial projections and estimates and their underlying assumptions;
statements regarding plans, objectives and expectations with respect to future operations, products and services; and
statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are
difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed
in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these
forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the
various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from
time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by
law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date
hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced
enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies,
such as public health epidemics and pandemics, including COVID-19, and other catastrophes; the impact of new or changes
in existing federal, state and international laws or regulations, including healthcare laws and regulations, or their
enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or breaches or our failure
to comply with any privacy or security laws or regulations, including any investigations, claims or litigation related thereto;
information technology disruptions; changes in economic and market conditions, as well as regulations that may negatively
affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and
develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs,
including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve
improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with
respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other
liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on
cost-effective and competitive terms; failure to effectively maintain and modernize our information systems; risks associated
with providing pharmacy, healthcare and other diversified products and services, including medical malpractice or
professional liability claims and non-compliance by any party with the pharmacy services agreement between us and
CaremarkPCS Health, L.L.C.; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible
impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible
assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of
capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy
of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of
outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further
increase the cost of financing; a downgrade in our financial strength ratings; the effects of any negative publicity related to
the health benefits industry in general or us in particular; events that may negatively affect our licenses with the Blue Cross
and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international
operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and
business combinations.
-56-

-- 57 of 188 --

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
For a discussion of our market risks, refer to Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,”
included in our 2022 Annual Report on Form 10-K. There have been no material changes to any of these risks since
December 31, 2022.
ITEM 4. CONTROLS AND PROCEDURES
We carried out an evaluation as of September 30, 2023, under the supervision and with the participation of our
management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and
operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer
concluded that our disclosure controls and procedures are effective in timely alerting them to material information relating to
us (including our consolidated subsidiaries) required to be disclosed in our reports under the Exchange Act. In addition, based
on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and
procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit
under the Exchange Act is accumulated and communicated to our management, including the Chief Executive Officer and
Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.
There have been no changes in our internal control over financial reporting that occurred during the three months ended
September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over
financial reporting.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
For information regarding legal proceedings at September 30, 2023, see the “Litigation and Regulatory Proceedings,”
and “Other Contingencies” sections of Note 11, “Commitments and Contingencies” of the Notes to Consolidated Financial
Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, which information is incorporated herein by
reference.
ITEM 1A. RISK FACTORS
There have been no material changes to the risk factors disclosed in our 2022 Annual Report on Form 10-K.
-57-

-- 58 of 188 --

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER
PURCHASES OF EQUITY SECURITIES
Issuer Purchases of Equity Securities
The following table presents information related to our repurchases of common stock for the periods indicated:
Period
Total Number
of Shares
Purchased1
Average
Price Paid
per Share
Total Number
of Shares
Purchased
as Part
of Publicly
Announced
Programs2
Approximate
Dollar Value
of Shares
that May Yet
Be Purchased
Under the
Programs
(in millions, except share and per share data)
July 1, 2023 to July 31, 2023 502,279 $ 442.38 500,755 $ 5,386
August 1, 2023 to August 31, 2023 386,749 $ 464.83 385,456 5,207
September 1, 2023 to September 30, 2023 176,840 449.35 176,309 5,128
1,065,868 1,062,520
1 Total number of shares purchased includes 3,348 shares delivered to or withheld by us in connection with employee
payroll tax withholding upon the exercise or vesting of stock awards. Stock grants to employees and directors and stock
issued for stock option plans and stock purchase plans in the consolidated changes in equity are shown net of these
shares purchased.
2 Represents the number of shares repurchased through the common stock repurchase program authorized by our Board of
Directors, which the Board of Directors evaluates periodically. During the three months ended September 30, 2023, we
repurchased 1,062,520 shares at a total cost of $480 under the program, including the cost of options to purchase shares.
The Board of Directors has authorized our common stock repurchase program since 2003. The most recent authorized
increase to the program was $5,000 on January 24, 2023 by our Audit Committee, pursuant to authorization granted by
the Board of Directors. No duration has been placed on our common stock repurchase program, and we reserve the right
to discontinue the program at any time.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
None.
ITEM 5. OTHER INFORMATION
Recast 2022 Annual Financial Information
We are filing Exhibit 99.1 to this Quarterly Report on Form 10-Q to recast certain prior years’ financial information and
related disclosures to reflect changes to our reportable segments beginning in the first quarter of 2023, as well as the impact
of the adoption of a new accounting standard related to the accounting for long-duration insurance contracts, which we
adopted on January 1, 2023, using a modified retrospective transition method as of January 1, 2021. The recast financial
information and related disclosures set forth in Exhibit 99.1 to this Quarterly Report on Form 10-Q present such financial
information and related disclosures as they would have appeared had we changed our reportable segments and adopted the
new accounting standard prior to January 1, 2023 and do not reflect events or developments that may have occurred
subsequent to the filing of our 2022 Annual Report on Form 10-K.
The information contained in Exhibit 99.1 to this report is incorporated herein by reference.
-58-

-- 59 of 188 --

Rule 10b5-1 Trading Plans
During the three months ended September 30, 2023, none of our directors or officers (as defined in Rule-1(f) of the
Securities Exchange Act of 1934, as amended) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or
“non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408 of Regulation S-K.
ITEM 6. EXHIBITS
Exhibit
Number Exhibit
3.1 Amended and Restated Articles of Incorporation of the Company, as amended and restated effective June 27,
2022, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 28,
2022.
3.2 Bylaws of the Company, as amended effective October 4, 2023, incorporated by reference to Exhibit 3.1 to the
Company’s Current Report on Form 8-K filed on October 5, 2023.
4.7 Upon the request of the U.S. Securities and Exchange Commission, the Company will furnish copies of any
other instruments defining the rights of holders of long-term debt of the Company or its subsidiaries.
10.9 (d) * Form of Employment Agreement between the Company and Mark Kaye.
10.11 * Offer Letter, by and between the Company and Mark Kaye, dated as of August 2, 2023, incorporated by
reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on August 8, 2023.
23 Consent of Independent Registered Public Accounting Firm.
31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act
Rules, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act
Rules, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002.
32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002.
99.1 Recast of certain financial information and related disclosures initially included in Part I, Item 1 “Business,”,
Part II Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” Part
II Item 8. “Financial Statements and Supplementary Data” and Part IV Item 15 (c) “Financial Statement
Schedule” of our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed on
February 15, 2023.
101 The following material from this Quarterly Report on Form 10-Q for the quarter ended September 30, 2023,
formatted in Inline XBRL (Inline Extensible Business Reporting Language): (i) the Consolidated Balance
Sheets; (ii) the Consolidated Statements of Income; (iii) the Consolidated Statements of Comprehensive Income;
(iv) the Consolidated Statements of Cash Flows; (v) the Consolidated Statements of Changes in Equity; (vi)
Notes to Consolidated Financial Statements; and (vii) the information under Part II, Item 5, “Other Information.”
The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within
the Inline XBRL document.
104 Cover Page Interactive Data File formatted in Inline XBRL and contained in Exhibit 101.
* Indicates management contracts or compensatory plans or arrangements.
-59-

-- 60 of 188 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned thereunto duly authorized.
ELEVANCE HEALTH, INC.
Registrant
October 18, 2023 By: /S/ JOHN E. GALLINA
John E. Gallina
Executive Vice President and Chief Financial Officer
(Duly Authorized Officer and Principal Financial Officer)
October 18, 2023 By: /S/ RONALD W. PENCZEK
Ronald W. Penczek
Chief Accounting Officer and Controller
(Principal Accounting Officer)
-60-

-- 61 of 188 --

CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Gail K. Boudreaux, certify that:
1. I have reviewed this report on Form 10-Q of Elevance Health, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly
present in all material respects the financial condition, results of operations and cash flows of the registrant as of,
and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in
this report our conclusions about the effectiveness of the disclosure controls and procedures, as of
the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that
occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the
case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal
control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of
directors (or persons performing the equivalent function):
a) all significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant’s ability to
record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a
significant role in the registrant’s internal control over financial reporting.
October 18, 2023 /s/ GAIL K. BOUDREAUX
President and Chief Executive Officer
Exhibit 31.1

-- 62 of 188 --

CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, John E. Gallina, certify that:
1. I have reviewed this report on Form 10-Q of Elevance Health, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly
present in all material respects the financial condition, results of operations and cash flows of the registrant as of,
and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in
this report our conclusions about the effectiveness of the disclosure controls and procedures, as of
the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that
occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the
case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal
control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of
directors (or persons performing the equivalent function):
a) all significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant’s ability to
record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a
significant role in the registrant’s internal control over financial reporting.
October 18, 2023 /s/ JOHN E. GALLINA
Executive Vice President and
Chief Financial Officer
Exhibit 31.2

-- 63 of 188 --

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Elevance Health, Inc. (the “Company”) on Form 10-Q for the period ended
September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gail K.
Boudreaux, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant
to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of
1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.
/s/ GAIL K. BOUDREAUX
Gail K. Boudreaux
President and Chief Executive Officer
October 18, 2023
Exhibit 32.1

-- 64 of 188 --

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Elevance Health, Inc. (the “Company”) on Form 10-Q for the period ended
September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John E. Gallina,
Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted
pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of
1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.
/s/ JOHN E. GALLINA
John E. Gallina
Executive Vice President and Chief Financial Officer
October 18, 2023
Exhibit 32.2

-- 65 of 188 --

EXHIBIT 99.1
EXPLANATORY NOTE
Elevance Health, Inc. (“we,” “our,” “us,” “Elevance Health” or the “Company”) is filing this Exhibit 99.1 to this
Quarterly Report on Form 10-Q to recast certain financial information and related disclosures included in Part I, Item 1
“Business,” Part II Item 7 “Management's Discussion and Analysis of Financial Condition and Results of Operations,” Part
II Item 8 “Financial Statements and Supplementary Data” and Part IV Item 15 (c) “Financial Statement Schedule” of our
Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange
Commission (“SEC”) on February 15, 2023 (our “2022 Form 10-K”), solely to reflect:
• The changes to our reportable segments beginning in the first quarter of 2023, as described in the “General”
section of Part I Item 1 “Business”, the “Overview” section of Part II Item 7 “Management's Discussion and
Analysis of Financial Condition and Results of Operations” and Note 1 “Organization” and Note 20 “Segment
Information” included in Part II Item 8 “Financial Statements and Supplementary Data” of this Exhibit 99.1.
• The impact of the adoption of a new accounting standard related to the accounting for long-duration insurance
contracts, which we adopted on January 1, 2023, using a modified retrospective transition method as of January 1,
2021, as described in Note 2 “Basis of Presentation and Significant Accounting Policies” included in Part II Item 8
“Financial Statements and Supplementary Data” of this Exhibit 99.1.
These items did not have a material effect on the trends impacting our results of operations for 2021 compared to 2020.
Accordingly, for the discussion of our results of operations for 2021 compared to 2020, see Part II Item 7 “Management's
Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for
the fiscal year ended December 31, 2021, which was filed with the SEC on February 16, 2022.
The recast financial information and related disclosures set forth in this Exhibit 99.1 are provided solely to present such
financial information and related disclosures in these items as they would have appeared had we changed our reportable
segments and adopted the new accounting standard prior to January 1, 2023. This Exhibit 99.1 does not reflect events or
developments that may have occurred subsequent to the filing of our 2022 Form 10-K with the SEC and does not otherwise
amend, update or modify any of the other disclosures made in our 2022 Form 10-K. Accordingly, the information in this
Exhibit 99.1 should be read in conjunction with our 2022 Form 10-K and our subsequent filings with the SEC.
FORWARD-LOOKING STATEMENTS
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally
not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,”
“project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements
include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding
plans, objectives and expectations with respect to future operations, products and services; and statements regarding future
performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and
generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or
projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking
statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and
other disclosures discussed in our reports filed with the SEC from time to time, which attempt to advise interested parties of
the factors that affect our business. Except to the extent required by law, we do not undertake to update or revise any forward-
looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include,
but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement
sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics,
including COVID-19, and other catastrophes; the impact of new or changes in existing federal, state and international laws or
regulations, including healthcare laws and regulations, or their enforcement or application; the impact of cyber-attacks or
other privacy or data security incidents or breaches or our failure to comply with any privacy or security laws or regulations,
including any investigations, claims or litigation related thereto; information technology disruptions; changes in economic
and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive
pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks
1

-- 66 of 188 --

and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex
regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid
Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a
negative change in our healthcare product mix; costs and other liabilities associated with litigation, government
investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; failure to
effectively maintain and modernize our information systems; risks associated with providing pharmacy, healthcare and other
diversified products and services, including medical malpractice or professional liability claims and non-compliance by any
party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; risks associated with mergers,
acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results
do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our
subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and
pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential
negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market
volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings;
the effects of any negative publicity related to the health benefits industry in general or us in particular; events that may
negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain
employees; risks associated with our international operations; and various laws and provisions in our governing documents
that may prevent or discourage takeovers and business combinations.
2

-- 67 of 188 --

PART I
ITEM 1. BUSINESS.
General
At Elevance Health, our purpose – to improve the health of humanity – is central to who we are. It inspires all we do and
is the driving force behind our unique approach to health. We know to meaningfully improve health we must take a broader
view. That is why our foundational approach looks at whole health and its most critical drivers: social, behavioral and
physical. We believe in working together to achieve our mission of improving lives and communities, simplifying healthcare
and expecting more. We strive to deliver on our mission by maximizing the power of partnerships, innovating to fuel growth
and health equity, and having a high-performance culture. Our strategy is to become a lifetime, trusted health partner through
the following four core focus areas:
• Whole Health – Partner to address physical, behavioral, social, and pharmacy needs to improve health, affordability,
quality, equity, and access for individuals and communities.
• Exceptional Experiences – Put the people we serve at the center of all that we do, to exceed expectations and
optimize health outcomes.
• Care Provider Enablement – Be the easiest payer to work with by supporting care provider partners with data,
insights, and tools they need to deliver exceptional care for our consumers.
• Digital Platform – Use digital technologies to improve efficiency and experiences, convert data into insights, and
create a platform that connects stakeholders from across the health ecosystem.
With an unyielding commitment to meeting the needs of our diverse customers, we are guided by the following values:
• Leadership – Redefine what is possible
• Community – Committed, connected, invested
• Integrity – Do the right thing, with a spirit of excellence
• Agility – Deliver today, transform tomorrow
• Diversity – Open our hearts and minds
We are one of the largest health insurers in the United States in terms of medical membership, serving approximately
47.5 million medical members through our affiliated health plans as of December 31, 2022. We offer a broad spectrum of
network-based managed care risk-based plans to Individual, Employer Group, Medicaid and Medicare markets. In addition,
we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance,
provider network access, medical management, care management and wellness programs, actuarial services and other
administrative services. We provide services to the federal government in connection with our Federal Health Products &
Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of
specialty services both to customers of our subsidiary health plans and also unaffiliated health plans, including pharmacy
services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services.
We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of
independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and
Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30
counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate
New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of
these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue
Shield or Empire Blue Cross. In addition, we conduct business through arrangements with other BCBS licensees as well as
other strategic partners. Through our subsidiaries, we also serve customers in numerous states as Amerigroup, Freedom
Health, HealthLink, HealthSun, MMM, Optimum Healthcare, Simply Healthcare, UniCare and/or Wellpoint. We offer
pharmacy services as CarelonRx and other health-care related services as Carelon Services, Aspire Health, Carelon
Behavioral Health and Caremore. We are licensed to conduct insurance operations in all 50 states, the District of Columbia
and Puerto Rico through our subsidiaries.
3

-- 68 of 188 --

As part of our name change to Elevance Health, in June 2022, we announced that over the next several years we will
organize our brand portfolio into the following core go-to-market brands:
• Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated
Blue Cross and/or Blue Shield licensed plans;
• Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the
Wellpoint name; and
• Carelon — this brand brings together our healthcare-related services and capabilities, including our formerly named
Diversified Business Group and IngenioRx businesses, under a single brand name.
Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime,
trusted health partner. Given this evolution, we reviewed and modified how we manage our business, monitor our
performance and allocate resources. As a result, we changed our reportable segments to the following beginning in the first
quarter of 2023: Health Benefits (aggregates our previously reported Commercial & Specialty Business and Government
Business segments), CarelonRx, Carelon Services (previously included in our Other segment) and Corporate & Other (our
businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses
not allocated to our other reportable segments).
For additional discussion, see “Reportable Segments” below in this “Business” section and Note 1 “Organization” and
Note 20, “Segment Information,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Exhibit
99.1.
We believe healthcare is local and that we have the strong local presence required to understand and meet local customer
needs with regard to any product they are enrolled in with us. Further, we believe we are well-positioned to deliver what
customers want: innovative, choice-based and affordable products; distinctive service; simplified transactions; and better
access to information for quality care. Our local presence, combined with our national expertise, has created opportunities for
collaborative programs that reward physicians and hospitals for clinical quality and excellence. We feel that our commitment
to health improvement and care management provides added value to customers and healthcare professionals. Ultimately, we
believe that practical and sustainable improvements in healthcare must focus on improving healthcare quality while managing
costs for total affordability. We have implemented initiatives driving payment innovation and partnered with providers to
lower cost and improve the quality of healthcare for our members, and we continue to develop new and innovative ways to
effectively manage risk and engage our members. Further, we continue to expand our financial arrangements with providers
to implement payment models that advance value-based care. We believe focusing on quality of care rather than volume of
care is the foundation for improving patient outcomes. Our value-based payment model supports patient-centered care by
improving collaboration between providers and health partners and delivering to our patients the right care, at the right time,
in the right place. In addition, we are focused on achieving efficiencies from our national scale while optimizing service
performance for our customers. Finally, we expect to continue to rationalize our portfolio of businesses and products and
align our investments to optimize our core businesses, invest in high-growth opportunities, and accelerate capabilities and
services.
Impact on Our Results of Operations
Our results of operations depend in large part on our ability to accurately predict and effectively manage healthcare costs
through effective contracting with providers of care to our members, product pricing, medical management and health and
wellness programs, including service coordination and case management for addressing complex and specialized healthcare
needs, innovative product design and our ability to maintain or achieve improvement in our Centers for Medicare and
Medicaid Services (“CMS”) Star ratings. CMS Star ratings affect Medicare Advantage plan reimbursements as well as our
eligibility to earn quality-based bonus payments for those plans. See “Regulation” below in this “Business” section for
additional information on our CMS Star ratings. For additional information on our networks and provider relations, product
pricing and healthcare cost management programs, see “Pricing and Underwriting of Our Products,” “Networks and Provider
Relations,” “Medical Management Programs,” “Care Management and Wellness Products and Programs” and “Healthcare
Quality Initiatives” below in this “Business” section.
Advances in medical technology, including new specialty drugs, the aging population, other demographic characteristics
and the COVID-19 pandemic continue to contribute to rising healthcare costs. Our managed care plans and products are
4

-- 69 of 188 --

designed to encourage providers and members to participate in quality, cost-effective health benefit programs by using the
full range of our innovative medical management services, health-outcomes based initiatives and health quality-based
financial incentives. We believe our market position and high business retention rates will enable us to realize the long-term
benefits of investing in preventive and early detection programs. Our ability to provide cost-effective health benefits products
and services is enhanced through a disciplined approach to internal cost containment, prudent management of our risk
exposure and successful integration of acquired businesses. In addition, our ability to manage general and administrative
costs continues to be a driver of our overall profitability.
Our future results of operations will also be impacted by certain external forces and resulting changes in our business
model and strategy. Changes to our business environment will continue as elected officials at the national and state levels
enact, and both elected officials and candidates for election propose, modifications to existing laws and regulations, including
changes to taxes and fees. For additional discussion, see “Regulation” below in this “Business” section and Part I, Item 1A
“Risk Factors” included in our 2022 Form 10-K.
Our results of operations are also impacted by levels and mix of membership, which can change as a result of the quality
and pricing of our health benefits products and services, an aging population, economic conditions, changes in
unemployment, the continued and future impact of the COVID-19 pandemic, acquisitions, entry into new markets and
expansions in or exits from existing markets. These membership trends could be negatively impacted by various factors that
could have a material adverse effect on our future results of operations such as general economic downturns that result in
business failures, failure to obtain new customers or retain existing customers, premium increases, benefit changes,
membership impacts caused by COVID-19, including how our members access healthcare services, or our exit from a
specific market. See Part I, Item 1A “Risk Factors” included in our 2022 Form 10-K and Part II, Item 7 “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” included in this Exhibit 99.1.
We continue to enhance interactions with customers, providers, brokers, agents, employees and other stakeholders
through digital technology and improvements to internal operations. Our approach includes not only the sales and distribution
of health benefits products through digital technology, but also implementing advanced capabilities that improve services
benefiting customers, agents, brokers and providers while optimizing administrative costs. These enhancements can also help
improve the quality, coordination and safety of healthcare through increased communications between patients and their
physicians.
Through our participation in various federal government programs, we generated approximately 28% of our total
consolidated revenues from agencies of the U.S. government for each of the years ended December 31, 2022, 2021 and 2020.
The majority of these revenues are contained in our Health Benefits segment as described below. An immaterial amount of
our total consolidated revenues is derived from activities outside of the U.S. and Puerto Rico.
Reportable Segments
Our Health Benefits segment offers a comprehensive suite of health plans and services to our Individual, Employer
Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid and FEHB program members. Our Health
Benefits segment also includes our National Government Services business. The Health Benefits segment offers health
products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and
provides a variety of specialty and other insurance products and services such as stop loss, dental, vision, life, disability and
supplemental health insurance benefits.
Our CarelonRx segment includes our pharmacy business. CarelonRx markets and offers pharmacy services to our
affiliated health plan customers, as well as to external customers outside of the health plans we own. CarelonRx offers a
comprehensive pharmacy services portfolio, which includes services such as formulary management, pharmacy networks,
specialty and home delivery pharmacy services and member services.
Our Carelon Services segment is focused on lowering the cost and improving the quality of healthcare by enabling and
creating new care delivery and payment models, with a special emphasis on serving those with complex and chronic
conditions. Carelon Services offers a broad array of healthcare-related services and capabilities to internal and external
customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity
services and subrogation services, as well as health and wellness programs.
5

-- 70 of 188 --

Our Corporate & Other segment includes our businesses that do not individually meet the quantitative threshold for an
operating segment, as well as corporate expenses not allocated to our other reportable segments.
For additional information, see Note 20, “Segment Information,” of the Notes to Consolidated Financial Statements
included in Part II, Item 8 of this Exhibit 99.1.
Membership
Our medical membership includes seven different customer types: Individual, Employer Group risk-based, Employer
Group fee-based, BlueCard®, Medicare, Medicaid and FEHB. In addition, we also serve customers who purchase one or more
of our other products or services that are often ancillary to our health business.
Our products are generally developed and marketed with an emphasis on the differing needs of our customers. In
particular, our product development and marketing efforts take into account the differing characteristics between the various
customers served by us, as well as the unique needs of educational and public entities, labor groups, the FEHB program,
national employers and state-run programs servicing low-income, high-risk and underserved markets. Overall, we seek to
establish pricing and product designs to provide value for our customers while achieving an appropriate level of profitability
for each of our customer categories balanced with the competitive objective to grow market share. We believe that one of the
keys to our success has been our focus on these distinct customer types, which better enables us to develop benefit plans and
services that meet our customers’ unique needs. Further, CarelonRx was built to simplify pharmacy care and focus on the
whole person, and we expect it will make it easier for our customers to achieve better health outcomes at a lower total cost of
care.
We market our Individual, Medicare and certain Employer Group products with a smaller employee base through direct
marketing activities and an extensive network of independent agents, brokers and retail partnerships. Products for commercial
customers with a larger employee base are generally sold through independent brokers or consultants retained by the
customer who work with industry specialists from our in-house sales force. In the Individual markets, we offer on-exchange
products through state- or federally-facilitated marketplaces (the “Public Exchange”) in compliance with the Patient
Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended (collectively,
the “ACA”) and off-exchange products. Federal subsidies are available for certain members, subject to income and family
size, who purchase Public Exchange products.
In 2022, we made the decision to expand our participation in the Public Exchange market for 2023 after also expanding
in 2022. As a result, for 2023 we are offering Individual Public Exchange products in 138 of the 143 rating regions in which
we operate, in comparison to 122 of 143 rating regions in 2022. Our strategy has been, and will continue to be, to only
participate in rating regions where we have an appropriate level of confidence that these markets are on a path toward
sustainability, including, but not limited to, factors such as expected financial performance, regulatory environment and
underlying market characteristics.
Being a licensee of the BCBS association of companies, of which there were 34 independent primary licensees including
us as of December 31, 2022, provides significant market value, especially when competing for very large multi-state
employer groups. For example, each BCBS member company is able to utilize other BCBS licensees’ substantial provider
networks and discounts when any BCBS member works or travels outside of the state in which their policy is written. This
program is referred to as BlueCard®. BlueCard® host members are generally members who reside in or travel to a state in
which an Elevance Health subsidiary is the Blue Cross and/or Blue Shield licensee and who are covered under an employer-
sponsored health plan serviced by a non-Elevance Health controlled BCBS licensee, which is the “home” plan. We perform
certain administrative functions for BlueCard® host members, including claims pricing and administration, for which we
receive service fees from the BlueCard® members’ home plan. Other administrative functions, including maintenance of
enrollment information and customer services, are performed by the home plan. See “BCBSA Licenses” below in this
“Business” section for additional information on our BCBSA licenses. We refer to members in our service areas licensed by
the BCBSA as our BCBS-branded, or Anthem BCBS, business. Non-BCBS-branded business refers to members in our non-
BCBS-branded, or Wellpoint plans, which include Amerigroup, Freedom Health, HealthSun, MMM, Optimum Healthcare
and Simply Healthcare plans, as well as HealthLink and UniCare members.
6

-- 71 of 188 --

For additional information describing each of our customer types and changes in medical membership over the last three
years, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Membership”
included in Part II, Item 7 of this Exhibit 99.1.
Product and Service Descriptions
Various forms of managed care products have been developed to contain the cost of healthcare by negotiating contracts
with hospitals, physicians and other providers to deliver high-quality healthcare to members at favorable rates. These
products usually feature medical management and other quality and cost optimization measures such as pre-admission review
and approval for certain non-emergency services, pre-authorization of outpatient surgical procedures, network credentialing
to determine that network physicians and hospitals have the required certifications and expertise, and various levels of care
management programs to help members better understand and navigate the healthcare system. In addition, providers may
have incentives to achieve certain quality measures, may share medical cost risk or may have other incentives to deliver
quality medical services in a cost-effective manner. Also, certain plans offer members incentives for healthy behaviors, such
as smoking cessation and weight management. Members are charged periodic, prepaid premiums and generally pay
copayments, coinsurance and/or deductibles when they receive services.
Health Benefits
• Commercial Risk-Based Products. We offer employer groups a diversified mix of managed care risk-based products
including: Preferred Provider Organization (“PPO”), Health Maintenance Organization (“HMO”), Consumer-Driven
Health Plans (“CDHP”), Traditional Indemnity and Point-of-Service (“POS”) plans. PPO plans generally provide
members the freedom to choose any healthcare provider, but require the member to pay a greater portion of the
provider’s fee in the event the member chooses not to use a provider participating in the PPO’s network. HMOs include
comprehensive managed care benefits generally through a participating network of physicians, hospitals and other
providers. CDHPs generally combine a high-deductible PPO plan with an employer-funded and/or employee-funded
personal care account, which may result in tax benefits to the employee and allow some or all of the dollars remaining in
the personal care account at year-end to be rolled over to the next year for future healthcare needs. Traditional indemnity
plans offer the member an option to select any healthcare provider for covered services, with coverage subject to
deductibles and coinsurance and with member cost-sharing usually limited by out-of-pocket maximums. POS products
blend the characteristics of HMO, PPO and indemnity plans. In general, POS plans allow members to choose to seek
care from a provider within the plan’s network or outside the network, subject to, among other things, certain deductibles
and coinsurance.
We also offer Individual risk-based products on and off the Public Exchange, covering essential health benefits (as
defined in the ACA) along with many other requirements and cost-sharing features.
• Commercial Fee-Based Products. We provide a broad array of managed care services to fee-based groups, including
claims processing, provider network access, medical management, care management and wellness programs, actuarial
services and other administrative services. Fee-based health plans are also able to use our provider networks and to
realize savings through our negotiated provider arrangements, while allowing employers the ability to design certain
health benefit plans in accordance with their own requirements and objectives. We also charge a premium to underwrite
stop loss insurance for employers that maintain fee-based plans but want to limit their retained risk.
In addition, we perform certain administrative functions for BlueCard® host members, discussed under “Membership”
above, including claims pricing and administration, for which we receive service fees from the BlueCard® members’
home plans. Other administrative functions, including maintenance of enrollment information and customer service, are
performed by the home plan.
• Specialty Products. We offer an array of products and services to both risk-based and fee-based customers in
conjunction with our health plans as well as to unaffiliated healthcare plans that are not Elevance Health subsidiaries.
◦ Stop Loss Insurance. Our stop loss insurance arrangements are built around our clients’ needs while assuming 100%
of the risk. We offer specific and aggregate plans that will provide options to meet our clients’ coverage terms,
budget and risk tolerance; active claims management to help avoid errors and missing claims; as well as cost
containment to assist our clients with claims and cost control.
7

-- 72 of 188 --

◦ Dental. Our dental plans include networks in certain states in which we operate and are offered on both a risk-based
and fee-based basis. Our members also have access to additional dental providers through our participation in the
National Dental GRID, a national dental network developed by and for BCBS plans that offers in-network discounts
across the country.
◦ Vision. Our vision plans include networks within the states in which we operate and are offered on both a risk-based
and fee-based basis.
◦ Life. We offer an array of competitive individual and group term life insurance benefit products. The life insurance
products include term life and accidental death and dismemberment.
◦ Disability. We offer short-term and long-term disability and leave of absence products.
◦ Supplemental Health. We offer supplemental health products, including accident, critical illness and hospital
indemnity, which provide coverage for specific conditions or circumstances.
• Medicare Plans. We offer a wide variety of plans, products and options to individuals age 65 and older such as
Medicare Advantage, including Special Needs Plans (“SNPs”), dual-eligible programs through Medicare-Medicaid Plans
(“MMPs”), Medicare Supplement plans and Medicare Part D Prescription Drug Plans (“Medicare Part D”).
Medicare Advantage plans provide Medicare beneficiaries with a managed care alternative to traditional Medicare and
often include a Medicare Part D benefit. In addition, our Medicare Advantage SNPs provide tailored benefits to special
needs individuals who are institutionalized or have severe or disabling chronic conditions and to dual-eligible customers,
who are low-income seniors and persons under age 65 with disabilities. Medicare Advantage SNPs are coordinated care
plans specifically designed to provide targeted care, covering all the healthcare services considered medically necessary
for members and often providing professional care coordination services, with personal guidance and programs that help
members maintain their health. Medicare Advantage membership also includes Medicare Advantage members in our
Group Retiree Solutions business who are retired members of commercial accounts or groups who are not affiliated with
our commercial accounts that have selected a Medicare Advantage product through us. MMP is a demonstration program
focused on serving members who are dually eligible for Medicaid and Medicare. Medicare Supplement plans typically
pay the difference between healthcare costs incurred by a beneficiary and amounts paid by the traditional Medicare Fee-
For-Service program. Medicare Part D offers a prescription drug plan to Medicare and MMP beneficiaries.
• Medicaid Plans and Other State-Sponsored Programs. Our Medicaid business includes our managed care alternatives
through public-funded healthcare programs, including Medicaid; Medicaid expansion programs; Temporary Assistance
for Needy Families (“TANF”); programs for seniors and people with disabilities (“SPD”); Children’s Health Insurance
Programs (“CHIP”); and specialty programs such as those focused on long-term services and support (“LTSS”), HIV/
AIDS, children living in foster care, behavioral health and/or substance abuse disorders, and intellectual disabilities and/
or developmental disabilities. The Medicaid program makes federal matching funds available to all states for the delivery
of healthcare benefits for low income and/or high medical risk individuals. These programs are managed by the
individual states based on broad federal guidelines. Our Medicaid plans also cover certain dual-eligible customers, as
previously described above, who also receive Medicare benefits. As of December 31, 2022, we provide Medicaid and
other state sponsored services, such as administrative services, in Arkansas, California, Colorado, Florida, Georgia,
Indiana, Iowa, Kentucky, Louisiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, North
Carolina, Ohio, Puerto Rico, South Carolina, Tennessee, Texas, Virginia, Washington, West Virginia and Wisconsin.
• Federal Employees Health Benefits Program. FEHB members consist of United States government employees and their
dependents within our geographic markets through our participation in the national contract between the BCBSA and the
U.S. Office of Personnel Management.
• Medicare Administrative Operations. Through our NGS subsidiary, we serve as a fiscal intermediary, carrier and
Medicare administrative contractor for the federal government by providing administrative services for the Medicare
program, Parts A and B, which generally provides coverage for persons who are 65 or older and for persons who are
under 65 and disabled or with end-stage renal disease. Part A of the Medicare program provides coverage for services
provided by hospitals, skilled nursing facilities and other healthcare facilities. Part B of the Medicare program provides
coverage for services provided by physicians, physical and occupational therapists and other professional providers, as
well as certain durable medical equipment and medical supplies.
8

-- 73 of 188 --

CarelonRx
Our subsidiary CarelonRx markets and offers pharmacy services to our affiliated health plan customers throughout the
country in our Health Benefits segment, as well as to customers outside of the health plans we own. Our comprehensive
pharmacy services portfolio includes features such as formulary management, pharmacy networks, a prescription drug
database, member services and mail order capabilities.
CarelonRx delegates certain pharmacy services, such as claims processing and prescription fulfillment, to CaremarkPCS
Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement that is set to
terminate on December 31, 2024. With CarelonRx, we retain the responsibilities for clinical and formulary strategy and
development, member and employer experiences, operations, sales, marketing, account management and retail network
strategy. From December 2009 through December 2019, we delegated certain pharmacy functions and administrative
services to Express Scripts Inc. (“Express Scripts”). We transitioned existing members from Express Scripts to
CarelonRx by January 1, 2020.
Carelon Services
Business units in Carelon Services offer a broad array of healthcare related services and capabilities to internal and
external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment
integrity services and subrogation services, as well as health and wellness programs. Key services offered include:
• Behavioral Health. We provide comprehensive behavioral health management services through clinical and network
administration. In a limited capacity, we also provide high-quality, evidence-based behavioral healthcare and
counseling services through licensed clinicians in convenient and accessible locations.
• Care Delivery. We provide highly integrated, personalized care to patients with chronic and complex conditions,
whether in their home, care centers, mobile units, skilled nursing facilities, hospitals, or virtually. Additionally, we
provide non-hospice, community based palliative care to deliver an extra layer of personalized support and whole-
person care.
• Advanced Analytics and Services. We leverage data, analytics, and insights to help improve outcomes and lower the
cost of care, by working to ensure that our members receive safe, appropriate, high-quality, cost-effective care and that
our providers are reimbursed accurately and timely.
Competition
The managed care industry is highly competitive, both nationally and in our local markets. Competition continues to be
intense due to aggressive marketing, pricing, bid activity for government-sponsored programs, business consolidations, new
strategic alliances, new competitors in the market, a proliferation of new products, technological advancements, the impact of
legislative reform, increased quality awareness and price sensitivity among customers and changing market practices, such as
increased usage of telehealth.
We believe that participants in the managed care industry compete for customers based on quality of service, price,
access to provider networks, access to care management and wellness programs (including health information), innovation,
effective use of digital technology, breadth and flexibility of products and benefits, expertise and reputation (including
National Committee on Quality Assurance (“NCQA”) accreditation status as well as CMS Star ratings), brand recognition
and financial stability. Our ability to attract and retain customers is substantially tied to our ability to distinguish ourselves
from our competitors in these areas.
We believe our exclusive right to market products under the most recognized brand in the industry, BCBS, in our most
significant markets provides us with greater brand recognition over competitive product offerings. Typically, we are the
largest participant in each of our BCBS branded markets, and thus are closely-watched by other health benefits companies.
Product pricing remains competitive and we strive to price our health benefit products and design our Medicare and
Medicaid bids consistent with anticipated underlying medical trends. We believe our pricing and bid strategy, based on
predictive modeling, proprietary research and data-driven processes, has positioned us to benefit from the potential growth
opportunities available through entry into new markets, expansions in existing markets and as a result of any future changes
9

-- 74 of 188 --

to the current regulatory scheme. We believe that our pricing and bid strategy, brand name and network quality will provide a
strong foundation for membership growth opportunities in the future.
Our provider networks give us a highly competitive unit cost position and provide distinctive service levels which allow
us to offer a broad range of affordable health benefit products to our customers. To build our provider networks, we compete
with other health benefits plans for the best contracts with hospitals, physicians and other providers. We believe that
physicians and other providers primarily consider customer volume, reimbursement rates, timeliness of reimbursement and
administrative service capabilities along with the reduction of non-value added administrative tasks when deciding whether to
contract with a health benefits plan.
At the sales and distribution level, we compete for qualified agents and brokers to recommend and distribute our
products. Strong competition exists among insurance companies and health benefits plans for agents and brokers with
demonstrated ability to secure new business and maintain existing accounts. We believe that the quality and price of our
products, support services, reputation and prior relationships, along with a reasonable commission structure, are the factors
agents and brokers consider in choosing whether to market our products. We believe that we have good relationships with our
agents and brokers, and that our products, support services and commission structure compare favorably to those of our
competitors in all of our markets.
In addition, the pharmacy industry is highly competitive, and CarelonRx is subject to competition from national, regional
and local pharmacy benefit managers, insurers, health plans, large retail pharmacy chains, large retail stores, supermarkets,
mail order pharmacies, web pharmacies and specialty pharmacies. Strong competition within the pharmacy industry has
generated greater demand for lower product and service pricing, increased revenue sharing and enhanced product and service
offerings.
Pricing and Underwriting of Our Products
We price our products based on our assessment of current healthcare claim costs and emerging healthcare cost trends,
combined with charges for administrative expenses, risk and profit. We continually review our product designs and pricing
guidelines on a national and regional basis so that our products remain competitive and consistent with our profitability goals
and strategies.
Our revenue on Medicare policies is based on annual bids submitted to CMS. We base the commercial and Medicaid
premiums we charge and our Medicare bids on our estimates of future medical costs over the fixed contract period. In
applying our pricing to each employer group and customer, we aim to maintain consistent, competitive and disciplined
underwriting standards. We employ our proprietary accumulated actuarial and financial data to determine underwriting and
pricing parameters for both our risk-based and fee-based businesses.
In most circumstances, our pricing and underwriting decisions follow a prospective rating process in which a fixed
premium is determined at the beginning of the contract period. For our risk-based business, any deviation, favorable or
unfavorable, from the medical costs assumed in determining the premium is our responsibility. Some of our larger groups
employ retrospective rating reviews, where positive experience is partially refunded to the group, and negative experience is
charged against a rate stabilization fund established from the group’s favorable experience or charged against future favorable
experience. In addition, our ACA and government risk-based contracts may include minimum medical loss ratio, risk
adjustment, or risk corridor arrangements, which also stabilize premiums based upon claims experience.
Our pharmacy pricing through CarelonRx is presented to market via discounts off the average wholesale price for drugs
dispensed through the retail, mail and specialty channels as well as through rebate projections. We utilize group-specific
script data, formulary, network and clinical care program selection combined with administrative expense, risk and profit
guidance to set market competitive pricing discounts and rebate projections. Pharmacy pricing guidelines guide the
underwriting process and undergo an annual external review process to ensure market competitiveness.
Networks and Provider Relations
Our relationships with physicians, hospitals and professionals that render healthcare services to our members are guided
by local, regional and national standards for network development, reimbursement and contract methodologies. While
following industry standards, we are simultaneously seeking to lead transformation efforts within our healthcare system,
10

-- 75 of 188 --

moving from a fragmented model premised on episodic intervention to one based on proactive, coordinated care built around
the needs of the patient. A key element of this transformation involves a transition from traditional fee-for-service payment
models to models where providers are paid based on the value, both in quality and affordability, of the care they deliver.
We establish “market-based” hospital reimbursement payments that we believe are fair, but aggressive, and among the
most competitive in the market. We also seek to ensure that physicians in our network are paid in a timely manner at
appropriate rates. In many instances, we deploy multi-year contracting strategies, including case rates or fixed rates, to limit
our exposure to medical cost inflation and to increase cost predictability. We maintain both broad and narrow provider
networks to ensure member choice, based on both price and access needs, while implementing programs designed to improve
the quality of care our members receive. Increasingly, we are supplementing our broad-based networks with smaller or more
cost-effective networks that are designed to be attractive to a more price-sensitive customer segment, such as Public
Exchange customers.
Our reimbursement strategies vary across markets and depend on the degree of consolidation and integration of
physician groups and hospitals. Under a fee-for-service reimbursement methodology for physicians, fee schedules are
developed at the state level based on an assessment of several factors and conditions, including the CMS resource-based
relative value system (“RBRVS”), medical practice cost inflation and physician supply. We utilize CMS RBRVS fee
schedules as a reference point for fee schedule development and analysis. The RBRVS structure was developed, maintained,
and updated by CMS and is used by the Medicare program and other major health plans. In addition, we have implemented
and continue to expand physician incentive contracting, or “pay-for-performance,” which ties physician payment levels to
performance on clinical measures.
While we generally do not delegate full financial responsibility to our physician providers in the form of capitation-
based reimbursement, we maintain capitation-based arrangements in certain markets where we determine that market
dynamics result in it being a useful method to lower costs and reduce underwriting risk. Our provider engagement and
contracting strategies have evolved to include value-based contracting arrangements that meet providers where they are in the
movement from traditional fee-for-service to value-based care. These programs are designed to support commercial,
Medicare and Medicaid programs and the unique characteristics of these populations. Our value-based contracting programs
are designed to reward our contracted providers for improving the overall quality of care they deliver by adhering to
evidence-based medicine. In addition, these value-based contracts also share with the providers total cost of care savings that
are achieved by adhering to evidence-based medicine over time. For providers who contract in one of our value-based
programs, we work with them to share gaps in care information and other important data to assist them in managing the care
of their patients. Often providers will also grant us access to data to support the efficient administration of program
components. This data can allow us to more efficiently capture information regarding the risk of our membership and the
overall adherence to evidence-based medicine, as well as information to more efficiently perform utilization management
administration.
Our hospital contracts provide for a variety of reimbursement arrangements depending on local market dynamics and
current hospital utilization efficiency. Most hospitals are reimbursed a fixed amount per day or reimbursed a per-case
amount, per admission, for inpatient covered services. A small percentage of hospitals, primarily rural, sole community
hospitals, are reimbursed on a discount from approved charge basis for covered services. Our “per-case” reimbursement
methods utilize many of the same attributes contained in Medicare’s Diagnosis Related Groups methodology. Hospital
outpatient services are reimbursed by fixed case rates, fee schedules or percent of approved charges. Our hospital contracts
recognize unique hospital attributes, such as academic medical centers or community hospitals, and the volume of care
performed for our members. To improve predictability of expected costs, we frequently use a multi-year contracting approach
with providers. In addition, the majority of our hospital contracts include a pay-for-performance component where
reimbursement levels are linked to improved clinical performance, patient safety and medical error reduction.
Seasonality
We experience seasonality in our Health Benefits segment. While our premium revenues are not seasonal, our benefit
costs typically increase during the year as our risk-based members pay their contractual portion of claims responsibility under
annual deductibles and reach their out-of-pocket maximum limits.
11

-- 76 of 188 --

Medical Management Programs
We have a broad array of medical management activities that facilitate improvements in the quality of care provided to
our members and promote cost-effective medical care. These medical management activities and programs are administered
and directed by physicians and nurses with the goal of ensuring that the care delivered to our members is supported by
appropriate medical and scientific evidence, is received on a timely basis and occurs in the most appropriate setting. The
medical management programs available to our members may vary depending on the particular plan or product in which they
participate.
Care coordination is one of the strategies we utilize and is based on nationally recognized criteria developed by third-
party medical specialists to help coordinate inpatient as well as outpatient care and monitor appropriate utilization of such
services. Our case management focuses on identifying membership that will require a high level of intervention and
providing assistance to manage their healthcare needs. Precertification is utilized to assess appropriateness of certain
hospitalizations and other medical services prior to the services being rendered. Our medical policy committee determines
our national policies and guidelines for the application of medical technologies, procedures and services and reviews these
policies and guidelines at least once a year or as new published clinical evidence becomes available. We are actively engaged
with our hospital and physician networks to enable them to improve medical and surgical care and achieve better outcomes
for our members. We also work with outside experts through a process of external review to provide our members
scientifically and clinically, evidence-based medical care. Our web-based tools allow our members to obtain or compare cost
estimates for care, including out-of-pocket costs.
We remain committed to assisting our members in making informed and value-based healthcare decisions, providing for
easier navigation of healthcare services and delivering a better healthcare experience.
Care Management and Wellness Products and Programs
We continue to expand our suite of integrated care management programs and tools. Availability of these programs and
tools to our members may depend on the particular plan or product in which they participate. Our care management tools and
programs are designed to increase quality and reduce medical costs for our members and help them make better decisions
about their well-being as they navigate the healthcare system. Our digital engagement platform, Sydney Health, is designed to
give our members access to personalized health and wellness resources; medical, pharmacy, dental, vision, life, and disability
benefits details; as well as virtual care services, all in one place. Our care management, infertility services and maternity
management programs serve as adjuncts to physician care. Through these programs, medical professionals help to educate
participants regarding their care and condition. Our 24/7 NurseLine offers access to qualified, registered nurses to allow our
members to make informed decisions about the appropriate level of care and avoid unnecessary worry. Our CareMore
subsidiary specializes in whole-person care for members with complex and chronic conditions to improve clinical outcomes
and patient wellbeing. Our Aspire Health subsidiary engages with members near end of life and/or requiring palliative care to
manage serious illnesses and improve quality of life during a difficult time. With our integrated information systems and
sophisticated data analytics, we help our members improve their compliance with evidence-based care guidelines, provide
personal care notes that alert members to potential gaps in care, enable more prudent healthcare choices and assist in the
realization of member out-of-pocket cost savings. Our employee assistance programs provide 24/7 telephonic support for
personal and crisis events and provide resources such as counseling and referral assistance with childcare, health and
wellness, financial issues, legal issues, adoption and daily living. We have a comprehensive behavioral health case
management program supporting a wide range of members who are impacted by their behavioral health condition, including
specialty areas such as eating disorders, anxiety, depression and substance abuse. The program assists members and their
families with obtaining appropriate behavioral health treatment, offering community resources, providing education and
telephonic support, and promoting provider collaboration.
Healthcare Quality Initiatives
Increasingly, the healthcare industry is able to define quality healthcare based on effective, safe, equitable and affordable
care in preventive health, outcomes of care and optimal care management for chronic disease. A key to our success has been
our ability to develop partnerships by working with our network physicians, hospitals, and social resources providers to
improve the quality outcomes of the healthcare and social impact services provided to our members, their families, and the
community-at-large. Our ability to promote quality medical care, address health-related social risks, and advance health
12

-- 77 of 188 --

equity has been recognized by NCQA, the largest and most respected national accreditation program for managed care health
plans.
Several quality healthcare measures, including the Healthcare Effectiveness Data and Information Set (“HEDIS®”), have
been incorporated into NCQA’s accreditation processes. HEDIS® measures range from preventive services, such as screening
mammography and pediatric immunization, to elements of care, including decreasing the complications of diabetes,
improving treatment for patients with heart disease, integration of behavioral health, and racial and ethnic stratification
measurement to help close healthcare disparities.
Through our AIM Specialty Health (“AIM”) subsidiary, we promote appropriate, safe and affordable member care in the
areas of imaging, sleep disorders, cardiac testing, oncology drugs and musculoskeletal procedures. These expanded specialty
benefit management solutions leverage clinical expertise and technology to engage provider communities and members in the
more effective and efficient use of outpatient services and to promote the most appropriate use of clinical services to improve
the quality of overall healthcare delivered to our members and members of other health plans that are covered under AIM’s
programs.
Through our myNEXUS, Inc. (“myNEXUS”) subsidiary, we perform management review for home health services
provided to Medicare members, with the goal of ensuring they receive appropriate, high-quality care and supporting their
transition back into the home. Effective management of these services can help reduce preventable hospital admissions and
readmissions, thereby improving healthcare outcomes for patients. Additionally, myNEXUS has developed programs to
address healthcare quality by identifying social determinants of health needs of our members and seeking to close gaps in
care through an in-home assessment. Both AIM and myNEXUS programs are examples of how we facilitate improvements in
the quality of care provided to our members and promote cost-effective medical care.
The physical aspects of health have been traditionally the focus and the priority for healthcare. However, unique life
circumstances and experiences impact every individual and their health. We seek to understand our members' health-related
social needs to create a healthcare system that synchronizes care delivery for physical, behavioral, social and pharmacy
needs. We are advancing our efforts through consistent screening of our members for their social needs by using industry-
standard tools such as the Protocol for Responding to & Assessing Patients’ Assets, Risks & Experiences, co-creating social
action plans with our members, connecting members to related social support services, and evaluating the entire process for
continuous quality improvement. We are committed to ensuring that all people, regardless of age, race or ethnicity, sexual
orientation, gender identity, disability, and geographic or financial access can receive individualized care. Harnessing data
gives a more complete picture of each individual and their health needs and can help make healthcare more personalized and
equitable. Strengthening communities has a positive effect on health therefore we value and nurture our local ties which are a
key component of our whole-health approach and drive us to work closely with community organizations that create support
networks. Using our data, we also identify the resources needed to support local residents, including the people who we
serve, to ensure those resources can better meet local needs.
BCBSA Licenses
We are a party to license agreements with the BCBSA that entitle us to the exclusive, and in certain areas, non-exclusive,
use of the Blue Cross and Blue Shield names and marks in assigned geographic territories. BCBSA is a national association
of independent Blue Cross and Blue Shield companies, the primary function of which is to promote and preserve the integrity
of the BCBS names and marks, as well as provide certain coordination among the member companies. Each BCBSA licensee
is an independent legal organization and is not responsible for obligations of other BCBSA member organizations. Although
previously we did not have a right to sell products and services using the BCBS names and marks outside of the states in
which we are licensed to sell BCBS products, under the terms of the subscriber settlement agreement and release
(“Subscriber Settlement Agreement”) among the class of plaintiffs, BCBSA and Blue Cross and/or Blue Shield licensees,
including us (the “Blue plans”), some large national employers with self-funded plans (specifically identified in the
Subscriber Settlement Agreement) have a right to request a second Blue plan bid in addition to a bid from the local Blue plan.
The Subscriber Settlement Agreement received final approval in August 2022. We are required to pay an annual license fee
to the BCBSA based on enrollment and also to comply with various requirements and restrictions regarding our operations
and our use of the BCBS names and marks. These requirements and restrictions include, among other things: minimum
capital and liquidity requirements; enrollment and customer service performance requirements; participation in programs that
provide portability of membership between plans; disclosures to the BCBSA relating to enrollment and financial conditions;
13

-- 78 of 188 --

disclosures as to the structure of the BCBS system in contracts with third parties and in public statements; plan governance
requirements; cybersecurity requirements; a requirement that at least 80% (or, in the case of Blue Cross of California,
substantially all) of a licensee’s annual combined local net revenue, as defined by the BCBSA, attributable to healthcare plans
and related services within its service areas must be sold, marketed, administered or underwritten under the BCBS names and
marks; a requirement that neither a plan nor any of its licensed affiliates may permit an entity other than a plan or a licensed
affiliate to obtain control of the plan or the licensed affiliate or to acquire a substantial portion of its assets related to
licensable services; governance requirements such as a requirement that we divide our Board of Directors into three classes
serving staggered three-year terms; a requirement that we guarantee certain contractual and financial obligations of our
licensed affiliates; and a requirement that we indemnify the BCBSA against any claims asserted against it resulting from the
contractual and financial obligations of any subsidiary that serves as a fiscal intermediary providing administrative services
for Medicare Parts A and B. In addition, a change of control or violation of the BCBSA ownership limitations on our capital
stock, impending financial insolvency or the appointment of a trustee or receiver or the commencement of any action against
us seeking our dissolution could cause a termination of our license agreements.
We believe that we and our licensed affiliates are currently in compliance with these standards. The standards under the
license agreements may be modified in certain instances by the BCBSA. See Part I, Item 1A, “Risk Factors” in our 2022
Form 10-K for additional details on the impact if we were not to comply with these license agreements and Note 14,
“Commitments and Contingencies – Litigation and Regulatory Proceedings – Blue Cross Blue Shield Antitrust Litigation” of
the Notes to our Consolidated Financial Statements included in Part II, Item 8 of this Exhibit 99.1 for additional information
on the Subscriber Settlement Agreement.
Regulation
General
Our operations are subject to comprehensive and detailed state, federal and international regulation throughout the
jurisdictions in which we do business. These laws and regulations, which can vary significantly from jurisdiction to
jurisdiction, restrict how we conduct our businesses and result in additional burdens and costs to us. Further, federal and state
laws and regulations are subject to amendments and changing interpretations in each jurisdiction. The application of these
complex legal and regulatory requirements to the detailed operation of our businesses creates areas of uncertainty. In
addition, there are numerous proposed healthcare laws and regulations at the federal and state levels, including single payer,
Medicare for All and public option proposals, some of which could materially adversely affect our businesses if they were to
be enacted.
Supervisory agencies, including federal and state regulators and departments of health, insurance and corporation, have
broad authority to:
• grant, suspend and revoke licenses to transact business;
• regulate our products and services in great detail;
• regulate, limit, or suspend our ability to market products, including participation in Medicare and the Public
Exchanges;
• determine through a procurement process our ability to participate in certain programs, including state Medicaid
programs;
• retroactively adjust premium rates;
• monitor our solvency and reserve adequacy;
• audit, and recovery of audit discrepancies, including risk adjustment data validation (“RADV”) audits;
• scrutinize our investment activities on the basis of quality, diversification and other quantitative criteria; and
• impose monetary and criminal sanctions for non-compliance with regulatory requirements.
To carry out these tasks, these government entities periodically examine our operations and accounts.
The health benefits business also may be adversely impacted by court and regulatory decisions that expand or invalidate
the interpretations of existing statutes and regulations. It is uncertain whether we could recoup, through higher premiums or
14

-- 79 of 188 --

other measures, the increased costs of mandated benefits or other increased costs caused by potential legislation, regulation or
court rulings. See Part I, Item 1A “Risk Factors” in our 2022 Form 10-K.
COVID-19
With the declaration of COVID-19 as a public health emergency (“PHE”), the federal and state governments have
enacted, and may continue to enact, legislation and regulations in response to the COVID-19 pandemic that have had, and we
expect will continue to have, a significant impact on health benefits, consumer eligibility for public programs and our cash
flows for all lines of business, and which have introduced increased uncertainty around our cost structure. These actions,
which are or have been in effect for various durations, provide, among other things: mandates to waive cost-sharing for
COVID-19 testing, vaccines and related services; financial support to healthcare providers; and mandates related to prior
authorizations, payment levels to providers, consumer enrollment windows and telehealth services. The Biden administration
renewed the PHE on January 11, 2023 and has indicated that they intend for the PHE to expire on May 11, 2023.
Under the Consolidated Appropriations Act of 2023, Congress decoupled Medicaid eligibility recertification from the
PHE. As a result, states may begin removing ineligible beneficiaries from their Medicaid programs starting April 1, 2023.
When recertifications resume, we expect a decline in our Medicaid membership. At the same time, we expect growth in our
commercial risk-based and fee-based plans and Medicare, including through the Public Exchanges, as members exiting
Medicaid in our 14 commercial states seek coverage elsewhere.
The Inflation Reduction Act of 2022
The Inflation Reduction Act of 2022 (the “Inflation Reduction Act”), which was signed into law in August 2022,
contains a variety of provisions that impact our business including an extension of the American Rescue Plan Act of 2021's
enhanced Premium Tax Credits (“PTC”) through 2025; imposing a new corporate alternative minimum tax; providing a one
percent excise tax on repurchases of stock made after December 31, 2022; allowing CMS to negotiate prices on a limited set
of prescription drugs in Medicare Parts B and D beginning in 2026; instituting caps on insulin cost sharing in Medicare Parts
B and D; redesigning of the Medicare Part D benefit; adding a requirement that drug manufacturers pay rebates if prices
increase beyond inflation; and delaying the implementation of the Trump Administration Medicare drug rebate rule to 2032.
The extension of the enhanced PTC will likely allow for growth in Individual exchange market enrollment as Medicaid
eligibility recertifications resume, supporting continuity of coverage for more people.
The Consolidated Appropriations Act of 2021
The Consolidated Appropriations Act of 2021 (the “2021 Appropriations Act”) has impacted us since passage and in the
future may have a material effect upon our business, including procedures and coverage requirements related to surprise
medical bills and new mandates for continuity of care for certain patients, price comparison tools, disclosure of broker
compensation, mental health parity reporting, and reporting on pharmacy benefits and drug costs. The requirements of the
2021 Appropriations Act applicable to us have varying effective dates, some of which were effective in December 2021 and
during 2022, and others of which have been extended into 2023 since the enactment of the 2021 Appropriations Act.
State Regulation of Insurance Companies and HMOs
Our insurance and HMO subsidiaries must obtain a certificate of authority and maintain that license in the jurisdictions
in which they conduct business. The National Association of Insurance Commissioners (“NAIC”) has adopted model
regulations that, where adopted by states, require expanded governance practices, risk and solvency assessment reporting and
the filing of periodic financial and operating reports. Most states have adopted these or similar measures to expand the scope
of regulations relating to corporate governance and internal control activities of HMOs and insurance companies. Health
insurers and HMOs are subject to state examination and periodic license renewal.
In addition, we are regulated as an insurance holding company and are subject to the insurance holding company acts of
the states in which our insurance company and HMO subsidiaries are domiciled. These acts contain certain reporting
requirements, as well as restrictions on transactions between an insurer or HMO and its affiliates, and may restrict the ability
of our regulated subsidiaries to pay dividends to our holding companies. These holding company laws and regulations
generally require registration with applicable state departments of insurance and the filing of reports describing capital
structure, ownership, financial condition, certain intercompany transactions, enterprise risks, corporate governance and
general business operations. State insurance holding company laws and regulations require notice or prior regulatory approval
15

-- 80 of 188 --

of transactions including acquisitions, material intercompany transfers of assets, guarantees and other transactions between
the regulated companies and their affiliates, including parent holding companies. Applicable state insurance holding company
acts also restrict the ability of any person to obtain control of an insurance company or HMO without prior regulatory
approval. “Control” is generally defined as the direct or indirect power to direct or cause the direction of the management and
policies of a person and is presumed to exist if a person directly or indirectly owns or controls 10% or more of the voting
securities of another person. Dispositions of control generally are also regulated under the state insurance holding company
acts.
The states of domicile of our regulated subsidiaries have statutory risk-based capital (“RBC”) requirements for health
and other insurance companies and HMOs based on the Risk-Based Capital (RBC) For Health Organizations Model Act.
These RBC requirements are intended to assess the capital adequacy of life and health insurers and HMOs, taking into
account the risk characteristics of a company’s investments and products. In general, under these laws, an insurance company
or HMO must submit a report of its RBC level to the insurance department or insurance commissioner of its state of domicile
for each calendar year. The law requires increasing degrees of regulatory oversight and intervention as a company’s RBC
declines. As of December 31, 2022, the RBC levels of our insurance and HMO subsidiaries exceeded all applicable
mandatory RBC requirements. For more information on RBC capital and additional liquidity and capital requirements for a
licensee of the BCBSA, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations–
Liquidity and Capital Resources–Capital Resources,” included in Part II, Item 7 of this Exhibit 99.1.
Ongoing Requirements and Changes Stemming from the ACA
Since its enactment in 2010, the ACA has introduced new risks, regulatory challenges and uncertainties, has impacted
our business model and strategy and has required changes in the way our products are designed, underwritten, priced,
distributed and administered. We expect the ACA will continue to significantly impact our business and results of operations,
including pricing, minimum medical loss ratios (“MLRs”) and the geographies in which our products are available. We also
expect further and ongoing regulatory guidance on a number of issues related to Medicare, including evolving methodology
for ratings and quality bonus payments. CMS also frequently proposes changes to its program that audits data submitted
under the risk adjustment programs in ways that could increase financial recoveries from plans. We will continue to evaluate
the impact of the ACA as any further developments occur.
Certain significant provisions of the ACA include, among others:
• The creation of Public Exchanges for individuals and small group customers.
• The establishment of minimum MLR thresholds by line of business for the commercial market (which may be
subject to more restrictive MLR thresholds under state regulations, such as those in New York). Medicare
Advantage or Medicare Part D prescription drug plans that do not meet the mandated threshold will have to pay a
minimum MLR rebate, will be subject to restricted enrollment if MLR is below the threshold for three consecutive
years, and are subject to contract termination if the plan’s MLR is below the threshold for five consecutive years. In
addition, state Medicaid programs are required to set managed care capitation rates such that a minimum MLR is
projected to be achieved; however, states are not required to collect remittances if the minimum MLR is not
achieved.
Approximately 52.3% and 17.5% of our premium revenue and medical membership, respectively, were subject to
the minimum MLR regulations as of and for the year ended December 31, 2022. Approximately 53.6% and 18.4%
of our premium revenue and medical membership, respectively, were subject to the minimum MLR regulations as of
and for the year ended December 31, 2021.
• The creation of an incentive payment program for Medicare Advantage plans. CMS developed the Medicare
Advantage Star ratings system, which awards between 1.0 and 5.0 Stars to Medicare Advantage plans based on
performance in several categories, including quality of care and customer service. The Star ratings are used by CMS
to award quality-based bonus payments to plans that receive a rating of 4.0 or higher. The methodology and
measures included in the Star ratings system can be modified by CMS annually. For payment year 2023, we expect
to have approximately 73% of our Medicare Advantage members in 4.0 or higher rated plans.
• The implementation of a Medicare Advantage payment formula, which prevents reimbursement rates from
increasing as much as otherwise would be expected.
16

-- 81 of 188 --

We continue to evaluate our experience in the Public Exchange markets. Based on the viability of the Public Exchanges
and availability of federal subsidies, we have made adjustments to our premium rates and geographic participation, including
a modest expansion in the Public Exchange markets in 2022 and further expansion into a limited number of additional
counties in 2023. Any variation from our expectations regarding acuity, enrollment levels, adverse selection, or other
assumptions utilized in setting premium rates could have a material adverse effect on our results of operations, financial
position, and cash flows, and may require further adjustments to our rates and participation going forward. As a result, for
2023 we are offering Individual Public Exchange products in 138 of the 143 rating regions in which we operate, in
comparison to 122 of 143 rating regions in 2022. Our strategy has been, and will continue to be, to only participate in rating
regions where we have an appropriate level of confidence that these markets are on a path toward sustainability, including,
but not limited to, factors such as expected financial performance, regulatory environment and underlying market
characteristics.
Drug Benefit and Pharmacy Benefit Manager Regulation
Pharmacy benefit managers (“PBMs”) are regulated at both the federal and state levels and must comply with federal and
state statutes and regulations governing labeling, packaging, advertising and adulteration of prescription drugs, dispensing of
controlled substances and licensing. In recent years the federal government has banned certain business practices, including
“gag clauses,” which prohibited pharmacists from informing patients when a lower cost drug was available as a substitute,
and “clawbacks,” which occurred when pharmacy benefit managers sought to recoup the difference between the reimbursed
cost of the drug and the patient’s copay when the drug itself was less expensive than the copay paid by the patient. Regulation
in the states varies dramatically and ranges from licensure of PBMs as third-party administrators, licensure specifically as a
pharmacy benefit manager, and licensure accompanied by additional disclosures and limitations of business practices to
varying degrees. The NAIC finalized a PBM model law that, if adopted widely, could result in a more standardized approach
to PBM regulation in the states in the future. Additionally, in December 2020, the U.S. Supreme Court let stand an Arkansas
law regulating PBMs, which could be a precursor to greater state regulation of PBMs in the future. In June 2021, the NAIC
announced a proposed white paper addressing PBMs and examining the impact of this Supreme Court case on its model law,
which could result in expansion of the NAIC model law and additional regulatory oversight, which could materially affect
current industry practices and our PBM business.
A number of proposals are being considered at the federal and state levels that would increase regulation of drug benefits
and pharmacy benefit managers. Such proposals under consideration include (1) regulation of rebates from drug
manufacturers that would require rebate dollars to be applied at the point-of-sale, (2) federal policy changes to set the prices
for a subset of drugs covered under the Medicare program, (3) reforms to the Medicare drug benefit, such as beneficiary cost-
sharing changes that aim to lower consumer costs, (4) attempts at both the federal and state levels to prohibit the use of
spread pricing contracts in both the commercial and Medicaid markets, and (5) electronic prior authorizations of drugs. These
reforms have the potential to have broad impacts on our PBM business and could materially adversely affect our business if
they are enacted.
Privacy, Confidentiality and Data Standards Regulation
The federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) and the administrative
simplification provisions of HIPAA impose a number of requirements on covered entities (including insurers, HMOs, group
health plans, providers and clearinghouses) and their business associates relating to the use, disclosure and safeguarding of
protected health information. These requirements include uniform standards of common electronic healthcare transactions;
privacy and security regulations; and unique identifier rules for employers, health plans and providers.
Also, the Health Information Technology for Economic and Clinical Health (“HITECH”) Act provisions of the
American Recovery and Reinvestment Act of 2009 and corresponding implementing regulations have imposed additional
requirements on the use and disclosure of protected health information such as additional data breach notification and
reporting requirements, contracting requirements for HIPAA business associate agreements, strengthened enforcement
mechanisms and increased penalties for HIPAA violations. Federal consumer protection laws may also apply in some
instances to privacy and security practices related to personally identifiable information.
The federal Gramm-Leach-Bliley Act generally places restrictions on the disclosure of non-public information to non-
affiliated third parties, and requires financial institutions, including insurers, to provide customers with notice regarding how
17

-- 82 of 188 --

their non-public personal information is used, including an opportunity to “opt out” of certain disclosures. State departments
of insurance and certain federal agencies adopted implementing regulations as required by federal law.
The Cybersecurity Information Sharing Act of 2015 encourages organizations to share cyber threat indicators with the
federal government and, among other things, directed HHS to develop a set of voluntary cybersecurity best practices for
organizations in the healthcare industry, which were issued in 2018.
In addition, Public Exchanges are required to adhere to privacy and security standards with respect to personally
identifiable information and to impose privacy and security standards that are at least as protective as those the Public
Exchange has implemented for itself on insurers offering plans through the Public Exchanges and their designated
downstream entities, including pharmacy benefit managers and other business associates. These standards may differ from,
and be more stringent than, HIPAA.
Furthermore, states have begun enacting more comprehensive privacy laws and regulations addressing consumer rights
to data protection or transparency that may affect our privacy and security practices, such as state laws like the California
Privacy Rights Act of 2020 that govern the use, disclosure and protection of member data and impose additional breach
notification requirements. The NAIC is planning potential revisions to one or more of its privacy model acts, which could
expand consumer privacy rights. State consumer protection laws may also apply to privacy and security practices related to
personally identifiable information, including information related to consumers and care providers. Complying with
conflicting cybersecurity regulations and varying enforcement philosophies, which may differ from state to state, requires
significant resources and may materially and adversely affect our ability to standardize our products and services across state
lines.
Federal regulations have been finalized in the following areas that will continue to materially impact our operations:
• Federal regulations on data interoperability that require claims data to be made available to third parties unaffiliated
with us; and
• Federal regulations requiring hospitals and health insurers to publish negotiated prices for services, including the
health plan price transparency regulations issued in October 2020 by the U.S. Departments of Health and Human
Services, Labor and Treasury (the “Health Plan Transparency Rule”).
Beginning in July 2022, the Health Plan Transparency Rule required us to disclose, on a monthly basis, detailed pricing
information regarding negotiated rates for all covered items and services between the plan or issuer and in-network providers
and historical payments to, and billed charges from, out-of-network providers. Additionally, beginning in 2023, we are now
required to make available to members personalized out-of-pocket cost information and the underlying negotiated rates for
500 covered healthcare items and services, including prescription drugs. In 2024, this requirement will expand to all items
and services.
Employee Retirement Income Security Act of 1974
The provision of services to certain employee welfare benefit plans is subject to the Employee Retirement Income
Security Act of 1974, as amended (“ERISA”), a complex set of laws and regulations subject to interpretation and
enforcement by the Internal Revenue Service and the Department of Labor. ERISA regulates certain aspects of the
relationships between us, the employers that maintain employee welfare benefit plans subject to ERISA and participants in
such plans. Some of our administrative services and other activities may also be subject to regulation under ERISA. In
addition, certain states require licensure or registration of companies providing third-party claims administration services for
benefit plans. We provide a variety of products and services to employee welfare benefit plans that are covered by ERISA.
Plans subject to ERISA can also be subject to state laws, and the question of whether and to what extent ERISA preempts a
state law has been, and will continue to be, interpreted by many courts.
Guaranty Fund Assessments
Under insolvency or guaranty association laws in most states, insurance companies and HMOs can be assessed for
amounts paid by guaranty funds for policyholder losses incurred when an insurance company or HMO becomes insolvent.
Most state insolvency or guaranty association laws currently provide for assessments based upon the amount of premiums
received on insurance underwritten within such state (with a minimum amount payable even if no premium is received).
18

-- 83 of 188 --

Under many of these guaranty association laws, assessments are made retrospectively. Some states permit insurers or HMOs
to recover assessments paid through full or partial premium tax offsets or through future policyholder surcharges. The amount
and timing of any future assessments cannot be predicted with certainty; however, future assessments are likely to occur.
International Regulation
We have various international subsidiaries, which provide back-office services, that are subject to different, and
sometimes more stringent, legal and regulatory requirements that vary widely by jurisdiction. In addition, our non-U.S.
operations are subject to U.S. laws regulating the conduct and activities of U.S.-based businesses operating abroad, including
but not limited to, the Foreign Corrupt Practices Act and corresponding foreign laws governing anti-bribery, anti-corruption
and anti-money laundering.
Human Capital
The foundation of our strategy starts with our culture, and our associates are critical to fulfilling our purpose of
improving the health of humanity. As of December 31, 2022, our employee population, including all full-time, part-time and
temporary workers, consisted of approximately 102,300 individuals, 79,000 in the United States and 23,300 internationally.
We have built a high-performance culture that we believe enhances our ability to deliver on our commitments and guides us
to address the challenges of today. We believe that our culture allows us to attract and retain talented and experienced
individuals to support the communities we serve. Our associates actively participate through associate engagement surveys
and online feedback tools. We leverage and monitor associate feedback and take action on responses.
Inclusion & Diversity
The diversity of our associates is central to achieving key strategies and improving performance. We strive to maintain a
diverse and inclusive workforce comprised of a vast array of backgrounds, life experiences and cultures, which we believe
enables a deeper connection with our members, allowing us to better serve our members and communities, and drives greater
business results. As of December 31, 2022, our U.S. associate population was approximately 77% female and 51% racially
and ethnically diverse, while 65% of our managers are female and 36% are racially or ethnically diverse.
Fair Pay
Elevance Health is committed to a fair pay workplace. We were in the first cohort of companies certified by the Fair Pay
Workplace (“FPW”), an independent certification that takes a holistic approach to pay equity, partnering to design an annual
pay equity action plan that includes a perpetual review of all positions, new hires and promotions to effect meaningful and
measurable change. This independent certification is based on a set of publicly available rules and standards and the endorsed
methodology of a group of leading experts from forward-thinking corporations, academia, human resources, data science and
the legal field. After partnering with and overseeing our review process, FPW has validated our analysis of our associate
population, which found that pay for females is within 1% of their male counterparts and pay for people of color is equal to
their white counterparts, after taking into account neutral job related factors.
Talent Development
Growing and developing our talent internally is key to our succession plans and our ability to lead at our best every day.
To inspire a high-performance culture and promote talent excellence, we offer individual, career and leadership development
opportunities, encouraging associates to continually learn and grow. We offer various instructor-led and virtual instructor-led
programs and maintain a vast curriculum of relevant, on-demand learning and development resources.
Health & Wellbeing
We have the privilege of touching the lives of millions of people each day, starting with the health of our own associates.
To improve the health and wellbeing of our associates, we offer a comprehensive compensation package, including
competitive salaries, a 401(k) plan and medical, dental, vision and disability coverage. In addition, we offer our associates
wellness and behavioral programs and tools to help them get and stay healthy and more easily manage their work and
personal lives.
19

-- 84 of 188 --

Information About Our Executive Officers
The following sets forth certain information regarding our executive officers and Chief Accounting Officer as of
February 1, 2023.
Name Age Position
Gail K. Boudreaux 62 President and Chief Executive Officer
John E. Gallina 63 Executive Vice President and Chief Financial Officer
Peter D. Haytaian
53 Executive Vice President and President, Carelon and
CarelonRx
Charles M. Kendrick, Jr.
57 Executive Vice President and President, Commercial &
Specialty Business Division
Gloria M. McCarthy
70 Executive Vice President and Chief Administrative
Officer
Felicia F. Norwood
63 Executive Vice President and President, Government
Business Division
Blair W. Todt 55 Executive Vice President and Chief Legal Officer
Ronald W. Penczek 58 Chief Accounting Officer and Controller
Ms. Boudreaux has served as our President and Chief Executive Officer and a Director of the Company since November
2017. Prior to joining us, she served as Chief Executive Officer of GKB Global Health, LLC (healthcare consulting firm)
from 2015 to November 2017. Prior thereto, Ms. Boudreaux was Executive Vice President of UnitedHealth Group
Incorporated (diversified healthcare company) from 2008 to 2015, including roles as Chief Executive Officer of
UnitedHealthCare (managed healthcare company), a subsidiary of UnitedHealth Group Incorporated from 2011 to 2014 and
President of the Commercial Business of UnitedHealthCare from 2008 to 2011. Before joining United HealthCare, she
worked at Health Care Service Corporation (“HCSC”) (health insurance company) as Executive Vice President of External
Operations from 2005 to 2008 and President of Blue Cross and Blue Shield of Illinois from 2002 to 2005. Before joining
HCSC, Ms. Boudreaux held various positions at Aetna, Inc. (“Aetna”) (managed healthcare company), including Senior Vice
President, Group Insurance.
Mr. Gallina has served as our Executive Vice President and Chief Financial Officer since 2016. Mr. Gallina joined
Elevance Health in 1994 and has held a variety of leadership roles across the organization. Prior to his current role, Mr.
Gallina served as Elevance Health’s Chief Financial Officer for the Commercial & Specialty Business Division from 2015 to
2016, and as Senior Vice President and Chief Accounting Officer from 2013 to 2015. Other leadership positions held during
his tenure include Senior Vice President, Chief Accounting Officer and Chief Risk Officer from 2011 to 2013, while also
holding the title of Controller from 2011 to 2013. Before joining the Company, Mr. Gallina spent 12 years with Coopers &
Lybrand in various positions, including as an Audit Senior Manager.
Mr. Haytaian has served as our Executive Vice President and President of Carelon (formerly known as our Diversified
Business Group) and CarelonRx (formerly known as IngenioRx) since October 2021. Prior to his current role, Mr. Haytaian
served as Executive Vice President and President of our Commercial & Specialty Business Division beginning in April 2018.
From June 2014 until April 2018, Mr. Haytaian served as our Executive Vice President and President of the Government
Business Division. Mr. Haytaian joined the Company in 2012 with our acquisition of Amerigroup Corporation
(“Amerigroup”) and served as President of our Medicaid business from 2013 until 2014. From 2005 to 2013, Mr. Haytaian
held several leadership positions with Amerigroup, including serving as Chief Executive Officer of the North Region for
Amerigroup’s Medicaid business from 2012 until 2013. Mr. Haytaian has extensive experience leading Medicare and
Medicaid programs with Amerigroup and, prior thereto, with Oxford Health Plans, Inc.
Mr. Kendrick has served as Executive Vice President and President of our Commercial & Specialty Business Division
since October 2021. From January 2021 until October 2021, Mr. Kendrick served as President of our Commercial Business
West Markets (California, Colorado, Indiana, Kentucky, Missouri, Nevada, Ohio and Wisconsin). Mr. Kendrick joined us in
1995, and has held numerous leadership roles across the organization, including serving as President, Anthem National
Accounts/Central Markets from 2015 until January 2021 and President of National Accounts and General Manager for
Anthem Blue Cross and Blue Shield of Georgia from 2010 until 2015.
20

-- 85 of 188 --

Ms. McCarthy has served as our Executive Vice President and Chief Administrative Officer since 2013. She was
Executive Vice President of Enterprise Execution and Efficiency from 2012 to 2013. Prior to that appointment, she served as
Senior Vice President for Operational Excellence from 2008 to 2012, as Senior Vice President of Service Operations from
2006 to 2008 and as Senior Vice President and Chief Operating Officer of our East Region from 2005 to 2006. Prior to our
acquisition of WellChoice, Inc. (“WellChoice”) in 2005, Ms. McCarthy served as Executive Vice President and Chief
Operating Officer of WellChoice.
Ms. Norwood has served as our Executive Vice President and President of the Government Business Division since June
2018. Prior to joining us, she was Director of The Department of Healthcare and Family Services for the State of Illinois from
2015 to June 2018. Prior to that appointment, Ms. Norwood held a variety of leadership roles at Aetna, with her most recent
role as President of the Mid-America Region for Aetna from 2010 until 2013.
Mr. Todt has served as our Executive Vice President and Chief Legal Officer since November 2020 and our interim head
of human resources and global security and safety team since January 2022. Prior to joining us, Mr. Todt served as Senior
Vice President, Legal, Compliance & Business Performance and Chief Legal Officer of HCSC from 2016 to July 2020. Prior
to joining HCSC, Mr. Todt held a variety of leadership roles at WellCare Health Plans, Inc. (health insurance company), with
his most recent role as Senior Vice President, Chief Legal and Administrative Officer and Secretary from 2010 until 2016.
Mr. Penczek has served as our Controller since November 2015 and as our Chief Accounting Officer since December
2015. He served as our Vice President and Controller from 2013 to 2015. Prior to that appointment, Mr. Penczek served as
Vice President and Assistant Controller from 2008 to 2013 and in various other roles in our finance department from 2006
until 2008. Before joining us in 2005, Mr. Penczek was a Staff Vice President with CNA Insurance from 2000 to 2005 and
had various positions with PricewaterhouseCoopers LLP from 1992 to 2000, including as a Manager.
Available Information
We are a large accelerated filer (as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”)) and are required, pursuant to Item 101 of Regulation S-K, to provide certain information regarding our
website and the availability of certain documents filed with or furnished to the U.S. Securities and Exchange Commission
(“SEC”). The SEC maintains a website that contains reports, proxy and information statements and other information
regarding issuers at www.sec.gov. Our website is www.elevancehealth.com. We have included our website address
throughout this Exhibit 99.1 as a textual reference only. The information contained on, or accessible through, our website is
not incorporated into this Exhibit 99.1 or any of our other SEC filings. We make available through our website, free of
charge, our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments
to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable
after we electronically file such material with or furnish it to the SEC. We also include on our website our Corporate
Governance Guidelines, our Code of Conduct and the charter of each standing committee of our Board of Directors. In
addition, we intend to disclose on our website any amendments to, or waivers from, our Code of Conduct that are required to
be publicly disclosed pursuant to rules of the SEC and the New York Stock Exchange. Elevance Health, Inc. is an Indiana
corporation incorporated on July 17, 2001.
21

-- 86 of 188 --

PART II
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS.
(In Millions, Except Per Share Data or As Otherwise Stated Herein)
On May 18, 2022, our shareholders approved a proposal to amend our amended and restated articles of incorporation to
change our name from Anthem, Inc. to Elevance Health, Inc. This amendment and name change went into effect on June 27,
2022. We began operating as Elevance Health, Inc. and trading under our new ticker symbol “ELV” on June 28, 2022.
References to the terms “we,” “our,” “us,” “Elevance Health” or the “Company” used throughout this Management’s
Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) refer to Elevance Health, Inc., an
Indiana corporation, and, unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states”
include the District of Columbia and Puerto Rico, unless the context otherwise requires.
This MD&A should be read in conjunction with our audited consolidated financial statements included in Part II, Item 8
of this Exhibit 99.1.
This MD&A generally discusses 2022 and 2021 items and year-over-year comparisons between 2022 and 2021. A
detailed discussion of 2020 items and year-over-year comparisons between 2021 and 2020 that are not included in this
Exhibit 99.1 can be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in
Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2021.
Overview
Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest
health insurers in the United States in terms of medical membership, serving approximately 47.5 million medical members
through our affiliated health plans as of December 31, 2022. We are an independent licensee of the Blue Cross and Blue
Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross
licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia,
Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in
the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of
Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue
Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. In addition, we conduct business through
arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve
customers in numerous states as Amerigroup, Freedom Health, HealthLink, HealthSun, MMM, Optimum Healthcare, Simply
Healthcare, UniCare and/or Wellpoint. We offer pharmacy services as CarelonRx and other health-care related services as
Carelon Services, Aspire Health, Carelon Behavioral Health and Caremore. We are licensed to conduct insurance operations
in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries.
As part of our name change to Elevance Health, in June 2022, we announced that over the next several years we will
organize our brand portfolio into the following core go-to-market brands:
• Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated
Blue Cross and/or Blue Shield licensed plans;
• Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the
Wellpoint name; and
• Carelon — this brand brings together our healthcare-related services and capabilities, including our formerly named
Diversified Business Group and IngenioRx businesses, under a single brand name.
Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime,
trusted health partner. Given this evolution, we reviewed and modified how we manage our business, monitor our
performance and allocate resources. As a result, we changed our reportable segments to the following beginning in the first
quarter of 2023: Health Benefits (aggregates our previously reported Commercial & Specialty Business and Government
Business segments), CarelonRx, Carelon Services (previously included in our Other segment) and Corporate & Other (our
22

-- 87 of 188 --

businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses
not allocated to our other reportable segments).
The results of operations discussed in this MD&A have been recast and are presented as they would have appeared had
we changed our reportable segments and adopted the new accounting standard discussed in the “Explanatory Note” above
prior to January 1, 2023.
Our results of operations discussed throughout this MD&A are determined in accordance with generally accepted
accounting principles (“GAAP”). We also calculate operating gain and operating margin to further aid investors in
understanding and analyzing our core operating results. Operating gain is calculated as total operating revenue less benefit
expense, cost of products sold and operating expense. Operating margin is calculated as operating gain divided by operating
revenue. Our definition of operating gain and operating margin may not be comparable to similarly titled measures reported
by other companies. We use these measures as a basis for evaluating segment performance, allocating resources, forecasting
future operating periods and setting incentive compensation targets. This information is not intended to be considered in
isolation or as a substitute for income before income tax expense, net income or fully-diluted earnings per share (“EPS”)
prepared in accordance with GAAP. For additional details on operating gain, see our “Reportable Segments Results of
Operations” discussion included in this MD&A. For a reconciliation of reportable segment operating revenue to the amounts
of total revenue included in the consolidated statements of income and a reconciliation of reportable segment operating gain
to income before income tax expense, see Note 20, “Segment Information,” of the Notes to Consolidated Financial
Statements included in Part II, Item 8 of this Exhibit 99.1.
Our operating revenue consists of premiums, product revenue, and service fees. Premium revenue is generated from risk-
based contracts where we indemnify our policyholders against costs for covered health and life insurance benefits. Product
revenue represents services performed by CarelonRx for unaffiliated pharmacy customers and includes ingredient costs (net
of any rebates or discounts), including co-payments made by or on behalf of the customer, and service fees. Unaffiliated
pharmacy customers include our fee-based employer groups that contract with CarelonRx for pharmacy services and external
customers outside of the health plans we own. Service fees come from fees from our fee-based customers for the processing
of transactions or network discount savings realized, revenues from our Medicare processing business and revenues from
other health-related businesses, including care management programs and miscellaneous other income.
Our benefit expense primarily includes costs of care for health services consumed by our risk-based members, such as
outpatient care, inpatient hospital care, professional services (primarily physician care) and pharmacy benefit costs. All four
components are affected both by unit costs and utilization rates. Unit costs include the cost of outpatient medical procedures
per visit, inpatient hospital care per admission, physician fees per office visit and prescription drug prices. Utilization rates
represent the volume of consumption of health services and typically vary with the age and health status of our members and
their social and lifestyle choices, along with clinical protocols and medical practice patterns in each of our markets. A portion
of benefit expense recognized in each reporting period consists of actuarial estimates of claims incurred but not yet paid by
us. Any changes in these estimates are recorded in the period the need for such an adjustment arises. While we offer a
diversified mix of managed care products and services through our managed care plans, our aggregate cost of care can
fluctuate based on a change in the overall mix of these products and services. Our managed care plans include: Preferred
Provider Organizations; Health Maintenance Organizations; Point-of-Service plans; traditional indemnity plans and other
hybrid plans, including Consumer-Driven Health Plans; and hospital only and limited benefit products.
We classify certain quality improvement costs as benefit expense. Quality improvement activities are those designed to
improve member health outcomes, prevent hospital readmissions and improve patient safety. They also include expenses for
wellness and health promotion provided to our members. These quality improvement costs may be comprised of expenses
incurred for: (i) medical management, including care coordination and case management; (ii) health and wellness, including
disease management services for such conditions as diabetes, high-risk pregnancies, congestive heart failure and asthma
management and wellness initiatives like weight-loss programs and smoking cessation treatments; and (iii) clinical health
policy, such as identification and use of best clinical practices to avoid harm, identifying clinical errors and safety concerns,
and identifying potential adverse drug interactions.
Our cost of products sold represents the cost of pharmaceuticals dispensed by CarelonRx for our unaffiliated pharmacy
customers (net of rebates or discounts), including any co-payments made by or on behalf of the customer, per-claim
23

-- 88 of 188 --

administrative fees for prescription fulfillment and certain direct costs related to sales and administration of customer
contracts.
Our operating expense consist of fixed and variable costs. Examples of fixed costs are depreciation, amortization and
certain facilities expenses. Certain variable costs, such as premium taxes, vary directly with premium volume. Commission
expense generally varies with premium or membership volume. Other variable costs, such as salaries and benefits, do not
vary directly with changes in premium but are more aligned with changes in membership. The acquisition or loss of a
significant block of business would likely impact staffing levels and thus, associated compensation expense. Other variable
costs include professional and consulting expenses and advertising. Other factors can impact our administrative cost
structure, including systems efficiencies, inflation and changes in productivity.
Our results of operations depend in large part on our ability to accurately predict and effectively manage healthcare costs
through effective contracting with providers of care to our members, product pricing, medical management and health and
wellness programs, innovative product design and our ability to maintain or achieve improvement in our Centers for
Medicare and Medicaid Services Star ratings. Several economic factors related to healthcare costs, such as regulatory
mandates of coverage as well as direct-to-consumer advertising by providers and pharmaceutical companies, have a direct
impact on the volume of care consumed by our members. The potential effect of escalating healthcare costs, any changes in
our ability to negotiate competitive rates with our providers and any regulatory or market-driven restrictions on our ability to
obtain adequate premium rates to offset overall inflation in healthcare costs, including increases in unit costs and utilization
resulting from the aging of the population and other demographics, the impact of epidemics and pandemics, as well as
advances in medical technology, may impose further risks to our ability to profitably underwrite our business and may have a
material adverse impact on our results of operations.
We intend to expand through a combination of organic growth, strategic acquisitions and efficient use of capital in both
existing and new markets. Our growth strategy is designed to enable us to take advantage of additional economies of scale, as
well as provide us access to new and evolving technologies and products. In addition, we believe geographic and product
diversity reduces our exposure to local or regional regulatory, economic and competitive pressures and provides us with
increased opportunities for growth. We market and offer pharmacy services through CarelonRx and other subsidiaries, and
we expect CarelonRx to continue to improve our ability to integrate pharmacy benefits within our medical and specialty
platform. We continued growing our government-sponsored business through organic growth and the acquisitions of MMM
Holdings, LLC (“MMM”) in 2021 and Integra MLTC, Inc. (“Integra”) in 2022. In all other markets, we intend to maintain
our position by delivering excellent service, offering competitively priced products, providing access to high-quality provider
networks and effectively capitalizing on the brand strength of the Blue Cross and Blue Shield names and marks.
For additional information about our business and reportable segments, see Part I, Item 1 “Business” and Note 20,
“Segment Information” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Exhibit 99.1.
COVID-19
The COVID-19 pandemic continues to evolve, putting pressure on the healthcare system, and it has impacted, and may
continue to impact, our membership, benefit expense and member behavior. The full extent of the impact of the COVID-19
pandemic will depend on future developments, which remain uncertain and cannot be predicted at this time. We will continue
to monitor the COVID-19 pandemic as well as resulting legislative and regulatory changes to manage our response and assess
and mitigate potential adverse impacts to our business. For additional discussion regarding the impact of and our risks and
trends related to the COVID-19 pandemic, see “Business Trends” below and Part I, Item 1A “Risk Factors” in our 2022 Form
10-K.
Business Trends
In 2022, we made the decision to modestly expand our participation in the Individual state- or federally-facilitated
marketplaces (the “Public Exchange”) for 2023 after also expanding in 2022. As a result, for 2023 we are offering Individual
Public Exchange products in 138 of the 143 rating regions in which we operate, in comparison to 122 of 143 rating regions in
2022. Our strategy has been, and will continue to be, to only participate in rating regions where we have an appropriate level
of confidence that these markets are on a path toward sustainability, including, but not limited to, factors such as expected
financial performance, regulatory environment and underlying market characteristics. Changes to our business environment
are likely to continue as elected officials at the national and state levels continue to enact, and both elected officials and
24

-- 89 of 188 --

candidates for election continue to propose, significant modifications to existing laws and regulations, including changes to
taxes and fees. In addition, the continuing growth in our government-sponsored business exposes us to increased regulatory
oversight.
Our CarelonRx subsidiary markets and offers PBM services to our affiliated health plan customers throughout the
country, as well as to customers outside of the health plans we own. Our comprehensive PBM services portfolio includes
features such as formulary management, pharmacy networks, a prescription drug database, member services and mail order
capabilities. CarelonRx delegates certain PBM administrative functions, such as claims processing and prescription
fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year
agreement that is set to terminate on December 31, 2024. With CarelonRx, we retain the responsibilities for clinical and
formulary strategy and development, member and employer experiences, operations, sales, marketing, account management
and retail network strategy.
Pricing Trends: We strive to price our health benefit products consistent with anticipated underlying medical cost
trends. We continue to closely monitor the COVID-19 pandemic (including new COVID-19 variants, which may be more
contagious or severe, or less responsive to treatment or vaccines) and the impacts it may have on our pricing, such as surges
in COVID-19 related hospitalizations, infection rates, the cost of COVID-19 vaccines, testing and treatment and the return of
non-COVID-19 healthcare utilization to our estimate of normal levels, based on historical utilization patterns. We frequently
make adjustments to respond to legislative and regulatory changes as well as pricing and other actions taken by existing
competitors and new market entrants. Product pricing in our Employer Group risk-based business remains competitive.
Revenues from the Medicare and Medicaid programs are dependent, in whole or in part, upon annual funding from the
federal government and/or applicable state governments. The Patient Protection and Affordable Care Act (the “ACA”)
imposed an annual Health Insurance Provider Fee (“HIP Fee”) on health insurers that write certain types of health insurance
on U.S. risks. We priced our affected products to cover the impact of the HIP Fee when it was in effect. The HIP Fee was in
effect for 2020 but was permanently repealed beginning in 2021.
Medical Cost Trends: Our medical cost trends are primarily driven by increases in the utilization of services across all
provider types and the unit cost increases of these services. We work to mitigate these trends through various medical
management programs such as care and condition management, program integrity and specialty pharmacy management and
utilization management, as well as benefit design changes. There are many drivers of medical cost trends that can cause
variance from our estimates, such as changes in the level and mix of services utilized, regulatory changes, aging of the
population, health status and other demographic characteristics of our members, epidemics, pandemics, advances in medical
technology, new high cost prescription drugs, provider contracting inflation, labor costs and healthcare provider or member
fraud.
At its onset, the COVID-19 pandemic caused a decrease in utilization of non-COVID-19 health services, which
decreased our claim costs in 2020. As the pandemic continued through 2021, our non-COVID-19 healthcare utilization
experience gradually increased and largely normalized, and our COVID-19 related healthcare expenses increased as new
variants (Delta and Omicron) emerged and vaccinations and boosters became available.
The Omicron variant increased confirmed COVID-19 cases to significant levels at the end of 2021 and the beginning of
2022. The COVID-19 surge quickly declined during the first quarter of 2022, with COVID-19 inpatient hospitalizations,
provider-based tests, visits and vaccinations all decreasing to lower levels by the end of the first half of 2022; concurrently,
non-COVID-19 healthcare utilization recovered from lower levels earlier in the year. Omicron sub-variant viruses as well as
costs associated with updated bivalent vaccinations drove modest increases in COVID-19 related healthcare expenses in the
second half of 2022, but the expected paid claims impact for the second half of 2022 are significantly lower than the winter
surge experienced in each of the prior two years. The ongoing cost and volume of covered services related to the COVID-19
pandemic and a future shift of government supplied vaccinations and treatments to privatized, full cost price points may have
an adverse effect on our future claim costs. We continue to closely monitor the COVID-19 pandemic and its impacts on our
medical cost trends.
For additional discussion regarding business trends, see Part I, Item 1 “Business” of this Exhibit 99.1.
25

-- 90 of 188 --

Regulatory Trends and Uncertainties
With the declaration of COVID-19 as a public health emergency (“PHE”), the federal and state governments enacted,
and may continue to enact, legislation and regulations in response to the COVID-19 pandemic that have had, and we expect
will continue to have, a significant impact on health benefits, consumer eligibility for public programs and our cash flows for
all of our lines of business and which have introduced increased uncertainty around our cost structure. These actions, which
are or have been in effect for various durations, provide, among other things: mandates to waive cost-sharing for COVID-19
testing, vaccines and related services; financial support to healthcare providers; and mandates related to prior authorizations,
payment levels to providers, consumer enrollment windows and telehealth services. The Biden administration renewed the
PHE on January 11, 2023 and has indicated that they intend for the PHE to expire on May 11, 2023.
Under the Consolidated Appropriations Act of 2023, Congress decoupled Medicaid eligibility recertification from the
PHE. As a result, states may begin removing ineligible beneficiaries from their Medicaid programs starting April 1, 2023.
When recertifications resume, we expect a decline in our Medicaid membership. At the same time, we expect growth in our
commercial risk-based and fee-based plans and Medicare, including through the Public Exchanges, as members exiting
Medicaid in our 14 commercial states seek coverage elsewhere.
The Inflation Reduction Act of 2022, which was signed into law in August 2022, contains a variety of provisions that
impact our business including an extension of the American Rescue Plan Act of 2021's enhanced Premium Tax Credits
(“PTC”) through 2025; imposing a new corporate alternative minimum tax; providing a one percent excise tax on repurchases
of stock made after December 31, 2022; allowing the Centers for Medicare and Medicaid Services (“CMS”) to negotiate
prices on a limited set of prescription drugs in Medicare Parts B and D beginning in 2026; instituting caps on insulin cost
sharing in Medicare Parts B and D; redesigning of the Medicare Part D benefit; adding a requirement that drug manufacturers
pay rebates if prices increase beyond inflation; and delaying the implementation of the Trump Administration Medicare drug
rebate rule to 2032. The extension of the enhanced PTC will likely allow for growth in Individual exchange market
enrollment as Medicaid eligibility recertifications resume, supporting continuity of coverage for more people.
The Consolidated Appropriations Act of 2021 (the “2021 Appropriations Act”) has impacted and in the future may have
a material effect upon our business, including procedures and coverage requirements related to surprise medical bills and new
mandates for continuity of care for certain patients, price comparison tools, disclosure of broker compensation, mental health
parity reporting and reporting on pharmacy benefits and drug costs. The requirements of the 2021 Appropriations Act
applicable to us have varying effective dates, some of which were effective in December 2021 and during 2022, and others of
which have been extended into 2023 since the enactment of the 2021 Appropriations Act.
The health plan price transparency regulations issued in October 2020 by the U.S. Departments of Health and Human
Services, Labor and Treasury required us to begin disclosing in July 2022, on a monthly basis, detailed pricing information
regarding negotiated rates for all covered items and services between the plan or issuer and in-network providers and
historical payments to, and billed charges from, out-of-network providers. Additionally, beginning in 2023, we are now
required to make available to members personalized out-of-pocket cost information and the underlying negotiated rates for
500 covered healthcare items and services, including prescription drugs. In 2024, this requirement will expand to all items
and services.
Since its enactment in 2010, the ACA has introduced new risks, regulatory challenges and uncertainties, has impacted
our business model and strategy and has required changes in the way our products are designed, underwritten, priced,
distributed and administered. We expect the ACA will continue to significantly impact our business and results of operations,
including pricing, minimum medical loss ratios and the geographies in which our products are available. We also expect
further and ongoing regulatory guidance on a number of issues related to Medicare, including evolving methodology for
ratings and quality bonus payments. CMS also frequently proposes changes to its program that audits data submitted under
the risk adjustment programs in ways that could increase financial recoveries from plans. We will continue to evaluate the
impact of the ACA as any further developments occur.
For additional discussion regarding regulatory trends and uncertainties, and risk factors that could cause actual results to
differ materially from those contained in forward-looking statements made in this Exhibit 99.1, see Part I, Item 1 “Business
— Regulation” in this Exhibit 99.1 and Part I, Item 1A “Risk Factors” in our 2022 Form 10-K.
26

-- 91 of 188 --

Other Significant Items
Business and Operational Matters
As mentioned above, we began operating as Elevance Health on June 28, 2022. This name change is intended to better
reflect our business and our journey from a traditional health benefits organization to a lifetime, trusted health partner.
Elevance Health supports health at every stage, offering health plans and clinical, behavioral, pharmacy and complex-care
solutions that promote whole health.
On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service & Indemnity
Company, d/b/a Blue Cross and Blue Shield of Louisiana, an independent licensee of the BCBSA that provides healthcare
plans to the Individual, Employer Group, Medicaid and Medicare markets, primarily in the State of Louisiana. This
acquisition aligns with our vision to be an innovative, valuable, and inclusive healthcare partner by providing care
management programs that improve the lives of the people we serve. The acquisition is expected to close by the end of the
fourth quarter of 2023 and is subject to standard closing conditions and customary approvals.
On November 9, 2022, we announced our entrance into an agreement with CarepathRx Aggregator, LLC to acquire its
specialty pharmacy division, which includes BioPlus Parent, LLC (“BioPlus”) and subsidiaries. BioPlus is one of the largest
independent specialty pharmacy organizations in the United States and seeks to connect payors and providers of specialty
pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition aligns
with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that
improve the lives of the people we serve. The acquisition closed on February 15, 2023, and initial purchase accounting has
not been finalized.
On May 5, 2022, we completed our acquisition of Integra. Integra is a managed long-term care plan that serves New
York state Medicaid members, enabling adults with long-term care needs and disabilities to live safely and independently in
their own homes.
On June 29, 2021, we completed our acquisition of MMM, including its Medicare Advantage plan, Medicaid plan and
other affiliated companies. MMM is a Puerto Rico-based integrated healthcare organization and seeks to provide its Medicare
Advantage and Medicaid members with a whole health experience through its network of specialized clinics and wholly
owned independent physician associations. This acquisition aligns with our vision to be an innovative, valuable and inclusive
healthcare partner by providing care management programs that improve the lives of the people we serve.
On April 28, 2021, we completed our acquisition of myNEXUS, Inc. (“myNEXUS”). myNEXUS is a comprehensive
home-based nursing management company for payors and, at the time of acquisition, delivered integrated clinical support
services for Medicare Advantage members across twenty states. This acquisition aligns with our strategy to manage
integrated, whole person multi-site care and support by providing national, large-scale expertise to manage nursing services
in the home and facilitate transitions of care.
For additional information, see Note 3, “Business Acquisitions,” of the Notes to Consolidated Financial Statements
included in Part II, Item 8 of this Exhibit 99.1.
In 2020, we introduced enterprise-wide initiatives to optimize our business and as a result, recorded a charge of $653 in
operating expense. We believe these initiatives largely represent the next step forward in our progression towards becoming a
more agile organization, including process automation and a reduction in our office space footprint. In the fourth quarters of
2022 and 2021, we identified additional office space reductions and related fixed asset impairments due to the continuing
COVID-19 pandemic and recorded net charges of $39 and $202, respectively, in operating expense. For additional
information, see Note 4, “Business Optimization Initiatives” and Note 18, “Leases” of the Notes to Consolidated Financial
Statements included in Part II, Item 8 of this Exhibit 99.1.
Litigation Matters
In the consolidated multi-district proceeding in the United States District Court for the Northern District of Alabama (the
“Court”) captioned In re Blue Cross Blue Shield Antitrust Litigation (“BCBSA Litigation”), the BCBSA and Blue Cross and/
or Blue Shield licensees, including us (the “Blue plans”) previously approved a settlement agreement and release with the
27

-- 92 of 188 --

plaintiffs representing a putative nationwide class of health plan subscribers (the “Subscriber Settlement Agreement”), which
agreement required the Court’s approval to become effective. Generally, the lawsuits in the BCBSA Litigation challenge
elements of the licensing agreements between the BCBSA and the independently owned and operated Blue plans. The cases
were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers. The Subscriber
Settlement Agreement applies only to the subscriber class. The defendants continue to contest the consolidated cases brought
by the provider plaintiffs.
In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the “Final Approval
Order”). In compliance with the Subscriber Settlement Agreement, the Company paid $506 into an escrow account in
September 2022, for an aggregate and full settlement payment by the Company of $596, which was previously accrued in
2020. Four notices of appeal of the Final Approval Order were filed by the September 2022 appeal deadline. Those appeals
are proceeding in the United States Court of Appeals for the Eleventh Circuit. In the event all appellate rights are exhausted
in a manner that affirms the Court’s Final Approval Order, the defendants’ payment and non-monetary obligations under the
Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with
the Subscriber Settlement Agreement. For additional information regarding the BCBSA Litigation, see Note 14,
“Commitments and Contingencies – Litigation and Regulatory Proceedings – Blue Cross Blue Shield Antitrust Litigation,” of
the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Exhibit 99.1.
Selected Operating Performance
During the year ended December 31, 2022, total medical membership increased by 2.2 million, or 4.8%. The increase in
medical membership was driven primarily by organic growth due to the continued temporary suspension of Medicaid
eligibility recertification during the COVID-19 pandemic, as well as organic growth in our Employer Group fee-based
membership.
Operating revenue for the year ended December 31, 2022 was $155,660, an increase of $18,717, or 13.7%, from the year
ended December 31, 2021. The increase in operating revenue was primarily driven by higher premium revenue in our
Medicaid business due to organic membership growth from the continued temporary suspension of Medicaid eligibility
recertification during the COVID-19 pandemic, the acquisition of Integra in the second quarter of 2022 and the acquisition of
Ohio Medicaid members through the purchase of a Medicaid contract in the first quarter of 2022. Membership growth in our
Medicare Advantage and commercial risk-based businesses, as well as premium rate increases to cover medical cost trends,
also generated higher premium revenue. Finally, the increase in operating revenue was further attributable to increased
pharmacy product revenue in our CarelonRx segment, resulting from growth in membership and higher script volume.
Net income for the year ended December 31, 2022 was $5,888, a decrease of $261, or 4.2%, from the year ended
December 31, 2021. The decrease in net income was primarily due to realized losses on financial instruments in 2022, as
compared to gains in 2021, and increased intangible amortization in 2022 related to recent acquisitions and the rebranding of
our products, as we expect to retire certain trade names in the future. These items were partially offset by operating gain
increases in all of our business segments.
Our fully-diluted shareholders' earnings per share (“EPS”) for the year ended December 31, 2022 was $24.28, a decrease
of $0.67, or 2.7%, from the year ended December 31, 2021. Our diluted shares for the year ended December 31, 2022 were
242.8, a decrease of 4.0, or 1.6%, compared to the year ended December 31, 2021. The decrease in EPS resulted from the
decline in net income, partially offset by the impact of lower average shares outstanding in 2022.
Operating cash flow for the year ended December 31, 2022 was $8,399, or approximately 1.4 times net income.
Operating cash flow for the year ended December 31, 2021 was $8,364, or approximately 1.4 times net income. The slight
increase in operating cash flow was primarily due to higher net income in 2022, when adjusted for the impact of investment
losses and gains, partially offset by the timing of working capital changes and the payment pursuant to the Subscriber
Settlement Agreement made in September 2022.
28

-- 93 of 188 --

Membership
Our medical membership includes the following customer types: Individual, Employer Group risk-based, Employer
Group fee-based, BlueCard®, Medicare, Medicaid and our Federal Employees Health Benefits (“FEHB”) Program. We refer
to members in our service areas licensed by the BCBSA as our BCBS-branded, or Anthem BCBS, business. Non-BCBS-
branded business refers to members in our non-BCBS-branded, or Wellpoint plans, which include Amerigroup, Freedom
Health, HealthSun, MMM, Optimum Healthcare and Simply Healthcare plans, as well as HealthLink and UniCare members.
In addition to the above medical membership, we also serve customers who purchase one or more of our other products or
services that are often ancillary to our health business.
• Individual consists of individual customers under age 65 and their covered dependents. Individual policies are
generally sold through independent agents and brokers, retail partnerships, our in-house sales force or via the Public
Exchanges. Individual business is sold on a risk-based basis. We offer on-exchange products through Public
Exchanges and off-exchange products. Federal premium subsidies are available only for certain Public Exchange
Individual products. Unsubsidized Individual customers are generally more sensitive to product pricing and, to a
lesser extent, the configuration of the network and the efficiency of administration. Customer turnover is generally
higher with Individual as compared to Employer Group risk-based. Individual business accounted for 1.7%, 1.7%
and 1.6% of our medical members at December 31, 2022, 2021 and 2020, respectively.
• Employer Group risk-based consists of employer customers who purchase products on a full-risk basis, which are
products for which we charge a premium and indemnify our policyholders against costs for health benefits.
Employer Group risk-based accounts include Local Group customers and National Accounts. Local Group consists
of those employer customers with less than 5% of eligible employees located outside of the headquarter state, as
well as customers with more than 5% of eligible employees located outside of the headquarter state with up to 5,000
eligible employees. In addition, Local Group includes Student Health members. National Accounts generally consist
of multi-state employer groups primarily headquartered in an Elevance Health service area with at least 5% of the
eligible employees located outside of the headquarter state and with more than 5,000 eligible employees. Some
exceptions are allowed based on broker and consultant relationships. Employer Group risk-based accounts are
generally sold through brokers or consultants who work with industry specialists from our in-house sales force and
are offered both on and off the Public Exchanges. Employer Group risk-based accounted for 8.4%, 8.8% and 8.9%
of our medical members at December 31, 2022, 2021 and 2020, respectively.
• Employer Group fee-based customers represent employer groups, Local Group, including UniCare members, and
National Accounts, who purchase fee-based products and elect to retain most or all of the financial risk associated
with their employees’ healthcare costs. Some fee-based customers choose to purchase stop loss coverage to limit
their retained risk. Employer Group fee-based accounts are generally sold through independent brokers or
consultants retained by the customer working with our in-house sales force. Employer Group fee-based accounted
for 42.4%, 42.7% and 45.5% of our medical members at December 31, 2022, 2021 and 2020, respectively.
• BlueCard® host customers represent enrollees of Blue Cross and/or Blue Shield plans not owned by Elevance Health
who receive healthcare services in our BCBSA licensed markets. BlueCard® membership consists of estimated host
members using the national BlueCard® program. Host members are generally members who reside in or travel to a
state in which an Elevance Health subsidiary is the Blue Cross and/or Blue Shield licensee and who are covered
under an employer-sponsored health plan issued by a non-Elevance Health controlled BCBSA licensee (the “home
plan”). We perform certain functions, including claims pricing and administration, for BlueCard® members, for
which we receive service fees from the BlueCard® members’ home plans. Other administrative functions, including
maintenance of enrollment information and customer service, are performed by the home plan. Host members are
computed using, among other things, the average number of BlueCard® claims received per month. BlueCard® host
membership accounted for 13.6%, 13.6% and 14.1% of our medical members at December 31, 2022, 2021 and
2020, respectively.
• Medicare customers are Medicare-eligible individual members age 65 and over who have enrolled in Medicare
Advantage, including Special Needs Plans (“SNPs”), also known as Medicare Advantage SNPs; dual-eligible
programs through Medicare-Medicaid Plans (“MMPs”); Medicare Supplement plans; and Medicare Part D
Prescription Drug Plans (“Medicare Part D”). Medicare Advantage plans provide Medicare beneficiaries with a
managed care alternative to traditional Medicare and often include a Medicare Part D benefit. In addition, our
29

-- 94 of 188 --

Medicare Advantage SNPs provide tailored benefits to special needs individuals who are institutionalized or have
severe or disabling chronic conditions and to dual-eligible customers, who are low-income seniors and persons
under age 65 with disabilities. Medicare Advantage SNPs are coordinated care plans specifically designed to provide
targeted care, covering all the healthcare services considered medically necessary for members and often providing
professional care coordination services, with personal guidance and programs that help members maintain their
health. Medicare Advantage membership also includes Medicare Advantage members in our Group Retiree
Solutions business who are retired members of commercial accounts or retired members of groups who are not
affiliated with our commercial accounts who have selected a Medicare Advantage product through us. Medicare
Supplement plans typically pay the difference between healthcare costs incurred by a beneficiary and amounts paid
by Medicare. Medicare Part D offers a prescription drug plan to Medicare and MMP beneficiaries. MMP, which was
established as a result of the passage of the ACA, is a demonstration program focused on serving members who are
dually eligible for Medicaid and Medicare. Medicare Supplement and Medicare Advantage products are marketed in
the same manner, primarily through independent agents and brokers. Medicare program business accounted for
6.2%, 6.2% and 5.5% of our medical members at December 31, 2022, 2021 and 2020, respectively.
• Medicaid membership represents eligible members who receive health benefits through publicly funded healthcare
programs, including Medicaid, ACA-related Medicaid expansion programs, Temporary Assistance for Needy
Families, programs for seniors and people with disabilities, Children’s Health Insurance Programs, and specialty
programs such as those focused on long-term services and support, HIV/AIDS, foster care, behavioral health and/or
substance abuse disorders, and intellectual disabilities or developmental disabilities, among others. Total Medicaid
program business accounted for 24.3%, 23.4% and 20.6% of our medical members at December 31, 2022, 2021 and
2020, respectively.
• FEHB members consist of United States government employees and their dependents who receive health benefits
within our geographic markets through our participation in the national contract between the BCBSA and the U.S.
Office of Personnel Management. FEHB business accounted for 3.4%, 3.6% and 3.8% of our medical members at
December 31, 2022, 2021 and 2020, respectively.
30

-- 95 of 188 --

The following table presents our medical membership by reportable segment and customer type as of December 31,
2022, 2021 and 2020. Also included below is other membership by product. The medical membership and other membership
presented are unaudited and in certain instances include estimates of the number of members represented by each contract at
the end of the period.
December 31 2022 vs. 2021 2021 vs. 2020
(In thousands) 2022 2021 2020 Change % Change Change % Change
Medical Membership
Individual 789 759 680 30 4.0 % 79 11.6 %
Employer Group Risk-Based 3,988 4,006 3,799 (18) (0.4) % 207 5.4 %
Commercial Risk-Based 4,777 4,765 4,479 12 0.3 % 286 6.4 %
BlueCard® 6,462 6,178 6,059 284 4.6 % 119 2.0 %
Employer Group Fee-Based 20,174 19,395 19,551 779 4.0 % (156) (0.8) %
Commercial Fee-Based 26,636 25,573 25,610 1,063 4.2 % (37) (0.1) %
Medicare Advantage 1,977 1,859 1,428 118 6.3 % 431 30.2 %
Medicare Supplement 947 952 933 (5) (0.5) % 19 2.0 %
Total Medicare 2,924 2,811 2,361 113 4.0 % 450 19.1 %
Medicaid 11,571 10,600 8,852 971 9.2 % 1,748 19.7 %
Federal Employees Health Benefits 1,623 1,625 1,623 (2) (0.1) % 2 0.1 %
Total Medical Membership 47,531 45,374 42,925 2,157 4.8 % 2,449 5.7 %
Other Membership
Life and Disability Members 4,834 4,782 5,064 52 1.1 % (282) (5.6) %
Dental Members 6,692 6,674 6,385 18 0.3 % 289 4.5 %
Dental Administration Members 1,586 1,491 1,316 95 6.4 % 175 13.3 %
Vision Members 9,813 8,031 7,536 1,782 22.2 % 495 6.6 %
Medicare Part D Standalone Members 271 438 413 (167) (38.1) % 25 6.1 %
December 31, 2022 Compared to December 31, 2021
Medical Membership
Total medical membership increased primarily due to organic growth, primarily driven by the continued temporary
suspension of Medicaid eligibility recertification during the COVID-19 pandemic. In addition, Medicaid membership was
positively impacted by the acquisition of Ohio Medicaid members through the purchase of a Medicaid contract in the first
quarter of 2022 and the acquisition of Integra in the second quarter of 2022. Medicare Advantage organic growth due to sales
exceeding lapses also contributed to the overall growth. Our Employer Group fee-based membership increased due to sales
exceeding lapses and positive in-group changes. BlueCard® membership increased due to membership activity at other
BCBSA plans whose members reside in or travel to our licensed areas. Individual membership increased due to our Public
Exchange expansion in 2022.
Other Membership
Our other membership can be impacted by changes in our medical membership, as our medical members often purchase
our other products that are ancillary to our health business. Life and disability membership increased primarily due to new
sales of disability products, partially offset by declines in our life membership. Dental membership increased primarily due to
new sales in our Employer Group risk-based accounts and penetration increases in our FEHB program, partially offset by the
loss of a significant Employer Group fee-based account. Dental administration membership increased primarily due to
increased sales to other BCBS plans associated with the FEHB program. Vision membership increased primarily due to the
launch of a new entry-level vision product in our Employer Group markets. Medicare Part D Standalone membership
declined as we discontinued certain legacy products.
31

-- 96 of 188 --

Consolidated Results of Operations
Our consolidated summarized results of operations and other information for the years ended December 31, 2022, 2021
and 2020 are as follows:
Change
Years Ended December 31 2022 vs. 2021 2021 vs. 2020
2022 2021 2020 $ % $ %
Total operating revenue $ 155,660 $ 136,943 $ 120,808 $ 18,717 13.7 % $ 16,135 13.4 %
Net investment income 1,485 1,378 877 107 7.8 % 501 57.1 %
Net (losses) gains on financial instruments (550) 318 182 (868) NM 136 74.7 %
Total revenues 156,595 138,639 121,867 17,956 13.0 % 16,772 13.8 %
Benefit expense 116,642 102,571 88,045 14,071 13.7 % 14,526 16.5 %
Cost of products sold 13,035 10,895 8,953 2,140 19.6 % 1,942 21.7 %
Operating expense 17,700 15,918 17,450 1,782 11.2 % (1,532) (8.8) %
Other expense1 1,618 1,260 1,181 358 28.4 % 79 6.7 %
Total expenses 148,995 130,644 115,629 18,351 14.0 % 15,015 13.0 %
Income before income tax expense 7,600 7,995 6,238 (395) (4.9) % 1,757 28.2 %
Income tax expense 1,712 1,846 1,666 (134) (7.3) % 180 10.8 %
Net income 5,888 6,149 4,572 (261) (4.2) % 1,577 34.5 %
Net loss attributable to noncontrolling
interests 6 9 — (3) (33.3) % 9 — %
Shareholders’ net income $ 5,894 $ 6,158 $ 4,572 $ (264) (4.3) % $ 1,586 34.7 %
Average diluted shares outstanding 242.8 246.8 254.3 (4.0) (1.6) % (7.5) (2.9) %
Diluted shareholders' net income per share $ 24.28 $ 24.95 $ 17.98 $ (0.67) (2.7) % $ 6.97 38.8 %
Effective tax rate 22.5 % 23.1 % 26.7 % (60)bp3 (360)bp3
Benefit expense ratio2 87.6 % 87.4 % 84.6 % 20bp3 280bp3
Operating expense ratio4 11.4 % 11.6 % 14.4 % (20)bp3 (280)bp3
Income before income tax expense as a
percentage of total revenues 4.9 % 5.8 % 5.1 % (90)bp3 70bp3
Shareholders’ net income as a percentage
of total revenues 3.8 % 4.4 % 3.8 % (60)bp3 60bp3
Certain of the following definitions are also applicable to all other results of operations tables in this discussion:
NM Not meaningful.
1 Includes interest expense, amortization of other intangible assets and loss on extinguishment of debt.
2 Benefit expense ratio represents benefit expense as a percentage of premium revenue. Premiums for the years ended December 31,
2022, 2021 and 2020 were $133,229, $117,373 and $104,109, respectively. Premiums are included in total operating revenue
presented above.
3 bp = basis point; one hundred basis points = 1%.
4 Operating expense ratio represents operating expense as a percentage of total operating revenue.
Year Ended December 31, 2022 Compared to the Year Ended December 31, 2021
Total operating revenue increased primarily as a result of higher premium revenue in our Medicaid business due to
organic membership growth from the continued temporary suspension of Medicaid eligibility recertification during the
COVID-19 pandemic, the acquisition of Integra in the second quarter of 2022 and the acquisition of Ohio Medicaid members
through the purchase of a Medicaid contract in the first quarter of 2022. Membership growth in our Medicare Advantage and
our commercial risk-based businesses, as well as premium rate increases to cover medical cost trends also generated higher
premium revenue. Finally, the increase in operating revenue was further attributable to increased pharmacy product revenue
in our CarelonRx segment, resulting from growth in membership and higher script volume.
Net investment income increased primarily due to higher income from fixed maturity securities, partially offset by
reduced investment income from alternative investments.
32

-- 97 of 188 --

We had net losses on financial instruments in 2022, as compared to net gains in 2021, as a result of increased net losses
on the sale of fixed maturity securities, reduced gains on the sale of equity securities and lower net gains on other invested
assets. These losses were partially offset by lower mark-to-market losses on equity securities still held.
Benefit expense increased primarily due to healthcare costs associated with organic membership growth in our Medicaid
and Medicare businesses and the acquisition of MMM in the second quarter of 2021. Membership growth and higher
healthcare costs in our commercial risk-based business, the acquisition of Integra in the second quarter of 2022 and the
acquisition of Ohio Medicaid members through the purchase of a Medicaid contract in the first quarter of 2022 also
contributed to higher benefit expense.
Our benefit expense ratio increased slightly primarily due to impact of continued membership increases in our Medicaid
business, partially offset by the realignment during 2022 of certain quality improvement costs, from benefit expenses to
operating expenses, due to regulatory clarification.
Cost of products sold reflects the cost of pharmaceuticals dispensed by CarelonRx for our unaffiliated pharmacy
customers. Cost of products sold increased as the corresponding pharmacy product revenues increased.
Operating expense increased primarily due to increased costs to support membership growth and from our acquisitions,
partially offset by lower business optimization charges in 2022 as compared to 2021.
Our operating expense ratio decreased primarily due to operating revenue growth in 2022 and lower business
optimization charges in 2022 as compared to 2021, partially offset by increased costs to support membership growth and the
impact of the realignment of certain quality improvement costs described above.
Other expense increased primarily due to additional amortization of intangible assets related to recent acquisitions and
the rebranding of our products. The amortization period of certain intangible assets was shortened to align with anticipated
dates the new branding will take place. In addition, certain indefinite-lived intangible assets have been reclassified as
definite-lived, and therefore, are now being amortized. For additional information regarding intangible asset amortization, see
Note 10, “Goodwill and Other Intangible Assets” of the Notes to Consolidated Financial Statements included in Part II, Item
8 of this Exhibit 99.1.
Our effective income tax rate decreased primarily due to the impact of geographic changes in our mix of earnings in
2022.
Our shareholders' net income as a percentage of total revenues decreased in 2022 as compared to 2021 as a result of all
the factors discussed above.
33

-- 98 of 188 --

Reportable Segments Results of Operations
The following table presents a summary of our reportable segment financial information for the years ended
December 31, 2022, 2021 and 2020:
Years Ended December 31
Change
2022 vs. 2021 2021 vs. 2020
2022 2021 2020 $ % $ %
Operating Revenue
Health Benefits $ 138,484 $ 121,728 $ 108,271 $ 16,756 13.8 % $ 13,457 12.4 %
CarelonRx 28,526 25,431 21,911 3,095 12.2 % 3,520 16.1 %
Carelon Services 12,277 9,648 5,720 2,629 27.2 % 3,928 68.7 %
Corporate & Other 1,017 602 337 415 68.9 % 265 78.6 %
Eliminations (24,644) (20,466) (15,431) (4,178) 20.4 % (5,035) 32.6 %
Total operating revenue $ 155,660 $ 136,943 $ 120,808 $ 18,717 13.7 % $ 16,135 13.4 %
Operating Gain (Loss)
Health Benefits1 $ 6,061 $ 5,884 $ 5,125 $ 177 3.0 % $ 759 14.8 %
CarelonRx2 1,868 1,684 1,361 184 10.9 % 323 23.7 %
Carelon Services3 455 118 28 337 285.6 % 90 321.4 %
Corporate & Other4 (101) (127) (154) 26 NM 27 NM
Operating Margin
Health Benefits 4.4 % 4.8 % 4.7 % (40) bp5 10 bp5
CarelonRx 6.5 % 6.6 % 6.2 % (10) bp5 40 bp5
Carelon Services 3.7 % 1.2 % 0.5 % 250 bp5 70 bp5
NM Not meaningful.
1 Includes expenses of $36 for business optimization initiatives in 2022; $153 for business optimization initiatives in 2021; $516 for business
optimization initiatives and $548 for the BCBSA Litigation in 2020.
2 Includes expenses of $1 for business optimization initiatives in 2021 and $4 for business optimization initiatives in 2020.
3 Includes expenses of $5 for business optimization initiatives in 2022; $33 for business optimization initiatives in 2021 and $126 for business
optimization initiatives in 2020.
4 Includes (credit) expense of $(2) for business optimization initiatives in 2022 and $11 for business optimization initiatives in 2020.
5 bp = basis point; one hundred basis points = 1%.
Year Ended December 31, 2022 Compared to the Year Ended December 31, 2021
Health Benefits
Operating revenue increased primarily due to higher premium revenue in our Medicaid business, including due to
organic membership growth from the continued temporary suspension of Medicaid eligibility recertification during the
COVID-19 pandemic, the acquisition of MMM at the end of the second quarter of 2021, the acquisition of Integra during the
second quarter of 2022 and the acquisition of Ohio Medicaid members through the purchase of a Medicaid contract in the
first quarter of 2022. Membership growth and premium rate increases to cover medical cost trends in our Medicare
Advantage business and commercial risk-based business also contributed to higher premium revenue.
The increase in operating gain was primarily driven by premium rate increases to cover medical cost trends in our
Medicare business, organic membership growth in our Medicaid business from the continued suspension of eligibility
recertifications during the COVID-19 pandemic and the acquisition of MMM in the second quarter of 2021. The increase in
operating gain was also due to improved medical underwriting performance in our commercial risk-based business and
reduced business optimization charges within the Health Benefits segment in 2022 as compared to 2021.These increases were
partially offset by additional administrative spend to support membership growth.
34

-- 99 of 188 --

CarelonRx
Operating revenue increased as a result of growth in membership and higher script volume.
The increase in operating gain was primarily a result of higher script volume, driven by growth in integrated medical and
pharmacy members in 2022 and favorable out-of-period adjustments to fee-based revenue in the second half of 2022.
Carelon Services
Operating revenue increased primarily due to higher revenue for expanded services performed by Carelon Services for
our Health Benefits segment in 2022 and the acquisition of myNEXUS in the second quarter of 2021. These increases were
partially offset by the reduction of external revenue due to the loss of a behavioral health contract in 2022.
The increase in operating gain was driven by overall improved performance and the acquisition of myNEXUS in the
second quarter of 2021.
Corporate & Other
Operating revenue increased primarily due to higher affiliated revenues in our international operations.
The decrease in operating loss was primarily due to a decline in unallocated corporate expenses in 2022.
Critical Accounting Policies and Estimates
We prepare our consolidated financial statements in conformity with GAAP. Application of GAAP requires management
to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and
accompanying notes and within this MD&A. We consider our most important accounting policies that require significant
estimates and management judgment to be those policies with respect to liabilities for medical claims payable, income taxes,
goodwill and other intangible assets, investments and retirement benefits, which are discussed below. Our other significant
accounting policies are summarized in Note 2, “Basis of Presentation and Significant Accounting Policies,” of the Notes to
Consolidated Financial Statements included in Part II, Item 8 of this Exhibit 99.1.
We continually evaluate the accounting policies and estimates used to prepare the consolidated financial statements. In
general, our estimates are based on historical experience, evaluation of current trends, information from third-party
professionals and various other assumptions that we believe to be reasonable under the known facts and circumstances.
Estimates can require a significant amount of judgment, and a different set of assumptions could result in material changes to
our reported results.
Medical Claims Payable
The most subjective accounting estimate in our consolidated financial statements is our liability for medical claims
payable. At December 31, 2022, this liability was $15,596 and represented 23% of our total consolidated liabilities. We
record this liability and the corresponding benefit expense for incurred but not paid claims, including the estimated costs of
processing such claims. Incurred but not paid claims include (1) an estimate for claims that are incurred but not reported, as
well as claims reported to us but not yet processed through our systems, which approximated 94%, or $14,736, of our total
medical claims liability as of December 31, 2022; and (2) claims reported to us and processed through our systems but not yet
paid, which approximated 6%, or $860, of the total medical claims payable as of December 31, 2022. The level of claims
payable processed through our systems but not yet paid may fluctuate from one period-end to the next, from approximately
1% to 6% of our total medical claims liability, due to timing of when claim payments are made.
Liabilities for both claims incurred but not reported and reported but not yet processed through our systems are
determined in the aggregate, employing actuarial methods that are commonly used by health insurance actuaries and meet
Actuarial Standards of Practice. Our reserving practice for claim liabilities is to consistently recognize the appropriate amount
of reserve within a level of confidence required by Actuarial Standards of Practice. We determine the amount of the liability
for incurred but not paid claims by following a detailed actuarial process that uses both historical claim payment patterns as
well as emerging medical cost trends to project our best estimate of claim liabilities. Under this process, historical paid claims
35

-- 100 of 188 --

data is formatted into “claim triangles,” which compare claim incurred dates to the dates of claim payments. This information
is analyzed to create “completion factors” that represent the average percentage of total incurred claims that have been paid
through a given date after being incurred. Completion factors are applied to claims paid through the period-end date to
estimate the ultimate claim expense incurred for the period. Actuarial estimates of incurred but not paid claim liabilities are
then determined by subtracting the actual paid claims from the estimate of the ultimate incurred claims.
For the most recent incurred months (typically the most recent two months), the percentage of claims paid for claims
incurred in those months is generally low. This makes the completion factor methodology less reliable for such months.
Therefore, incurred claims for recent months are not projected from historical completion and payment patterns; rather, they
are projected by estimating the claims expense for those months based on recent claims expense levels and healthcare trend
levels (“trend factors”).
Because the reserve methodology is based upon historical information, it must be adjusted for known or suspected
operational and environmental changes. These adjustments are made by our actuaries based on their knowledge and their
estimate of emerging impacts to benefit costs and payment speed. Circumstances to be considered in developing our best
estimate of reserves include changes in utilization levels, unit costs, mix of business, benefit plan designs, provider
reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim
submission patterns and operational changes resulting from business combinations. A comparison of prior period liabilities to
re-estimated claim liabilities based on subsequent claims development is also considered in making the liability
determination. In our comparison to prior periods, the methods and assumptions are not changed as reserves are recalculated;
rather, the availability of additional paid claims information drives changes in the re-estimate of the unpaid claim liability. To
the extent appropriate, changes in such development are recorded as a change to current period benefit expense. We had
increased estimation uncertainty on our incurred but not reported liability at December 31, 2022 and December 31, 2021.
Slowdowns in claims submission patterns and increases in utilization levels for COVID-19 testing and treatment are the
primary factors that lead to the increased estimation uncertainty.
We regularly review and set assumptions regarding cost trends and utilization when initially establishing claim liabilities.
We continually monitor and adjust the claims liability and benefit expense based on subsequent paid claims activity. If it is
determined that our assumptions regarding cost trends and utilization are materially different than actual results, our income
statement and financial position could be impacted in future periods. Adjustments of prior year estimates may result in
additional benefit expense or a reduction of benefit expense in the period an adjustment is made. Further, due to the
considerable variability of healthcare costs, adjustments to claim liabilities occur each period and are sometimes significant as
compared to the net income recorded in that period. Prior period development is recognized immediately upon the actuary’s
judgment that a portion of the prior period liability is no longer needed or that an additional liability should have been
accrued. That determination is made when sufficient information is available to ascertain that the re-estimate of the liability is
reasonable.
Although there are many factors that are used as a part of the estimation of our medical claims payable liability, the two
key assumptions having the most significant impact on our incurred but not paid claims liability as of December 31, 2022
were the completion and trend factors. As discussed above, these two key assumptions can be influenced by utilization levels,
unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes,
claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business
combinations.
There is variation in the reasonable choice of completion factors by duration for durations of three months through
twelve months where the completion factors have the most significant impact. As previously discussed, completion factors
tend to be less reliable for the most recent months and therefore are not specifically utilized for months one and two. In our
analysis for the claim liabilities at December 31, 2022, the variability in months three to five was estimated to be between 40
and 90 basis points, while months six through twelve have much lower estimated variability ranging from 0 to 30 basis
points.
The difference in completion factor assumptions results in variability of 2%, or approximately $266, in the December 31,
2022 incurred but not paid claims liability, depending on the completion factors chosen. It is important to note that the
completion factor methodology inherently assumes that historical completion rates will be reflective of the current period.
36

-- 101 of 188 --

However, it is possible that the actual completion rates for the current period will develop differently from historical patterns
and therefore could fall outside the possible variations described herein.
The other major assumption used in the establishment of the December 31, 2022 incurred but not paid claim liability was
the trend factors. In our analysis for the period ended December 31, 2022, there was a 310 basis point differential in the high
and low trend factors. This range of trend factors would imply variability of 3%, or approximately $522, in the incurred but
not paid claims liability, depending upon the trend factors used. Because historical trend factors are often not representative
of current claim trends, the trend experience for the most recent six to nine months, plus knowledge of recent events likely
affecting current trends, have been taken into consideration in establishing the incurred but not paid claims liability at
December 31, 2022. The COVID-19 pandemic continues to have an impact on claim costs for recent dates of service, which
could have an influence on our trend factors. We will continue to monitor emerging experience in order to better understand
the possible implications to our reserves.
See Note 12, “Medical Claims Payable,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of
this Exhibit 99.1, for a reconciliation of the beginning and ending balance for medical claims payable for the years ended
December 31, 2022, 2021 and 2020. Components of the total incurred claims for each year include amounts accrued for
current year estimated claims expense as well as adjustments to prior year estimated accruals. In Note 12, “Medical Claims
Payable,” the line labeled “Net incurred medical claims: Prior years redundancies” accounts for those adjustments made to
prior year estimates. The impact of any reduction of “Net incurred medical claims: Prior years redundancies” may be offset as
we establish the estimate of “Net incurred medical claims: Current year.” Our reserving practice is to consistently recognize
the actuarial best estimate of our ultimate liability for our claims. When we recognize a release of the redundancy, we
disclose the amount that is not in the ordinary course of business, if material.
The ratio of current year medical claims paid as a percent of current year net medical claims incurred was 87.3% for
2022, 87.8% for 2021 and 87.7% for 2020. This ratio serves as an indicator of claims processing speed whereby 2022 claims
were processed at a slightly slower speed than 2021 and 2020.
We calculate the percentage of prior year redundancies in the current year as a percent of prior year net incurred claims
payable less prior year redundancies in the current year in order to demonstrate the development of the prior year reserves.
For the year ended December 31, 2022, this metric was 7.0%, largely driven by favorable trend factor development at the end
of 2021. For the year ended December 31, 2021, this metric was 18.1%, reflecting the estimation uncertainty due to
COVID-19 at the end of 2020, and was largely driven by favorable trend factor development at the end of 2020 as well as
favorable completion factor development from 2020. For the year ended December 31, 2020, this metric was 8.0%, largely
driven by favorable trend factor development at the end of 2019 as well as favorable completion factor development from
2019.
We calculate the percentage of prior year redundancies in the current year as a percent of prior year net incurred medical
claims to indicate the percentage of redundancy included in the preceding year calculation of current year net incurred
medical claims. We believe this calculation supports the reasonableness of our prior year estimate of incurred medical claims
and the consistency in our methodology. For the year ended December 31, 2022, this metric was 0.9%, which was calculated
using the redundancy of $869. This metric was 2.0% for 2021 and 0.8% for 2020. We believe these metrics support the
reasonableness of our estimates. The 2021 metric was impacted by the estimation uncertainty due to COVID-19.
The following table shows the variance between total net incurred medical claims as reported in Note 12, “Medical
Claims Payable,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Exhibit 99.1, for each
of 2021 and 2020 and the incurred claims for such years had it been determined retrospectively (computed as the difference
37

-- 102 of 188 --

between “net incurred medical claims – current year” for the year shown and “net incurred medical claims – prior years
redundancies” for the immediately following year):
Years Ended December 31
2021 2020
Total net incurred medical claims, as reported $ 98,737 $ 84,457
Retrospective basis, as described above 99,571 83,391
Variance $ (834) $ 1,066
Variance to total net incurred medical claims, as reported (0.8) % 1.3 %
Given that our business is primarily short tailed (which means that medical claims are generally paid within twelve
months of the member receiving service from the provider), the variance to total net incurred medical claims, as reported
above, is used to assess the reasonableness of our estimate of ultimate incurred medical claims for a given calendar year with
the benefit of one year of experience. We expect that substantially all of the development of the 2022 estimate of medical
claims payable will be known during 2023.
The 2021 variance to total net incurred medical claims, as reported of (0.8)% was less than the 2020 percentage of
1.3%. This was primarily driven by the fact that the change in the prior year redundancy reported for 2021 as compared to
2020 was less than the change in the prior year redundancy reported for 2020 as compared to 2019.
Income Taxes
We account for income taxes in accordance with the Financial Accounting Standards Board (“FASB”) guidance, which
requires, among other things, the separate recognition of deferred tax assets and deferred tax liabilities. Such deferred tax
assets and deferred tax liabilities represent the tax effect of temporary differences between financial reporting and tax
reporting measured at tax rates enacted at the time the deferred tax asset or liability is recorded. A valuation allowance must
be established for deferred tax assets if it is “more likely than not” that all or a portion may be unrealized. Our judgment is
required in determining an appropriate valuation allowance.
At each financial reporting date, we assess the adequacy of the valuation allowance by evaluating each of our deferred
tax assets based on the following:
• the types of temporary differences that created the deferred tax asset;
• the amount of taxes paid in prior periods and available for a carry-back claim;
• the tax rate at which the deferred tax assets will likely be utilized in the future;
• the forecasted future taxable income, and therefore, likely future deduction of the deferred tax item;
• the implementation of tax planning strategies to recover those deferred tax assets; and
• any significant other issues impacting the likely realization of the benefit of the temporary differences.
Although realization is not assured, we believe it is more likely than not that the deferred tax assets will be realized.
We, like other companies, frequently face challenges from tax authorities regarding the amount of taxes due. These
challenges include questions regarding the timing and amount of deductions that we have taken on our tax returns. In
evaluating any additional tax liability associated with various positions taken in our tax return filings, we record additional
liabilities for potential adverse tax outcomes. Based on our evaluation of our tax positions, we believe we have appropriately
accrued for uncertain tax benefits, as required by the applicable guidance. To the extent we prevail in matters we have
accrued for, our future effective tax rate would be reduced and net income would increase. If we are required to pay more
than accrued, our future effective tax rate would increase and net income would decrease. Our effective tax rate and net
income in any given future period could be materially impacted.
In the ordinary course of business, we are regularly audited by federal and other tax authorities, and from time to time,
these audits result in proposed assessments. We believe our tax positions comply with applicable tax law, and we intend to
defend our positions vigorously through the federal, state and local, and foreign appeals processes. We believe we have
38

-- 103 of 188 --

adequately provided for any reasonably foreseeable outcome related to these matters. Accordingly, although their ultimate
resolution may require additional tax payments, we do not anticipate any material impact on our results of operations or
financial condition from these matters.
For additional information, see Note 8, “Income Taxes,” of the Notes to Consolidated Financial Statements included in
Part II, Item 8 of this Exhibit 99.1.
Goodwill and Other Intangible Assets
Our consolidated goodwill at December 31, 2022 was $24,383 and other intangible assets were $10,315. The sum of
goodwill and other intangible assets represented 33.8% of our total consolidated assets and 95.7% of our consolidated
shareholders’ equity at December 31, 2022.
We follow FASB guidance for business combinations and goodwill and other intangible assets, which specifies the types
of acquired intangible assets that are required to be recognized and reported separately from goodwill. Under the guidance,
goodwill and other intangible assets (with indefinite lives) are not amortized but are tested for impairment at least annually.
Furthermore, goodwill and other intangible assets are allocated to reporting units for purposes of the annual impairment test.
Our impairment tests require us to make assumptions and judgments regarding the estimated fair value of our reporting units,
which include goodwill and other intangible assets. In addition, certain other intangible assets with indefinite lives, such as
trademarks, are also tested separately.
We complete our annual impairment tests of existing goodwill and other intangible assets with indefinite lives during the
fourth quarter of each year. These tests involve the use of estimates related to the fair value of goodwill at the reporting unit
level and other intangible assets with indefinite lives, and require a significant degree of management judgment and the use of
subjective assumptions. Certain interim impairment tests are also performed when potential impairment indicators exist or
changes in our business or other triggering events occur. We have the option of first performing a qualitative assessment for
each reporting unit to determine whether it is more likely than not that the fair value of a reporting unit is less than its
carrying amount, which is an indication that our goodwill may be impaired. These qualitative impairment tests include
assessing events and factors that could affect the fair value of the indefinite-lived intangible assets. Our procedures include
assessing our financial performance, macroeconomic conditions, industry and market considerations, various asset specific
factors and entity specific events. If we determine that a reporting unit’s goodwill may be impaired after utilizing these
qualitative impairment analysis procedures, we are required to perform a quantitative impairment test.
Our quantitative impairment test utilizes the projected income and market valuation approaches for goodwill and the
projected income approach for our indefinite lived intangible assets. Use of the projected income and market valuation
approaches for our goodwill impairment test reflects our view that both valuation methodologies provide a reasonable
estimate of fair value. The projected income approach is developed using assumptions about future revenue, expenses and net
income derived from our internal planning process. These estimated future cash flows are then discounted. Our assumed
discount rate is based on our industry’s weighted-average cost of capital. Market valuations are based on observed multiples
of certain measures including revenue; earnings before interest, taxes, depreciation and amortization; and book value of
invested capital (debt and equity) and include market comparisons to publicly traded companies in our industry.
We did not incur any impairment losses as a result of our 2022 annual impairment tests, as it was determined that it is
more likely than not that the estimated fair values of our reporting units were substantially in excess of the carrying values as
of December 31, 2022. Additionally, we do not believe that the estimated fair values of our reporting units are at risk of
becoming impaired in the next twelve months.
If estimated fair values are less than the carrying values of goodwill and other intangibles with indefinite lives in future
annual impairment tests, or if significant impairment indicators are noted relative to other intangible assets subject to
amortization, we may be required to record impairment losses against future income.
For additional information, see Note 3, “Business Acquisitions” and Note 10, “Goodwill and Other Intangible Assets” of
the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Exhibit 99.1.
39

-- 104 of 188 --

Investments
Current and long-term marketable investment securities were $27,657 at December 31, 2022 and represented 26.9% of
our total consolidated assets at December 31, 2022. We classify fixed maturity securities in our investment portfolio as
“available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current
operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity.
Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to
contractual maturity.
Our impairment review is subjective and requires a high degree of judgment. We conduct this review on a quarterly
basis, using both qualitative and quantitative factors. Such factors considered include the extent to which a security’s market
value has been less than its cost, the reasons for the decline in value (i.e., credit event compared to liquidity, general credit
spread widening, currency exchange rate or interest rate factors), financial condition and near term prospects of the issuer,
including the credit ratings and changes in the credit ratings of the issuer, recommendations of investment advisors, and
forecasts of economic, market or industry trends.
If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it
is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we
write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements
of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not
have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit
component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment
loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated
other comprehensive (loss) income. Furthermore, unrealized losses entirely caused by non-credit-related factors related to
fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in
accumulated other comprehensive (loss) income.
The credit component of an impairment is determined primarily by comparing the net present value of projected future
cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our
best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of
purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the
underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default
rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding
probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated
with a default.
We have a committee of accounting and investment associates and management that is responsible for managing the
impairment review process. We believe that we have adequately reviewed our investment securities for impairment and that
our investment securities are carried at fair value. We have established an allowance for credit loss and recorded credit loss
expense as a reflection of our expected impairment losses. Given the inherent uncertainty of changes in market conditions
and the significant judgments involved, there is continuing risk that declines in fair value may occur and additional
impairment losses on investments may be recorded in future periods.
In addition to marketable investment securities, we held additional long-term investments of $5,685, or 5.5% of total
consolidated assets, at December 31, 2022. These long-term investments consisted primarily of certain other equity
investments, the cash surrender value of corporate-owned life insurance policies and mortgage loans. Due to their less liquid
nature, these investments are classified as long-term.
Through our investing activities, we are exposed to financial market risks, including those resulting from changes in
interest rates and changes in equity market valuations. We manage market risks through our investment policy, which
establishes credit quality limits and limits on investments in individual issuers. Ineffective management of these risks could
have an impact on our future results of operations and financial condition. Our investment portfolio includes fixed maturity
securities with a fair value of $26,704 at December 31, 2022. The weighted-average credit rating of these securities was “A”
as of December 31, 2022. Included in this balance are investments in fixed maturity securities of states, municipalities and
political subdivisions of $890 that are guaranteed by third parties. With the exception of 16 securities with a fair value of $9,
40

-- 105 of 188 --

these securities are all investment-grade and carry a weighted-average credit rating of “AA” as of December 31, 2022. The
securities are guaranteed by a number of different guarantors, and we do not have any material exposure to any single
guarantor, neither indirectly through the guarantees, nor directly through investment in the guarantor. Further, due to the high
underlying credit rating of the issuers, the weighted-average credit rating of the fixed maturity securities without a guarantee,
for which such information is available, was “A” as of December 31, 2022.
Fair values of fixed maturity and equity securities are based on quoted market prices, where available. These fair values
are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination
of fair value in accordance with FASB guidance for fair value measurements and disclosures. We have controls in place to
review the pricing services’ qualifications and procedures used to determine fair values. In addition, we periodically review
the pricing services’ pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable.
We obtain quoted market prices for each security from the pricing services, which are derived through recently reported
trades for identical or similar securities, making adjustments through the reporting date based upon available market
observable information. For securities not actively traded, the pricing services may use quoted market prices of comparable
instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar
securities. Inputs that are often used in these valuation methodologies include, but are not limited to, broker quotes,
benchmark yields, credit spreads, default rates and prepayment speeds. As we are responsible for the determination of fair
value, we perform analysis on the prices received from the pricing services to determine whether the prices are reasonable
estimates of fair value. Our analysis includes procedures such as a review of month-to-month price fluctuations and price
comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing
services during the years ended December 31, 2022 and 2021.
In certain circumstances, it may not be possible to derive pricing model inputs from observable market activity, and
therefore, such inputs are estimated internally. Such securities are designated Level III in accordance with FASB guidance.
Securities designated Level III at December 31, 2022 totaled $581 and represented approximately 1.7% of our total assets
measured at fair value on a recurring basis. Our Level III securities primarily consisted of certain corporate securities and
equity securities for which observable inputs were not always available and the fair values of these securities were estimated
using inputs including, but not limited to, prepayment speeds, credit spreads, default rates and benchmark yields.
For additional information, see Part II, Item 7A, “Quantitative and Qualitative Disclosures about Market Risk” included
in our 2022 Form 10-K and Note 2, “Basis of Presentation and Significant Accounting Policies,” Note 5, “Investments,” and
Note 7, “Fair Value” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Exhibit 99.1.
Retirement Benefits
Pension Benefits
We sponsor defined benefit pension plans for some of our employees. These plans are accounted for in accordance with
FASB guidance for retirement benefits, which requires that amounts recognized in financial statements be determined on an
actuarial basis. As permitted by the guidance, we calculate the value of plan assets as described below. Further, the difference
between our expected rate of return and the actual performance of plan assets, as well as certain changes in pension liabilities,
are amortized over future periods.
An important factor in determining our pension expense is the assumption for expected long-term return on plan assets.
As of our December 31, 2022 measurement date, we selected a weighted-average long-term rate of return on plan assets of
6.58%. We use a total portfolio return analysis in the development of our assumption. Factors such as past market
performance, the long-term relationship between fixed maturity and equity securities, interest rates, inflation and asset
allocations are considered in the assumption. The assumption includes an estimate of the additional return expected from
active management of the investment portfolio. Peer data and an average of historical returns are also reviewed for
appropriateness of the selected assumption. We believe our assumption of future returns is reasonable. However, if we lower
our expected long-term return on plan assets, future contributions to the pension plan and pension expense would likely
increase.
This assumed long-term rate of return on assets is applied to a calculated value of plan assets, which recognizes changes
in the fair value of plan assets in a systematic manner over three years, producing the expected return on plan assets that is
41

-- 106 of 188 --

included in the determination of pension expense. We apply a corridor approach to amortize unrecognized actuarial gains or
losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater of the projected
benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime of the
workforce as a component of pension expense. The net deferral of past asset gains or losses affects the calculated value of
plan assets and, ultimately, future pension expense.
The discount rate reflects the current rate at which the pension liabilities could be effectively settled at the end of the year
based on our most recent measurement date. We use the annual spot rate approach for setting our discount rate. Under the
spot rate approach, individual spot rates from a full yield curve of published rates are used to discount each plan’s cash flows
to determine the plan’s obligation. At the December 31, 2022 measurement date, the weighted-average discount rate under
the annual spot rate approach was 5.18%, compared to 2.70% at the December 31, 2021 measurement date. The net effect of
changes in the discount rate, as well as the net effect of other changes in actuarial assumptions and experience, have been
deferred and amortized as a component of pension expense in accordance with FASB guidance.
In managing the plan assets, our objective is to be a responsible fiduciary while minimizing financial risk. Plan assets
include a diversified mix of equity securities, investment grade fixed maturity securities and other types of investments across
a range of sectors and levels of capitalization to maximize long-term return for a prudent level of risk. In addition to
producing a reasonable return, the investment strategy seeks to minimize the volatility in our expense and cash flow.
Other Postretirement Benefits
We provide some associates with certain medical, vision and dental benefits upon retirement. We use various actuarial
assumptions, including a discount rate and the expected trend in healthcare costs, to estimate the costs and benefit obligations
for our retiree benefits.
At our December 31, 2022 measurement date, the selected discount rate for all plans was 5.12%, compared to a discount
rate of 2.49% at the December 31, 2021 measurement rate. We developed this rate using the annual spot rate approach as
described above.
The assumed healthcare cost trend rates used to measure the expected cost of pre-Medicare (those who are not currently
eligible for Medicare benefits) other benefits at our December 31, 2022 measurement date was 8.00% for 2023 with a gradual
decline to 4.50% by the year 2035. The assumed healthcare cost trend rates used to measure the expected cost of post-
Medicare (those who are currently eligible for Medicare benefits) other benefits at our December 31, 2022 measurement date
was 6.50% for 2023 with a gradual decline to 4.50% by the year 2035. These estimated trend rates are subject to change in
the future.
For additional information regarding our retirement benefits, see Note 11, “Retirement Benefits” of the Notes to
Consolidated Financial Statements included in Part II, Item 8 of this Exhibit 99.1.
New Accounting Pronouncements
For information regarding new accounting pronouncements that were issued or became effective during the year ended
December 31, 2022 that had, or are expected to have, a material impact on our financial position, results of operations or
financial statement disclosures, see the “Recently Adopted Accounting Guidance” section of Note 2, “Basis of Presentation
and Significant Accounting Policies,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this
Exhibit 99.1.
Liquidity and Capital Resources
Introduction
Our cash receipts result primarily from premiums, product revenue, service fees, investment income, proceeds from the
sale or maturity of our investment securities, proceeds from borrowings, and proceeds from the issuance of common stock
under our employee stock plans. Cash disbursements result mainly from claims payments, administrative expenses, taxes,
purchases of investment securities, interest expense, payments on borrowings, acquisitions, capital expenditures, repurchases
of our debt securities and common stock and the payment of cash dividends. Cash outflows fluctuate with the amount and
42

-- 107 of 188 --

timing of settlement of these transactions. Any future decline in our profitability would likely have an unfavorable impact on
our liquidity.
We manage our cash, investments and capital structure so we are able to meet the short-term and long-term obligations
of our business while maintaining financial flexibility and liquidity. We forecast, analyze and monitor our cash flows to
enable investment and financing within the overall constraints of our financial strategy.
A substantial portion of the assets held by our regulated subsidiaries are in the form of cash and cash equivalents and
investments. After considering expected cash flows from operating activities, we generally invest cash that exceeds our near
term obligations in longer term marketable fixed maturity securities to improve our overall investment income returns. Our
investment strategy is to make investments consistent with insurance statutes and other regulatory requirements, while
preserving our asset base. Our investments are generally available-for-sale to meet liquidity and other needs. Our subsidiaries
pay out excess capital annually in the form of dividends to their respective parent companies for general corporate use, as
permitted by applicable regulations.
The availability of financing in the form of debt or equity is influenced by many factors, including our profitability,
operating cash flows, debt levels, debt ratings, contractual restrictions, regulatory requirements and market conditions. The
securities and credit markets have in the past experienced higher than normal volatility. Interest rates on fixed debt income
securities increased in 2022 and may continue to do so in 2023, which could increase our borrowing costs if we elect to issue
debt. During recent years, the federal government and various governmental agencies have taken a number of steps to
strengthen the regulation of the financial services market. In addition, governments around the world have developed their
own plans to provide stability and security in the credit markets and to ensure adequate capital in certain financial institutions.
A summary of our major sources and uses of cash and cash equivalents for the years ended December 31, 2022, 2021
and 2020 is as follows:
Years Ended December 31 $ Change
2022 2021 2020 2022 vs. 2021 2021 vs. 2020
Sources of Cash:
Net cash provided by operating activities $ 8,399 $ 8,364 $ 10,688 $ 35 $ (2,324)
Issuances of commercial paper and short- and long-term debt,
net of repayments 862 2,719 — (1,857) 2,719
Issuances of common stock under employee stock plans 182 203 176 (21) 27
Other sources of cash, net 762 — 315 762 (315)
Total sources of cash 10,205 11,286 11,179 (1,081) 107
Uses of Cash:
Purchases of investments, net of proceeds from sales,
maturities, calls and redemptions (2,338) (4,056) (3,433) 1,718 (623)
Repurchase and retirement of common stock (2,316) (1,900) (2,700) (416) 800
Purchases of subsidiaries, net of cash acquired (649) (3,476) (1,976) 2,827 (1,500)
Purchases of property and equipment (1,152) (1,087) (1,021) (65) (66)
Repayments of commercial paper and short- and long-term
debt, net of issuances — — (298) — 298
Cash dividends (1,229) (1,104) (954) (125) (150)
Other uses of cash, net — (514) — 514 (514)
Total uses of cash (7,684) (12,137) (10,382) 4,453 (1,755)
Effect of foreign exchange rates on cash and cash equivalents (14) (10) 7 (4) (17)
Net increase (decrease) in cash and cash equivalents $ 2,507 $ (861) $ 804 $ 3,368 $ (1,665)
43

-- 108 of 188 --

Liquidity—Year Ended December 31, 2022 Compared to Year Ended December 31, 2021
The slight increase in cash provided by operating activities was primarily due to higher net income in 2022, when
adjusted for the impact of investment losses and gains, partially offset by the timing of working capital changes and the
payment pursuant to the Subscriber Settlement Agreement made in September 2022.
Other significant changes in sources and uses of cash year-over-year included lower amounts used for purchases of
subsidiaries, net of cash acquired and reduced cash used for purchases of investments, net of proceeds from sales, maturities,
calls and redemptions. These decreased uses of cash were partially offset by reduced net proceeds received from the issuance
of commercial paper and short-term and long-term debt and increased use of cash for share repurchases.
Financial Condition
We maintained a strong financial condition and liquidity position, with consolidated cash, cash equivalents and
investments in fixed maturity and equity securities of $35,044.0 at December 31, 2022. Since December 31, 2021, total cash,
cash equivalents and investments in fixed maturity and equity securities increased by $1,384, primarily due to cash generated
from operations. This increase was partially offset by cash used for acquisitions, common stock repurchases, purchases of
property and equipment and cash dividends paid to shareholders.
Many of our subsidiaries are subject to various government regulations that restrict the timing and amount of dividends
and other distributions that may be paid to their respective parent companies. Certain accounting practices prescribed by
insurance regulatory authorities, or statutory accounting practices, differ from GAAP. Changes that occur in statutory
accounting practices, if any, or other regulatory requirements, could impact our subsidiaries’ future dividend capacity. In
addition, we have agreed to certain undertakings to regulatory authorities, including the requirement to maintain certain
capital levels in certain of our subsidiaries.
At December 31, 2022, we held $1,209 of cash, cash equivalents and investments at the parent company, which are
available for general corporate use, including investment in our businesses, acquisitions, potential future common stock
repurchases and dividends to shareholders, repurchases of debt securities and debt and interest payments.
Periodically, we access capital markets and issue debt (“Notes”) for long-term borrowing purposes, for example, to
refinance debt, to finance acquisitions or for share repurchases. Certain of these Notes may have a call feature that allows us
to redeem the Notes at any time at our option and/or a put feature that allows a Note holder to redeem the Notes upon the
occurrence of both a change in control event and a downgrade of the Notes below an investment grade rating. For more
information on our debt, including redemptions and issuances, see Note 13, “Debt” of the Notes to Consolidated Financial
Statements included in Part II, Item 8 of this Exhibit 99.1.
We calculate our consolidated debt-to-capital ratio, a non-GAAP measure, from the amounts presented on our audited
consolidated balance sheets included in Part II, Item 8 of this Exhibit 99.1. Our debt-to-capital ratio is calculated as total debt
divided by total debt plus total shareholders’ equity. Total debt is the sum of short-term borrowings, current portion of long-
term debt and long-term debt, less current portion. We believe our debt-to-capital ratio assists investors and rating agencies in
measuring our overall leverage and additional borrowing capacity. In addition, our bank covenants include a maximum debt-
to-capital ratio that we cannot and did not exceed. Our debt-to-capital ratio may not be comparable to similarly titled
measures reported by other companies. Our consolidated debt-to-capital ratio was 39.9% and 38.9% as of December 31, 2022
and 2021, respectively.
Our senior debt is rated “A” by S&P Global Ratings, “BBB” by Fitch Ratings, Inc., “Baa2” by Moody’s Investor
Service, Inc. and “bbb+” by AM Best Company, Inc. We intend to maintain our senior debt investment grade ratings. If our
credit ratings are downgraded, our business, liquidity, financial condition and results of operations could be adversely
impacted by limitations on future borrowings and a potential increase in our borrowing costs.
Capital Resources
We have a shelf registration statement on file with the Securities and Exchange Commission to register an unlimited
amount of any combination of debt or equity securities in one or more offerings. Specific information regarding terms and
securities being offered will be provided at the time of an offering. Proceeds from future offerings are expected to be used for
44

-- 109 of 188 --

general corporate purposes, including, but not limited to, the repayment of debt, investments in or extensions of credit to our
subsidiaries and the financing of possible acquisitions or business expansions.
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes.
In April 2022, we amended and restated the credit agreement for the 5-Year Facility to, among other things, extend the
maturity date of the 5-Year Facility from June 2024 to April 2027 and increase the amount of credit available under the 5-
Year Facility from $2,500 to $4,000. Also in April 2022, concurrently with the amendment and restatement of the 5-Year
Facility, we terminated our 364-day senior revolving credit facility that provided for credit in the amount of $1,000, which
was scheduled to mature in June 2022. Our ability to borrow under the 5-Year Facility is subject to compliance with certain
covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to
increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. We do not believe the restrictions
contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of December 31, 2022,
we were in compliance with all of our debt covenants under the 5-Year Facility. There were no amounts outstanding under
the 5-Year Facility at December 31, 2022.
Through certain subsidiaries, we have entered into multiple 364-day lines of credit (the “Subsidiary Credit Facilities”)
with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provide combined credit up to $200.
Our ability to borrow under the Subsidiary Credit Facilities is subject to compliance with certain covenants. At December 31,
2022, we had no outstanding borrowings under the Subsidiary Credit Facilities.
We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general
corporate purposes. In July 2022, we increased the amount available under the commercial paper program from $3,500 to
$4,000. Should commercial paper issuance become unavailable, we have the ability to use a combination of cash on hand
and/or our 5-Year Facility, which provides for credit in the amount of $4,000, to redeem any outstanding commercial paper
upon maturity. At December 31, 2022, we had $0 outstanding under our commercial paper program.
While there is no assurance in the current economic environment, we believe the lenders participating in our 5-Year
Facility and Subsidiary Credit Facilities, if market conditions allow, would be willing to provide financing in accordance with
their legal obligations.
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan
Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively the
“FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral
requirements. At December 31, 2022, we had $265 of outstanding short-term borrowings from the FHLBs.
As discussed in “Financial Condition” above, many of our subsidiaries are subject to various government regulations
that restrict the timing and amount of dividends and other distributions that may be paid. Based upon these requirements, we
currently estimate that approximately $3,500 of dividends will be paid to us by our subsidiaries during 2023. During 2022,
we received $3,097 of dividends from our subsidiaries.
In addition to regulations regarding the timing and amount of dividends, our regulated subsidiaries’ states of domicile
have statutory risk-based capital (“RBC”) requirements for health and other insurance companies and health maintenance
organizations largely based on the National Association of Insurance Commissioners (“NAIC”) Risk-Based Capital (RBC)
For Health Organizations Model Act (“RBC Model Act”). These RBC requirements are intended to measure capital
adequacy, taking into account the risk characteristics of an insurer’s investments and products. The NAIC sets forth the
formula for calculating the RBC requirements, which are designed to take into account asset risks, insurance risks, interest
rate risks and other relevant risks with respect to an individual insurance company’s business. In general, under the RBC
Model Act, an insurance company must submit a report of its RBC level to the state insurance department or insurance
commissioner, as appropriate, at the end of each calendar year. Our regulated subsidiaries’ respective RBC levels as of
December 31, 2022, which was the most recent date for which reporting was required, were in excess of all applicable
mandatory RBC requirements. In addition to exceeding these RBC requirements, we are in compliance with the liquidity and
capital requirements for a licensee of the BCBSA and with the tangible net worth requirements applicable to certain of our
California subsidiaries. For additional information, see Note 22, “Statutory Information” of the Notes to Consolidated
Financial Statements included in Part II, Item 8 of this Exhibit 99.1.
45

-- 110 of 188 --

Future Sources and Uses of Liquidity
Short-Term Liquidity Requirements
As previously described, our cash disbursements result mainly from claims payments, administrative expenses, taxes,
purchases of investment securities, interest expense, payments on borrowings, acquisitions, capital expenditures, repurchases
of our debt securities and common stock and the payment of cash dividends. We believe cash on hand, operating cash
receipts, investments and amounts available under our commercial paper program, our 5-Year Facility and our Subsidiary
Credit Facilities and borrowings available from the FHLBs will be adequate to fund our expected cash disbursements over the
next twelve months.
Long-Term Liquidity Requirements
As of December 31, 2022, our long-term cash disbursements required under various contractual obligations and
commitments were:
• Debt and interest expense: Future debt and estimated interest payments were $25,804, with $2,674 due within the next
twelve months. For additional information, see Note 13 “Debt” of the Notes to Consolidated Financial Statements
included in Part II, Item 8 of this Exhibit 99.1.
• Operating leases: We lease office space and certain computer equipment, for which the future estimated payments were
$1,028, with $206 due within the next twelve months. For additional information, see Note 18 “Leases” of the Notes to
Consolidated Financial Statements included in Part II, Item 8 of this Exhibit 99.1.
• Other liabilities: These liabilities primarily consist of future policy reserves, projected other postretirement benefits,
deferred compensation, supplemental executive retirement plan liabilities and certain other miscellaneous long-term
obligations. Amounts due within twelve months were $26, with $1,040 due in future periods. Estimated future payments
for funded pension benefits have been excluded from these numbers, as we had no funding requirements under the
Employee Retirement Income Security Act of 1974, as amended, at December 31, 2022, as a result of the value of the
assets in the plans. In addition, gross liabilities for uncertain tax positions and interest for which we cannot reasonably
estimate the timing of the resolutions with the respective taxing authorities have not been included. For further
information, see Note 8, “Income Taxes” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of
this Exhibit 99.1.
• Purchase obligations: These obligations include estimated payments for future services under contractual arrangements
from third-party service vendors. Amounts due within the next twelve months for these purchase obligations were
$1,124, while longer term payments were $2,927. For further information, see Note 14, “Commitments and
Contingencies” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Exhibit 99.1.
• Investment commitments: These include unfunded capital commitments for alternative investments and low-income
housing tax credits. Estimated amounts due were $1,504, including $314 due within the next twelve months.
In addition to the contractual obligations and commitments discussed above, we have a variety of other contractual
agreements related to acquiring materials and services used in our operations. However, we do not believe these other
agreements contain material noncancelable commitments.
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases
and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is
at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity
needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
On January 24, 2023, our Audit Committee declared a quarterly cash dividend to shareholders of $1.48 per share on the
outstanding shares of our common stock. This quarterly dividend is payable on March 24, 2023 to the shareholders of record
as of March 10, 2023.
Under our Board of Directors’ authorization, we maintain a common stock repurchase program. As of December 31,
2022, we had Board authorization of $1,876 to repurchase our common stock. On January 24, 2023, our Audit Committee,
pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to our common stock repurchase
46

-- 111 of 188 --

program. No duration has been placed on our common stock repurchase program, and we reserve the right to discontinue the
program at any time. We intend to utilize this authorization over a multi-year period, subject to market and industry
conditions.
We believe that funds from future operating cash flows, cash and investments and funds available under our credit
facilities and/or from public or private financing sources will be sufficient for future operations and commitments, and for
capital acquisitions and other strategic transactions.
We do not have any off-balance sheet derivative instruments, guarantee transactions, agreements or other contractual
arrangements or any indemnification agreements that will require funding in future periods. We have not transferred assets to
an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not hold any variable
interest in an unconsolidated entity where such entity provides us with financing, liquidity, market risk or credit risk support.
See Note 2 “Subsidiary Transactions” of the Notes to Condensed Financial Statements included in Part IV, Item 15 of this
Exhibit 99.1 for additional detail on the Elevance Health, Inc. parent guarantees of certain subsidiaries.
47

-- 112 of 188 --

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
Elevance Health, Inc.
CONSOLIDATED FINANCIAL STATEMENTS
Years ended December 31, 2022, 2021 and 2020
Contents
Reports of Independent Registered Public Accounting Firm (PCAOB ID:42) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
Audited Consolidated Financial Statements:
Consolidated Balance Sheets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
Consolidated Statements of Income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
Consolidated Statements of Comprehensive Income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
Consolidated Statements of Cash Flows . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
Consolidated Statements of Shareholders’ Equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
Notes to Consolidated Financial Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
48

-- 113 of 188 --

Report of Independent Registered
Public Accounting Firm
To the Shareholders and the Board of Directors of Elevance Health, Inc.
Opinion on Internal Control Over Financial Reporting
We have audited Elevance Health, Inc.’s internal control over financial reporting as of December 31, 2022, based on criteria
established in Internal Control–Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway
Commission (2013 framework) (the COSO criteria). In our opinion, Elevance Health, Inc. (the Company) maintained, in all
material respects, effective internal control over financial reporting as of December 31, 2022, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States)
(PCAOB), the consolidated balance sheets of Elevance Health, Inc. as of December 31, 2022 and 2021, the related consolidated
statements of income, comprehensive income, shareholders’ equity and cash flows for each of the three years in the period ended
December 31, 2022, and the related notes and financial statement schedule listed in the Index at Item 15(c) and our report dated
February 15, 2023 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its
assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on
Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over
financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be
independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material
respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material
weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and
performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable
basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that
(1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of
the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of
financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the
company are being made only in accordance with authorizations of management and directors of the company; and (3) provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s
assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because
of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ Ernst & Young LLP
Indianapolis, Indiana
February 15, 2023
49

-- 114 of 188 --

Report of Independent Registered
Public Accounting Firm
To the Shareholders and the Board of Directors of Elevance Health, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Elevance Health, Inc. (the Company) as of December 31, 2022
and 2021, the related consolidated statements of income, comprehensive income, shareholders’ equity, and cash flows for each of
the three years in the period ended December 31, 2022, and the related notes and financial statement schedule listed in the Index at
Item 15(c) (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements
present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its
operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally
accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States)
(PCAOB), the Company’s internal control over financial reporting as of December 31, 2022, based on criteria established in
Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013
framework), and our report dated February 15, 2023 expressed an unqualified opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the
Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error
or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements,
whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a
test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was
communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are
material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The
communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as
a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter
or on the account or disclosures to which it relates.
50

-- 115 of 188 --

Valuation of Incurred but Not Paid Claims
Description of the
Matter
Medical claims payable was $15,596 million at December 31, 2022, a significant portion of which
related to the Company’s estimate for claims that are incurred but not paid. As discussed in Note 2
to the consolidated financial statements, the Company’s liability for incurred but not paid claims is
determined using actuarial methods that include a number of factors and assumptions, including
completion factors, which represent the average percentage of total incurred claims that have been
paid through a given date after being incurred based on historical paid claims data, and trend factors,
which represent an estimate of claims expense based on recent claims expense levels and healthcare
cost levels. There is significant uncertainty inherent in determining management’s best estimate of
completion and trend factors, which are used to calculate actuarial estimates of incurred but not paid
claims.
Auditing management’s estimate of incurred but not paid claims was complex and required the
involvement of our actuarial specialists due to the highly judgmental nature of the completion and
trend factor assumptions used in the valuation process. The significant judgment was primarily due
to the sensitivity of management’s best estimate of completion and trend factor assumptions, which
have a significant impact on the valuation of incurred but not paid claims.
How We Addressed
the Matter in Our
Audit
We obtained an understanding, evaluated the design and tested the operating effectiveness of
controls over the Company’s actuarial process for estimating the liability for incurred but not paid
claims. These audit procedures included among others, testing management review controls over
completion and trend factor assumptions and the review and approval processes that management
has in place for estimating the liability for incurred but not paid claims.
To test the Company’s liability for incurred but not paid claims, our audit procedures included,
among others, testing the completeness and accuracy of the underlying claims and membership data
recorded in the source claims processing and disbursement systems to the data used by management
in developing completion and trend factor assumptions and agreeing a sample of incurred and paid
claims to source documentation. With the support of actuarial specialists, we analyzed the
Company’s completion and trend factor assumptions based on historical claim experience and
emerging cost trends, and independently calculated a range of reasonable reserve estimates for
comparison to management’s best estimate of the liability for incurred but not paid claims.
Additionally, we performed a review of the prior period liabilities for incurred but not paid claims to
subsequent claims development.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 1944.
Indianapolis, Indiana
February 15, 2023, except for Note 2 and Note 20, as to which the date is October 18, 2023
51

-- 116 of 188 --

Elevance Health, Inc.
Consolidated Balance Sheets
December 31,
2022 December 31,
2021
(In millions, except share data)
Assets
Current assets:
Cash and cash equivalents $ 7,387 $ 4,880
Fixed maturity securities (amortized cost of $28,226 and $25,641; allowance for credit losses of $9 and $6) 25,952 26,267
Equity securities 953 1,881
Premium receivables 7,083 5,681
Self-funded receivables 4,663 4,010
Other receivables 4,298 3,749
Other current assets 5,281 4,654
Total current assets 55,617 51,122
Long-term investments:
Fixed maturity securities (amortized cost of $789 and $616; allowance for credit losses of $0 and $0) 752 632
Other invested assets 5,685 5,225
Property and equipment, net 4,316 3,919
Goodwill 24,383 24,228
Other intangible assets 10,315 10,615
Other noncurrent assets 1,687 1,715
Total assets $ 102,755 $ 97,456
Liabilities and equity
Liabilities
Current liabilities:
Medical claims payable $ 15,596 $ 13,518
Other policyholder liabilities 5,933 5,521
Unearned income 1,112 1,153
Accounts payable and accrued expenses 5,607 4,970
Short-term borrowings 265 275
Current portion of long-term debt 1,500 1,599
Other current liabilities 9,683 7,849
Total current liabilities 39,696 34,885
Long-term debt, less current portion 22,349 21,157
Reserves for future policy benefits 803 753
Deferred tax liabilities, net 2,015 2,815
Other noncurrent liabilities 1,562 1,683
Total liabilities 66,425 61,293
Commitments and Contingencies—Note 14
Shareholders’ equity
Preferred stock, without par value, shares authorized - 100,000,000; shares issued and outstanding - none — —
Common stock, par value $0.01, shares authorized - 900,000,000; shares issued and outstanding - 237,958,067 and
241,770,746 2 2
Additional paid-in capital 9,084 9,148
Retained earnings 29,647 27,142
Accumulated other comprehensive loss (2,490) (197)
Total shareholders’ equity 36,243 36,095
Noncontrolling interests 87 68
Total equity 36,330 36,163
Total liabilities and equity $ 102,755 $ 97,456
See accompanying notes.
52

-- 117 of 188 --

Elevance Health, Inc.
Consolidated Statements of Income
Years Ended December 31
(In millions, except per share data) 2022 2021 2020
Revenues
Premiums $ 133,229 $ 117,373 $ 104,109
Product revenue 14,978 12,657 10,384
Service fees 7,453 6,913 6,315
Total operating revenue 155,660 136,943 120,808
Net investment income 1,485 1,378 877
Net (losses) gains on financial instruments (550) 318 182
Total revenues 156,595 138,639 121,867
Expenses
Benefit expense 116,642 102,571 88,045
Cost of products sold 13,035 10,895 8,953
Operating expense 17,700 15,918 17,450
Interest expense 851 798 784
Amortization of other intangible assets 767 441 361
Loss on extinguishment of debt — 21 36
Total expenses 148,995 130,644 115,629
Income before income tax expense 7,600 7,995 6,238
Income tax expense 1,712 1,846 1,666
Net income 5,888 6,149 4,572
Net loss attributable to noncontrolling interests 6 9 —
Shareholders’ net income $ 5,894 $ 6,158 $ 4,572
Shareholders’ net income per share
Basic $ 24.56 $ 25.26 $ 18.23
Diluted $ 24.28 $ 24.95 $ 17.98
Dividends per share $ 5.12 $ 4.52 $ 3.80
See accompanying notes.
53

-- 118 of 188 --

Elevance Health, Inc.
Consolidated Statements of Comprehensive Income
Years Ended December 31
(In millions) 2022 2021 2020
Net income $ 5,888 $ 6,149 $ 4,572
Other comprehensive (loss) income, net of tax:
Change in net unrealized gains/losses on investments (2,260) (457) 428
Change in non-credit component of impairment losses on investments (3) 2 —
Change in net unrealized gains/losses on cash flow hedges 10 11 12
Change in net periodic pension and postretirement costs (70) 123 (1)
Change in future policy benefits 32 (7) —
Foreign currency translation adjustments (13) (9) 7
Other comprehensive (loss) income (2,304) (337) 446
Net loss attributable to noncontrolling interests 6 9 —
Other comprehensive loss attributable to noncontrolling interests 11 2 —
Total shareholders’ comprehensive income $ 3,601 $ 5,823 $ 5,018
See accompanying notes.
54

-- 119 of 188 --

Elevance Health, Inc.
Consolidated Statements of Cash Flows
Years Ended December 31
(In millions) 2022 2021 2020
Operating activities
Net income $ 5,888 $ 6,149 $ 4,572
Adjustments to reconcile net income to net cash provided by operating activities:
Net losses (gains) on financial instruments 550 (318) (182)
Equity in net earnings of other invested assets (293) (562) (51)
Depreciation and amortization 1,675 1,302 1,154
Deferred income taxes (115) 342 (540)
Impairment of property and equipment 7 73 198
Share-based compensation 264 255 283
Changes in operating assets and liabilities:
Receivables, net (2,510) (2,138) (256)
Other invested assets 11 (70) (32)
Other assets 133 41 (283)
Policy liabilities 2,411 2,523 3,528
Unearned income (42) (113) 202
Accounts payable and other liabilities 824 719 1,978
Income taxes (338) 140 72
Other, net (66) 21 45
Net cash provided by operating activities 8,399 8,364 10,688
Investing activities
Purchases of investments (24,946) (18,669) (19,492)
Proceeds from sale of investments 11,988 10,269 11,318
Maturities, calls and redemptions from investments 10,620 4,344 4,741
Changes in securities lending collateral (301) (956) (849)
Purchases of subsidiaries, net of cash acquired (649) (3,476) (1,976)
Purchases of property and equipment (1,152) (1,087) (1,021)
Other, net (120) (63) (45)
Net cash used in investing activities (4,560) (9,638) (7,324)
Financing activities
Net (repayments of) proceeds from commercial paper borrowings (300) 50 (150)
Proceeds from long-term borrowings 3,071 3,462 2,484
Repayments of long-term borrowings (1,899) (1,068) (1,932)
Proceeds from short-term borrowings 1,365 1,325 970
Repayments of short-term borrowings (1,375) (1,050) (1,670)
Changes in securities lending payable 302 956 849
Changes in bank overdrafts 933 (376) 486
Repurchase and retirement of common stock (2,316) (1,900) (2,700)
Cash dividends (1,229) (1,104) (954)
Proceeds from issuance of common stock under employee stock plans 182 203 176
Taxes paid through withholding of common stock under employee stock plans (93) (102) (128)
Other, net 41 27 2
Net cash (used in) provided by financing activities (1,318) 423 (2,567)
Effect of foreign exchange rates on cash and cash equivalents (14) (10) 7
Change in cash and cash equivalents 2,507 (861) 804
Cash and cash equivalents at beginning of year 4,880 5,741 4,937
Cash and cash equivalents at end of year $ 7,387 $ 4,880 $ 5,741
See accompanying notes.
55

-- 120 of 188 --

Elevance Health, Inc.
Consolidated Statements of Shareholders’ Equity
Total Shareholders’ Equity
Common Stock Additional
Paid-in
Capital
Accumulated
Other
Comprehensive
(Loss) Income Noncontrolling
Interests Total
Equity	(In millions) Number
of Shares Par
Value Retained
Earnings
January 1, 2020 252.9 $ 3 $ 9,448 $ 22,538 $ (296) $ — $ 31,693
Net income — — — 4,572 — — 4,572
Other comprehensive income — — — — 446 — 446
Repurchase and retirement of
common stock (9.4) — (353) (2,347) — — (2,700)
Dividends and dividend equivalents — — — (961) — — (961)
Issuance of common stock under
employee stock plans, net of
related tax benefits 1.9 — 330 — — — 330
Convertible debenture repurchases
and conversions — — (181) — — — (181)
December 31, 2020 245.4 3 9,244 23,802 150 — 33,199
Adoption of Accounting Standards
Update 2018-12 (Note 2) — — — — (12) — (12)
January 1, 2021 245.4 3 9,244 23,802 138 — 33,187
Net income — — — 6,158 — (9) 6,149
Other comprehensive loss — — — — (335) (2) (337)
Accumulated noncontrolling interest — — — — — 79 79
Repurchase and retirement of
common stock (5.1) (1) (192) (1,707) — — (1,900)
Dividends and dividend equivalents — — — (1,111) — — (1,111)
Issuance of common stock under
employee stock plans, net of
related tax benefits 1.5 — 355 — — — 355
Convertible debenture repurchases
and conversions — — (259) — — — (259)
December 31, 2021 241.8 2 9,148 27,142 (197) 68 36,163
Adoption of Accounting Standards
Update 2020-06 (Note 2) — — — (23) — — (23)
January 1, 2022 241.8 2 9,148 27,119 (197) 68 36,140
Net income — — — 5,894 — (6) 5,888
Other comprehensive loss — — — — (2,293) (11) (2,304)
Noncontrolling interests adjustment — — — — — 36 36
Repurchase and retirement of
common stock (4.8) — (184) (2,132) — — (2,316)
Dividends and dividend equivalents — — — (1,234) — — (1,234)
Issuance of common stock under
employee stock plans, net of
related tax benefits 1.0 — 352 — — — 352
Convertible debenture repurchases
and conversions — — (232) — — — (232)
December 31, 2022 238.0 $ 2 $ 9,084 $ 29,647 $ (2,490) $ 87 $ 36,330
See accompanying notes.
56

-- 121 of 188 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements
December 31, 2022
(In Millions, Except Per Share Data or As Otherwise Stated Herein)
1. Organization
On May 18, 2022, our shareholders approved a proposal to amend our amended and restated articles of incorporation to
change our name from Anthem, Inc. to Elevance Health, Inc. This amendment and name change went into effect on June 27,
2022. We began operating as Elevance Health, Inc. and trading under our new ticker symbol “ELV” on June 28, 2022.
References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial
Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and
indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico, unless the context
otherwise requires.
Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest
health insurers in the United States in terms of medical membership, serving approximately 47.5 million medical members
through our affiliated health plans as of December 31, 2022. We offer a broad spectrum of network-based managed care risk-
based plans to Individual, Employer Group, Medicaid and Medicare markets. In addition, we provide a broad array of
managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access,
medical management, care management and wellness programs, actuarial services and other administrative services. We
provide services to the federal government in connection with our Federal Health Products & Services business, which
administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to
customers of our subsidiary health plans and also unaffiliated health plans, including pharmacy services and dental, vision,
life, disability and supplemental health insurance benefits, as well as integrated health services.
We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of
independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and
Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30
counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate
New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of
these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue
Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees as well as other
strategic partners. Through our subsidiaries, we also serve customers in numerous states as Amerigroup, Freedom Health,
HealthLink, HealthSun, MMM, Optimum Healthcare, Simply Healthcare, UniCare and/or Wellpoint. We offer pharmacy
services as CarelonRx and other health-care related services as Carelon Services, Aspire Health, Carelon Behavioral Health
and Caremore. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico
through our subsidiaries.
As part of our name change to Elevance Health, in June 2022, we announced that over the next several years we will
organize our brand portfolio into the following core go-to-market brands:
• Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated
Blue Cross and/or Blue Shield licensed plans;
• Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the
Wellpoint name; and
• Carelon — this brand brings together our healthcare-related services and capabilities, including our formerly named
Diversified Business Group and IngenioRx businesses, under a single brand name.
Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime,
trusted health partner. Given this evolution, we reviewed and modified how we manage our business, monitor our
performance and allocate resources. As a result, we changed our reportable segments to the following beginning in the first
57

-- 122 of 188 --

quarter of 2023: Health Benefits (aggregates our previously reported Commercial & Specialty Business and Government
Business segments), CarelonRx, Carelon Services (previously included in our Other segment) and Corporate & Other (our
businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses
not allocated to our other reportable segments). For additional discussion, see Note 20, “Segment Information.”
2. Basis of Presentation and Significant Accounting Policies
Basis of Presentation: The accompanying consolidated financial statements include the accounts of Elevance Health and
its subsidiaries and have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”). All
significant intercompany accounts and transactions have been eliminated in consolidation.
The accompanying consolidated financial statements and the notes to the consolidated financial statements have been
recast and are presented as they would have appeared had we changed our reportable segments, discussed in Note 20, and
adopted the new accounting standard, discussed in this Note 2 below, prior to January 1, 2023.
Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar
(“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the
period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during
the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our
consolidated statements of comprehensive income.
Reclassifications: Certain prior year amounts have been reclassified to conform to the current year presentation.
Use of Estimates: The preparation of consolidated financial statements in conformity with GAAP requires us to make
estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes.
Our most significant estimate relates to estimates and judgments for medical claims payable. Actual results could differ from
those estimates.
Cash and Cash Equivalents: Cash and cash equivalents includes available cash and all highly liquid investments with
maturities of three months or less when purchased. We control a number of bank accounts that are used exclusively to hold
customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain
regulatory requirements. These amounts totaled $258 and $173 at December 31, 2022 and 2021, respectively, and are
included in the cash and cash equivalents line on our consolidated balance sheets.
Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those
securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we
classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy
contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.
If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it
is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we
write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements
of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not
have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit
component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment
loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated
other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed
maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated
other comprehensive loss.
The credit component of an impairment is determined primarily by comparing the net present value of projected future
cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our
best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of
purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the
underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default
rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
58

-- 123 of 188 --

probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated
with a default.
For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on
anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the
effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the
securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date
of the securities. Such adjustments are reported within net investment income.
The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains
and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations, and are
reported under the caption “Other invested assets” in our consolidated balance sheets.
We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other
members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the
caption “Other invested assets” in our consolidated balance sheets.
We use the equity method of accounting for investments in companies in which our ownership interest may enable us to
influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of
these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under
the caption “Other invested assets” in our consolidated balance sheets.
Investment income is recorded when earned. All securities sold resulting in investment realized gains and losses are
recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific
securities sold.
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred
to independent brokers or dealers in exchange for cash and securities collateral. Under Financial Accounting Standards Board
(“FASB”) guidance related to accounting for transfers and servicing of financial assets and extinguishments of liabilities, we
recognize the collateral as an asset, which is reported in other current assets on our consolidated balance sheets, and we
record a corresponding liability for the obligation to return the collateral to the borrower, which is reported in other current
liabilities. The securities on loan are reported in the applicable investment category on our consolidated balance sheets.
Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive income as a
separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can
fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than
the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned
securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly.
Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any
shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments
to higher quality and shorter duration instruments.
Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is
based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.
Premium receivables include the uncollected amounts from insured groups, individuals and government programs.
Premium receivables are reported net of an allowance for doubtful accounts of $152 and $142 at December 31, 2022 and
2021, respectively.
Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers. Self-
funded receivables are reported net of an allowance for doubtful accounts of $68 and $50 at December 31, 2022 and 2021,
respectively.
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due
from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables
are reported net of an allowance for doubtful accounts of $744 and $648 at December 31, 2022 and 2021, respectively.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
59

-- 124 of 188 --

Income Taxes: We file a consolidated U.S. federal income tax return. Deferred income tax assets and liabilities are
recognized for temporary differences between the financial statement and tax return basis of assets and liabilities based on
enacted tax rates and laws and are reported net on our consolidated balance sheets. The deferred tax benefits of the deferred
tax assets are recognized to the extent realization of such benefits is more likely than not. Deferred income tax expense or
benefit generally represents the net change in deferred income tax assets and liabilities during the year, excluding the impact
from amounts initially recorded for business combinations, if any, and amounts recorded to accumulated other
comprehensive income. Current income tax expense represents the tax consequences of revenues and expenses currently
taxable or deductible on various income tax returns for the year reported.
The Internal Revenue Code subjects a U.S. shareholder to tax on Global Intangible Low-Taxed Income (“GILTI”)
earned by certain foreign subsidiaries. We have elected to account for GILTI tax in the year the tax is incurred.
The Inflation Reduction Act of 2022 includes a provision that imposes a new corporate alternative minimum tax (the
“Corporate AMT”) that became effective for us beginning January 1, 2023. We have elected to account for the effects of the
Corporate AMT on deferred tax assets and carryforwards and tax credits in the period they arise. Additionally, the Inflation
Reduction Act of 2022 imposes an excise tax on the fair market value of net stock repurchases made after December 31,
2022. We do not believe the Corporate AMT will have a material impact on our consolidated financial position, results of
operations, cash flows or related disclosures.
We account for income tax contingencies in accordance with FASB guidance that contains a model to address
uncertainty in tax positions and clarifies the accounting for income taxes by prescribing a minimum recognition threshold,
which all income tax positions must achieve before being recognized in the financial statements.
Property and Equipment: Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is
computed principally by the straight-line method over estimated useful lives ranging from fifteen to thirty years for buildings
and improvements, three to five years for computer equipment and software, and the lesser of the remaining life of the
building lease, if any, or seven years for furniture and other equipment. Leasehold improvements are depreciated over the
term of the related lease. Certain costs related to the development or purchase of internal-use software are capitalized and
amortized over estimated useful lives ranging from three to ten years.
Goodwill and Other Intangible Assets: FASB guidance requires business combinations to be accounted for using the
acquisition method of accounting, and it also specifies the types of acquired intangible assets that are required to be
recognized and reported separately from goodwill. Goodwill represents the excess of the cost of acquisition over the fair
value of net assets acquired. Other intangible assets represent the values assigned to customer relationships, provider and
hospital networks, Blue Cross and Blue Shield and other trademarks, licenses and other agreements, such as non-compete
agreements. Goodwill and other intangible assets are allocated to reportable segments based on the relative fair value of the
components of the businesses acquired.
Goodwill and other intangible assets with indefinite lives are not amortized but are tested for impairment at least
annually. Goodwill and other intangible assets are allocated to reporting units for purposes of the annual goodwill impairment
test. Other intangible assets with indefinite lives, such as trademarks, are tested for impairment separately. We complete our
annual impairment tests of existing goodwill and other intangible assets with indefinite lives during the fourth quarter of each
year. Our impairment tests require us to make assumptions and judgments regarding the estimated fair value of our reporting
units, including goodwill and other intangible assets with indefinite lives. Certain interim impairment tests are also performed
when potential impairment indicators exist or changes in our business or other triggering events occur.
FASB guidance allows for qualitative assessments of whether it is more likely than not that the fair value of a reporting
unit is less than its carrying amount for purposes of a goodwill impairment analysis and whether it is more likely than not that
an indefinite-lived intangible asset is impaired for purposes of an indefinite-lived intangible asset impairment analysis.
Estimated fair values developed based on our assumptions and judgments might be different if other reasonable assumptions
and estimates were to be used. Qualitative analysis involves assessing situations and developments that could affect key
drivers used to evaluate whether the fair value of our goodwill and indefinite-lived intangible assets are impaired. Our
procedures include assessing our financial performance, macroeconomic conditions, industry and market considerations,
various asset specific factors, and entity specific events.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
60

-- 125 of 188 --

Quantitative analysis must be performed if qualitative analyses are not conclusive. Entities also have the option to bypass
the assessment of qualitative factors and proceed directly to performing quantitative analyses. Fair value for purposes of a
quantitative goodwill impairment test is calculated using a blend of the projected income and market valuation approaches.
The projected income approach is developed using assumptions about future revenue, expenses and net income derived from
our internal planning process. Our assumed discount rate is based on our industry’s weighted-average cost of capital and
reflects volatility associated with the cost of equity capital. Market valuations include market comparisons to publicly traded
companies in our industry and are based on observed multiples of certain measures including revenue; earnings before
interest, taxes, depreciation and amortization (“EBITDA”); and book value of invested capital.
A goodwill impairment loss is recognized to the extent that the carrying amount exceeds the asset’s fair value. This
determination consists of a one-step test comparing the fair value of a reporting unit, including goodwill, to its carrying
amount. If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized. This goodwill
impairment loss is equal to the excess of the reporting unit’s carrying amount over its fair value.
Fair value for purposes of a quantitative impairment test for indefinite-lived intangible assets is estimated using a
projected income approach. We recognize an impairment loss when the estimated fair value of indefinite-lived intangible
assets is less than the carrying value. If significant impairment indicators are noted relative to other intangible assets subject
to amortization, we may be required to record impairment losses against future income.
Derivative Financial Instruments: We primarily invest in the following types of derivative financial instruments:
interest rate swaps, futures, forward contracts, put and call options, collars, swaptions, embedded derivatives and warrants.
Derivatives embedded within non-derivative instruments, such as options embedded in convertible fixed maturity securities,
are bifurcated from the host instrument when the embedded derivative is not clearly and closely related to the host
instrument. Our use of derivatives is limited by statutes and regulations promulgated by the various regulatory bodies to
which we are subject, and by our own derivative policy. Our derivative use is generally limited to hedging purposes, on an
economic basis, and we generally do not use derivative instruments for speculative purposes.
We have exposure to economic losses due to interest rate risk arising from changes in the level or volatility of interest
rates. We attempt to mitigate our exposure to interest rate risk through active portfolio management, including rebalancing
our existing portfolios of assets and liabilities, as well as changing the characteristics of investments to be purchased or sold
in the future. In addition, derivative financial instruments are used to modify the interest rate exposure of certain liabilities or
forecasted transactions. These strategies include the use of interest rate swaps and forward contracts, which are used to lock-
in interest rates or to hedge, on an economic basis, interest rate risks associated with variable rate debt. We have used these
types of instruments as designated hedges against specific liabilities.
All investments in derivatives are recorded as assets or liabilities at fair value. If certain correlation, hedge effectiveness
and risk reduction criteria are met, a derivative may be specifically designated as a hedge of exposure to changes in fair value
or cash flow. The accounting for changes in the fair value of a derivative depends on the intended use of the derivative and
the nature of any hedge designation thereon. Amounts excluded from the assessment of hedge effectiveness, if any, are
reported in results of operations immediately. If the derivative is not designated as a hedge, the gain or loss resulting from the
change in the fair value of the derivative is recognized in results of operations in the period of change. Cash flows associated
with the settlement of non-designated derivatives are shown on a net basis in investing activity in our consolidated statements
of cash flow.
From time to time, we may also purchase derivatives to hedge, on an economic basis, our exposure to foreign currency
exchange fluctuations associated with the operations of certain of our subsidiaries. We generally use futures or forward
contracts for these transactions. We generally do not designate these contracts as hedges and, accordingly, the changes in fair
value of these derivatives are recognized in results of operations immediately.
Credit exposure associated with non-performance by the counterparties to derivative instruments is generally limited to
the uncollateralized fair value of the asset related to instruments recognized in the consolidated balance sheets. We attempt to
mitigate the risk of non-performance by selecting counterparties with high credit ratings and monitoring their
creditworthiness and by diversifying derivatives among multiple counterparties. At December 31, 2022, we believe there
were no material concentrations of credit risk with any individual counterparty.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
61

-- 126 of 188 --

We generally enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions
with the same counterparty. Certain of our derivative agreements also contain credit support provisions that require us or the
counterparty to post collateral if there are declines in the derivative fair value or our credit rating. The derivative assets and
derivative liabilities are reported at their fair values net of collateral and netting by the counterparty.
Retirement Benefits: We recognize the funded status of pension and other postretirement benefit plans on the
consolidated balance sheets based on fiscal-year-end measurements of plan assets and benefit obligations. Prepaid pension
benefits represent prepaid costs related to defined benefit pension plans and are reported with other noncurrent assets.
Postretirement benefits represent outstanding obligations for retiree medical, life, vision and dental benefits. Liabilities for
pension and other postretirement benefits are reported with noncurrent assets, current liabilities and noncurrent liabilities
based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the
benefit obligation exceeds the fair value of plan assets.
We determine the expected return on plan assets using the calculated value of plan assets, which recognizes changes in
the fair value of plan assets in a systematic manner over three years. We apply a corridor approach to amortize unrecognized
actuarial gains or losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater
of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime
of the workforce as a component of net periodic benefit cost.
The discount rate reflects the current rate at which the pension liabilities could be effectively settled at the end of the year
based on our most recent measurement date. We use the annual spot rate approach for setting our discount rate. Under the
spot rate approach, individual spot rates from a full yield curve of published rates are used to discount each plan’s cash flows
to determine the plan’s obligations.
The assumed healthcare cost trend rates used to measure the expected cost of other postretirement benefits are based on
an initial assumed healthcare cost trend rate declining to an ultimate healthcare cost trend rate over a select number of years.
Medical Claims Payable: Liabilities for medical claims payable include estimated provisions for incurred but not paid
claims on an undiscounted basis, as well as estimated provisions for expenses related to the processing of claims. Incurred but
not paid claims include (1) an estimate for claims that are incurred but not reported, as well as claims reported to us but not
yet processed through our systems; and (2) claims reported to us and processed through our systems but not yet paid.
Liabilities for both claims incurred but not reported and reported but not yet processed through our systems are
determined in the aggregate, employing actuarial methods that are commonly used by health insurance actuaries and meet
Actuarial Standards of Practice. Our reserving practice for claim liabilities is to consistently recognize the appropriate amount
of reserve within a level of confidence required by Actuarial Standards of Practice. We determine the amount of the liability
for incurred but not paid claims by following a detailed actuarial process that uses both historical claim payment patterns as
well as emerging medical cost trends to project our best estimate of claim liabilities. Under this process, historical paid claims
data is formatted into “claim triangles,” which compare claim incurred dates to the dates of claim payments. This information
is analyzed to create “completion factors” that represent the average percentage of total incurred claims that have been paid
through a given date after being incurred. Completion factors are applied to claims paid through the period-end date to
estimate the ultimate claim expense incurred for the period. Actuarial estimates of incurred but not paid claim liabilities are
then determined by subtracting the actual paid claims from the estimate of the ultimate incurred claims.
For the most recent incurred months (typically the most recent two months), the percentage of claims paid for claims
incurred in those months is generally low. This makes the completion factor methodology less reliable for such months.
Therefore, incurred claims for recent months are not projected from historical completion and payment patterns; rather, they
are projected by estimating the claims expense for those months based on recent claims expense levels and healthcare trend
levels (“trend factors”).
We regularly review and set assumptions regarding cost trends and utilization when initially establishing claim liabilities.
We continually monitor and adjust the claims liability and benefit expense based on subsequent paid claims activity. If it is
determined that our assumptions regarding cost trends and utilization are materially different than actual results, our income
statement and financial position could be impacted in future periods.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
62

-- 127 of 188 --

Premium deficiencies are recognized when it is probable that expected claims and administrative expenses will exceed
future premiums on existing medical insurance contracts without consideration of investment income. Determination of
premium deficiencies for longer duration life and disability contracts includes consideration of investment income. For
purposes of premium deficiencies, contracts are deemed to be either short or long duration and are grouped in a manner
consistent with our method of acquiring, servicing and measuring the profitability of such contracts. Once established,
premium deficiencies are released commensurate with actual claims experience over the remaining life of the contract. No
premium deficiencies were established at December 31, 2022 or 2021.
Benefit expense includes incurred medical claims as well as quality improvement expenses for our risk-based members.
Quality improvement activities are those designed to improve member health outcomes, prevent hospital readmissions and
improve patient safety. They also include expenses for wellness and health promotion provided to our members.
Other Policyholder Liabilities: Other policyholder liabilities include rate stabilization reserves associated with
retrospectively rated insurance contracts and certain case-specific reserves. Other policyholder liabilities also include
liabilities for premium refunds based upon the minimum medical loss ratio (“MLR”), the relative health risk of members, and
other contractual or regulatory requirements. Rate stabilization reserves represent accumulated premiums that exceed what
customers owe us based on actual claim experience. The timing of payment of these retrospectively rated refunds is based on
the contractual terms with our customers and can vary from period to period based on the specific contractual requirements.
We are required to meet certain minimum MLR thresholds prescribed by the Patient Protection and Affordable Care Act
and the Health Care and Education Reconciliation Act of 2010, as amended (collectively the “ACA”). If we do not meet or
exceed the minimum MLR thresholds specified by the ACA, we are required to pay rebates to certain customers. Minimum
MLR rebates are calculated by subsidiary, state and applicable line of business in accordance with regulations issued by the
Department of Health and Human Services (“HHS”). Such calculations are made using estimated calendar year medical loss
expense and premiums, as defined by HHS.
We follow HHS guidelines for determining the types of expenses that may be included in our minimum MLR rebate
calculations, which differ from benefit expense and premiums as reported in our consolidated financial statements prepared in
conformity with GAAP. Certain amounts reported as expense in our consolidated GAAP financial statements may be
reported as a reduction of premiums in accordance with HHS regulations. In addition, profit amounts included in our
payments to third-party administrative service providers are recorded as benefit expense in our consolidated GAAP financial
statements, while HHS does not allow for the inclusion of these expenses within the medical loss expense for purposes of
calculating minimum MLR.
Reserves for Future Policy Benefits: Reserves for future policy benefits include liabilities for life and long-term
disability insurance policy benefits based upon interest, mortality and morbidity assumptions from published actuarial tables,
modified based upon our experience. Future policy benefits also include liabilities for insurance policies for which some of
the premiums received in earlier years are intended to pay anticipated benefits to be incurred in future years. Future policy
benefits are continually monitored and reviewed, and when reserves are adjusted, differences are reflected in benefit expense.
We believe that our liabilities for future policy benefits, along with future premiums received, are adequate to satisfy our
ultimate benefit liability; however, these estimates are inherently subject to a number of variable circumstances.
Consequently, the actual results could differ materially from the amounts recorded in our consolidated financial statements.
Revenue Recognition: Premiums for risk-based contracts are recognized as revenue over the period insurance coverage
is provided, and, if applicable, net of amounts recognized for MLR rebates, risk adjustment, reinsurance and risk corridor
under contractual premium stabilization arrangements, the ACA or other regulatory requirements. Premiums may also
include performance incentives and penalties, which are recognized based on contractual terms. We estimate amounts
receivable and payable under these contractual terms, and to the extent that such estimated amounts vary from the final
amounts paid, the adjustments are included in earnings in the period of final settlement. Premium payments from contracted
government agencies are based on eligibility lists produced by the government agencies. Premiums related to the unexpired
contractual coverage periods are reflected in the accompanying consolidated balance sheets as unearned income. Premiums
include revenue adjustments for retrospectively rated contracts where revenue is based on the estimated loss experience of the
contract. Premium rates for certain lines of business are subject to approval by the Department of Insurance of each
respective state. Additionally, delays in annual premium rate changes from contracted government agencies require that we
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
63

-- 128 of 188 --

defer the recognition of any increases to the period in which the premium rates become final. The value of the impact can be
significant in the period in which it is recognized depending on the magnitude of the premium rate increase, the membership
to which it applies and the length of the delay between the effective date of the rate increase and the final contract date.
Premium rate decreases are recognized in the period the change in premium rate becomes effective and the change in the rate
is known, which may be prior to the period when the contract amendment affecting the rate is finalized.
Service fees include revenue from certain group contracts that provide for the group to be at risk for all, or with
supplemental insurance arrangements, a portion, of their claims experience. We charge these fee-based groups an
administrative fee, which is based on the number of members in a group and the group’s claim experience. In addition,
service fees include amounts received for the administration of Medicare, certain other government programs, and
administrative services arrangements of our Carelon (Diversified Business Group) subsidiaries, now known as Carelon.
Generally, these fee-based arrangements include services which constitute a single suite of services provided and for which
consideration is based upon an agreed-upon rate, regardless of the amount of services provided in a given period. As with
premiums, these fee-based arrangements may include terms with retroactive rate or membership adjustments, performance
incentives and penalties, each of which is a form of variable consideration within the transaction price. As such, these fee-
based arrangements contain a single performance obligation that constitutes a series, and revenue is recognized over time as
the services are performed. All benefit payments under these programs are excluded from benefit expense.
The determination of whether services are distinct performance obligations that should be accounted for separately or
combined as one unit of accounting may require significant judgment. The estimation of variable consideration to be
recognized requires significant judgment in the determination of the level of achievement of performance incentives, service
level achievements subject to performance penalties, and the completion level of tasks subject to implementation fees.
Product revenue includes revenue for services performed by CarelonRx for unaffiliated pharmacy customers.
Unaffiliated pharmacy customers include our fee-based groups that have contracted with CarelonRx for pharmacy services
and third-party health plans. Product revenues and costs of goods sold for our affiliated health plans are eliminated in
consolidation. Product revenue for pharmacy services is recognized using the gross method at the negotiated contract price
when CarelonRx has concluded that it is the principal and it controls the services before prescription drugs are transferred to
the customer. CarelonRx determined it is the principal due to its contractual rights to design and develop a listing of
prescription drugs offered to the customer (formulary management); its control over establishing the pharmacy network
available to the customer to have its prescription fulfilled (network management); and its discretion over establishing the
pricing for prescription drugs. Overall, control over these activities indicate CarelonRx is primarily responsible for fulfilling
the promise to provide pharmacy services. Product revenue includes ingredient costs (net of any rebates or discounts),
including any co-payments made by or on behalf of the customer, and administrative fees. CarelonRx recognizes revenue
when control of the prescription drugs is transferred to customers, in an amount it expects to be entitled to in exchange for the
products or services provided.
For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs
recorded on our consolidated balance sheet at December 31, 2022. Revenue recognized in 2022 and 2021 from performance
obligations related to prior years, such as due to changes in transaction price, was not material. For contracts that have an
original expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled
contractual performance obligations and contracts with variable consideration related to undelivered performance obligations
is not material.
Cost of Products Sold: CarelonRx’s cost of products sold includes the cost of prescription drugs dispensed to
unaffiliated pharmacy customers (net of rebates or discounts). Cost of products sold includes per-claim administrative fees
for prescription fulfillment by its vendor and certain CarelonRx direct costs related to sales and administration of customer
contracts.
Share-Based Compensation: Our current compensation philosophy provides for share-based compensation, including
stock options, restricted stock awards and an employee stock purchase plan. Stock options are granted for a fixed number of
shares with an exercise price at least equal to the fair value of the shares at the date of the grant. Restricted stock awards are
issued at the fair value of the stock on the grant date. The employee stock purchase plan allows for a purchase price per share
which is 90% of the fair value of a share of common stock on the lower of the first or last trading day of the plan quarter. The
employee stock purchase plan discount is recognized as compensation expense based on GAAP guidance. All other share-
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
64

-- 129 of 188 --

based payments to employees are recognized as compensation expense in our consolidated statements of income based on
their fair values. Additionally, excess tax benefits, which result from actual tax benefits realized when awards vest or options
are exercised exceeding deferred tax benefits previously recognized based on grant date fair value, are recognized as tax
benefits in the consolidated statements of income.
Advertising and Marketing Costs: We use print, broadcast and other advertising to promote our products and to develop
our corporate image. We market our products through direct marketing activities and an extensive network of independent
agents, brokers and retail partnerships for Individual and Medicare customers, and for certain Employer Group risk-based
customers with a smaller employee base. Products for Employer Group risk-based customers with a larger employee base are
generally sold through independent brokers or consultants retained by the customer who work with industry specialists from
our in-house sales force. In the Individual and Group markets, we offer products through state or federally facilitated
marketplaces, or Public Exchanges, and off-exchange products. The cost of advertising and marketing for product promotion
is expensed as incurred, while advertising and marketing costs associated with our corporate image are expensed when first
aired. Total advertising and marketing expense was $511, $588 and $558 for the years ended December 31, 2022, 2021 and
2020, respectively.
Health Insurance Provider Fee: The ACA imposed an annual Health Insurance Provider Fee (“HIP Fee”) on health
insurers that wrote certain types of health insurance on U.S. risks, which was permanently repealed effective January 1, 2021.
The HIP Fee was non-deductible for federal income tax purposes. Our affected products were priced to cover the increased
operating and income tax expenses associated with the HIP Fee when it was in effect. The HIP Fee was $15,523 for 2020 and
was permanently eliminated beginning in 2021. For the year ended December 31, 2020, we recognized $1,570 as operating
expense related to the HIP Fee.
Leases: We lease office space and certain computer and related equipment under noncancelable operating leases. We
determine whether an arrangement is or contains a lease at its inception. We recognize lease liabilities based on the present
value of the minimum lease payments not yet paid by using the lease term, any amounts probable of being owed under any
residual value guarantees and the discount rate determined at lease commencement. As our leases do not generally provide an
implicit rate, we use our incremental secured borrowing rate commensurate with the underlying lease terms to determine the
present value of our lease payments. Our lease liabilities may include amounts for options to extend or terminate a lease when
it is reasonably certain that we will exercise that option. We recognize operating right-of-use (“ROU”) assets at an amount
equal to the lease liability adjusted for prepaid or accrued rent, the remaining balance of any lease incentives and unamortized
initial direct costs.
The operating lease liabilities are reported in other current liabilities and other noncurrent liabilities and the related ROU
assets are reported in other noncurrent assets on our consolidated balance sheets. Lease expense for our operating leases is
calculated on a straight-line basis over the lease term and is reported in operating expense on our consolidated statements of
income. For our office space leases, we account for the lease and non-lease components (such as common area maintenance)
as a single lease component. We also do not recognize a lease liability or ROU asset for our office space leases whose lease
terms, at commencement, are twelve months or less and that do not include a purchase option or option to extend that we are
reasonably certain to exercise.
We assess our ROU assets for impairment when there are indicators of impairment and compare the carrying amount of
the ROU asset to its estimated undiscounted future cash flows. If the estimated undiscounted future cash flows are less than
the carrying amount of the ROU asset, an impairment calculation is performed. An impairment loss is recorded for the
difference of the ROU asset’s carrying value that exceeds its estimated discounted cash flows. During the years ended
December 31, 2022, 2021 and 2020, we recorded $34, $136 and $258, respectively, for impairment and abandonment of
ROU assets. See Note 18, “Leases” for additional information about the ROU asset impairment and abandonment charges.
Earnings per Share: Earnings per share amounts, on a basic and diluted basis, have been calculated based upon the
weighted-average common shares outstanding for the period.
Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the
weighted-average number of common shares outstanding for the period. Diluted earnings per share may include the dilutive
effect of stock options, restricted stock and convertible debentures, using the treasury stock method. The treasury stock
method assumes exercise of stock options and vesting of restricted stock, with the assumed proceeds used to purchase
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
65

-- 130 of 188 --

common stock at the average market price for the period. The difference between the number of shares assumed issued and
the number of shares assumed purchased represents the dilutive shares.
Recently Adopted Accounting Guidance: In January 2021, the FASB issued Accounting Standards Update No. 2021-01,
Reference Rate Reform (Topic 848) (“ASU 2021-01”). The amendments in ASU 2021-01 provide optional expedients and
exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that
reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of the
reference rate reform. The provisions must be applied at a Topic, Subtopic, or Industry Subtopic level for all transactions
other than derivatives, which may be applied at a hedging relationship level. We adopted ASU 2021-01 on January 7, 2021,
and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
In October 2020, the FASB issued Accounting Standards Update No. 2020-08, Codification Improvements to Subtopic
310-20, Receivables—Nonrefundable Fees and Other Costs (“ASU 2020-08”). The amendments in ASU 2020-08 clarify
when an entity should assess whether a callable debt security is within the scope of accounting guidance, which impacts the
amortization period for nonrefundable fees and other costs. ASU 2020-08 became effective for interim and annual reporting
periods beginning after December 15, 2020. The amendments were applied on a prospective basis as of the beginning of the
period of adoption for existing or newly purchased callable debt securities. We adopted ASU 2020-08 on January 1, 2021,
and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt—Debt with Conversion and Other
Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting
for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). The amendments eliminate two of
the three accounting models that require separate accounting for convertible features of debt securities, simplify the contract
settlement assessment for equity classification, require the use of the if-converted method for all convertible instruments in
the diluted earnings per share calculation and expand disclosure requirements. The amendments became effective for our
annual and interim reporting periods beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022
using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a
decrease to our deferred tax liabilities of $8, and a corresponding cumulative-effect reduction to our opening retained
earnings of $23, eliminating the bifurcation of the embedded conversion option; these amounts were not material to our
overall consolidated financial position. The adoption of ASU 2020-06 did not have an impact on our results of operations or
our consolidated cash flows. Use of the if-converted method did not have an impact on our overall earnings per share
calculation.
In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying
the Accounting for Income Taxes (“ASU 2019-12”). The amendments in ASU 2019-12 remove certain exceptions to the
general principles in Accounting Standards Codification Topic 740. The amendments also clarify and amend existing
guidance to improve consistent application. The amendments became effective for our annual reporting periods beginning
after December 15, 2020. The transition method (retrospective, modified retrospective, or prospective basis) related to the
amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are
to be applied on a prospective basis. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have an impact
on our consolidated financial position, results of operations or cash flows.
In November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic
944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 make changes to the
effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic
944): Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in
November 2018. The amendments in ASU 2020-11 extended the original effective date by one year, with the amendments
required for our interim and annual reporting periods beginning after December 15, 2022. This standard requires the
Company to review cash flow assumptions for its long-duration insurance contracts at least annually and recognize the effect
of changes in future cash flow assumptions in net income. This standard also requires the Company to update discount rate
assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used
to discount the Company’s reserves for future policy benefits will be based on an estimate of the yield for an upper-medium
grade fixed-income instrument with a duration profile matching that of the Company’s liabilities. In addition, this standard
changes the amortization method for deferred acquisition costs. The Company adopted the new standard on January 1, 2023,
using the modified retrospective transition method for changes to the liability for future policy benefits and deferred
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
66

-- 131 of 188 --

acquisition costs as of the earliest period presented, January 1, 2021. As a result of applying the long-duration standard using
the modified retrospective method, adjustments of $(131), $54 and $0, respectively, were made to shareholders’ net income
for the years ended December 31, 2022, 2021 and 2020, which include adjustments to benefit expense of $155, $(74) and $0,
respectively. In addition, the following balance sheet adjustments were made at years ended December 31, 2022 and 2021:
$(17) and $(4), respectively, to total assets; $47 and $(39), respectively, to total liabilities; $13 and $(19), respectively, to
accumulated other comprehensive loss; and $(64) and $35, respectively to shareholders’ equity and total equity. The adoption
did not have a material impact on our consolidated financial position, results of operations, cash flows, or related disclosures.
There were no other new accounting pronouncements that were issued or became effective during the year ended
December 31, 2022 that had, or are expected to have, a material impact on our financial position, results of operations, cash
flows or financial statement disclosures.
3. Business Acquisitions
Completed Acquisitions
During the year ended December 31, 2022, we completed business combinations for total cash consideration of
approximately $752. These acquisitions included Integra MLTC, Inc. (“Integra”), acquired May 2022, which is a managed
long-term care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities
to live safely and independently in their own homes. The purchase prices for all business combinations were allocated to the
tangible and intangible net assets acquired based on management’s initial estimates of their fair values, of which $89 was
allocated to finite-lived intangible assets, $250 to indefinite-lived intangible assets, and $145 to goodwill. The intangible
assets and goodwill acquired were assigned to our Health Benefits reportable segment. The majority of goodwill is deductible
for income tax purposes. As of December 31, 2022, the initial accounting for the acquisitions completed in 2022 had not been
finalized. Any subsequent adjustments made to the assets acquired or liabilities assumed during the measurement period will
be recorded as an adjustment to goodwill. The proforma effects of these acquisitions for prior periods were not material to
our consolidated results of operations.
During the year ended December 31, 2021, we completed business combinations for total cash consideration of
approximately $4,021. These acquisitions included myNEXUS, Inc. (“myNEXUS”), acquired April 2021, a comprehensive
home-based nursing management company for payors, and MMM Holdings, LLC (“MMM”), acquired June 2021, including
its Medicare Advantage plan, Medicaid plan, and other affiliated companies. The purchase prices for all business
combinations were allocated to the tangible and intangible net assets acquired based on management’s final estimates of their
fair values, of which $1,577 was allocated to finite-lived intangible assets, $20 to indefinite-lived intangible assets, and
$2,531 to goodwill, including measurement period adjustments of $10 during the year ended December 31, 2022. Of these
amounts, $795 was allocated to our Carelon Services reportable segment and $3,333 to our Health Benefits reportable
segment. The majority of goodwill is not deductible for income tax purposes.
Acquired tangible assets (liabilities) at the acquisition date were:
2022 2021
Cash, cash equivalents and short-term investments $ 170 $ 808
Accounts receivable and other current assets 240 295
Property, equipment and other long-term assets 109 102
Medical claims and other policyholder liabilities payable (185) (571)
Accounts payable and other current liabilities (20) (179)
Other long-term liabilities (15) (6)
Deferred tax liabilities (32) (556)
Total net tangible assets $ 267 $ (107)
The preliminary purchase price allocations for the various business combinations are subject to adjustment as valuation
analyses, primarily related to intangible assets and contingent and tax liabilities, are finalized.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
67

-- 132 of 188 --

Acquisition date fair values and weighted-average useful lives assigned to intangible assets include:
2022 2021
Fair Value
Weighted
Average
Useful Life Fair Value
Weighted
Average
Useful Life
Customer-related $ 85 10 years $ 1,313 13 years
Provider and hospital relationships 2 15 years 240 14 years
Other 2 0.5 years 24 13 years
State Medicaid licenses 250 Indefinite 20 Indefinite
Total intangible assets $ 339 $ 1,597
The results of operations and financial condition of acquired entities have been included in our consolidated results and
the results of the corresponding operating segment as of the date of acquisition. Through December 31, 2022, the impact of
the acquired entities on revenue and net earnings was not material. Unaudited pro forma revenues for the years ended
December 31, 2022 and 2021 as if the acquisitions had occurred on January 1, 2021 were immaterial for both periods. The
pro forma effects of the acquisitions on net earnings were immaterial for both years.
Pending Acquisitions
Louisiana Health Service & Indemnity Company (d/b/a Blue Cross and Blue Shield of Louisiana)
On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service & Indemnity
Company, d/b/a Blue Cross and Blue Shield of Louisiana, an independent licensee of the BCBSA that provides healthcare
plans to the Individual, Employer Group, Medicaid and Medicare markets, primarily in the State of Louisiana. This
acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care
management programs that improve the lives of the people we serve. The acquisition is expected to close by the end of the
fourth quarter of 2023 and is subject to standard closing conditions and customary approvals.
BioPlus Parent, LLC
On November 9, 2022, we announced our entrance into an agreement with CarepathRx Aggregator, LLC to acquire its
specialty pharmacy division, which includes BioPlus Parent, LLC (“BioPlus”) and subsidiaries. BioPlus is one of the largest
independent specialty pharmacy organizations in the United States and seeks to connect payors and providers of specialty
pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition aligns
with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that
improve the lives of the people we serve. The acquisition was completed on February 15, 2023, and initial purchase
accounting for the acquisition has not been finalized.
4. Business Optimization Initiatives
We believe that our properties are adequate and suitable for our business as presently conducted; however, we are
continuing to evaluate our real estate strategy as it relates to the changing needs of a more hybrid remote workforce. As a
result, during 2022, we identified additional reductions of office space and recorded a net charge of $39 in operating expense.
This charge includes $34 for impairment and abandonment of operating-lease related ROU assets and $7 for impairment and
abandonment of property and equipment. In addition, we released $2 of employee termination costs, as reflected in the table
below. The net charges (benefits) recognized in the Health Benefits, CarelonRx, Carelon Services and Corporate & Other
segments in 2022, were $36, $0, $5 and $(2), respectively. See Note 20, “Segment Information” for a discussion of our
segments.
During 2021, we identified reductions of office space and recorded a charge of $202 in operating expense. This charge
included $136 for impairment and abandonment of operating-lease related ROU assets and $66 for impairment and
abandonment of property and equipment. The charges recognized in the Health Benefits, CarelonRx, Carelon Services and
Corporate & Other segments in 2021, were $168, $1, $33 and $0, respectively.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
68

-- 133 of 188 --

During 2020, our management introduced enterprise-wide initiatives to optimize our business and, as a result, we
recorded a charge of $653 in operating expense. This charge included $258 for impairment and abandonment of operating-
lease related ROU assets, $198 for impairment and abandonment of property and equipment and $197 for future payments for
employee termination costs in connection with the repositioning and reskilling of our workforce. The charges recognized in
the Health Benefits, CarelonRx, Carelon Services and Corporate & Other segments in 2020, were $516, $4, $122 and $11,
respectively.
A summary of the activity for the year ended December 31, 2022 and ending balance at December 31, 2022, related to
the liability for employee termination costs previously incurred in 2020, is as follows:
Health
Benefits CarelonRx Carelon
Services Corporate &
Other Total
2020 Business Optimization Initiatives
Liabilities for employee termination costs at January 1,
2022 $ 118 $ 1 $ — $ 3 $ 122
Payments (38) — — (1) (39)
Releases — — — (2) (2)
Total liabilities for employee termination costs ending
balance at December 31, 2022 $ 80 $ 1 $ — $ — $ 81
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
69

-- 134 of 188 --

5. Investments
Certain prior year residential and commercial mortgage-backed securities have been reclassified throughout this Note 5
and Note 7, “Fair Value” to conform to the current year presentation.
A summary of current and long-term fixed maturity securities, available-for-sale, at December 31, 2022 and 2021 is as
follows:
Cost or
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Allowance
For
Credit
Losses Estimated
Fair Value
December 31, 2022
Fixed maturity securities:
United States Government securities $ 1,502 $ 2 $ (103) $ — $ 1,401
Government sponsored securities 82 1 (5) — 78
Foreign government securities 321 1 (46) (2) 274
States, municipalities and political subdivisions, tax-exempt 4,389 19 (265) — 4,143
Corporate securities 13,721 31 (1,218) (5) 12,529
Residential mortgage-backed securities 2,978 9 (324) — 2,663
Commercial mortgage-backed securities 2,055 1 (176) (2) 1,878
Other asset-backed securities 3,967 12 (241) — 3,738
Total fixed maturity securities $ 29,015 $ 76 $ (2,378) $ (9) $ 26,704
December 31, 2021
Fixed maturity securities:
United States Government securities $ 1,443 $ 7 $ (18) $ — $ 1,432
Government sponsored securities 65 4 (1) — 68
Foreign government securities 353 7 (13) — 347
States, municipalities and political subdivisions, tax-exempt 5,321 310 (10) — 5,621
Corporate securities 12,044 401 (78) (4) 12,363
Residential mortgage-backed securities 2,492 48 (22) — 2,518
Commercial mortgage-backed securities 1,632 29 (16) (2) 1,643
Other asset-backed securities 2,907 24 (24) — 2,907
Total fixed maturity securities $ 26,257 $ 830 $ (182) $ (6) $ 26,899
Other asset-backed securities primarily consist of collateralized loan obligations and other debt securities.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
70

-- 135 of 188 --

For fixed maturity securities in an unrealized loss position at December 31, 2022 and 2021, the following table
summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in
an unrealized loss position.
Less than 12 Months 12 Months or Greater
Number of
Securities Estimated
Fair Value
Gross
Unrealized
Loss Number of
Securities Estimated
Fair Value
Gross
Unrealized
Loss
(Securities are whole amounts)
December 31, 2022
Fixed maturity securities:
United States Government securities 61 $ 701 $ (40) 38 $ 442 $ (63)
Government sponsored securities 39 73 (4) 6 5 (1)
Foreign government securities 150 100 (10) 198 142 (36)
States, municipalities and political
subdivisions, tax-exempt 1,398 2,615 (147) 396 652 (118)
Corporate securities 3,551 7,826 (549) 2,204 3,521 (669)
Residential mortgage-backed securities 1,341 1,435 (121) 496 982 (203)
Commercial mortgage-backed securities 457 1,082 (76) 324 719 (100)
Other asset-backed securities 784 2,203 (124) 398 1,074 (117)
Total fixed maturity securities 7,781 $ 16,035 $ (1,071) 4,060 $ 7,537 $ (1,307)
December 31, 2021
Fixed maturity securities:
United States Government securities 51 $ 990 $ (11) 27 $ 176 $ (7)
Government sponsored securities — — — 1 1 (1)
Foreign government securities 188 143 (8) 68 41 (5)
States, municipalities and political
subdivisions, tax-exempt 281 634 (9) 8 16 (1)
Corporate securities 1,846 3,310 (57) 403 485 (21)
Residential mortgage-backed securities 422 1,295 (19) 63 44 (3)
Commercial mortgage-backed securities 272 676 (8) 66 137 (8)
Other asset-backed securities 511 1,707 (19) 50 85 (5)
Total fixed maturity securities 3,571 $ 8,755 $ (131) 686 $ 985 $ (51)
Unrealized losses on our securities shown in the table above have not been recognized into income because, as of
December 31, 2022, we do not intend to sell these investments and it is likely that we will not be required to sell these
investments prior to their anticipated recovery. The declines in fair values are largely due to increasing interest rates driven
by the higher rate of inflation and other market conditions.
Allowances for credit losses have been recorded in the amounts of $9 and $6 at December 31, 2022 and 2021,
respectively, for declines in fair value due to unfavorable changes in the credit quality characteristics that impact our
assessment of collectability of principal and interest.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
71

-- 136 of 188 --

The amortized cost and fair value of fixed maturity securities at December 31, 2022, by contractual maturity, are shown
below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to
prepay obligations.
Amortized
Cost Estimated
Fair Value
Due in one year or less $ 726 $ 720
Due after one year through five years 7,489 7,095
Due after five years through ten years 9,512 8,703
Due after ten years 6,255 5,645
Mortgage-backed securities 5,033 4,541
Total fixed maturity securities $ 29,015 $ 26,704
Equity Securities
A summary of current equity securities at December 31, 2022 and 2021 is as follows:
December 31,
2022 December 31,
2021
Equity Securities:
Exchange traded funds $ 822 $ 1,750
Common equity securities 43 42
Private equity securities 88 89
Total $ 953 $ 1,881
Investment Income
The major categories of net investment income for the years ended December 31, 2022, 2021 and 2020 are as follows:
2022 2021 2020
Fixed maturity securities $ 971 $ 755 $ 725
Equity securities 48 43 71
Cash equivalents 77 5 28
Other invested assets 432 616 91
Investment income 1,528 1,419 915
Investment expenses (43) (41) (38)
Net investment income $ 1,485 $ 1,378 $ 877
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
72

-- 137 of 188 --

Investment (Losses) Gains
Net investment (losses) gains for the years ended December 31, 2022, 2021 and 2020 are as follows:
2022 2021 2020
Net gains (losses):
Fixed maturity securities:
Gross realized gains from sales $ 52 $ 170 $ 175
Gross realized losses from sales (469) (44) (105)
Impairment (losses) recoveries recognized in income (31) 1 (7)
Net realized gains on fixed maturity securities (448) 127 63
Equity securities:
Unrealized (losses) gains recognized on equity securities still held (78) 2 133
Net realized (losses) gains recognized on equity securities sold (102) (73) 61
Net (losses) gains on equity securities (180) (71) 194
Other investments:
Gross gains 96 293 18
Gross losses (64) (22) —
Impairment losses recognized in income (34) (16) (91)
Net (losses) gains on other investments (2) 255 (73)
Net (losses) gains on investments $ (630) $ 311 $ 184
A primary objective in the management of our fixed maturity and equity portfolios is to maximize total return relative to
underlying liabilities and respective liquidity needs. In achieving this goal, assets may be sold to take advantage of market
conditions or other investment opportunities as well as tax considerations. Sales will generally produce realized gains and
losses. In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited
to: (i) changes in the investment environment; (ii) expectations that the fair value could deteriorate further; (iii) desire to
reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.
Total proceeds from sales, maturities, calls or redemptions of fixed maturity securities was $22,048, $10,565 and
$11,122 for the years ended December 31, 2022, 2021 and 2020, respectively.
A significant judgment in the valuation of investments is the determination of when a credit loss has occurred. We follow
a consistent and systematic process for recognizing impairments on securities that sustain credit declines in value. We have
established a committee responsible for the impairment review process. The decision to impair a security incorporates both
quantitative criteria and qualitative information. The impairment review process considers a number of factors including, but
not limited to: (i) the extent to which the fair value is less than book value, (ii) the financial condition and near term prospects
of the issuer, (iii) our intent and ability to retain impaired investments for a period of time sufficient to allow for any
anticipated recovery in fair value, (iv) our intent to sell or the likelihood that we will need to sell a fixed maturity security
before recovery of its amortized cost basis, (v) whether the debtor is current on interest and principal payments, (vi) the
reasons for the decline in value (i.e., credit event compared to liquidity, general credit spread widening, currency exchange
rate or interest rate factors) and (vii) general market conditions and industry or sector specific factors. When a decision has
been made to sell an impaired security or it is more likely than not that the impaired security will be required to be disposed
of prior to recovery of its cost basis, the security is written down to fair value at the reporting date. For all other impaired
securities, if the impairment is deemed to be credit related, an allowance is created.
Investment securities are exposed to various risks, such as interest rate, market and credit. Due to the level of risk
associated with certain investment securities and the level of uncertainty related to changes in the value of investment
securities, it is possible that changes in these risk factors in the near term could have a material adverse impact on our results
of operations or shareholders’ equity.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
73

-- 138 of 188 --

At December 31, 2022 and 2021, there were no individual investments that exceeded 10% of shareholders’ equity.
At December 31, 2022 and 2021, there were eight and two, respectively, fixed maturity investments that did not produce
income during the years then ended.
As of December 31, 2022 and 2021, we had committed approximately $1,504 and $1,558, respectively, to future capital
calls from various third-party investments in exchange for an ownership interest in the related entities.
As of December 31, 2022 and 2021, we had committed approximately $185 and $329, respectively, to future investments
in rated notes.
At December 31, 2022 and 2021, securities with carrying values of approximately $752 and $632, respectively, were
deposited by our insurance subsidiaries under requirements of regulatory authorities.
Accrued Investment Income
Accrued investment income totaled $245 and $205 at December 31, 2022 and 2021, respectively. We recognize accrued
investment income under the caption “Other receivables” on our consolidated balance sheets.
Securities Lending Programs
The fair value of the collateral received at the time of the securities lending transactions amounted to $2,457 and $2,155
at December 31, 2022 and 2021, respectively. The value of the collateral represented 102% of the market value of the
securities on loan at each of December 31, 2022 and 2021.
We recognize the collateral as an asset under the caption “Other current assets” in our consolidated balance sheets, and
we recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption “Other
current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance
sheets.
At December 31, 2022 and 2021, the remaining contractual maturities of our securities lending transactions included
overnight and continuous transactions of cash for $2,221 and $1,874, respectively, United States Government securities for
$224 and $281, respectively, and residential mortgage-backed securities for $12 and $0, respectively.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
74

-- 139 of 188 --

6. Derivative Financial Instruments
We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward
contracts, put and call options, collars, swaptions, embedded derivatives and warrants. We also enter into master netting
agreements which reduce credit risk by permitting net settlement of transactions. At December 31, 2022 and 2021, we had
received collateral of $57 and $18, respectively, related to our derivative financial instruments.
A summary of the aggregate contractual or notional amounts and estimated fair values related to derivative financial
instruments at December 31, 2022 and 2021 is as follows:
Contractual/
Notional
Amount Balance Sheet Location
Estimated Fair Value
Asset (Liability)
December 31, 2022
Hedging instruments
Interest rate swaps - fixed to floating $ 1,125 Other assets/other liabilities $ 3 $ (60)
Non-hedging instruments
Derivatives embedded in convertible fixed
maturity securities 18 Fixed Maturity Securities 4 —
Interest rate swaps 5 Equity securities/other assets/
other liabilities — —
Options — Other assets/other liabilities 1 —
Collars 19 Equity securities 23 (9)
Futures 358 Equity securities 2 (2)
Subtotal non-hedging 400 Subtotal non-hedging 30 (11)
Total derivatives $ 1,525 Total derivatives 33 (71)
Amounts netted (12) 12
Net derivatives $ 21 $ (59)
December 31, 2021
Hedging instruments
Interest rate swaps - fixed to floating $ 825 Other assets/other liabilities $ 23 $ (5)
Non-hedging instruments
Interest rate swaps 119 Equity securities/other assets/
other liabilities — (5)
Options 100 Other assets/other liabilities — —
Collars 19 Equity securities 21 (17)
Futures 344 Equity securities 3 (2)
Subtotal non-hedging 582 Subtotal non-hedging 24 (24)
Total derivatives $ 1,407 Total derivatives 47 (29)
Amounts netted (21) 21
Net derivatives $ 26 $ (8)
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
75

-- 140 of 188 --

Fair Value Hedges
We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-
term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to the
LIBOR or the Secured Overnight Financing Rate. A summary of our outstanding fair value hedges at December 31, 2022 and
2021 is as follows:
Type of Fair Value Hedges
Year
Entered
Into
Outstanding Notional Amount Interest Rate
Received Expiration Date	2022 2021
Interest rate swap 2022 $ 150 $ — 5.500 % April 15, 2032
Interest rate swap 2022 75 — 4.101 September 1, 2027
Interest rate swap 2022 75 — 2.250 November 15, 2029
Interest rate swap 2021 150 150 2.550 September 15, 2030
Interest rate swap 2021 100 100 2.250 November 15, 2029
Interest rate swap 2020 75 75 4.101 September 1, 2027
Interest rate swap 2018 50 50 4.101 September 1, 2027
Interest rate swap 2018 450 450 3.300 January 15, 2023
Total notional amount outstanding $ 1,125 $ 825
The following amounts were recorded on our consolidated balance sheets related to cumulative basis adjustments for fair
value hedges at December 31, 2022 and 2021:
Balance Sheet Classification in Which
Hedged Item is Included
Carrying Amount of Hedged Liability
Cumulative Amount of Fair Value Hedging
Adjustment Included in the Carrying Amount of
the Hedged Liability
2022 2021 2022 2021
Long-term debt $ 22,349 $ 21,157 $ (57) $ 18
Cash Flow Hedges
We have entered into a series of forward starting pay fixed interest rate swaps with the objective of eliminating the
variability of cash flows in the interest payments on future financings that were anticipated at the time of entering into the
swaps. During 2022 and 2021, swaps in the notional amount of $700 and $450, respectively, were terminated.
The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive
loss, net of tax, was $229 and $239 at December 31, 2022 and 2021, respectively. As of December 31, 2022, the total amount
of amortization over the next twelve months for all cash flow hedges is estimated to increase interest expense by
approximately $13. No amounts were excluded from effectiveness testing.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
76

-- 141 of 188 --

Non-Hedging Derivatives
A summary of the effect of non-hedging derivatives on our consolidated statements of income for the years ended
December 31, 2022, 2021 and 2020 is as follows:
Type of Non-hedging Derivatives Income Statement Location of
Gain (Loss) Recognized
Derivative
(Loss) Gain
Recognized
Year ended December 31, 2022
Derivatives embedded in convertible securities Net (losses) gains on financial instruments $ (3)
Interest rate swaps Net (losses) gains on financial instruments (4)
Options (including swaptions) Net (losses) gains on financial instruments 13
Collars Net (losses) gains on financial instruments 10
Futures Net (losses) gains on financial instruments 64
Total $ 80
Year ended December 31, 2021
Interest rate swaps Net (losses) gains on financial instruments $ (4)
Collars Net (losses) gains on financial instruments 4
Futures Net (losses) gains on financial instruments 7
Total $ 7
Year ended December 31, 2020
Interest rate swaps Net (losses) gains on financial instruments $ (1)
Options Net (losses) gains on financial instruments (5)
Futures Net (losses) gains on financial instruments 4
Total $ (2)
7. Fair Value
Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of
judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair
value measurements and disclosures, are as follows:
Level Input: Input Definition:
Level I Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement
date.
Level II Inputs other than quoted prices included in Level I that are observable for the asset or liability through
corroboration with market data at the measurement date.
Level III Unobservable inputs that reflect management’s best estimate of what market participants would use in
pricing the asset or liability at the measurement date.
The following methods, assumptions and inputs were used to determine the fair value of each class of the following
assets and liabilities recorded at fair value in the consolidated balance sheets:
Cash equivalents: Cash equivalents primarily consist of highly rated money market funds with maturities of three
months or less, and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature
of the funds, we designate all cash equivalents as Level I.
Fixed maturity securities, available-for-sale: Fair values of available-for-sale fixed maturity securities are based on
quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which
generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements and
disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
77

-- 142 of 188 --

subdivisions, mortgage-backed securities, United States Government securities, foreign government securities, and certain
other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of
comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets
for similar securities. We have controls in place to review the pricing services’ qualifications and procedures used to
determine fair values. In addition, we periodically review the pricing services’ pricing methodologies, data sources and
pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies
include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also
have certain fixed maturity securities, primarily collateralized loan obligation securities and corporate debt securities, that are
designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or discounted
cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates
and prepayment speeds that are not observable in the markets.
Equity securities: Fair values of equity securities are generally designated as Level I and are based on quoted market
prices. For certain equity securities, quoted market prices for the identical security are not always available, and the fair value
is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II.
We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each
security’s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these
private equity securities are generally based on either broker quotes or discounted cash flow projections using assumptions
for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes,
depreciation and amortization, and/or revenue multiples that are not observable in the markets.
Securities lending collateral: Fair values of securities lending collateral are based on quoted market prices, where
available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II
inputs for the determination of fair value, to facilitate fair value measurements and disclosures.
Derivatives: Fair values are based on the quoted market prices by the financial institution that is the counterparty to the
derivative transaction. We independently verify prices provided by the counterparties using valuation models that incorporate
market observable inputs for similar derivative transactions. Derivatives are designated as Level II securities. Derivatives
presented within the fair value hierarchy table below are presented on a gross basis and not on a master netting basis by
counterparty.
In addition, the following methods and assumptions were used to determine the fair value of each class of pension
benefit plan assets and other benefit plan assets not defined above (see Note 11, “Retirement Benefits,” for fair values of
benefit plan assets):
Mutual funds: Fair values are based on quoted market prices, which represent the net asset value (“NAV”) of the shares
held.
Partnership investments: Fair values are estimated based on the plan’s proportionate share of the undistributed partners’
capital as reported in audited financial statements of the partnership. In accordance with FASB guidance, certain investments
that are measured at fair value using the NAV per share as a practical expedient or the fair value measurement alternative
have been classified in the fair value hierarchy. The fair value amounts presented are intended to permit reconciliation of the
fair value hierarchy to the total investments of the master trust.
Commingled fund: Fair value is based on NAV per fund share, primarily derived from the quoted prices in active markets
on the underlying equity securities.
Contract with insurance company: Fair value of the contract in the insurance company general investment account is
determined by the insurance company based on the fair value of the underlying investments of the account.
Investment in DOL 103-12 trust: Fair value is based on the plan’s proportionate share of the fair value of investments
held by the trust, qualified as a Department of Labor Regulation 2520.103-12 entity (“DOL 103-12 trust”) as reported in the
audited financial statements of the trust, where the trustee applies fair value measurements to the underlying investments of
the trust.
Life insurance contracts: Fair value is based on the cash surrender value of the policies as reported by the insurer.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
78

-- 143 of 188 --

A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at
December 31, 2022 and 2021 is as follows:
Level I Level II Level III Total
December 31, 2022
Assets:
Cash equivalents $ 3,567 $ — $ — $ 3,567
Fixed maturity securities, available-for-sale:
United States Government securities — 1,401 — 1,401
Government sponsored securities — 78 — 78
Foreign government securities — 274 — 274
States, municipalities and political subdivisions, tax-exempt — 4,143 — 4,143
Corporate securities — 12,392 137 12,529
Residential mortgage-backed securities — 2,663 — 2,663
Commercial mortgage-backed securities — 1,878 — 1,878
Other asset-backed securities — 3,382 356 3,738
Total fixed maturity securities, available-for-sale — 26,211 493 26,704
Equity securities:
Exchange traded funds 822 — — 822
Common equity securities 2 41 — 43
Private equity securities — — 88 88
Total equity securities 824 41 88 953
Other invested assets - common equity securities 103 — — 103
Securities lending collateral — 2,457 — 2,457
Derivatives - other assets — 3 — 3
Total assets $ 4,494 $ 28,712 $ 581 $ 33,787
Liabilities:
Derivatives - other liabilities $ — $ (60) $ — $ (60)
Total liabilities $ — $ (60) $ — $ (60)
December 31, 2021
Assets:
Cash equivalents $ 2,415 $ — $ — $ 2,415
Fixed maturity securities, available-for-sale:
United States Government securities — 1,432 — 1,432
Government sponsored securities — 68 — 68
Foreign government securities — 347 — 347
States, municipalities and political subdivisions, tax-exempt — 5,621 — 5,621
Corporate securities — 12,027 336 12,363
Residential mortgage-backed securities — 2,513 5 2,518
Commercial mortgage-backed securities — 1,643 — 1,643
Other asset-backed securities — 2,888 19 2,907
Total fixed maturity securities, available-for-sale — 26,539 360 26,899
Equity securities:
Exchange traded funds 1,750 — — 1,750
Common equity securities 8 34 — 42
Private equity securities — — 89 89
Total equity securities 1,758 34 89 1,881
Other invested assets - common equity securities 138 — — 138
Securities lending collateral — 2,155 — 2,155
Derivatives - other assets — 19 — 19
Total assets $ 4,311 $ 28,747 $ 449 $ 33,507
Liabilities:
Derivatives - other liabilities $ — $ (1) $ — $ (1)
Total liabilities $ — $ (1) $ — $ (1)
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
79

-- 144 of 188 --

A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level
III inputs for the years ended December 31, 2022, 2021 and 2020 is as follows:
Corporate
Securities
Residential
Mortgage-
backed
Securities
Other Asset-
Backed
Securities Equity
Securities Total
Year ended December 31, 2022
Beginning balance at January 1, 2022 $ 336 $ 5 $ 19 $ 89 $ 449
Total gains (losses):
Recognized in net income — — (1) — (1)
Recognized in accumulated other comprehensive income (1) — (16) — (17)
Purchases 56 — 370 17 443
Sales (210) — (14) (18) (242)
Settlements (41) — — — (41)
Transfers into Level III 9 — — — 9
Transfers out of Level III (12) (5) (2) — (19)
Ending balance at December 31, 2022 $ 137 $ — $ 356 $ 88 $ 581
Change in unrealized gains or losses included in net income
related to assets still held at December 31, 2022 $ — $ — $ — $ — $ —
Year ended December 31, 2021
Beginning balance at January 1, 2021 $ 325 $ 2 $ 5 $ 60 $ 392
Total gains (losses):
Recognized in net income 2 — — 17 19
Recognized in accumulated other comprehensive income 3 — — — 3
Purchases 179 4 17 16 216
Sales (18) — — (4) (22)
Settlements (157) — — — (157)
Transfers into Level III 3 — — — 3
Transfers out of Level III (1) (1) (3) — (5)
Ending balance at December 31, 2021 $ 336 $ 5 $ 19 $ 89 $ 449
Change in unrealized gains or losses included in net income
related to assets still held at December 31, 2021 $ — $ — $ — $ 18 $ 18
Year ended December 31, 2020
Beginning balance at January 1, 2020 $ 303 $ 2 $ 7 $ 85 $ 397
Total gains (losses):
Recognized in net income (3) — — (19) (22)
Recognized in accumulated other comprehensive income (5) — — — (5)
Purchases 85 — — 16 101
Sales (19) — — (22) (41)
Settlements (44) — (2) — (46)
Transfers into Level III 10 — — — 10
Transfers out of Level III (2) — — — (2)
Ending balance at December 31, 2020 $ 325 $ 2 $ 5 $ 60 $ 392
Change in unrealized gains or losses included in net income
related to assets still held at December 31, 2020 $ — $ — $ — $ (19) $ (19)
There were no individually material transfers into or out of Level III during the years ended December 31, 2022, 2021 or
2020.
Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured
at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note
3, “Business Acquisitions,” we completed our acquisition of Integra in 2022 and the acquisitions of myNEXUS and MMM
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
80

-- 145 of 188 --

during 2021. The net assets acquired in our acquisitions of Integra, myNEXUS, and MMM and resulting goodwill and other
intangible assets were recorded at fair value primarily using Level III inputs. The majority of assets acquired and liabilities
assumed were recorded at their carrying values as of the respective date of acquisition, as their carrying values approximated
their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our
acquisitions of Integra, myNEXUS and MMM were internally estimated based on the income approach. The income
approach estimates fair value based on the present value of the cash flows that the assets could be expected to generate in the
future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Other
than the assets acquired and liabilities assumed in our acquisitions of Integra, myNEXUS and MMM described above, there
were no material assets or liabilities measured at fair value on a nonrecurring basis during the years ended December 31,
2022 or 2021.
Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our
policy is to obtain quoted market prices in active markets to estimate fair values for recognition and disclosure purposes.
Where quoted market prices in active markets are not available, fair values are estimated using discounted cash flow
analyses, broker quotes, unobservable inputs or other valuation techniques. These techniques are significantly affected by our
assumptions, including discount rates and estimates of future cash flows. The use of assumptions for unobservable inputs for
the determination of fair value involves a level of judgment and uncertainty. Changes in assumptions that reasonably could
have been different at the reporting date may result in a higher or lower determination of fair value. Changes in fair value
measurements, if significant, may affect performance of cash flows.
Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally
to obtain quoted prices for each security from third-party pricing services, which are derived through recently reported trades
for identical or similar securities making adjustments through the reporting date based upon available market observable
information. As we are responsible for the determination of fair value, we perform analysis on the prices received from the
pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our
internal treasury personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation
techniques and inputs used. Our analysis includes procedures such as a review of month-to-month price fluctuations and price
comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing
services during the years ended December 31, 2022, 2021 or 2020.
In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB
guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to
estimate fair value, whether or not such values are recognized in the consolidated balance sheets.
Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes,
intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures.
Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.
The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables,
other receivables, unearned income, accounts payable and accrued expenses, and certain other current liabilities approximate
fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below.
The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is
recorded at its carrying value on the consolidated balance sheets:
Other invested assets: Other invested assets primarily include our investments in limited partnerships, joint ventures and
other non-controlled corporations and mortgage loans, as well as the cash surrender value of corporate-owned life insurance
policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in
the entities’ undistributed earnings, which approximates fair value. Mortgage loans are carried at amortized cost, which
approximates fair value. The carrying value of corporate-owned life insurance policies represents the cash surrender value as
reported by the respective insurer, which approximates fair value.
Short-term borrowings: The fair value of our short-term borrowings is based on quoted market prices for the same or
similar debt, or if no quoted market prices were available, on the current market interest rates estimated to be available to us
for debt of similar terms and remaining maturities.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
81

-- 146 of 188 --

Long-term debt—commercial paper: The carrying amount for commercial paper approximates fair value, as the
underlying instruments have variable interest rates at market value.
Long-term debt—senior unsecured notes and surplus notes: The fair values of our notes are based on quoted market
prices in active markets for the same or similar debt, or, if no quoted market prices are available, on the current market
observable rates estimated to be available to us for debt of similar terms and remaining maturities.
Long-term debt—convertible debentures: The fair value of our convertible debentures is based on the quoted market
price in the active private market in which the convertible debentures trade.
A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value
on our consolidated balance sheets at December 31, 2022 and 2021 is as follows:
Carrying
Value
Estimated Fair Value
Level I Level II Level III Total
December 31, 2022
Assets:
Other invested assets $ 5,582 $ — $ — $ 5,582 $ 5,582
Liabilities:
Debt:
Short-term borrowings 265 — 265 — 265
Notes 23,786 — 21,861 — 21,861
Convertible debentures 63 — 463 — 463
December 31, 2021
Assets:
Other invested assets $ 5,087 $ — $ — $ 5,087 $ 5,087
Liabilities:
Debt:
Short-term borrowings 275 — 275 — 275
Commercial paper 300 — 300 — 300
Notes 22,384 — 25,150 — 25,150
Convertible debentures 72 — 687 — 687
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
82

-- 147 of 188 --

8. Income Taxes
The components of deferred income taxes at December 31, 2022 and 2021 are as follows:
2022 2021
Deferred income tax assets:
Accrued expenses $ 379 $ 511
Bad debt reserves 301 246
Insurance reserves 166 146
Lease liabilities 200 216
Retirement liabilities 173 170
Deferred compensation 34 35
Federal and state operating loss carryforwards 208 201
Investment basis 340 —
Other 267 207
Subtotal 2,068 1,732
Less: valuation allowance (203) (212)
Total deferred income tax assets 1,865 1,520
U.S. federal and state intangible assets 2,059 2,071
Foreign (including Puerto Rico) intangible assets 380 452
Capitalized software 601 777
Depreciation and amortization 62 45
Investment basis — 295
Retirement assets 317 314
Lease right-of-use asset 123 126
Prepaid expenses 201 152
Total deferred income tax liabilities 3,743 4,232
Net deferred income tax liabilities $ 1,878 $ 2,712
We recognized $137 and $103 of deferred tax asset under the caption “Other noncurrent assets” at December 31, 2022
and 2021, respectively. We recognized $2,015 and $2,815 of deferred tax liability under the caption “Deferred tax liabilities,
net” at December 31, 2022 and 2021.
As of December 31, 2022, we have established U.S. deferred taxes for undistributed earnings from certain non-U.S.
subsidiaries, which are included in the Investment basis component above, consistent with prior years.
Significant components of the provision for income taxes for the years ended December 31, 2022, 2021 and 2020 consist
of the following:
2022 2021 2020
Current tax expense:
Federal $ 1,469 $ 1,467 $ 1,724
Foreign (including Puerto Rico) 98 18 7
State and local 179 165 461
Total current tax expense 1,746 1,650 2,192
Deferred tax expense (benefit) (34) 196 (526)
Total income tax expense $ 1,712 $ 1,846 $ 1,666
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
83

-- 148 of 188 --

State and local current tax expense is reported gross of federal benefit in the preceding table, and includes amounts
related to audit settlements, uncertain tax positions, state tax credits and true up of prior years’ tax. Such items are included
on a net of federal tax basis in multiple lines in the following rate reconciliation table.
A reconciliation of income tax expense recorded in the consolidated statements of income and amounts computed at the
statutory federal income tax rate for the years ended December 31, 2022, 2021 and 2020 is as follows:
2022 2021 2020
Amount Percent Amount Percent Amount Percent
Amount at statutory rate $ 1,595 21.0 % $ 1,679 21.0 % $ 1,310 21.0 %
State and local income taxes net of federal tax
expense/benefit 236 3.1 259 3.3 235 3.8
Tax exempt interest and dividends received
deduction (19) (0.3) (22) (0.3) (22) (0.4)
HIP fee — — — — 330 5.3
Basis adjustments from recent acquisitions — — — — (110) (1.8)
Other, net (100) (1.3) (70) (0.9) (77) (1.2)
Total income tax expense $ 1,712 22.5 % $ 1,846 23.1 % $ 1,666 26.7 %
During the year ended December 31, 2022, we recognized income tax expense of $1,712, or $7.05 per diluted share. The
decrease in effective income tax rate is primarily due to the impact of geographic changes in the mix of 2022 earnings.
During the year ended December 31, 2021, we recognized income tax expense of $1,846, or $7.48 per diluted share. The
HIP Fee payment was eliminated beginning in 2021.
During the year ended December 31, 2020, we recognized income tax expense of $1,666, or $6.55 per diluted share,
which included income tax expense of $330, or $1.30 per diluted share, as a result of the non-tax deductibility of the HIP Fee
payment.
The change in the carrying amount of gross unrecognized tax benefits from uncertain tax positions for the years ended
December 31, 2022 and 2021 is as follows:
2022 2021
Balance at January 1 $ 271 $ 249
Additions based on:
Tax positions related to current year 22 10
Tax positions related to prior years 57 17
Reductions based on:
Tax positions related to prior years (1) (5)
Balance at December 31 $ 349 $ 271
The table above excludes interest, net of related tax benefits, which is treated as income tax expense (benefit) under our
accounting policy. The interest is included in the amounts described in the following paragraph.
The amount of unrecognized tax benefits that would impact our effective tax rate in future periods, if recognized, was
$328 and $250 at December 31, 2022 and 2021, respectively. Also included in the table above, at December 31, 2022, is $2
that would be recognized as an adjustment to additional paid-in capital, which would not affect our effective tax rate. In
addition to the contingent liabilities included in the table above, we filed protective state income tax refund claims of
approximately $92 and $310 for 2022 and 2017, respectively. There were no equivalent protective state income tax refund
claims filed in 2021, 2020, 2019 or 2018.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
84

-- 149 of 188 --

For the years ended December 31, 2022, 2021 and 2020 we recognized net interest expense of $13, $9 and $7,
respectively. We had accrued approximately $55 and $42 for the payment of interest at December 31, 2022 and 2021,
respectively.
As of December 31, 2022, as further described below, certain tax years remain open to examination by the Internal
Revenue Service (“IRS”) and various state, local and foreign authorities. As a result of these examinations and discussions
with taxing agencies, we have recorded amounts for uncertain tax positions. It is anticipated that the amount of unrecognized
tax benefits will change in the next twelve months due to possible settlements of audits and changes in temporary items.
However, the ultimate resolution of these items is dependent on the completion of negotiations with various taxing
authorities. While it is difficult to determine when other tax settlements will actually occur, it is reasonably possible that one
could occur in the next twelve months and our unrecognized tax benefits could be reduced within a range of approximately
$33 to $143.
We are a member of the IRS Compliance Assurance Process (“CAP”). The objective of CAP is to reduce taxpayer
burden and uncertainty while assuring the IRS of the accuracy of tax returns prior to filing, thereby reducing or eliminating
the need for post-filing examinations.
As of December 31, 2022, the IRS examination of our 2022 and 2021 tax years continues to be in process.
In certain states, we pay premium taxes in lieu of state income taxes. Premium taxes are reported in operating expense.
At December 31, 2022, we had federal net operating loss carryforwards of $160 that will expire beginning 2032 through
2042 and $109 that have an indefinite carryforward period. State net operating loss carryforwards expire beginning 2023
through 2042, with some having an indefinite carryforward period.
Income taxes receivable totaled $440 and $173 at December 31, 2022 and 2021, respectively. We recognize the income
tax receivable as an asset under the caption “Other current assets” in our consolidated balance sheets.
During 2022, 2021 and 2020, federal income taxes paid totaled $1,594, $1,299 and $1,790, respectively.
9. Property and Equipment
A summary of property and equipment at December 31, 2022 and 2021 is as follows:
2022 2021
Computer software, purchased and internally developed $ 5,604 $ 6,115
Computer equipment, furniture and other equipment 828 1,314
Leasehold improvements 648 641
Building and improvements 38 172
Land and improvements 1 17
Property and equipment, gross 7,119 8,259
Accumulated depreciation and amortization (2,803) (4,340)
Property and equipment, net $ 4,316 $ 3,919
Depreciation expense for 2022, 2021 and 2020 was $123, $136 and $176, respectively. Amortization expense on
computer software and leasehold improvements for 2022, 2021 and 2020 was $661, $532 and $462, respectively, which
includes amortization expense on computer software, both purchased and internally developed, for 2022, 2021 and 2020 of
$599, $485 and $412, respectively. Capitalized costs related to the internal development of software of $5,354 and $5,626 at
December 31, 2022 and 2021, respectively, are reported with computer software.
Impairment of property and equipment for the years ended December 31, 2022, 2021 and 2020 was $7, $73, and $198,
respectively, which is included in operating expense and primarily related to our activities disclosed in Note 4, “Business
Optimization Initiatives.”
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
85

-- 150 of 188 --

10. Goodwill and Other Intangible Assets
A summary of the change in the carrying amount of goodwill for our segments (see Note 20, “Segment Information”) for
2022 and 2021 is as follows:
Health
Benefits CarelonRx Carelon
Services Total
Balance as of January 1, 2021 $ 19,924 $ 48 $ 1,719 $ 21,691
Acquisitions and adjustments 2,018 11 508 2,537
Balance as of December 31, 2021 21,942 59 2,227 24,228
Acquisitions and adjustments 146 — 9 155
Balance as of December 31, 2022 $ 22,088 $ 59 $ 2,236 $ 24,383
Accumulated impairment as of December 31, 2022 $ — $ — $ — $ —
As required by FASB guidance, we completed annual impairment tests of existing goodwill and other intangible assets
with indefinite lives during 2022, 2021 and 2020. We perform these annual impairment tests during the fourth quarter. FASB
guidance also requires interim impairment testing to be performed when potential impairment indicators exist. These tests
involve the use of estimates related to the fair value of goodwill and intangible assets with indefinite lives and require a
significant degree of management judgment and the use of subjective assumptions. Qualitative testing procedures include
assessing our financial performance, macroeconomic conditions, industry and market considerations, various asset specific
factors and entity specific events. For quantitative testing, the fair values are estimated using the projected income and market
valuation approaches, incorporating Level III internal estimates for inputs, including, but not limited to, revenue projections,
income projections, cash flows and discount rates. We did not incur any impairment losses in 2022, 2021 or 2020, as the
estimated fair values of our reporting units were substantially in excess of their carrying values.
The components of other intangible assets as of December 31, 2022 and 2021 are as follows:
2022 2021
Gross
Carrying
Amount Accumulated
Amortization
Net
Carrying
Amount
Gross
Carrying
Amount Accumulated
Amortization
Net
Carrying
Amount
Intangible assets with finite lives:
Customer relationships $ 5,791 $ (3,693) $ 2,098 $ 5,598 $ (3,236) $ 2,362
Provider and hospital relationships 326 (146) 180 324 (129) 195
Other 1,010 (440) 570 610 (141) 469
Total 7,127 (4,279) 2,848 6,532 (3,506) 3,026
Intangible assets with indefinite lives:
Blue Cross and Blue Shield and other
trademarks 5,991 — 5,991 6,299 — 6,299
State Medicaid licenses 1,476 — 1,476 1,290 — 1,290
Total 7,467 — 7,467 7,589 — 7,589
Other intangible assets $ 14,594 $ (4,279) $ 10,315 $ 14,121 $ (3,506) $ 10,615
In 2022, due to our acquisition of Integra, we recorded intangible assets and due to our new branding strategy,
reclassified $308 of trademarks with indefinite lives to Intangible assets with finite lives - Other. In addition, the amortization
period of certain intangible assets was shortened to align with the anticipated dates the new branding will take place.
Intangible assets, along with the related accumulated amortization, are removed from the table above at the end of the
fiscal year in which they become fully amortized.
As of December 31, 2022, the estimated amortization expense for each of the five succeeding years is as follows: 2023,
$806; 2024, $370; 2025, $311; 2026, $258; and 2027, $221.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
86

-- 151 of 188 --

11. Retirement Benefits
We sponsor various non-contributory employee defined benefit plans through certain subsidiaries.
The Elevance Health Cash Balance Plan A (formerly the Anthem Cash Balance Plan A) and the Elevance Health Cash
Balance Plan B (formerly the Anthem Cash Balance Plan B) are cash balance pension plans covering certain eligible
employees of the affiliated companies that participate in these plans. Effective January 1, 2006, benefits were curtailed, with
the result that most participants stopped accruing benefits but continue to earn interest on benefits accrued prior to the
curtailment. Certain participants subject to collective bargaining and certain other participants who met grandfathering rules
continued to accrue benefits. Participants who did not receive credits and/or benefit accruals were included in the Elevance
Health Cash Balance Plan A, while employees who were still receiving credits and/or benefits participated in the Elevance
Health Cash Balance Plan B. Effective January 1, 2019, benefits under the Elevance Health Cash Balance Plan B were
curtailed. All grandfathered participants no longer have pay credits added to their accounts but continue to earn interest on
existing account balances. Participants continue to earn years of pension service for vesting purposes. Several pension plans
acquired through various corporate mergers and acquisitions were merged into these plans in prior years.
The Employees’ Retirement Plan of Blue Cross of California (the “BCC Plan”) is a defined benefit pension plan that
covers eligible employees of Blue Cross of California who are covered by a collective bargaining agreement. Effective
January 1, 2007, benefits were curtailed under the BCC Plan with the result that no Blue Cross of California employees hired
or rehired after December 31, 2006 are eligible to participate in the BCC Plan.
All of the plans’ assets consist primarily of equity securities, fixed maturity securities, investment funds and cash. The
funding policies for all plans are to contribute amounts at least sufficient to meet the minimum funding requirements set forth
in the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), as further amended by the Pension
Protection Act of 2006, and in accordance with income tax regulations, plus such additional amounts as are necessary to
provide assets sufficient to meet the benefits to be paid to plan participants.
The following tables disclose consolidated “pension benefits,” which include the defined benefit pension plans described
above, and consolidated “other benefits,” which include postretirement health and welfare benefits including medical, vision
and dental benefits offered to certain employees. Calculations were computed using assumptions at the December 31
measurement dates.
The reconciliation of the benefit obligation is as follows:
Pension Benefits Other Benefits
2022 2021 2022 2021
Benefit obligation at beginning of year $ 1,859 $ 2,009 $ 343 $ 399
Service cost — — — 1
Interest cost 52 34 7 5
Plan participant contributions — — 17 17
Actuarial (gain) loss (362) (33) (54) (31)
Settlements (74) (90) — —
Benefits paid (60) (61) (36) (48)
Benefit obligation at end of year $ 1,415 $ 1,859 $ 277 $ 343
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
87

-- 152 of 188 --

The changes in the fair value of plan assets are as follows:
Pension Benefits Other Benefits
2022 2021 2022 2021
Fair value of plan assets at beginning of year $ 2,216 $ 2,186 $ 371 $ 391
Actual return on plan assets (352) 174 (61) 33
Employer contributions 4 7 — —
Plan participant contributions — — 17 17
Settlements (74) (90) — (29)
Benefits paid (60) (61) (28) (41)
Fair value of plan assets at end of year $ 1,734 $ 2,216 $ 299 $ 371
The net amount included in the consolidated balance sheets is as follows:
Pension Benefits Other Benefits
2022 2021 2022 2021
Noncurrent assets $ 363 $ 415 $ 22 $ 28
Current liabilities (6) (6) — —
Noncurrent liabilities (38) (52) — —
Net amount at December 31 $ 319 $ 357 $ 22 $ 28
The net amounts included in accumulated other comprehensive income (loss) that have not been recognized as
components of net periodic benefit costs are as follows:
Pension Benefits Other Benefits
2022 2021 2022 2021
Net actuarial (loss) gain $ (672) $ (625) $ 5 $ 36
Prior service credit — — 3 8
Net amount before tax at December 31 $ (672) $ (625) $ 8 $ 44
The accumulated benefit obligation for the defined benefit pension plans was $1,413 and $1,857 at December 31, 2022
and 2021, respectively.
As of December 31, 2022, certain pension plans had accumulated benefit obligations in excess of plan assets. Such plans
had accumulated benefit obligation and fair value of plan assets of $44 and $0, respectively. In addition, certain plans had
projected benefit obligations in excess of plan assets. Such plans had projected benefit obligation and fair value of plan assets
of $44 and $0, respectively.
The weighted-average assumptions used in calculating the benefit obligations for all plans are as follows:
Pension Benefits Other Benefits
2022 2021 2022 2021
Discount rate 5.18 % 2.70 % 5.12 % 2.49 %
Rate of compensation increase 3.00 % 3.00 % 3.00 % 3.00 %
Expected rate of return on plan assets 6.58 % 5.02 % 6.57 % 6.43 %
Interest crediting rate 4.25 % 3.82 % 3.89 % 1.56 %
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
88

-- 153 of 188 --

The components of net periodic benefit credit included in the consolidated statements of income are as follows:
2022 2021 2020
Pension Benefits
Interest cost $ 52 $ 34 $ 47
Expected return on assets (101) (134) (138)
Recognized actuarial loss 16 25 24
Settlement loss 28 26 29
Net periodic benefit credit $ (5) $ (49) $ (38)
Other Benefits
Service cost $ — $ 1 $ 1
Interest cost 7 5 10
Expected return on assets (26) (26) (25)
Amortization of prior service credit (4) (4) (7)
Net periodic benefit credit $ (23) $ (24) $ (21)
During the years ended December 31, 2022, 2021 and 2020, we incurred total settlement losses of $28, $26 and $29,
respectively, as lump-sum payments exceeded the service cost and interest cost components of net periodic benefit cost for
certain of our plans.
The weighted-average assumptions used in calculating the net periodic benefit cost for all plans are as follows:
2022 2021 2020
Pension Benefits
Discount rate 2.70 % 2.24 % 3.11 %
Rate of compensation increase 3.00 % 3.00 % 3.00 %
Expected rate of return on plan assets 5.02 % 6.72 % 7.33 %
Interest crediting rate 3.82 % 3.82 % 3.82 %
Other Benefits
Discount rate 2.49 % 1.99 % 2.93 %
Rate of compensation increase 3.00 % 3.00 % 3.00 %
Expected rate of return on plan assets 6.43 % 6.60 % 7.00 %
Interest crediting rate 1.56 % 0.87 % 1.81 %
The assumed healthcare cost trend rates used to measure the expected cost of pre-Medicare (those who are not currently
eligible for Medicare benefits) other benefits at our December 31, 2022 measurement date was 8.00% for 2023, with a
gradual decline to 4.50% by the year 2035. The assumed healthcare cost trend rates used to measure the expected cost of
post-Medicare (those who are currently eligible for Medicare benefits) other benefits at our December 31, 2022 measurement
date was 6.50% for 2023, with a gradual decline to 4.50% by the year 2035. These estimated trend rates are subject to change
in the future.
Plan assets include a diversified mix of equity securities, investment grade fixed maturity securities and other types of
investments across a range of sectors and levels of capitalization to maximize long-term return for a prudent level of risk. The
weighted-average target allocation for pension benefit plan assets is 37% equity securities, 58% fixed maturity securities, and
5% to all other types of investments. Equity securities primarily include a mix of domestic securities, foreign securities and
mutual funds invested in equities. Fixed maturity securities primarily include treasury securities, corporate bonds and asset-
backed investments issued by corporations and the U.S. government. Other types of investments include insurance contracts
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
89

-- 154 of 188 --

designed specifically for employee benefit plans, a commingled fund comprised primarily of equity securities and certain
partnership interests.
The partnerships hold various types of underlying assets such as real estate and investments in oil and gas companies.
Generally, the partnership interests are not redeemable and are transferable only with the consent of the general partner.
Unfunded commitments related to all partnership interests totaled approximately $2 and $3 at December 31, 2022 and 2021,
respectively.
As of December 31, 2022, there were no significant concentrations of investments in the pension benefit assets or other
benefit assets. No plan assets were invested in Elevance Health common stock.
Pension benefit assets and other benefit assets recorded at fair value are categorized based upon the level of judgment
associated with the inputs used to measure their fair value.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
90

-- 155 of 188 --

The fair values of our pension benefit assets and other benefit assets by asset category and level inputs at December 31,
2022, excluding cash, investment income receivable and amounts due to/from brokers, resulting in a net asset of $36, and
excluding estimated claims settlements to be paid from other benefit assets of ($17), are as follows (see Note 7, “Fair Value,”
for additional information regarding the definition of level inputs):
Level I Level II Level III Total
December 31, 2022
Pension Benefit Assets:
Equity securities:
U.S. securities $ 489 $ — $ — $ 489
Foreign securities 145 — — 145
Mutual funds 39 — — 39
Fixed maturity securities:
Government securities — 247 — 247
Corporate securities — 275 — 275
Asset-backed securities — 185 — 185
Other types of investments:
Commingled fund — 93 — 93
Insurance company contracts — — 154 154
Total pension benefit assets at fair value $ 673 $ 800 $ 154 1,627
Partnership investments 71
Total pension benefit assets $ 1,698
Other Benefit Assets:
Equity securities:
U.S. securities $ 7 $ — $ — $ 7
Foreign securities 1 — — 1
Mutual funds 17 — — 17
Fixed maturity securities:
Government securities — 3 — 3
Corporate securities — 3 — 3
Asset-backed securities — 3 — 3
Other types of investments:
Commingled fund — 2 — 2
Life insurance contracts — — 270 270
Investment in DOL 103-12 trust — 10 — 10
Total other benefit assets $ 25 $ 21 $ 270 $ 316
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
91

-- 156 of 188 --

The fair values of our pension benefit assets and other benefit assets by asset category and level inputs at December 31,
2021, excluding cash, investment income receivable and amounts due to/from brokers, resulting in a net asset of $48, and
excluding estimated claims settlements to be paid from other benefit assets of ($29), are as follows:
Level I Level II Level III Total
December 31, 2021
Pension Benefit Assets:
Equity securities:
U.S. securities $ 682 $ — $ — $ 682
Foreign securities 204 — — 204
Mutual funds 49 — — 49
Fixed maturity securities:
Government securities — 395 — 395
Corporate securities — 379 — 379
Asset-backed securities — 98 — 98
Other types of investments:
Commingled fund — 106 — 106
Insurance company contracts — — 179 179
Total pension benefit assets at fair value $ 935 $ 978 $ 179 2,092
Partnership investments 78
Total pension benefit assets $ 2,170
Other Benefit Assets:
Equity securities:
U.S. securities $ 10 $ — $ — $ 10
Foreign securities 2 — — 2
Mutual funds 24 — — 24
Fixed maturity securities:
Government securities — 4 — 4
Corporate securities — 4 — 4
Asset-backed securities — 3 — 3
Other types of investments:
Commingled fund — 2 — 2
Life insurance contracts — — 338 338
Investment in DOL 103-12 trust — 11 — 11
Total other benefit assets $ 36 $ 24 $ 338 $ 398
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
92

-- 157 of 188 --

A reconciliation of the beginning and ending balances of plan assets measured at fair value using Level III inputs for the
years ended December 31, 2022, 2021 and 2020 is as follows:
Insurance
Company
Contracts
Life
Insurance
Contracts Total
Year ended December 31, 2022
Beginning balance at January 1, 2022 $ 179 $ 338 $ 517
Actual return on plan assets relating to assets still held at the reporting date (22) (53) (75)
Purchases 9 — 9
Sales (12) (15) (27)
Ending balance at December 31, 2022 $ 154 $ 270 $ 424
Year ended December 31, 2021
Beginning balance at January 1, 2021 $ 189 $ 323 $ 512
Actual return on plan assets relating to assets still held at the reporting date (6) 26 20
Purchases 5 — 5
Sales (9) (11) (20)
Ending balance at December 31, 2021 $ 179 $ 338 $ 517
Year ended December 31, 2020
Beginning balance at January 1, 2020 $ 175 $ 294 $ 469
Actual return on plan assets relating to assets still held at the reporting date 7 29 36
Purchases 15 — 15
Sales (8) — (8)
Ending balance at December 31, 2020 $ 189 $ 323 $ 512
There were no other transfers into or out of Level III during the years ended December 31, 2022, 2021 or 2020.
Our current funding strategy is to fund an amount at least equal to the minimum required funding as determined under
ERISA with consideration of maximum tax deductible amounts. We may elect to make discretionary contributions up to the
maximum amount deductible for income tax purposes. For the years ended December 31, 2022, 2021 and 2020, no material
contributions were necessary to meet ERISA required funding levels. However, during each of the years ended December 31,
2022, 2021 and 2020, we made tax deductible discretionary contributions to the pension benefit plans of $4, $7, and $7,
respectively. Employer contributions to other benefit plans represent discretionary contributions and do not include payments
to retirees for current benefits.
Our estimated future payments for pension benefits and other benefits, which reflect expected future service, as
appropriate, are as follows:
Pension
Benefits Other
Benefits
2023 $ 125 $ 32
2024 120 30
2025 118 29
2026 116 28
2027 113 27
2028 - 2032 526 110
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
93

-- 158 of 188 --

In addition to the defined benefit plans, we maintain the Elevance Health 401(k) Plan (formerly the Anthem 401(k)
Plan), which is a qualified defined contribution plan covering substantially all employees. Voluntary employee contributions
are matched by us subject to certain limitations. Contributions made by us totaled $275, $241 and $221 during 2022, 2021
and 2020, respectively.
12. Medical Claims Payable
A reconciliation of the beginning and ending balances for medical claims payable for the years ended December 31,
2022, 2021 and 2020 is as follows:
2022 2021 2020
Gross medical claims payable, beginning of year $ 13,282 $ 11,135 $ 8,647
Ceded medical claims payable, beginning of year (21) (46) (33)
Net medical claims payable, beginning of year 13,261 11,089 8,614
Business combinations and purchase adjustments 133 420 339
Net incurred medical claims:
Current year 113,414 100,440 85,094
Prior years redundancies (869) (1,703) (637)
Total net incurred medical claims 112,545 98,737 84,457
Net payments attributable to:
Current year medical claims 98,997 88,156 74,629
Prior years medical claims 11,600 8,829 7,692
Total net payments 110,597 96,985 82,321
Net medical claims payable, end of year 15,342 13,261 11,089
Ceded medical claims payable, end of year 6 21 46
Gross medical claims payable, end of year $ 15,348 $ 13,282 $ 11,135
Amounts incurred related to prior years vary from previously estimated liabilities as the claims are ultimately settled.
Liabilities at any period-end are continually reviewed and re-estimated as information regarding actual claims payments, or
runout, becomes known. This information is compared to the originally established year end liability. Negative amounts
reported for incurred medical claims related to prior years result from claims being settled for amounts less than originally
estimated. The prior year redundancy of $869 shown above for the year ended December 31, 2022 represents an estimate
based on paid claim activity from January 1, 2022 to December 31, 2022. Medical claim liabilities are usually described as
having a “short tail,” which means that they are generally paid within twelve months of the member receiving service from
the provider. Accordingly, the majority of the $869 redundancy relates to claims incurred in calendar year 2021.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
94

-- 159 of 188 --

The following table provides a summary of the two key assumptions having the most significant impact on our incurred
but not paid liability estimates for the years ended December 31, 2022, 2021 and 2020, which are the completion and trend
factors. These two key assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs,
provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing
patterns, claim submission patterns and operational changes resulting from business combinations. We had increased
estimation uncertainty on our incurred but not reported liability at December 31, 2022 and December 31, 2021. Slowdowns in
claims submission patterns and increases in utilization levels for COVID-19 testing and treatment are the primary factors that
lead to the increased estimation uncertainty.
Favorable Developments
by Changes in Key Assumptions
2022 2021 2020
Assumed trend factors $ (859) $ (1,429) $ (599)
Assumed completion factors (10) (274) (38)
Total $ (869) $ (1,703) $ (637)
The favorable development recognized in 2022 resulted primarily from trend factors in late 2021 developing more
favorably than originally expected as well as a smaller contribution from completion factor development.
The favorable development recognized in 2021 resulted primarily from trend factors in late 2020 developing more
favorably than originally expected as well as a smaller but significant contribution from completion factor development.
The favorable development recognized in 2020 resulted primarily from trend factors in late 2019 developing more
favorably than originally expected as well as a smaller contribution from completion factor development.
The reconciliation of net incurred medical claims to benefit expense included in the consolidated statements of income is
as follows:
Years Ended December 31
2022 2021 2020
Total net incurred medical claims $ 112,545 $ 98,737 $ 84,457
Quality improvement and other claims expense 4,097 3,834 3,588
Benefit expense $ 116,642 $ 102,571 $ 88,045
Incurred claims development, net of reinsurance, for the years ended December 31, 2022, 2021 and 2020 is as follows:
Cumulative Incurred Claims and Allocated
Claim Adjustment Expenses, Net of Reinsurance
2020 2021
Claim Years (Unaudited) (Unaudited) 2022
2020 & Prior $ 93,410 $ 91,708 $ 91,683
2021 100,860 100,016
2022 113,547
Total $ 305,246
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
95

-- 160 of 188 --

Paid claims development, net of reinsurance, for the years ended December 31, 2022, 2021 and 2020 is as follows:
Cumulative Paid Claims and Allocated Claim
Adjustment Expenses, Net of Reinsurance
2020 2021
Claim Years (Unaudited) (Unaudited) 2022
2020 & Prior $ 82,322 $ 91,151 $ 91,488
2021 88,156 99,419
2022 98,997
Total $ 289,904
At December 31, 2022, the total of incurred but not reported liabilities plus expected development on reported claims
was $195, $597 and $14,550 for the claim years 2020 and prior, 2021 and 2022, respectively.
At December 31, 2022, the cumulative number of reported claims was 360, 440 and 404 for the claim years 2020 and
prior, 2021 and 2022, respectively.
The information about incurred claims development, paid claims development and cumulative number of reported claims
for the years ended December 31, 2020 and 2021 is unaudited and presented as supplementary information.
The cumulative number of reported claims for each claim year has been developed using historical data captured by our
claim payment systems. The provided claim amounts are not a precise tool for understanding utilization of medical services.
They could be impacted by a variety of factors, including changes in provider billing practices, provider reimbursement
arrangements, mix of services, benefit design or processing systems. The cumulative number of reported claims has been
provided to comply with FASB accounting standards and is not used by management in its claims analysis. Our cumulative
number of reported claims may not be comparable to similar measures reported by other health benefits companies.
The reconciliation of incurred and paid claims development information for the three years ended December 31, 2022,
reflected in the tables above, to the consolidated ending balance for medical claims payable included in the consolidated
balance sheet, as of December 31, 2022, is as follows:
Total
Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance $ 305,246
Less: Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance 289,904
Net medical claims payable, end of year 15,342
Ceded medical claims payable, end of year 6
Insurance lines other than short duration 248
Gross medical claims payable, end of year $ 15,596
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
96

-- 161 of 188 --

13. Debt
Short-term Borrowings
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan
Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively,
the “FHLBs”). As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral
requirements. At December 31, 2022 and 2021, $265 and $275, respectively, were outstanding under our short-term FHLB
borrowings. Outstanding short-term FHLB borrowings at December 31, 2022 had fixed interest rates of 4.240%.
Through certain subsidiaries, we have entered into multiple 364-day lines of credit (the “Subsidiary Credit Facilities”)
with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provide combined credit of up to $200.
The interest rate on each line of credit is based on the LIBOR rate plus a predetermined rate. Our ability to borrow under the
lines of credit is subject to compliance with certain covenants. At each of December 31, 2022 and 2021, $0 was outstanding
under our Subsidiary Credit Facilities.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
97

-- 162 of 188 --

Long-term Debt
The carrying value of our long-term debt at December 31, 2022 and 2021 consists of the following:
2022 2021
Senior unsecured notes:
2.950%, due 2022 $ — $ 749
3.125%, due 2022 — 850
3.300%, due 2023 1,000 1,014
0.450%, due 2023 500 499
3.350%, due 2024 849 848
3.500%, due 2024 798 797
2.375%, due 2025 1,252 1,253
5.350%, due 2025 398 —
1.500%, due 2026 746 745
3.650%, due 2027 1,592 1,592
4.101%, due 2028 1,234 1,251
2.875%, due 2029 820 820
2.250%, due 2030 1,071 1,089
2.550%, due 2031 968 992
4.100%, due 2032 595 —
5.500%, due 2032 644 —
5.950%, due 2034 334 334
5.850%, due 2036 396 396
6.375%, due 2037 364 364
5.800%, due 2040 114 114
4.625%, due 2042 859 859
4.650%, due 2043 974 974
4.650%, due 2044 767 767
5.100%, due 2044 548 548
4.375%, due 2047 1,388 1,387
4.550%, due 2048 840 839
3.700%, due 2049 812 812
3.125%, due 2050 988 987
3.600%, due 2051 1,233 1,232
4.550%, due 2052 689 —
6.100%, due 2052 741 —
4.850%, due 2054 247 247
Surplus note:
9.000%, due 2027 25 25
Senior convertible debentures:
2.750%, due 2042 63 72
Variable rate debt:
Commercial paper program — 300
Total long-term debt 23,849 22,756
Current portion of long-term debt (1,500) (1,599)
Long-term debt, less current portion $ 22,349 $ 21,157
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
98

-- 163 of 188 --

All debt is a direct obligation of Elevance Health, Inc., except for the surplus note, the FHLB borrowings and the
Subsidiary Credit Facilities.
We generally issue senior unsecured notes (“Notes”) for long-term borrowing purposes. Certain of these Notes may have
a call feature that allows us to redeem the Notes at any time at our option and/or a put feature that allows a Note holder to
redeem the Notes upon the occurrence of both a change in control event and a downgrade of the Notes below an investment
grade rating.
On February 8, 2023, we issued $500 aggregate principal amount of 4.900% Notes due 2026 (the “2026 Notes”), $1,000
aggregate principal amount of 4.750% Notes due 2033 (the “2033 Notes”), and $1,100 aggregate principal amount of 5.125%
Notes due 2053 (the “2053 Notes”) under our shelf registration statement. Interest on the 2026 Notes is payable semi-
annually in arrears on February 8 and August 8 of each year, commencing August 8, 2023. Interest on the 2033 Notes and
2053 Notes is payable semi-annually in arrears on February 15 and August 15 of each year, commencing August 15, 2023.
We intend to use the proceeds for working capital and general corporate purposes, including, but not limited to, the funding
of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share
repurchase program.
On December 1, 2022, we repaid, at maturity, the $750 outstanding balance of our 2.950% senior unsecured notes.
On November 4, 2022, we issued $400 aggregate principal amount of 5.350% Notes due 2025, $650 aggregate principal
amount of 5.500% Notes due 2032 and $750 aggregate principal amount of 6.100% Notes due 2052 under our shelf
registration statement. Interest on these notes is payable semi-annually in arrears on April 15 and October 15 of each year,
commencing April 15, 2023. We used the net proceeds for working capital and general corporate purposes, such as the
funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our
share repurchase program.
On May 16, 2022, we repaid, at maturity, the $850 outstanding balance of our 3.125% senior unsecured notes.
On April 29, 2022, we issued $600 aggregate principal amount of 4.100% Notes due 2032 and $700 aggregate principal
amount of 4.550% Notes due 2052 under our shelf registration statement. Interest on these notes is payable semi-annually in
arrears on May 15 and November 15 of each year, commencing November 15, 2022. We used the net proceeds for working
capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term and long-term debt and
the repurchase of our common stock pursuant to our share repurchase program.
On May 15, 2021, we redeemed the $700 outstanding principal balance of our 3.700% Notes due August 15, 2021 at a
redemption price equal to 100% of the aggregate principal amount of the notes being redeemed, plus accrued and unpaid
interest.
On March 17, 2021, we issued $500 aggregate principal amount of 0.450% Notes due 2023, $750 aggregate principal
amount of 1.500% Notes due 2026, $1,000 aggregate principal amount of 2.550% Notes due 2031 and $1,250 aggregate
principal amount of 3.600% Notes due 2051 under our shelf registration statement. Interest on these notes is payable
semiannually in arrears on March 15 and September 15 of each year, commencing September 15, 2021. We used the net
proceeds for working capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term
and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.
Additionally, during the year ended December 31, 2021, we repurchased $52 of outstanding principal amount of certain
other senior unsecured notes, plus applicable premium for early redemption plus accrued and unpaid interest, for cash totaling
$67. We recognized a loss on extinguishment of debt of $15 for the repurchase of these notes.
On November 23, 2020, we repaid, at maturity, the $900 outstanding balance of our 2.500% senior unsecured notes. On
August 17, 2020, we repaid, at maturity, the $700 outstanding balance of our 4.350% senior unsecured notes.
Additionally, during the year ended December 31, 2020, we repurchased $79 of outstanding principal amount of certain
other senior unsecured notes, plus applicable premium for early redemption plus accrued and unpaid interest, for cash totaling
$109. We recognized a loss on extinguishment of debt of $30 for the repurchase of these notes.
On May 5, 2020, we issued $400 aggregate principal amount of additional senior notes pursuant to a reopening of our
existing 2.375% Notes due 2025 (the “2025 Notes”), $1,100 aggregate principal amount of 2.250% Notes due 2030 (the
“2030 Notes”), and $1,000 aggregate principal amount of 3.125% Notes due 2050 (the “2050 Notes”) under our shelf
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
99

-- 164 of 188 --

registration statement. The 2025 Notes constitute an additional issuance of our 2.375% notes due 2025, of which $850
aggregate principal amount was issued on September 9, 2019. Interest on the 2025 Notes is deemed to have accrued from
January 15, 2020 and is payable semi-annually in arrears on January 15 and July 15 of each year, commencing July 15, 2020.
Interest on the 2030 Notes and 2050 Notes is payable semi-annually in arrears on May 15 and November 15 of each year,
commencing November 15, 2020. The proceeds were used for working capital and general corporate purposes, such as the
funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our
share repurchase program.
The surplus note is an unsecured obligation of Anthem Insurance Companies, Inc. (“Anthem Insurance”), a wholly
owned subsidiary, and is subordinate in right of payment to all of Anthem Insurance’s existing and future indebtedness. Any
payment of interest or principal on the surplus note may be made only with the prior approval of the Indiana Department of
Insurance (“IDOI”) and only out of capital and surplus funds of Anthem Insurance that the IDOI determines to be available
for the payment under Indiana insurance laws.
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes.
On April 18, 2022, we amended and restated the credit agreement for the 5-Year Facility to, among other things, extend the
maturity date of the 5-Year Facility from June 2024 to April 2027 and increase the amount of credit available under the 5-
Year Facility from $2,500 to $4,000. Also on April 18, 2022, concurrently with the amendment and restatement of the 5-Year
Facility, we terminated our 364-day senior revolving credit facility that provided for credit in the amount of $1,000, which
was scheduled to mature in June 2022 (the “2021 364-Day Facility”). In June 2021, we terminated our 364-day senior
revolving credit facility (the “prior 364-Day Facility”), which was scheduled to mature in June 2021, and entered into the
2021 364-Day Facility with a group of lenders for general corporate purposes. Our ability to borrow under the 5-Year Facility
is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of
not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. As of
December 31, 2022, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.9%. We do not
believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As
of December 31, 2022, we were in compliance with all of our debt covenants under the 5-Year Facility. There were no
amounts outstanding under the 5-Year Facility, the 2021 364-Day Facility or the prior 364-Day Facility at any time during
the years ended December 31, 2022 or 2021.
We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general
corporate purposes. In July 2022, we increased the amount available under the commercial paper program from $3,500 to
$4,000. At December 31, 2022, we had $0 outstanding under our commercial paper program. At December 31, 2021, we had
$300 outstanding under our commercial paper program with a weighted-average interest rate of 0.150%. Commercial paper
borrowings have been classified as long-term debt at December 31, 2022 and 2021, as our general practice and intent is to
replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an
uninterrupted period extending for more than one year, and we have the ability to redeem our commercial paper with
borrowings under the credit facilities described above.
Convertible Debentures
On October 9, 2012, we issued $1,500 of senior convertible debentures (the “Debentures”) in a private offering to
qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The
Debentures are governed by an indenture dated as of October 9, 2012 between us and The Bank of New York Mellon Trust
Company, N.A., as trustee (the “Indenture”). The Debentures bear interest at a rate of 2.750% per year, payable semi-
annually in arrears in cash on April 15 and October 15 of each year, and mature on October 15, 2042, unless earlier
redeemed, repurchased or converted into shares of common stock at the applicable conversion rate. The Debentures also have
a contingent interest feature that requires us to pay additional interest based on certain thresholds and for certain events, as
defined in the Indenture, beginning on October 15, 2022. As of October 15, 2022, one of these events had occurred and
contingent interest began accruing on the Debentures at a rate of 0.50% of the average trading price of a Debenture for the ten
consecutive trading days ended October 14, 2022. Contingent interest will be payable on April 15, 2023, to holders of the
Debentures as of the April 1, 2023 record date.
Holders may convert their Debentures at their option prior to the close of business on the business day immediately
preceding April 15, 2042, only under the following circumstances: (1) during any fiscal quarter if the last reported sale price
of our common stock for at least 20 trading days during a period of 30 consecutive trading days ending on the last trading day
of the preceding fiscal quarter is greater than or equal to 130% of the applicable conversion price on each applicable trading
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
100

-- 165 of 188 --

day; (2) during the five business day period after any 10 consecutive trading day period (the “measurement period”) in which
the trading price per $1,000 (whole dollars) principal amount of Debentures for each trading day of that measurement period
was less than 98% of the product of the last reported sale price of our common stock and the applicable conversion rate on
each such day; (3) if we call any or all of the Debentures for redemption, at any time prior to the close of business on the
business day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events, as defined
in the Indenture. On and after April 15, 2042 and until the close of business on the third scheduled trading day immediately
preceding the Debentures’ maturity date of October 15, 2042, holders may convert their Debentures into common stock at
any time irrespective of the preceding circumstances. The Debentures are redeemable at our option at any time on or after
October 20, 2022, upon the occurrence of certain events, as defined in the Indenture.
On February 13, 2023, we delivered notice to redeem all of the outstanding Debentures. The Debentures will be
redeemed on March 15, 2023 at a redemption price equal to 100% of the principal amount of the Debentures plus accrued and
unpaid interest to, but excluding, the date of redemption.
Upon conversion of the Debentures, we will deliver cash up to the aggregate principal amount of the Debentures
converted. With respect to any conversion obligation in excess of the aggregate principal amount of the Debentures
converted, we have the option to settle the excess with cash, shares of our common stock or a combination thereof based on a
daily conversion value, determined in accordance with the Indenture. The initial conversion rate for the Debentures was
13.2319 shares of our common stock per Debenture, which represented a 25% conversion premium based on the closing price
of $60.46 per share of our common stock on October 2, 2012 (the date the Debentures’ terms were finalized) and is
equivalent to an initial conversion price of $75.575 per share of our common stock.
During the year ended December 31, 2022, $41 aggregate principal amount of the Debentures was surrendered for
conversion by certain holders in accordance with the terms and provisions of the Indenture. We elected to settle the excess of
the principal amount of the conversion with cash for total payments of $299. During the year ended December 31, 2021, $54
aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms
and provisions of the Indenture. We elected to settle the excess of the principal amount of the conversions with cash for total
payments of $302. We recognized a loss on the extinguishment of debt related to the Debentures of $6, based on the fair
values of the debt on the conversion settlement dates. During the year ended December 31, 2020, $56 aggregate principal
amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms and provisions of
the Indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments of $222.
We recognized a loss on the extinguishment of debt related to the Debentures of $6, based on the fair values of the debt on
the conversion settlement dates.
As of December 31, 2022, our common stock was last traded at a price of $512.97 per share. If the remaining Debentures
had been converted or matured at December 31, 2022, we would have been obligated to pay the principal of the Debentures
plus an amount in cash or shares equal to $402. The Debentures and underlying shares of our common stock have not been
and will not be registered under the Securities Act, or any state securities laws, and may not be offered or sold in the United
States absent registration or an applicable exemption from registration requirements.
We accounted for the Debentures in accordance with the FASB cash conversion guidance for debt with conversion and
other options at the time of issue. As a result, the value of the embedded conversion option, net of deferred taxes and equity
issuance costs, was bifurcated from its debt host and recorded as a component of additional paid-in capital in our consolidated
balance sheets. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which
resulted in an increase to our reported debt outstanding of $31, a decrease of our deferred tax liabilities of $8 and a
corresponding cumulative-effect reduction to our opening retained earnings of $23, eliminating the bifurcation of the
embedded conversion option.
The following table summarizes, at December 31, 2022, the related balances, conversion rate and conversion price of the
Debentures:
Outstanding principal amount $ 63
Net debt carrying amount $ 63
Conversion rate (shares of common stock per $1,000 of principal amount) 14.3238
Effective conversion price (per $1,000 of principal amount) $ 69.8139
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
101

-- 166 of 188 --

During the years ended December 31, 2022, 2021 and 2020, we recognized $2, $4 and $6, respectively, of interest
expense related to the Debentures, of which $2, $3 and $5, respectively, represented interest expense recognized at the stated
interest rate of 2.750% and $0, $1 and $1, respectively, represented interest expense resulting from amortization of the debt
discount.
Interest paid on our total outstanding debt during 2022, 2021 and 2020 was $878, $822, and $794, respectively.
We were in compliance with all applicable covenants under all of our outstanding debt agreements at December 31, 2022
and 2021.
Future maturities of all long-term debt outstanding at December 31, 2022 are as follows: 2023, $1,500; 2024, $1,647;
2025, $1,650; 2026, $746; 2027, $1,592 and thereafter, $16,714.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
102

-- 167 of 188 --

14. Commitments and Contingencies
Litigation and Regulatory Proceedings
In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or
proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint or in other court
filings the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to
the cases described below, we contest liability and/or the amount of damages in each matter and believe we have meritorious
defenses.
Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated
financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to
income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In
addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a
previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or
range of loss.
With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses,
or the range of possible losses in excess of the amount, if any, accrued, for various reasons, including but not limited to
some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages,
(iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the
class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be
resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. For
those legal proceedings where a loss is probable, or reasonably possible, and for which it is possible to reasonably estimate
the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of
established reserves is, in the aggregate, from $0 to approximately $250 at December 31, 2022. This estimated aggregate
range of reasonably possible losses is based upon currently available information taking into account our best estimate of
such losses for which such an estimate can be made.
Blue Cross Blue Shield Antitrust Litigation
We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue
Shield licensees (the “Blue plans”) across the country. Cases filed in twenty-eight states were consolidated into a single,
multi-district proceeding captioned In re Blue Cross Blue Shield Antitrust Litigation that is pending in the U.S. District Court
for the Northern District of Alabama (the “Court”). Generally, the suits allege that the BCBSA and the Blue plans have
conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage
of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard® and National Accounts
programs and other arrangements in violation of the Sherman Antitrust Act (“Sherman Act”) and related state laws. The cases
were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers.
In April 2018, the Court issued an order on the parties’ cross motions for partial summary judgment, determining that the
defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of
review, and the BlueCard® program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of
reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of
the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of
genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed.
The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the “Subscriber
Settlement Agreement”), which agreement required the Court’s approval to become effective. The Subscriber Settlement
Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non-
monetary obligations including (i) eliminating the “national best efforts” rule in the BCBSA license agreements (which rule
limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers
with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue
plan.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
103

-- 168 of 188 --

In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following
which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to
opt out of the class. A small number of subscribers submitted valid opt-outs by the July 2021 opt-out deadline. A fairness
hearing was held in October 2021 and the Court took the request for final approval under advisement. In February 2022, the
Court ordered the issuance of a supplemental notice to self-funded account class members. The notice process was completed
in March 2022.
In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the “Final Approval
Order”). The Court amended its Final Approval Order in September 2022, further clarifying the injunctive relief that may be
available to subscribers who submitted valid opt-outs. In September 2022, an objector filed a motion to amend the Final
Approval Order, which the Court denied. In compliance with the Subscriber Settlement Agreement, the Company paid $506
into an escrow account in September 2022, for an aggregate and full settlement payment by the Company of $596, which was
previously accrued in 2020.
Four notices of appeal of the Final Approval Order were filed by the September 2022 appeal deadline. Those appeals are
proceeding in the United States Court of Appeals for the Eleventh Circuit. In the event that all appellate rights are exhausted
in a manner that affirms the Court’s Final Approval Order, the defendants’ payment and non-monetary obligations under the
Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with
the Subscriber Settlement Agreement.
In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for
class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for
class certification until the Court determines the standard of review applicable to the providers’ claims. In May 2021, the
defendants and provider plaintiffs filed renewed standard of review motions. In June 2021, the parties filed summary
judgment motions not critically dependent on class certification. In February 2022, the Court issued orders (i) granting certain
defendants’ motion for partial summary judgment against the provider plaintiffs who had previously released claims against
such defendants, and (ii) granting the provider plaintiffs’ motion for partial summary judgment, holding that Ohio v.
American Express Co. does not affect the standard of review in this case. In August 2022, the Court issued orders (i) granting
in part the defendants’ motion regarding the antitrust standard of review, holding that for the period of time after the
elimination of the “national best efforts” rule, the rule of reason applies to the provider plaintiffs’ market allocation
conspiracy claims, and (ii) denying the provider plaintiffs’ motion for partial summary judgment on the standard of review,
reaffirming its prior holding that the providers’ group boycott claims are subject to the rule of reason. In November 2022, the
Court issued an order requiring the parties to submit supplemental briefs on certain questions related to providers’ renewed
motion for class certification. We intend to continue to vigorously defend the provider litigation, which we believe is without
merit; however, its ultimate outcome cannot be presently determined.
A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed.
Those actions are: Alaska Air Group, Inc., et al. v. Anthem, Inc., et al., No. 2:21-cv-01209-AMM (N.D. Ala.); JetBlue
Airways Corp., et al. v. Anthem, Inc., et al., No. 2:22-cv-00558-GMB (N.D. Ala.); Metropolitan Transportation Authority v.
Blue Cross and Blue Shield of Alabama et al., No. 2:22-cv-00265-RDP (N.D. Ala.); Bed Bath & Beyond Inc. v. Anthem, Inc.,
No. 2:22-cv-01256-SGC (N.D. Ala.); Hoover, et al. v. Blue Cross Blue Shield Association, et al., No. 2:22-cv-00261-RDP
(N.D. Ala.); and VHS Liquidating Trust v. Blue Cross of California, et al., No. RG21106600 (Cal. Super.). We intend to
continue to vigorously defend these follow-on cases, which we believe are without merit; however, their ultimate outcome
cannot be presently determined.
Blue Cross of California Taxation Litigation
In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue Cross) (“BCC”) was
named as a defendant in a California taxpayer action filed in Los Angeles County Superior Court (the “Superior Court”)
captioned Michael D. Myers v. State Board of Equalization, et al. This action was brought under a California statute that
permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to enforce
governing law. Plaintiff contends that BCC, a licensed Health Care Service Plan, is an “insurer” for purposes of taxation
despite acknowledging it is not an “insurer” under regulatory law. At the time, under California law, “insurers” were
required to pay a gross premiums tax (“GPT”) calculated as 2.35% on gross premiums. As a licensed Health Care Service
Plan, BCC has paid the California Corporate Franchise Tax (“CFT”), the tax paid by California businesses generally.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
104

-- 169 of 188 --

Plaintiff contends that BCC must pay the GPT rather than the CFT and seeks a writ of mandate directing the taxing
agencies to collect the GPT and an order requiring BCC to pay GPT back taxes, interest, and penalties for the eight-year
period prior to the filing of the complaint.
Because the GPT is constitutionally imposed in lieu of certain other taxes, BCC has filed protective tax refund claims
with the City of Los Angeles, the California Department of Health Care Services and the Franchise Tax Board to protect its
rights to recover certain taxes previously paid should BCC eventually be determined to be subject to the GPT for the tax
periods at issue in the litigation.
In March 2018, the Superior Court denied BCC’s motion for judgment on the pleadings and similar motions brought by
other entities. In December 2020, the Superior Court granted BCC’s motion for summary judgment, dismissing the plaintiff’s
lawsuit. In November 2021, the plaintiff appealed the summary judgment order. BCC’s responding brief was filed in March
2022 and Plaintiff’s reply was filed in May 2022. We estimate that the appeal will be heard in March 2023. We intend to
vigorously defend the appeal of this lawsuit.
Express Scripts, Inc. Pharmacy Benefit Management Litigation
In March 2016, we filed a lawsuit against Express Scripts, Inc. (“Express Scripts”), our vendor at the time for PBM
services, captioned Anthem, Inc. v. Express Scripts, Inc., in the U.S. District Court for the Southern District of New York (the
“District Court”). The lawsuit seeks to recover over $14,800 in damages for pharmacy pricing that is higher than competitive
benchmark pricing under the agreement between the parties (the “ESI PBM Agreement”), over $158 in damages related to
operational breaches, as well as various declarations under the ESI PBM Agreement, including that Express Scripts: (i)
breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to provide
competitive benchmark pricing to us through the term of the ESI PBM Agreement; (iii) has breached the ESI PBM
Agreement; and (iv) is required under the ESI PBM Agreement to provide post-termination services, at competitive
benchmark pricing, for one year following any termination.
Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the
periodic pricing review under the ESI PBM Agreement, and (ii) that it has no obligation to ensure that we receive any
specific level of pricing, that we have no contractual right to any change in pricing under the ESI PBM Agreement and that
its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that we have
been unjustly enriched by its payment of $4,675 at the time we entered into the ESI PBM Agreement. In March 2017, the
District Court granted our motion to dismiss Express Scripts’ counterclaims for (i) breach of the implied covenant of good
faith and fair dealing, and (ii) unjust enrichment with prejudice. After such ruling, Express Scripts’ only remaining claims
were for breach of contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment,
which we opposed. In March 2022, the District Court granted in part and denied in part Express Scripts’ motion for summary
judgment. The District Court dismissed our declaratory judgment claim, our breach of contract claim for failure to prove
damages and most of our operational breach claims. As a result of the summary judgment decision, the only remaining claims
as of the filing of our 2022 Form 10-K are (i) our operational breach claim based on Express Scripts’ prior authorization
processes and (ii) Express Scripts’ counterclaim for breach of the market check provision of the ESI PBM Agreement.
Express Scripts filed a second motion for summary judgment in June 2022, challenging our remaining operational breach
claims, which we opposed in July 2022. We intend to appeal the earlier summary judgment decision at the appropriate time,
vigorously pursue our claims and defend against counterclaims, which we believe are without merit; however, the ultimate
outcome of this litigation cannot be presently determined.
Medicare Risk Adjustment Litigation
In March 2020, the U.S. Department of Justice (“DOJ”) filed a civil lawsuit against Elevance Health, Inc. (f/k/a Anthem,
Inc.) in the U.S. District Court for the Southern District of New York (the “New York District Court”) in a case captioned
United States v. Anthem, Inc. The DOJ’s suit alleges, among other things, that we falsely certified the accuracy of the
diagnosis data we submitted to the Centers for Medicare and Medicaid Services (“CMS”) for risk-adjustment purposes under
Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these
purported acts, we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which
enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed
an amended complaint in July 2020, alleging the same causes of action but revising some of its factual allegations. In
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
105

-- 170 of 188 --

September 2020, we filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the
lawsuit, and a motion to strike certain allegations in the amended complaint. In an opinion and order issued October 3, 2022,
the New York District Court denied our motions, and the case will now proceed in that court. In November 2022, we filed an
answer. We intend to continue to vigorously defend this suit, which we believe is without merit; however, the ultimate
outcome cannot be presently determined.
Investigations of CareMore and HealthSun
With the assistance of outside counsel, we are conducting investigations of risk-adjustment practices involving data
submitted to CMS (unrelated to our retrospective chart review program) at CareMore Health Plans, Inc. (“CareMore”), one of
our California subsidiaries, and HealthSun Health Plans, Inc. (“HealthSun”), one of our Florida subsidiaries. Our CareMore
investigation has resulted in the termination of CareMore’s relationship with one contracted provider in California. Our
HealthSun investigation has focused on risk adjustment practices initiated prior to our acquisition of HealthSun in December
2017 that continued after the acquisition. We have voluntarily self-disclosed the existence of both of our investigations to
CMS and the Criminal and Civil Divisions of the DOJ. We are cooperating with the ongoing investigations of the Criminal
and Civil Divisions of the DOJ related to these risk adjustment practices, and have entered into a tolling agreement with the
Civil Division of the DOJ related to its investigation. We are analyzing the scope of potential data corrections to be submitted
to CMS and have begun to submit data corrections to CMS. We have also asserted indemnity claims for escrowed funds
under the HealthSun purchase agreement for, among other things, breach of healthcare and financial representation
provisions, based on the conduct discovered during our investigation. While certain elements of the escrow claims were
resolved in the fourth quarters of 2021 and 2022, litigation in the Delaware Court of Chancery related to the remaining
indemnity claims for escrowed funds remains ongoing.
Other Contingencies
From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve
claims for coverage encountered in the ordinary course of business. We, like Health Maintenance Organizations (“HMOs”)
and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, Preferred
Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees
arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results
in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability
under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage
claims.
In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the
character incidental to our business and are from time to time involved as a party in various governmental investigations,
audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include
routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and
subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the
imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our
business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material
adverse effect on our consolidated financial position or results of operations.
Contractual Obligations and Commitments
In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related
management and support services through June 2025. The new agreement supersedes certain prior agreements for such
services and includes provisions for additional services not provided under those agreements. Our remaining commitment
under this agreement at December 31, 2022 is approximately $761. We will have the ability to terminate the agreement upon
the occurrence of certain events, subject to early termination fees.
In the second quarter of 2019, we began using our pharmacy benefits manager CarelonRx, formerly known as
IngenioRx, to market and offer PBM services to our affiliated health plan customers, as well as to external customers outside
of the health plans we own. The comprehensive PBM services portfolio includes, but is not limited to, formulary
management, pharmacy networks, prescription drug database, member services and mail order capabilities. CarelonRx
delegates certain PBM administrative functions, such as claims processing and prescription fulfillment, to CaremarkPCS
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
106

-- 171 of 188 --

Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement, which is set to terminate
on December 31, 2024. With CarelonRx, we retain the responsibilities for clinical and formulary strategy and development,
member and employer experiences, operations, sales, marketing, account management and retail network strategy.
Vulnerability from Concentrations
Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents,
investment securities, premium receivables and instruments held through hedging activities. All investment securities are
managed by professional investment managers within policies authorized by our Board of Directors. Such policies limit the
amounts that may be invested in any one issuer and prescribe certain investee company criteria. Concentrations of credit risk
with respect to premium receivables are limited due to the large number of employer groups that constitute our customer base
in the states in which we conduct business. As of December 31, 2022, there were no significant concentrations of financial
instruments in a single investee, industry or geographic location.
15. Capital Stock
Stock Incentive Plans
Our Board of Directors has adopted the 2017 Elevance Health Incentive Compensation Plan, formerly known as the
2017 Anthem Incentive Compensation Plan (“2017 Incentive Plan”), which has been approved by our shareholders. The term
of the 2017 Incentive Plan is such that no awards may be granted on or after May 18, 2027. The 2017 Incentive Plan gives
authority to the Compensation Committee of the Board of Directors to make incentive awards to our non-employee directors,
employees and consultants, consisting of stock options, stock, restricted stock, restricted stock units, cash-based awards,
stock appreciation rights, performance shares and performance units. The 2017 Incentive Plan limits the number of available
shares for issuance to 37.5 shares, subject to adjustment as set forth in the 2017 Incentive Plan.
Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares
at the grant date. Stock options vest over three years in equal annual installments and generally have a term of ten years from
the grant date.
Certain option grants contain provisions whereby the employee continues to vest in the award subsequent to termination
due to retirement. Our attribution method for newly granted awards considers all vesting and other provisions, including
retirement eligibility, in determining the requisite service period over which the fair value of the awards will be recognized.
Awards of restricted stock or restricted stock units are issued at the fair value of the stock on the grant date and may also
include one or more performance measures that must be met for the award to vest. For restricted stock or restricted stock
units without performance measures, the restrictions lapse in three equal annual installments. Restricted stock or restricted
stock units with performance measures vest in three year installments. Performance units issued in 2022 will vest in 2025,
based on certain revenue and earnings targets over the three year period of 2022 to 2024. Performance units issued in 2021
will vest in 2024, based on certain revenue and earnings targets over the three year period of 2021 to 2023. Performance units
issued in 2020 will vest in 2023, based on certain revenue and earnings targets over the three year period of 2020 to 2022.
For the years ended December 31, 2022, 2021 and 2020, we recognized share-based compensation expense of $264,
$255 and $283, respectively, as well as related tax benefits of $66, $65 and $74, respectively.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
107

-- 172 of 188 --

A summary of stock option activity for the year ended December 31, 2022 is as follows:
Number of
Shares
Weighted-Average
Option Price
per Share
Weighted-Average
Remaining
Contractual Life
(Years)
Aggregate
Intrinsic
Value
Outstanding at January 1, 2022 2.9 $ 255.50
Granted 0.5 452.67
Exercised (0.5) 242.79
Forfeited or expired (0.1) 339.20
Outstanding at December 31, 2022 2.8 293.28 6.35 $ 622
Exercisable at December 31, 2022 1.6 239.89 5.14 $ 448
The intrinsic value of options exercised during the years ended December 31, 2022, 2021 and 2020 amounted to $120,
$121 and $147, respectively. We recognized tax benefits of $31, $32 and $40 during the years ended December 31, 2022,
2021 and 2020, respectively, from option exercises and disqualifying dispositions. During the years ended December 31,
2022, 2021 and 2020, we received cash of $120, $148 and $129, respectively, from exercises of stock options.
The total fair value of restricted stock awards that vested during the years ended December 31, 2022, 2021 and 2020 was
$261, $287 and $335, respectively.
A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for
the year ended December 31, 2022 is as follows:
Restricted
Stock Shares
and Units
Weighted-Average
Grant Date
Fair Value
per Share
Nonvested at January 1, 2022 1.3 $ 299.65
Granted 0.6 453.70
Vested (0.6) 301.89
Forfeited (0.1) 347.73
Nonvested at December 31, 2022 1.2 357.21
During the year ended December 31, 2022, we granted approximately 0.2 restricted stock units that are contingent upon
us achieving certain revenue and earnings targets over the three year period of 2022 to 2024. These grants have been included
in the activity shown above, but will be subject to adjustment at the end of 2024, based on results in the three year period.
As of December 31, 2022, the total remaining unrecognized compensation expense related to nonvested stock options
and restricted stock, including restricted stock units and performance units, amounted to $35 and $176, respectively, which
will be amortized over the weighted-average remaining requisite service periods of 9 months and 12 months, respectively.
As of December 31, 2022, there were approximately 14.0 shares of common stock available for future grants under the
2017 Incentive Plan.
Fair Value
We use a binomial lattice valuation model to estimate the fair value of all stock options granted. Expected volatility
assumptions used in the binomial lattice model are based on an analysis of implied volatility of publicly traded options on our
stock and historical volatility of our stock price. The risk-free interest rate is derived from the U.S. Treasury strip rates at the
time of the grant. The expected term of the options was derived from the outputs of the binomial lattice model, which
incorporates post-vesting forfeiture assumptions based on an analysis of historical data. The dividend yield was based on our
estimate of future dividend yields. Similar groups of employees that have dissimilar exercise behavior are considered
separately for valuation purposes. We utilize the multiple-grant approach for recognizing compensation expense associated
with each separately vesting portion of the share-based award.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
108

-- 173 of 188 --

The following weighted-average assumptions were used to estimate the fair values of options granted during the years
ended December 31, 2022, 2021 and 2020:
2022 2021 2020
Risk-free interest rate 1.97 % 1.44 % 1.30 %
Volatility factor 29.00 % 30.00 % 26.00 %
Dividend yield (annual) 1.10 % 1.50 % 1.40 %
Weighted-average expected life (years) 5.10 5.50 4.30
The following weighted-average fair values were determined for the years ending December 31, 2022, 2021 and 2020:
2022 2021 2020
Options granted during the year $ 116.92 $ 79.91 $ 54.05
Restricted stock awards granted during the year 453.70 317.70 272.37
The binomial lattice option-pricing model requires the input of subjective assumptions including the expected stock price
volatility. Because our stock option grants have characteristics significantly different from those of traded options, and
because changes in the subjective input assumptions can materially affect the fair value estimate, in our opinion, existing
models do not necessarily provide a reliable single measure of the fair value of our stock option grants.
Employee Stock Purchase Plan
We have registered 14.0 shares of common stock for the Employee Stock Purchase Plan (the “Stock Purchase Plan”),
which is intended to provide a means to encourage and assist employees in acquiring a stock ownership interest in Elevance
Health. Pursuant to the terms of the Stock Purchase Plan, an eligible employee is permitted to purchase no more than $25,000
(actual dollars) worth of stock in any calendar year, based on the fair value of the stock at the end of each plan quarter.
Employees become participants by electing payroll deductions from 1% to 15% of gross compensation. Once purchased, the
stock is accumulated in the employee’s investment account. The Stock Purchase Plan allows participants to purchase shares
of our common stock at a discounted price per share of 90% of the fair value of a share of common stock on the lower of the
first or last trading day of the plan quarter purchase period. The Stock Purchase Plan discount was recognized as
compensation expense for the year ended December 31, 2022, based on GAAP guidance. During the years ended
December 31, 2022, 2021 and 2020, we issued 0.1, 0.1 and 0.2 shares, respectively, under the Stock Purchase Plan, and we
received cash of $62, $55 and $47, respectively, for such shares. As of December 31, 2022, 4.3 shares were available for
issuance under the Stock Purchase Plan.
Use of Capital and Stock Repurchase Program
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases
and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is
at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity
needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
109

-- 174 of 188 --

A summary of the cash dividend activity for the years ended December 31, 2022 and 2021 is as follows:
Declaration Date Record Date Payment Date Cash Dividend
per Share Total
Year ended December 31, 2022
January 25, 2022 March 10, 2022 March 25, 2022 $ 1.28 $ 309
April 19, 2022 June 10, 2022 June 24, 2022 1.28 309
July 19, 2022 September 9, 2022 September 23, 2022 1.28 306
October 18, 2022 December 5, 2022 December 21, 2022 1.28 305
Year ended December 31, 2021
January 26, 2021 March 10, 2021 March 25, 2021 $ 1.13 $ 277
April 20, 2021 June 10, 2021 June 25, 2021 1.13 278
July 20, 2021 September 10, 2021 September 24, 2021 1.13 276
October 19, 2021 December 3, 2021 December 21, 2021 1.13 273
On January 24, 2023, our Audit Committee declared a quarterly cash dividend to shareholders of $1.48 per share on the
outstanding shares of our common stock. This quarterly dividend is payable on March 24, 2023 to the shareholders of record
as of March 10, 2023.
Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On January 26, 2021,
our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to our
common stock repurchase program. On January 24, 2023, our Audit Committee, pursuant to authorization granted by the
Board of Directors, authorized a $5,000 increase to our common stock repurchase program. No duration has been placed on
our common stock repurchase program, and we reserve the right to discontinue the program at any time. We intend to utilize
this authorization over a multi-year period, subject to market and industry conditions. Repurchases may be made from time to
time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are affected
from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements,
and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock
repurchase program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the
program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on
a pro rata basis to additional paid-in capital and retained earnings.
A summary of common stock repurchases for the years ended December 31, 2022 and 2021 is as follows:
Years Ended December 31
2022 2021
Shares repurchased 4.8 5.1
Average price per share $ 478.99 $ 371.46
Aggregate cost $ 2,316 $ 1,900
Authorization remaining at end of year $ 1,876 $ 4,192
We expect to utilize the remaining authorized amount over a multi-year period, subject to market and industry
conditions.
For additional information regarding the use of capital for debt security repurchases, see Note 13, “Debt.”
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
110

-- 175 of 188 --

16. Accumulated Other Comprehensive (Loss) Income
A reconciliation of the components of accumulated other comprehensive (loss) income at December 31, 2022, 2021, and
2020 is as follows:
2022 2021 2020
Net unrealized investment gains:
Beginning of year balance $ 492 $ 949 $ 521
Other comprehensive (loss) income before reclassifications, net of tax benefit (expense) of
$926, $121, and $(160), respectively (2,614) (357) 478
Amounts reclassified from accumulated other comprehensive income, net of tax benefit
(expense) of $(94), $27, and $(13), respectively 354 (100) (50)
Other comprehensive (loss) income (2,260) (457) 428
End of year balance (1,768) 492 949
Non-credit components of impairments on investments:
Beginning of year balance — (2) (2)
Other comprehensive income, net of tax (expense) benefit of $0, $(1),and $0, respectively (3) 2 —
End of year balance (3) — (2)
Net cash flow hedges:
Beginning of year balance (239) (250) (262)
Other comprehensive income, net of tax expense of $(6), $(3), and $(3), respectively 10 11 12
End of year balance (229) (239) (250)
Pension and other postretirement benefits:
Beginning of year balance (429) (552) (551)
Other comprehensive income (loss), net of tax expense of $(23), $(36), and $(2),
respectively (70) 123 (1)
End of year balance (499) (429) (552)
Future policy benefits
Beginning of year balance (19) — —
Adoption of ASU 2018-12 — (12) —
Other comprehensive income (loss), net of tax (expense) benefit of (10), $2, and $0,
respectively 32 (7) —
End of year balance 13 (19) —
Foreign currency translation adjustments:
Beginning of year balance (4) 5 (2)
Other comprehensive (loss) income, net of tax benefit (expense) of $6, $2, and $(2) (13) (9) 7
End of year balance (17) (4) 5
Total:
Total beginning of year accumulated other comprehensive (loss) income (197) 150 (296)
Adoption of ASU 2018-12 — (12) —
Total other comprehensive (loss) income, net of tax benefit (expense) of $799, $112, and
$(154), respectively (2,304) (337) 446
Total other comprehensive loss attributable to noncontrolling interests, net of tax
(expense) benefit of $(3), $1, and $0, respectively 11 2 —
Total end of year accumulated other comprehensive (loss) income $ (2,490) $ (197) $ 150
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
111

-- 176 of 188 --

17. Reinsurance
We reinsure certain risks with other companies and assume risk from other companies. We remain primarily liable to
policyholders under ceded insurance contracts and are contingently liable for amounts recoverable from reinsurers in the
event that such reinsurers do not meet their contractual obligations.
A summary of direct, assumed and ceded premiums earned for the years ended December 31, 2022, 2021 and 2020 is as
follows:
2022 2021 2020
Direct $ 128,867 $ 113,149 $ 100,832
Assumed 4,426 4,298 3,356
Ceded (64) (74) (79)
Net premiums $ 133,229 $ 117,373 $ 104,109
Percentage—assumed to net premiums 3.3% 3.7% 3.2%
The difference between written premiums and earned premiums is immaterial in each of the years presented above.
A summary of net premiums earned by segment (see Note 20, “Segment Information”) for the years ended December 31,
2022, 2021 and 2020 is as follows:
2022 2021 2020
Reportable segments:
Health Benefits $ 131,964 $ 115,725 $ 102,643
Carelon Services 1,265 1,648 1,466
Net premiums $ 133,229 $ 117,373 $ 104,109
The effect of reinsurance on benefit expense for the years ended December 31, 2022, 2021 and 2020 is as follows:
2022 2021 2020
Direct $ 112,964 $ 98,933 $ 85,168
Assumed 3,730 3,719 2,967
Ceded (52) (81) (90)
Net benefit expense $ 116,642 $ 102,571 $ 88,045
18. Leases
We lease office space and certain computer and related equipment using noncancelable operating leases. Our leases have
remaining lease terms of 1 year to 12 years.
The information related to our leases is as follows:
Balance Sheet Location December 31, 2022 December 31, 2021
Operating Leases
ROU assets Other noncurrent assets $ 604 $ 628
Lease liabilities, current Other current liabilities 181 133
Lease liabilities, noncurrent Other noncurrent liabilities 751 864
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
112

-- 177 of 188 --

Years Ended December 31
2022 2021 2020
Lease Expense
Operating lease expense $ 143 $ 261 $ 438
Short-term and variable lease expense 35 45 50
Sublease income (3) (4) (9)
Total lease expense $ 175 $ 302 $ 479
Our activities as disclosed in Note 4, “Business Optimization Initiatives,” include reducing our office space footprint. As
a result, we performed an interim impairment test during the years ended December 31, 2022, 2021 and 2020, and recorded
impairment charges of $34, $136 and $258, respectively, for impairment and abandonment of ROU assets which are included
in the operating lease expense shown above.
Years Ended December 31
2022 2021
Other information
Operating cash paid for amounts included in the measurement of lease liabilities,
operating leases $ 204 $ 198
ROU assets obtained in exchange for new lease liabilities, operating leases $ 113 $ 334
Weighted average remaining lease term in years, operating leases 7 7
Weighted average discount rate, operating leases 2.98 % 2.69 %
At December 31, 2022, future lease payments for noncancelable operating leases with initial or remaining terms of one
year or more are as follows:
2023 $ 206
2024 179
2025 145
2026 111
2027 77
Thereafter 310
Total future minimum payments 1,028
Less imputed interest (96)
Total lease liabilities $ 932
19. Earnings per Share
The denominator for basic and diluted earnings per share at December 31, 2022, 2021 and 2020 is as follows:
2022 2021 2020
Denominator for basic earnings per share—weighted-average shares 240.0 243.8 250.8
Effect of dilutive securities—employee stock options, non-vested restricted stock
awards, convertible debentures and equity units 2.8 3.0 3.5
Denominator for diluted earnings per share 242.8 246.8 254.3
During the years ended December 31, 2022, 2021 and 2020, weighted-average shares related to certain stock options of
0.4, 0.2 and 1.2, respectively, were excluded from the denominator for diluted earnings per share because the stock options
were anti-dilutive.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
113

-- 178 of 188 --

During the years ended December 31, 2022, 2021 and 2020, we issued approximately 0.2, 0.3 and 0.3 restricted stock
units, respectively, of which vesting was contingent upon us meeting certain earnings targets. Contingent restricted stock
units are excluded from the denominator for diluted earnings per share and are included only if and when the contingency is
met. The 2022 contingent restricted stock units are being measured over the three year period of 2022 through 2024, the 2021
contingent restricted stock units are being measured over the three year period of 2021 through 2023 and the 2020 contingent
restricted stock units are being measured over the three year period of 2020 through 2022. Contingent restricted stock units
generally vest in March of the year following each measurement period.
20. Segment Information
As discussed in Note 1 “Organization”, we are reorganizing our brand portfolio into three core go-to-market brands over
the next several years. Our branding strategy reflects the evolution of our business from a traditional health insurance
company to a lifetime, trusted health partner. Given this evolution, we reviewed and modified how we manage our business,
monitor our performance and allocate resources. As a result, we changed our reportable segments to the following beginning
in the first quarter of 2023: Health Benefits (aggregates our previously reported Commercial & Specialty Business and
Government Business segments), CarelonRx, Carelon Services (previously included in our Other segment) and Corporate &
Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate
expenses not allocated to our other reportable segments).
Our Health Benefits segment offers a comprehensive suite of health plans and services to our Individual, Employer
Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid and FEHB program members. Our Health
Benefits segment also includes our National Government Services business. The Health Benefits segment offers health
products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and
provides a variety of specialty and other insurance products and services such as stop loss, dental, vision, life, disability and
supplemental health insurance benefits.
Our CarelonRx segment includes our pharmacy business. CarelonRx markets and offers pharmacy services to our
affiliated health plan customers, as well as to external customers outside of the health plans we own. CarelonRx offers a
comprehensive pharmacy services portfolio, which includes services such as formulary management, pharmacy networks,
specialty and home delivery pharmacy services and member services.
Our Carelon Services segment is focused on lowering the cost and improving the quality of healthcare by enabling and
creating new care delivery and payment models, with a special emphasis on serving those with complex and chronic
conditions. Carelon Services offers a broad array of healthcare-related services and capabilities to internal and external
customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity
services and subrogation services, as well as health and wellness programs.
Our Corporate and Other segment includes our businesses that do not individually meet the quantitative threshold for an
operating segment, as well as corporate expenses not allocated to our other reportable segments.
We define operating revenues to include premium income, product revenue and service fees. Operating revenues are
derived from premiums and fees received, primarily from the sale and administration of health benefits and pharmacy
products and services. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and
operating expense.
Affiliated revenues represent revenues or costs for services provided to our subsidiaries by CarelonRx and Carelon
Services, in addition to certain back-office services provided by our international businesses, which are recorded at cost or
management’s estimate of fair market value. These affiliated revenues are eliminated in consolidation. For segment reporting,
we present all capitation risk arrangements on a gross basis; therefore, eliminations also include adjustments for capitated risk
arrangements that are recognized on a net basis under GAAP.
Through our participation in various federal government programs, we generated approximately 28% of our total
consolidated revenues from agencies of the U.S. government for each of the years ended December 31, 2022, 2021, and
2020. The majority of these revenues are contained in our Health Benefits segment. An immaterial amount of our total
consolidated revenues is derived from activities outside of the U.S. and Puerto Rico.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
114

-- 179 of 188 --

The accounting policies of the segments are consistent with those described in the summary of significant accounting
policies in Note 2, “Basis of Presentation and Significant Accounting Policies,” except that all capitation risk arrangements
are reported on a gross basis with an adjustment included in eliminations for capitated risk arrangements that are presented on
a net basis under GAAP. We evaluate performance of the reportable segments based on operating gain or loss as defined
above. We evaluate net investment income, net gains (losses) on financial instruments, interest expense, amortization
expense, gain or loss on extinguishment of debt, income taxes and assets and liabilities on a consolidated basis, as these items
are managed in a corporate shared service environment and are not the responsibility of segment operating management.
Financial data by reportable segment for the years ended December 31, 2022, 2021 and 2020 is as follows:
Carelon
Health
Benefits CarelonRx Carelon
Services Total Corporate
& Other Eliminations Total
Year Ended December 31, 2022
Premiums $ 131,964 $ — $ 1,499 $ 1,499 $ — $ (234) $ 133,229
Product revenue — 14,978 — 14,978 — — 14,978
Service fees 6,520 — 882 882 51 — 7,453
Operating revenue -
unaffiliated 138,484 14,978 2,381 17,359 51 (234) 155,660
Operating revenue - affiliated — 13,548 9,896 23,444 966 (24,410) —
Operating revenue - total $ 138,484 $ 28,526 $ 12,277 $ 40,803 $ 1,017 $ (24,644) $ 155,660
Operating gain (loss) $ 6,061 $ 1,868 $ 455 $ 2,323 $ (101) $ — $ 8,283
Year Ended December 31, 2021
Premiums $ 115,725 $ — $ 1,786 $ 1,786 $ — $ (138) $ 117,373
Product revenue — 12,657 — 12,657 — — 12,657
Service fees 6,003 — 842 842 68 — 6,913
Operating revenue -
unaffiliated 121,728 12,657 2,628 15,285 68 (138) 136,943
Operating revenue - affiliated — 12,774 7,020 19,794 534 (20,328) —
Operating revenue - total $ 121,728 $ 25,431 $ 9,648 $ 35,079 $ 602 $ (20,466) $ 136,943
Operating gain (loss) $ 5,884 $ 1,684 $ 118 $ 1,802 $ (127) $ — $ 7,559
Year Ended December 31, 2020
Premiums $ 102,643 $ — $ 1,466 $ 1,466 $ — $ — $ 104,109
Product revenue — 10,384 — 10,384 — — 10,384
Service fees 5,628 — 643 643 44 — 6,315
Operating revenue -
unaffiliated 108,271 10,384 2,109 12,493 44 — 120,808
Operating revenue - affiliated — 11,527 3,611 15,138 293 (15,431) —
Operating revenue - total $ 108,271 $ 21,911 $ 5,720 $ 27,631 $ 337 $ (15,431) $ 120,808
Operating gain (loss) $ 5,125 $ 1,361 $ 28 $ 1,389 $ (154) $ — $ 6,360
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
115

-- 180 of 188 --

Asset, liability and equity details by reportable segment have not been disclosed, as we do not internally report such
information.
A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated
statements of income for the years ended December 31, 2022, 2021 and 2020 is as follows:
2022 2021 2020
Reportable segments’ operating revenues $ 155,660 $ 136,943 $ 120,808
Net investment income 1,485 1,378 877
Net (losses) gains on financial instruments (550) 318 182
Total revenues $ 156,595 $ 138,639 $ 121,867
A reconciliation of reportable segments’ operating gain to income before income tax expense included in our
consolidated statements of income for the years ended December 31, 2022, 2021 and 2020 is as follows:
2022 2021 2020
Income before income tax expense $ 7,600 $ 7,995 $ 6,238
Net investment income (1,485) (1,378) (877)
Net losses (gains) on financial instruments 550 (318) (182)
Interest expense 851 798 784
Amortization of other intangible assets 767 441 361
Loss on extinguishment of debt — 21 36
Reportable segments’ operating gain $ 8,283 $ 7,559 $ 6,360
21. Related Party Transactions
We have an equity investment in APC Passe, LLC, which offers Medicaid products in Arkansas. During the years ended
December 31, 2022, 2021 and 2020, in the normal course of business, we assumed premiums of $501, $462 and $446,
respectively, from APC Passe, LLC, which is included in our total assumed premiums (see Note 17, “Reinsurance”).
22. Statutory Information
The majority of our insurance and HMO subsidiaries report their accounts in conformity with accounting practices
prescribed or permitted by state insurance regulatory authorities, commonly referred to as statutory accounting, which vary in
certain respects from GAAP. However, certain of our insurance and HMO subsidiaries, including BCC, Blue Cross of
California Partnership Plan, Inc., Golden West Health Plan, Inc., Beacon Health Options of California, Inc. and CareMore
Health Plan are regulated by the California Department of Managed Health Care (“DMHC”) and report their accounts in
conformity with GAAP (these entities are collectively referred to as the “DMHC regulated entities”). Typical differences of
GAAP reporting as compared to statutory reporting are the recognition of all assets including those that are non-admitted for
statutory purposes and recognition of all deferred tax assets without regard to statutory limits. The National Association of
Insurance Commissioners (“NAIC”) developed a codified version of the statutory accounting principles, designed to foster
more consistency among the states for accounting guidelines and reporting. Prescribed statutory accounting practices are set
forth in a variety of publications of the NAIC as well as state laws, regulations and general administrative rules.
Our statutory basis insurance and HMO subsidiaries are subject to risk-based capital (“RBC”) requirements. RBC is a
method developed by the NAIC to determine the minimum amount of statutory capital appropriate for an insurance company
or HMO to support its overall business operations in consideration of its size and risk profile. The formula for determining
the amount of RBC specifies various factors, weighted based on the perceived degree of risk, which are applied to certain
financial balances and financial activity. Below minimum RBC requirements are classified within certain levels, each of
which requires specified corrective action. Additionally, the DMHC regulated entities are subject to capital and solvency
requirements as prescribed by the DMHC. As of December 31, 2022 and 2021, all of our regulated subsidiaries exceeded the
minimum applicable mandatory RBC requirements and/or capital and solvency requirements of their applicable
governmental regulator.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
116

-- 181 of 188 --

The statutory RBC necessary to satisfy regulatory requirements of our statutory basis insurance and HMO subsidiaries
was approximately $7,900 and $6,962 as of December 31, 2022 and 2021, respectively. The tangible net equity required for
the DMHC regulated entities was approximately $710 and $690 as of December 31, 2022 and 2021, respectively. Statutory-
basis capital and surplus of our insurance and HMO subsidiaries and capital and surplus of our other regulated subsidiaries,
excluding the DMHC regulated entities, was $19,048 and $16,178 at December 31, 2022 and 2021, respectively. GAAP
equity of the DMHC regulated entities was $3,795 and $3,886 at December 31, 2022 and 2021, respectively.
Our ability to pay dividends and credit obligations is significantly dependent on receipt of dividends from our
subsidiaries. The payment of dividends to us by our insurance and HMO subsidiaries without prior approval of the insurance
departments of each subsidiary’s domiciliary jurisdiction is limited by formula. Dividends in excess of these amounts are
subject to prior approval by the respective state insurance departments or the DMHC. During 2022, our insurance and HMO
subsidiaries paid aggregate cash dividends of $3,097 to the parent company, including cash dividends which required prior
approval from regulatory authorities. We currently estimate that approximately $3,500 of dividends will be paid to the parent
company in 2023.
Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
117

-- 182 of 188 --

PART IV
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.
(c) Financial Statement Schedule
Schedule II—Condensed Financial Information of Registrant (Parent Company Only).
Schedule II—Condensed Financial Information of Registrant
Elevance Health, Inc. (Parent Company Only)
Balance Sheets
(In millions, except share data) December 31,
2022 December 31,
2021
Assets
Current assets:
Cash and cash equivalents $ 942 $ 630
Fixed maturity securities (amortized cost of $175 and $512; allowance for credit losses of $0 and $1) 163 515
Equity securities 104 49
Other receivables 55 40
Net due from subsidiaries — 446
Other current assets 721 655
Total current assets 1,985 2,335
Other invested assets 783 808
Property and equipment, net 187 207
Deferred tax assets, net 313 77
Investments in subsidiaries 58,978 56,410
Other noncurrent assets 240 265
Total assets $ 62,486 $ 60,102
Liabilities and shareholders’ equity
Liabilities
Current liabilities:
Accounts payable and accrued expenses $ 894 $ 559
Net due to subsidiaries 789 —
Current portion of long-term debt 1,500 1,599
Other current liabilities 361 344
Total current liabilities 3,544 2,502
Long-term debt, less current portion 22,324 21,132
Other noncurrent liabilities 375 373
Total liabilities 26,243 24,007
Commitments and contingencies—Note 5
Shareholders’ equity
Preferred stock, without par value, shares authorized - 100,000,000; shares issued and outstanding -
none — —
Common stock, par value $0.01, shares authorized - 900,000,000; shares issued and outstanding -
237,958,067 and 241,770,746 2 2
Additional paid-in capital 9,084 9,148
Retained earnings 29,647 27,142
Accumulated other comprehensive loss (2,490) (197)
Total shareholders’ equity 36,243 36,095
Total liabilities and shareholders’ equity $ 62,486 $ 60,102
See accompanying notes.
118

-- 183 of 188 --

Elevance Health, Inc. (Parent Company Only)
Statements of Income
Years ended December 31
(In millions) 2022 2021 2020
Revenues
Net investment income $ 4 $ 6 $ 65
Net gains on financial instruments 2 6 28
Service fees 7 24 22
Total revenues 13 36 115
Expenses
Operating expense 188 119 169
Interest expense 845 794 779
Loss on extinguishment of debt — 21 36
Total expenses 1,033 934 984
Loss before income tax credits and equity in net income of subsidiaries (1,020) (898) (869)
Income tax credits (461) (244) (386)
Equity in net income of subsidiaries 6,453 6,812 5,055
Shareholders’ net income $ 5,894 $ 6,158 $ 4,572
See accompanying notes.
119

-- 184 of 188 --

Elevance Health, Inc. (Parent Company Only)
Statements of Comprehensive Income
Years ended December 31
(in millions) 2022 2021 2020
Shareholders' net income $ 5,894 $ 6,158 $ 4,572
Other comprehensive (loss) income, net of tax:
Change in net unrealized gains/losses on investments (2,249) (455) 428
Change in non-credit component of impairment losses on investments (3) 2 —
Change in net unrealized gains/losses on cash flow hedges 10 11 12
Change in net periodic pension and postretirement costs (70) 123 (1)
Change in future policy benefits 32 (7) —
Foreign currency translation adjustments (13) (9) 7
Other comprehensive (loss) income (2,293) (335) 446
Total shareholders’ comprehensive income $ 3,601 $ 5,823 $ 5,018
See accompanying notes.
120

-- 185 of 188 --

Elevance Health, Inc. (Parent Company Only)
Statements of Cash Flows
Years ended December 31
(In millions) 2022 2021 2020
Net cash provided by operating activities $ 1,447 $ 2,038 $ 4,810
Investing activities
Purchases of investments (367) (2,059) (2,729)
Proceeds from sales, maturities, calls and redemptions of investments 618 2,449 2,593
Repayment (issuance) of note to subsidiary 1,500 (1,500) —
Capitalization of subsidiaries (411) (807) (2,460)
Changes in securities lending collateral 36 173 (234)
Purchases of property and equipment, net of sales (47) (77) (107)
Other, net — — 11
Net cash provided by (used in) investing activities 1,329 (1,821) (2,926)
Financing activities
Net (repayments of) proceeds from commercial paper borrowings (300) 50 (150)
Proceeds from long-term borrowings 3,071 3,462 2,484
Repayments of long-term borrowings (1,899) (1,068) (1,932)
Changes in securities lending payable (36) (173) 234
Repurchase and retirement of common stock (2,316) (1,900) (2,700)
Cash dividends (1,290) (1,158) (1,000)
Proceeds from issuance of common stock under employee stock plans 182 203 176
Taxes paid through withholding of common stock under employee stock plans (93) (102) (128)
Other, net 217 399 14
Net cash used in financing activities (2,464) (287) (3,002)
Change in cash and cash equivalents 312 (70) (1,118)
Cash and cash equivalents at beginning of year 630 700 1,818
Cash and cash equivalents at end of year $ 942 $ 630 $ 700
See accompanying notes.
121

-- 186 of 188 --

Elevance Health, Inc.
(Parent Company Only)
Notes to Condensed Financial Statements
December 31, 2022
(In Millions, Except Per Share Data)
1. Basis of Presentation and Significant Accounting Policies
In the parent company only financial statements of Elevance Health, Inc. (“Elevance Health”), Elevance Health’s
investment in subsidiaries is stated at cost plus equity in undistributed earnings of the subsidiaries. Elevance Health’s share of
net income of its unconsolidated subsidiaries is included in income using the equity method of accounting.
Certain amounts presented in the parent company only financial statements are eliminated in the consolidated financial
statements of Elevance Health.
Elevance Health’s parent company only financial statements should be read in conjunction with Elevance Health’s
audited consolidated financial statements and the accompanying notes included in Part II, Item 8 of this Exhibit 99.1.
2. Subsidiary Transactions
Dividends from Subsidiaries
Elevance Health received cash dividends from subsidiaries of $3,097, $3,134 and $3,618 during 2022, 2021 and 2020,
respectively.
Dividends to Subsidiaries
Certain subsidiaries of Elevance Health own shares of Elevance Health common stock. Elevance Health paid cash
dividends to subsidiaries related to these shares of common stock in the amount of $61, $54 and $46 during 2022, 2021 and
2020, respectively.
Investments in Subsidiaries
Capital contributions to subsidiaries were $411, $3,271 and $2,460 during 2022, 2021 and 2020, respectively.
Amounts Due From and To Subsidiaries
At December 31, 2022 and 2021, Elevance Health reported amounts due (to) from subsidiaries of $(789) and $446,
respectively. The amounts due (to) and from subsidiaries primarily include amounts for allocated operating expenses or daily
cash management activities. These items are routinely settled, and as such, are classified as current liabilities or assets.
In June 2021 Elevance Health entered into a short-term loan agreement with a subsidiary for the amount of $1,500,
which is also included in amounts due from subsidiaries at December 31, 2021. This loan was repaid in February 2022.
Guarantees on Behalf of Subsidiaries
Elevance Health guarantees contractual or financial obligations or solvency requirements for certain of its subsidiaries.
These guarantees approximated $550 at December 31, 2022. There were no payments made on these guarantees in 2022.
3. Derivative Financial Instruments
The information regarding derivative financial instruments contained in Note 6, “Derivative Financial Instruments,” of
the Notes to Consolidated Financial Statements of Elevance Health and its subsidiaries, included in Part II, Item 8 of this
Exhibit 99.1, is incorporated herein by reference.
122

-- 187 of 188 --

4. Long-Term Debt
The information regarding long-term debt contained in Note 13, “Debt,” of the Notes to Consolidated Financial
Statements of Elevance Health and its subsidiaries, included in Part II, Item 8 of this Exhibit 99.1, is incorporated herein by
reference.
5. Commitments and Contingencies
The information regarding commitments and contingencies contained in Note 14, “Commitments and Contingencies,” of
the Notes to Consolidated Financial Statements of Elevance Health and its subsidiaries, included in Part II, Item 8 of this
Exhibit 99.1, is incorporated herein by reference.
6. Capital Stock
The information regarding capital stock contained in Note 15, “Capital Stock,” of the Notes to Consolidated Financial
Statements of Elevance Health and its subsidiaries, included in Part II, Item 8 of this Exhibit 99.1, is incorporated herein by
reference.
123

-- 188 of 188 --